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Summary 
The generation of an effective immune response relies on the coordinated 
migration and interaction of cells of the immune system. Interactions between 
leukocytes and other cells occur within secondary lymphoid organs or at sites of 
inflammation. These interactions are tightly policed by a family of small 
chemotactic cytokines, or chemokines, that drive leukocyte migration. 
Chemokines and their receptors are broadly divided into two functional groups, 
homeostatic and inflammatory. Typically homeostatic chemokines and their 
receptors regulate leukocyte migration to and within secondary lymphoid organs, 
whereas inflammatory chemokines and their receptors control migration of cells 
to sites of inflammation. However, this division is now blurred, as some 
inflammatory chemokine receptors also possess clear homeostatic roles. One 
such receptor is the chemokine receptor CCR2, which binds a number of 
inflammatory chemokines, including CCL2, CCL7 and CCL12. Further complexity 
is added to the chemokine biology field by the discovery of atypical chemokine 
receptors, which lack the capacity to signal in manner similar to conventional 
chemokine receptors, and are proposed to act as chemokine scavengers. The 
most frequently studied atypical chemokine receptor, D6, scavenges 
inflammatory chemokines, with a number of ligands overlapping with those of 
CCR2. 
CCR2 has been reported to play a non-redundant role in the egress of Ly6Chi 
monocytes from the bone marrow (BM) during homeostasis and inflammation. 
However, the role of CCR2 on other cell types has not been fully characterised 
and it is not known how much other CCR2+ cells may contribute to the role 
ascribed to CCR2 in several diseases, such as collagen-induced arthritis (CIA) and 
atherosclerosis. In addition, there is currently limited information about the 
leukocytic expression of D6, which can also bind CCL2. Although more 
information is available about CCR2, there are several conflicts reported 
between surface levels of CCR2 detected by antibody and transcript levels. To 
gain a true understanding of the function of these receptors in diseases it is 
crucial to have an accurate profile of CCR2 and D6 expression in vivo and 
subsequently determine the function of CCR2 and/or D6 on these cells. 
Therefore, the primary aim of this thesis was to generate a detailed profile of 
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CCR2 expression by leukocytes, focusing mainly on the spleen, but including 
lymph nodes (LNs), blood and BM. 
In Chapter 3, I demonstrate that currently available anti-murine CCR2 antibodies 
are unreliable, as they were either unable to detect CCR2 or could only detect 
high levels of CCR2. I describe a novel technique using fluorescently labelled 
CCL2 (CCL2AF647), which substantially enhanced CCR2 detection and enabled a 
detailed characterisation of D6 activity. Using this method, I present a 
comprehensive analysis of CCR2 and D6 expression on mouse leukocytes. CCR2 
expression was primarily limited to myeloid cells, dendritic cells (DCs), and 
natural killer (NK) cells, with lymphoid cells having low levels of CCR2. 
Interestingly, my data illustrates that D6 expression is not as restricted as 
published data suggests, as several cell populations, such as plasmacytoid DCs 
(pDCs) and some monocyte populations were found to express both CCR2 and D6. 
Furthermore, I present preliminary evidence that suggests that CCR2 might 
exhibit cell-type specific responses to its ligands. 
I also systematically analysed the cellular composition of lymphoid organs and 
the blood of CCR2 knock-out (KO) mice and compared it to age- and gender-
matched wild-type (WT) controls. These studies revealed that CCR2 deletion 
only affected the distribution of cells of monocytic origin during homeostasis. In 
contrast, the results described in Chapter 4 demonstrated that systemic 
inflammation induced by lipopolysaccharide (LPS) affected the frequency of 
several populations possessing CCR2 activity, including Ly6Chi monocytes and 
conventional DCs (cDCs). I also present data that suggests that LPS temporally 
regulates CCR2 and D6 activity in a cell type-specific manner. 
In Chapter 5, I detail the identification of two subsets of pDCs, present in the 
spleen, BM, blood, and LNs that differ in their expression of CCR2 and D6. Both 
subsets were able to stimulate naïve T cell proliferation and responded to toll-
like receptor 7 (TLR7) and TLR9 stimulation, in terms of interferon alpha (IFNα) 
production and expression of activation markers. However, transcriptomics and 
flow cytometry did reveal some notable differences between these two subsets 
and deficiency in D6 or CCR2 led to changes in the surface immunophenotype of 
pDCs at certain anatomical locations. I also demonstrate that pDCs are able to 
4 
 
migrate efficiently towards CCL2 in vitro, but that CCR2 was not required for the 
reported CCL2 dependent migration of pDCs to imiquimod-inflamed skin. 
Taking these results together, I have established CCL2AF647 as a novel sensitive 
method of CCR2 detection, which facilitated the identification of two pDC 
subsets. Although I was unable to find a role for CCR2 on pDCs, further study 
might better define the function that CCR2, and D6, plays on pDCs. In Chapter 6 
I discuss my findings, relating the results to published data and forming 
conclusions and hypotheses that can be examined further in future experiments. 
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Abbreviations 
The following abbreviations are used throughout this thesis: 
aa  amino acid 
AF647  alexafluor647 
AIRE  autoimmune regulator 
ANOVA analysis of variance 
APC  allophycocyanin 
Ag  antigen 
APCs  antigen-presenting cells 
Arp2/3  actin related protein 2/3 
β-ME  β-mercaptoethanol 
B16FL  B16 melanoma line secreting Flt3L 
BM  bone marrow 
BM-pDC BM derived pDCs 
cAMP  cyclic adenosine monophosphate 
CCL  CC chemokine ligand 
CCR  CC chemokine receptor 
CD  cluster of differentiation 
cDC  conventional dendritic cell 
Cdc42  cell division control protein 42 homolog 
cDNA  complementary DNA 
CDP  common DC progenitors 
CFA  Complete Freund’s adjuvant 
CFSE  5-carboxyfluoresceindiacetate succinimidyl ester 
CHO  Chinese hamster ovary 
CHO-Flt3L Flt3L from transfected CHO cell line 
CIA  collagen-induced arthritis 
CLP  common lymphoid progenitor 
CM  conditioned media 
CMP  common myeloid progenitor 
CpG  cytosine phosphodiester guanine oligodeoxynucleotide 
C-terminal carboxy terminal 
CXCL  CXC chemokine ligand 
CXCR  CXC chemokine receptor 
CX3CL  CX3C chemokine ligand 
CX3CR  CX3C chemokine receptor 
DAG  diacyl glycerol 
°C  degrees Celsius 
DC  dendritic cell 
DNA  deoxyribonucleic acid 
DSS  dextran sodium sulphate 
DTR  diphtheria toxin receptor 
EAE  experimental autoimmune encephalomyelitis 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
Erk  extracellular signal-regulated kinase 
FACS  fluorescence activated cell sorting 
FC  fold-change 
FCS  foetal calf serum 
FITC  fluorescein isothiocyanate 
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Flt3  Fms-like tyrosine kinase 3 
Flt3L  Flt3 ligand 
FMO  fluorescence minus one 
FSC  forward scatter 
GAG  glycosaminoglycan 
GALT  gut associated lymphoid tissue 
GC-RMA GC-robust multi-array average 
GDP  guanosine diphosphate 
GM-CSF granulocyte macrophage- colony stimulating factor 
ΔMFI  geometric mean fluorescence intensity 
GMP  granulocyte-monocyte progenitor 
GFP  green fluorescent protein 
GPCR  G-protein coupled receptor 
GRK  G-protein coupled receptor kinase 
GTP  guanosine triphosphate 
h  human 
HBSS  Hanks Balanced Salt Solution 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HEK  human embryonic kidney 
HEV  high endothelial venule 
hi  high 
hrs  hours 
ICAM  intercellular adhesion molecule 
ifitm  IFN induced transmembrane protein 
IFN  interferon 
Ig  Immunoglobulin 
IL  interleukin 
Immgen Immunological Genome Project 
iNOS  inducible nitric oxide synthase 
inter  intermediate 
i.p.  intraperitoneally 
IP3  inositol triphosphate 
IRF  IFN regulatory factor 
i.v.  intravenously 
JAK  Janus kinase 
kD  kilodaltons 
KO  knock-out 
LCs  Langerhans cells 
LFA1  leukocyte function-associated Ag 1 
LN  lymph node 
Lo  low 
LPS  lipopolysaccharide 
LTα1β2 lymphotoxin α1β2 
LTβR  LTα1β2 receptor 
LTi  lymphoid tissue inducer 
LTin  lymphoid tissue initiator 
LTo  lymphoid tissue organiser 
m  murine 
MCMV  murine cytomegalovirus 
MDP  macrophage DC precursors 
MHCII  major histocompatibility complex class II 
mins  minutes 
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µg  microgram 
µl  microlitre 
ml  millilitre 
MLN  mesenteric LN 
mM  millimolar 
MMP  matrix metalloproteinase 
mRNA  messenger RNA 
MZ  marginal zone 
ng  nanogram 
NK cells natural killer cells 
nM  nanomolar 
N-terminal amino-terminal 
OVA  ovalbumin 
p  probability 
PAK  p21-activated kinase 
PALS  periarteriolar lymphoid sheath 
PAMPs  pathogen-associated molecular patterns 
PB  pacific blue 
PBS  phosphate buffered saline 
pDC  plasmacytoid DC 
PDCA1  pDC Ag-1 
PE  phycoerythrin 
PerCP  peridinin-chlorophyll-protein 
Phe  phenylalanine 
PIP2  phosphatidylinositol bisphosphate 
PI3K  phosphatidylinositol-3-kinase 
PKC  protein kinase C 
PLC  phospholipase C 
PLN  peripheral LN 
plt/plt paucity of LN T cells mutation 
PP  Peyer’s patch 
PRR  pattern recognition receptor 
QPCR  quantitative polymerase chain reaction 
R848  resiquimod 
Rarg  retinoic acid receptor gamma 
RFP  red fluorescent protein 
rh  recombinant human 
RIN  RNA integrity number 
RMA  robust multi-array average 
RNA  ribonucleic acid 
RPM  revolutions per minute 
RPMI  Roswell Park Memorial Institute-1640 medium 
RQ  relative quantity 
RT  room temperature 
RT-PCR reverse transcriptase-polymerase chain reaction 
s.c.  subcutaneously 
SD  standard deviation 
secs  seconds 
SLE  systemic lupus erythematosus 
SN  supernatant 
SOCS  suppressor of cytokine signalling 
S1P  sphingosine-1-phosphate 
S1P1  S1P receptor 1 
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Src  sarcoma 
SSC  side scatter 
STAT  signal transducer and activator of transcription 
TCR  T cell receptor 
Th  T helper 
TipDC  TNF and iNOS producing DC 
TLR  Toll-like receptor 
TNFα   tumour necrosis factor alpha 
TPA  12-O-tetradecanoylphorbol-13-acetate 
TRAIL  TNF-related apoptosis-inducing ligand 
Treg  regulatory T cell 
Tyr  tyrosine 
vs.  versus 
WASP  Wiskott-Aldrich syndrome protein 
WT  wild-type 
XCL  XC chemokine ligand 
XCR  XC chemokine receptor 
xg  times gravity 
Chapter 1 – Introduction 
The immune system is at the forefront of defence against pathogens, the 
development of autoimmunity and immunopathology, and participates in the 
repair of damaged tissues. The ability to coordinate these responses requires a 
complex and highly organised system of cells and organs. The first line of 
defence against invading pathogens are organs, such as the skin and mucosal 
tissues, which act as physical barriers, protecting the body from initial injury or 
infection. A more coordinated response against pathogens is provided by the 
immune cells and organs of the lymphoid system. 
The organs of the lymphoid system can be divided into primary and secondary 
lymphoid organs. Primary lymphoid organs, such as the bone marrow (BM) or 
thymus, are the sites of leukocyte generation, differentiation and maturation. 
Following their generation, naïve leukocytes leave these primary lymphoid 
organs and enter the blood. Several leukocyte populations, such as neutrophils 
(Eash et al., 2010) and monocytes (Serbina and Pamer, 2006), are dependent on 
members of the large family of chemotactic cytokines, known as chemokines, for 
their egress from the BM. Furthermore, CXCR4 and its ligand CXCL12 are 
involved in haematopoietic stem cell retention in the BM, as inhibition of the 
CXCL12-CXCR4 axis mobilises stem cells (Sharma et al., 2011). Chemokines and 
their receptors also play a role in the generation of naïve leukocytes by 
coordinating the migration of developmental precursors within the organ. For 
example, cell migration during T cell development in the thymus is dependent 
on several homeostatic chemokine receptors, particularly CCR7 and CCR9 
(Misslitz et al., 2004; Förster et al., 2008; Nitta et al., 2008). Once in the 
periphery, leukocytes are guided by chemokines to secondary lymphoid organs, 
such as the spleen and lymph nodes (LNs). Alternatively they patrol the blood 
and tissues for pathogens. In response to a pathogen or sterile inflammation and 
tissue damage, leukocytes exhibit either a rapid response with low specificity or 
a highly specific response, and it is this distinction that divides the immune 
system into two branches: the innate and adaptive immune systems. The innate 
immune system provides a rapid response, which unlike the adaptive immune 
system is not antigen (Ag) specific, but is driven by the recognition of specific 
molecules on pathogens, known as pathogen associated molecular patterns 
(PAMPs). In contrast, the adaptive immune system is highly Ag specific. The 
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coordinated interaction between the innate and adaptive arms of the immune 
system is required to produce an effective immune response. Dendritic cells 
(DCs) are a critical component of this interaction. At sites of inflammation DCs 
take up Ag and mature as they migrate in a chemokine dependent manner to LNs 
via the lymphatics. Within the LN, chemokines direct the interaction of Ag 
loaded DCs with naïve T lymphocytes, and the subsequent interaction of T and B 
lymphocytes. The newly differentiated plasmablasts are located in the red pulp 
of the spleen and produce antibody (Mebius and Kraal, 2005). In contrast, 
activated T lymphocytes exit LNs and migrate to the original site of Ag 
encounter where they complement the existing response produced by cells of 
the innate immune system. This highly coordinated response allows for the 
eradication of pathogens. However, not all immune responses are beneficial, as 
activation of the immune system against harmless Ag, such as self-peptides, can 
be detrimental, leading to pathology. The immune system can discriminate 
between harmless and pathogenic Ags and in a process known as immune 
tolerance, lymphocytes are rendered non-reactive to harmless Ag or can develop 
into regulatory T cells that actively suppress immune responses. Allergic 
responses and autoimmune diseases, such as Crohn’s disease are caused by a 
break in tolerance to a harmless Ag (Sartor, 2006). Therefore, tight regulation of 
immune responses is required to maintain a healthy pathogen-free host that 
does not develop destructive autoimmunity. 
In this Introduction, I will describe the role that chemokines and their receptors 
play in the development and maintenance of lymphoid organs, with a more 
detailed account of their function in secondary lymphoid organs. I will also 
discuss the role of inflammatory chemokines and the innate immune system, 
providing a detailed review of the DC system. Finally, I will summarise the roles 
that the CCL2 chemokine receptors, CCR2 and D6, have been reported to play in 
the immune system. It is these chemokine receptors that form the focus of my 
thesis. 
1.1 Chemokines  
Chemokines are small secreted chemotactic cytokines, approximately 8-12 kDa 
in size (Allen et al., 2007). Primarily known for their ability to direct migration 
of immune cells, this is not their only role, being important for angiogenesis, 
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tumour metastasis, wound healing, development and maintenance of immune 
tissues, and response to infection (Raman et al., 2011). The majority of 
chemokines are secreted proteins, however two chemokines CXCL16 and CX3CL1 
are tethered to extracellular surfaces by mucin-like stalks. In fact the 
interaction of all chemokines with components of the extracellular matrix is a 
key aspect of their biology. Moreover, the membrane-bound chemokines can be 
cleaved to release soluble, diffusible protein (Murphy et al., 2000; Allen et al., 
2007). Secreted and membrane-bound chemokines share similarities in their 
tertiary structure, despite variability in their primary amino acid (aa) sequence. 
The conserved tertiary structure of chemokines consists of a disordered N-
terminus that contains signalling and receptor binding domains. The disordered 
N-terminus is followed by a long N-loop, β-sheets and a C-terminal α-helical tail 
(Figure 1-1) (Allen et al., 2007). This conserved structure is important for 
binding to chemokine receptors with variations in aa sequence, dictating 
receptor specificity. 
 
Figure 1-1: Structure of the CC-chemokine ligand, CCL2. 
Schematic representation (A) and the crystal structure (B) of CCL2, illustrating the features of the 
conserved tertiary structure of chemokines. Schematic representation was adapted from 
(Deshmane et al., 2009) and the crystal structure was adapted from (Salanga and Handel, 2011). 
1.1.1 Nomenclature and classification 
In the late 90s, various bioinformatic and cloning strategies led to a large 
expansion of the number of identified chemokines (Murphy et al., 2000). 
Previously, they were identified in the culture media of stimulated cells. The 
proteins required for induction of directed cell migration were purified and 
sequencing of these proteins identified them as chemokines (Wells et al., 1998; 
Murphy et al., 2000). Historically, chemokines were named based on their 
identified functions, however this meant chemokines had several alternative 
names. Thus, within the chemokine research field there was a call for a more 
systematic nomenclature to be established. This standardised method to classify 
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chemokines is based on their structure, which is dictated by the number and 
spacing of conserved cysteine residues within their primary sequence (i.e. CC, 
CXC, CX3C and XC). Furthermore, chemokines are numbered according to when 
the gene encoding the chemokine was first reported. There are four families of 
chemokines: CC chemokines, CXC chemokines, C chemokines and CX3C, all 
members of which are listed in Table 1-1 (Murphy et al., 2000; Rossi and Zlotnik, 
2000). 
CC chemokines, like CXC and CX3C chemokines, have four conserved cysteine 
residues, although some contain additional cysteine residues not present in 
other chemokines (e.g. CCL21). These four cysteine residues help in the 
retention of the functional tertiary structure, plus the similarity in structure 
within a chemokine family, because two disulphide bonds are formed between 
the first and third cysteine residues and between the second and fourth 
cysteines (Figure 1-1) (Rossi and Zlotnik, 2000). CC chemokines are the largest 
chemokine family and possess two adjacent cysteine residues near their N-
terminus. Likewise, CXC chemokines possess two cysteines residues near their N-
terminus, but these cysteine residues are separated by a single non-conserved 
aa. The CX3C family has only one member, CX3CL1 which has three non-
conserved aas between its first two cysteine residues. Members of the C family 
of chemokines have only two conserved cysteine residues in the whole protein 
joined by one disulphide bond, which helps in the maintenance of the similar 
tertiary structure of this family of chemokines. These two cysteine residues 
correspond to the second and fourth cysteine residues in members of the other 
three chemokine families (Rossi and Zlotnik, 2000; Comerford and Nibbs, 2005; 
Charo and Ransohoff, 2006). 
As Table 1-1 illustrates there is variability within the chemokine families 
between species. Several chemokines, such as CCL13 through to CCL16 exist in 
humans, but not in mice, whereas CCL9, CCL10 and CCL12 exist in mice, but not 
in humans (Murphy et al., 2000). Also, CCL8, a CCR2 ligand in humans, should 
really be considered as a different chemokine in mice because in this species it 
binds only CCR8 (Islam et al., 2011). There is also variation between individuals 
of the same species. For example, some chemokines, such as hCCL3, exist as 
different isoforms. The hCCL3 isoforms, CCL3 and CCL3L1, differ in their amino 
termini and they also have one aa change in the body of the protein (Mueller et 
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al., 2006). However, they are functionally distinct with clear differences in 
receptor specificity (Townson et al., 2002). Moreover, some individuals lack 
CCL3L1, whilst others have from 1 to 10 copies of this gene (Townson et al., 
2002; Gonzalez et al., 2005). This is functionally significant in the context of HIV 
(Gonzalez et al., 2005). The large degree of redundancy within the chemokine 
system means that the significance of many of these differences has yet to be 
elucidated (Mestas and Hughes, 2004). However, it has been proposed that this 
apparent “redundancy” within the chemokine system provides robust outputs, 
even in the presence of genetic alterations (Mantovani, 1999). In contrast, the 
use of animals deficient in a chemokine receptor or ligand, such as CCR2 
(Serbina and Pamer, 2006), CCR7 (Luther et al., 2000; Förster et al., 2008) and 
CXCR4 (Ma et al., 1998) has illustrated that some chemokine receptors play 
indispensible roles on specific cell populations. These roles shall be discussed 
later. 
CXC Family  
Systemic Nomenclature 
Alternative names Receptor(s) 
CXCL1 GROα, KC CXCR1, CXCR2 
CXCL2 GROβ, MIP-2 CXCR2 
CXCL3 GROγ, DCIP-1 CXCR2 
CXCL4 PF4 hCXCR3B 
CXCL5 ENA-78, mGCP-2, LIX CXCR2 
hCXCL6 GCP-2 CXCR1, CXCR2 
CXCL7 NAP-2 CXCR2 
hCXCL8 IL-8 CXCR1, CXCR2 
CXCL9 Mig CXCR3, CCR3 
CXCL10 IP-10 CXCR3, CCR3 
CXCL11 I-TAC CXCR3, CCR3 
CXCL12 SDF-1 CXCR4 
CXCL13 BCA-1, BLC CXCR5 
CXCL14 BRAK, Bolekine Unknown 
mCXCL15 Lungkine, WECHE Unknown 
CXCL16 SCYB16, SR-PSOX CXCR6 
 
C Family  
Systemic Nomenclature 
Alternative names Receptor(s) 
XCL1 Lymphotactin, SCM-1α XCR1 
hXCL2 SCM-1β XCR1 
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CX3C Family  
Systemic Nomenclature 
Alternative names Receptor(s) 
CX3CL1 Fractalkine, Neurotactin CX3CR1 
 
CC Family  
Systemic Nomenclature 
Alternative names Receptor(s) 
CCL1 I-309, TCA-3 CCR8 
CCL2 MCP-1, JE, MACF CCR2 
CCL3 MIP-1αS, MIP-1α CCR1, CCR5 
hCCL3L1 MIP-1αP, MIP-1α CCR1, CCR3, CCR5 
CCL4 MIP-1β CCR5 
hCCL4L1 MIP-1β CCR5 
CCL5 RANTES CCR1, CCR3, CCR5 
mCCL6 C10, MRP-1 CCR1 
CCL7 MCP-3, MARC CCR1, CCR2, CCR3, CCR5 
CCL8 MCP-2 hCCR2, hCCR3, mCCR8 
mCCL9 MIP-1γ, MRP-1, CCF18	   CCR1 
mCCL10 MIP-1γ, MRP-1, CCF18 CCR1 
CCL11 Eotaxin CCR3, CXCR3 
mCCL12 MCP-5 CCR2 
hCCL13 MCP-4 CCR2, CCR3 
hCCL14 HCC-1 CCR1 
hCCL15 HCC-2, Lkn-1, MIP-1δ CCR1, CCR3 
hCCL16 HCC-4, LEC, LCC-1 CCR1, CCR2, CCR5 
CCL17 TARC CCR4 
hCCL18 DC-CK1, PARC PITPNM3 
CCL19 ELC, MIP-3β, exodus-3 CCR7 
CCL20 MIP-3α, LARC, exodus-1 CCR6 
CCL21 SLC, 6Ckine, exodus-2 CCR7 
CCL22 MDC, STCP-1, ABCD-1 CCR4 
hCCL23 MPIF-1 CCR1 
CCL24 Eotaxin-2, MPIF-2 CCR3 
CCL25 TECK CCR9 
hCCL26 Eotaxin-3 CCR1, CCR2, CCR3, CCR5, CX3CR1 
CCL27 C-TACK, PESKY, Eskine CCR10 
CCL28 MEC CCR3, CCR10 
Table 1-1: Systematic nomenclature for chemokines. 
Chemokines listed according to the systemic nomenclature with their alternative names and 
receptor(s). Chemokines preceded with h indicates that the chemokine is present in humans, but 
not mice, whereas the prefix m designates chemokines present in mice, but not humans.
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1.1.2 Chemokine mediated control of cell movement 
Chemokines possess the ability to regulate and coordinate leukocyte migration 
and positioning within tissues. The regulation of leukocytes is the principal focus 
of my thesis, so my Introduction will focus on this key aspect of chemokine 
biology. The roles of chemokines in leukocyte migration can broadly be divided 
into two categories: firstly, chemokine-induced activation of integrins required 
for rapid leukocyte adhesion to endothelial surfaces and secondly, chemokine-
induced rearrangements in the cells cytoskeleton via actin polymerisation, which 
is likely to be critical for interstitial navigation (Kinashi, 2005; Vicente-
Manzanares et al., 2009; Schumann et al., 2010). Surface adhesion via 
chemokine-induced activation of integrins is critical for haptic movement, both 
random migration (haptokinesis) and migration along gradients of immobilised 
chemokine ligands (haptotaxis). It also plays a role in the induction of cell 
adhesion, such as occurs to leukocytes on endothelial surfaces. However, 
migration can also occur independently of firm adhesion, using soluble 
homogenous chemokine signals to trigger random migration (chemokinesis) or 
directed migration along soluble chemokine gradients (chemotaxis) (Schumann 
et al., 2010). 
The extravasation of cells from the blood to tissues is a multi-step process, 
involving selectin-mediated rolling of cells, chemokine-induced integrin 
activation, integrin-induced cell arrest, and transmigration of cells across the 
endothelium (Handel et al., 2005) (Figure 1-2). This occurs continuously during 
homeostasis at many locations, most notably the high endothelial venules (HEVs) 
of LNs. During tissue inflammation, selectins are upregulated on endothelial 
cells in the tissue, which allows passing cells to roll along the endothelium. 
Sensing of chemokines presented by endothelial cells that are specific for 
chemokine receptors on the rolling cell leads to chemokine-induced integrin 
activation, which leads to cell arrest on the endothelium (Handel et al., 2005; 
Kinashi, 2005; Grailer et al., 2009).The role of chemokines in this simple 
paradigm has been expanded recently to demonstrate that leukocytes can 
migrate on endothelial cells after their arrest. For example, neutrophils have 
been reported to exhibit CXCR2 dependent haptotaxis, along an intravascular 
gradient of CXCR2 ligand presented on endothelial cells, towards a site of 
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inflammation (McDonald et al., 2010). Also, Ly6Clo monocytes are constitutively 
motile on endothelial cells in a CX3CR1 dependent manner (Auffray et al., 2007). 
Some chemokine receptors, such as CCR2, can mediate leukocyte 
transendothelial migration using chemokine ligands stored within vesicles 
underneath the plasma membrane of endothelial cells. Thus, in some cases 
transendothelial migration can occur even when the availability of chemokine 
presented on endothelial cells is low (Shulman et al., 2011). 
The multiprocess of leukocyte extravasation can be summarised in several major 
steps (Figure 1-2) (Alon and Feigelson, 2002; Handel et al., 2005). First, 
leukocytes express L-selectin (also known as CD62L), which weakly binds to 
endothelial cells expressing L-selectin ligands, such as CD34. This mediates 
rolling of cells along the endothelial surface. Next, chemokines expressed 
and/or presented on glycosaminoglycans (GAGs) by endothelial cells bind to 
their appropriate chemokine receptor on the rolling leukocytes (Stein et al., 
2000; Alon and Feigelson, 2002; Handel et al., 2005). Chemokine receptor 
engagement induces conformational changes in leukocyte integrin molecules, 
such as leukocyte function-associated Ag 1 (LFA1), leading to clustering on 
integrins, which are now in a high-affinity state (Stein et al., 2000; Alon and 
Feigelson, 2002). However, chemokine receptor activation is insufficient to 
induce robust integrin activation in the absence of shear flow/stress (Alon and 
Feigelson, 2009). These integrins interact with adhesion molecules (e.g. 
intercellular adhesion molecule (ICAM)-1) on the surface of endothelial cells, 
which leads to firm adhesion of the leukocyte to endothelial cell surface (Stein 
et al., 2000; Alon and Feigelson, 2002). The arrested leukocyte then accesses 
underlying inflamed tissue by migrating between (paracellular) or through 
(transcellular) endothelial cells, Figure 1-2 shows paracellular trans-migration 
(Förster et al., 2008). 
The migration of cells into underlying tissues is facilitated by chemokine-induced 
polarisation of the actomyosin cytoskeleton (Kinashi, 2005; Vicente-Manzanares 
et al., 2009; Schumann et al., 2010). The leading edge of the cell has a 
concentrated expression of the appropriate chemokine receptor, and binding of 
further chemokine to the receptors facilitates coordinated integrin activation, 
which propel the cell forward through the endothelium towards the chemokine 
expressed in the inflamed tissue. This process has been extensively studied in 
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vitro, but it is still unclear whether true chemokine gradients exist within 
lymphoid tissues and inflamed tissues in vivo (Nieto et al., 1997). However, 
Schumann et al. have shown that a combination of immobilised CCL21, and 
soluble CCL19 and CCL21 gradients can direct DC migration within LNs 
(Schumann et al., 2010). Immobilised CCL21, in the absence of soluble CCL19 or 
CCL21 results in haptokinetic migration by DCs. In contrast, following truncation 
of anchoring residues of CCL21 by DCs, a soluble form of CCL21 is produced, 
which like soluble CCL19 can trigger chemotactic movement of DCs. Therefore, 
it has been reported that the directional CCR7 dependent migration of DCs 
within LNs after entry from the subcapsular sinus is a combined effect of 
immobilised CCL21 triggering integrin activation and cell adhesion, plus a soluble 
CCL19/CCL21 gradient providing directional cues (Schumann et al., 2010). CCR7 
and its ligands have also been shown to be important for the intranodal motility 
of T cells, as in the absence of CCR7 or its ligands T cell motility was reduced 
(Worbs et al., 2007). 
The extravasation of cells is heavily chemokine-dependent, as inhibition of 
chemokine receptor signalling via pertussis toxin treatment causes a subsequent 
inhibition in integrin activation, and blocks extravasation of cells (Cyster and 
Goodnow, 1995; Warnock et al., 1998). The presentation of chemokines on cell 
surfaces is intrinsic to their function in promoting extravasation of leukocytes 
into tissues. The majority of chemokines are soluble and secreted, but are bound 
to GAGS and presented on the surface of endothelial cells (Handel et al., 2005). 
GAGs are negatively charged polysaccharides that are covalently attached to a 
protein core forming proteoglycans that interact with several circulating 
proteins, including basic chemokines. However, other stromal components, such 
as the fibroblastic reticular cell network of the LN and spleen can present CCL21 
and guide T cell migration within these secondary lymphoid organs (Bajénoff et 
al., 2006; Bajénoff et al., 2008). The interaction of chemokines with GAGs can 
lead to the generation of chemokine oligomers, and it is argued that the 
formation of oligomers and dimers may act to sequester ligands, thereby 
regulating the local chemokine concentration and availability (Lau et al., 2004; 
Comerford and Nibbs, 2005; Allen et al., 2007). GAGs can also protect bound 
chemokines from the action of proteases, such as matrix mellatoproteinases 
(MMPs) and CD26. MMPs and CD26 cleave the N-termini of chemokines and 
Chapter 1  26 
 
modulate their activity. MMP-mediated truncated CCL2, 7, and 13 lose their 
agonistic actions on CCR2 and CCR3 in vitro. However, they retain their ability 
to bind their respective receptors. Thus MMP cleavage converts them into 
antagonists, blocking binding of uncleaved ligands. Likewise, CD26 cleavage of 
CCL5 causes it to lose its agonist actions on CCR1 and CCR3, while retaining its 
ability to bind CCR5 (Comerford and Nibbs, 2005; Handel et al., 2005; Allen et 
al., 2007). Furthermore, GAGs may exhibit selectivity in their presentation of 
chemokines, thus discriminating which cell types are recruited (Middleton et al., 
2002). By changing the concentration or availability of local chemokine 
monomers, GAGs, chemokine multimers and proteases can alter chemokine 
gradients, thus modifying the direction of cell migration and also which cells are 
recruited. 
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Figure 1-2: Leukocyte extravasation from blood vessels into underlying tissue. 
Leukocyte extravasation is a multi-step process. Firstly selectin-mediated tethering of leukocytes in 
the bloodstream slows their movement, allowing them to roll along the endothelium. Rolling cells 
that express the appropriate chemokine receptor are activated by chemokines presented by GAGs 
on the endothelium surface. The chemokine-induced activation of cells leads to a high affinity 
integrin-mediated firm adhesion and arrest of cells. The cell transmigrates through the vascular 
endothelium and into the underlying tissue. Adapted from (Handel et al., 2005). 
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1.2 Chemokine receptors 
Chemokine receptors are members of one of the most diverse class of surface 
receptor families, the G-protein coupled receptor (GPCR) superfamily. Like 
other GPCRs, chemokine receptors are seven transmembrane domain receptors 
that are coupled to heterotrimeric G-protein complexes. The C-terminus and 
three intracellular loops of the receptor face into the cytoplasm, and the G-
protein is associated with the C-terminus (Murdoch and Finn, 2000). The 
presence of the canonical sequence DRYLAIV within their second intracellular 
loop is also important for G-protein coupling and signalling (Nibbs et al., 2003; 
Ulvmar et al., 2011). The N-terminus and three extracellular loops of the 
receptor are exposed outside of the cell (Murdoch and Finn, 2000). The binding 
of ligands to their respective receptors is proposed to be a two-site interaction. 
The N-terminus of the receptor is thought to bind to the N-loop of chemokine 
ligands, and the disordered N–terminal signalling domain of the ligand is thought 
to interact with the extracellular loops of the receptor and access the hole 
created by the seven transmembrane domains (Rajagopalan and Rajarathnam, 
2006). The N-terminus of the receptor is rich in negatively charged residues and 
also contains sulphated tyrosine residues, both of which are essential in 
mediating high affinity ligand binding (Preobrazhensky et al., 2000; Rajagopalan 
and Rajarathnam, 2006). Upon ligand binding, the canonical DRYLAIV sequence 
found in the second intracellular loop of the receptor is vital for inducing 
intracellular signalling (Murphy et al., 2000; Rot and von Andrian, 2004). 
Many chemokines are known to bind to more than one receptor, and several 
receptors are known to bind multiple ligands (Rot and von Andrian, 2004; 
Salanga et al., 2009). However, some chemokines still have no identified 
receptor (Table 1-1). Most receptors generally bind to ligands that are restricted 
to one class of chemokines, such as CC or CXC ligands. For example, CXCR bind 
CXC chemokines, CCR bind CC ligands, XCR1 binds C chemokines and CX3CR1 
binds CX3CL1 (Murphy et al., 2000; Rossi and Zlotnik, 2000). There are some 
exceptions, as CXCR3 can be antagonised by CCL11, and CXCL9, 10 and 11 are all 
antagonists of CCR3 (Rot and von Andrian, 2004). Systematic nomenclature for 
chemokine receptors is based on the class of chemokine that they bind followed 
by a number depending on when they were first discovered. 
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1.2.1 Chemokine receptor signalling 
Binding of a chemokine to its respective receptor initiates signalling events, 
starting with the activation of the associated G-protein. The heterotrimeric G-
protein contains three subunits Gα, β and γ. There are four families of Gα 
subunits, Gαs, Gαi/o, Gαq/11 and Gα12/13 all with several family members. 
Primarily Gαi/o subunits are responsible for regulating chemotaxis (Mellado et 
al., 2001; Rot and von Andrian, 2004; Cotton and Claing, 2009; Salanga et al., 
2009). Gα subunits in their inactive resting state are bound by guanosine 
diphosphate (GDP). Chemokine receptor activation by ligand binding leads to a 
conformational change of the intracellular domains of the receptor, and a 
resultant exchange of GDP for guanosine triphosphate (GTP). The heterotrimeric 
G-protein is destabilised by GTP binding, leading to the dissociation of the α 
subunit and a complex composed of β and γ subunits (Mellado et al., 2001; Rot 
and von Andrian, 2004; Cotton and Claing, 2009; Salanga et al., 2009). The 
system has an internal shut off switch because Gα subunits have intrinsic GTPase 
activity that hydrolyses bound GTP, thereby reuniting the α subunit with the βγ 
complex, and reforming the inactive heterotrimer (Figure 1-3) (Mellado et al., 
2001; Rot and von Andrian, 2004). 
Both the α subunit and the βγ subunits complex mediate chemokine-induced 
signals. The targets of each of these subunits differ, with some overlap (Figure 
1-3) (Mellado et al., 2001; Rot and von Andrian, 2004; Cotton and Claing, 2009). 
Gα subunits control the activation of the GTPase RhoA (Cotton and Claing, 
2009), which is involved in chemokine-induced rapid integrin activation and, as a 
consequence, leukocyte arrest (Giagulli et al., 2004). Furthermore, Gα subunit 
triggers signal transduction by the Src kinase, which leads ultimately to the 
activation of a small GTPase Rac, which is involved in cell migration (Cotton and 
Claing, 2009). The Gβγ complex can lead to the activation of Rac through an 
alternative pathway initiating with the activation of the protein kinase PI3K. Rac 
activates two downstream effectors, WASP and PAK, which stimulate the actin 
related protein (Arp) 2/3, thereby inducing actin polymerisation (Rot and von 
Andrian, 2004). The Gα subunit is also able to activate adenylate cyclase, 
leading to cAMP production, which ultimately results in the activation of Erk, 
which modulates cell migration (Cotton and Claing, 2009). Both the Gα and Gβγ 
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can activate two different pathways involving phospholipase C (PLC). Firstly the 
Gα subunit activates PLC, which activates protein kinase C (PKC), leading to the 
activation of calmodulin, which enhances cell motility. In contrast the activation 
of PLC by Gβγ subunits complex leads to the cleavage of a phospholipid, PIP2 
generating two products DAG and IP3. IP3 is involved in calcium mobilisation 
(Murphy et al., 2000; Mellado et al., 2001; Cotton and Claing, 2009). The role of 
calcium mobilisation in leukocyte migration is unclear. Some studies indicate 
that increased calcium mobilisation is required for chemotaxis, whereas T cells 
have been shown to migrate in response to CCR4 ligands independent of calcium 
mobilisation (Pettit and Fay, 1998; Cronshaw et al., 2006). Thus, many 
chemokine-induced signalling pathways induce cell migration, however in the 
absence of Cdc42 activation leukocytes fail to comprehend a directional 
chemokine gradient and instead exhibit random migration. It is only following 
activation of Cdc42, by either the Gα or Gβγ subunits that migration becomes 
unidirectional. The Gα subunit directly activates Cdc42 and Gβγ subunits 
complex indirectly activate Cdc42 via PAK1 (Rot and von Andrian, 2004; Cotton 
and Claing, 2009). 
Chemokine induced migration of cells can also be regulated by suppressor of 
cytokine signalling (SOCS) proteins. SOCS proteins are a small family of 8 
proteins that regulate signal transduction of cytokine signalling pathways. SOCS 
proteins have been shown to inhibit cell migration in response to chemokines, as 
SOCS1 and SOCS3 expression by a fibroblast cell line and HEK cells inhibited 
migration of the cells towards CCL11 (Stevenson et al., 2010). Overexpression of 
SOCS3 by a pro-B cell line inhibited CXCL12 induced polarisation of the cells. 
Furthermore, immature and mature B cells from SOCS3 deficient mice had 
increased CXCL12-induced adhesion (Le et al., 2007). In contrast to Stevenson et 
al. who found that expression of SOCS proteins inhibited migration of cells 
(Stevenson et al., 2010), Le et al. found that in the absence of SOCS3, immature 
B cells were retained in the BM (Le et al., 2007). Le et al. proposed that the 
enhanced adhesion properties of the B cells might impede CXCR4-dependent 
egress of B cells from the BM (Le et al., 2007). 
Further complexity is added to chemokine receptor signalling, as the pathways 
induced and the subsequent outcome of activation depends on a variety of 
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factors, such as cell type, receptor and ligand. Earlier I mentioned a potential 
redundancy of chemokine receptors and ligands, however it is now proposed that 
different chemokines interacting with the same receptor may activate different 
signalling pathways (Murphy et al., 2000). The promiscuity of chemokine 
receptors and their ligands might exist to provide robust immune responses. 
Many pathogens attempt to subvert the chemokine system, therefore 
“redundancy” ensures robustness of response in the face of pathogen-mediated 
chemokine subversion (Finlay and McFadden, 2006). Furthermore, this area is 
complicated by the fact that chemokine receptors, like other GPCRs are subject 
to receptor dimerisation forming both homodimers and heterodimers, which may 
influence downstream signalling events (Salanga et al., 2009). Chemokine 
receptor dimerisation is reported to result in the association and activation of 
JAKs, which in turns leads to the phosphorylation and activation of STATs. STATs 
can then promote transcription of STAT responsive genes (Rodríguez-Frade et 
al., 1999; Mellado et al., 2001). 
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Figure 1-3: Chemokine receptor signalling cascade. 
The 7 transmembrane chemokine receptor is associated with a heterotrimeric G-protein, consisting 
of α, β and γ subunits. (A) In a resting state the Gα subunit is rendered inactive by the binding of 
GDP. (B) Upon ligand binding the intracellular domains of the chemokine receptor undergo a 
conformational change leading to the exchange of GDP for GTP. (C) Binding of GTP leads to the 
dissociation of the heterotrimeric protein from the receptor, as two entities the Gα subunit and a 
Gβγ complex. Both the Gα subunit and Gβγ complex lead to the initiation of signalling cascades, 
with some initial effector proteins shown, which result in cell migration, integrin activation, actin 
polymerisation and calcium mobilisation. (D) Intrinsic GTPase activity of the Gα subunit hydrolyses 
GTP to GDP, leading the reunion of the Gα subunit with the Gβγ complex, forming the inactive G-
protein heterotrimer. The heterotrimer reassociates with a chemokine receptor. Adapted from (Rot 
and von Andrian, 2004; Cotton and Claing, 2009). 
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1.2.2 Receptor desensitisation 
Typically following chemokine-mediated activation of a receptor, the receptor is 
internalised, whereupon it is either recycled back to the cell surface or targeted 
for lysosomal degradation. Recycling of the receptor allows it to bind more 
ligand and repeat the process again. By controlling the surface level of 
receptors, or the activity of the receptors, the strength and duration of the 
response can be altered (Rot and von Andrian, 2004; Cotton and Claing, 2009; 
Neel et al., 2009). Following prolonged ligand exposure, a receptor can become 
unresponsive to further ligand in a process known as receptor desensitisation. 
Desensitisation of receptors is controlled by phosphorylation of the receptor. G-
protein-coupled receptor kinases (GRKs) phosphorylate the intracellular loops 
and/or C-terminus of ligand-bound receptors, which serve as binding sites for β-
arrestin proteins. Binding of β-arrestins leads to steric hindrance of the G-
protein interaction with the receptor, thereby preventing further activation of 
the receptor in response to additional ligand (Rot and von Andrian, 2004; Vroon 
et al., 2006; Premont and Gainetdinov, 2007; Cotton and Claing, 2009). 
Chemokine-induced receptor signalling can also be silenced by downregulation of 
the number of surface receptors. Binding of β-arrestin can stimulate clathrin-
mediated receptor downregulation by targeting internalised receptors to 
endosomal compartments where they are degraded or resensitised (Neel et al., 
2009). In contrast to their role in receptor desensitisation, GRKs may also 
contribute to signal transduction events, because although GRK6 deletion 
enhanced CXCR4 dependent migration of neutrophils to CXCL12, it decreased 
CXCR4 dependent migration of lymphocytes (Vroon et al., 2006; Cotton and 
Claing, 2009). 
1.3 Atypical Chemokine Receptors 
Some chemokine receptors appear not to be subject to desensitisation and are 
termed atypical chemokine receptors (Hansell et al., 2006; 2011b). There are 
now five identified atypical chemokine receptors (Table 1-2), which are unable 
to mediate signalling upon chemokine ligand binding in a manner similar to the 
“classical” chemokine receptors. Furthermore, this apparent lack of signalling 
capacity is accompanied by an inability to mediate chemotaxis in response to 
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chemokine ligand. The best-characterised atypical chemokine receptor D6 forms 
a main point of focus in my thesis, so this section focuses on D6 biology.  
Following its cloning in 1997 (Bonini and Steiner, 1997; Nibbs et al., 1997a; 
1997b), D6 was identified as a highly promiscuous receptor for proinflammatory 
CC chemokines, including, but not limited to CCL2-5, CCL11, CCL17 and CCL22. 
The ligand binding profile of human D6 has been better characterised than 
murine D6 (Mantovani et al., 2006; Graham, 2009; Hansell et al., 2011b). Ross 
Kinstrie tested all other chemokines on human D6 and none, other than those in 
Table 1-2, bound D6 (personal communication from Rob Nibbs). However, using 
cells transfected with murine D6 (Nibbs et al., 1997a) and also primary cells, 
such as innate-like B cells (Hansell et al., 2011b), murine D6 has also been shown 
to interact with many inflammatory CC chemokines. The ligand binding profiles 
of human and murine D6 are summarised in Table 1-2. The binding of any of its 
many ligands could not activate the conventional signalling pathways described 
earlier, nor could it drive chemotaxis (Mantovani et al., 2006; Graham, 2009; 
Hansell et al., 2011b). D6 possesses an altered DRYLAIV sequence, the sequence 
involved in G-protein coupling and signalling, in D6 it is changed to DKYLEIV 
(Nibbs et al., 1997a). Immunofluorescent staining or imaging of HEK293 cells 
transfected with human D6 has facilitated the analysis of the cellular 
distribution of D6. The majority of D6 is found in intracellular vesicles and cell 
surface protein only accounts for ~5% of D6 protein (Weber et al., 2004). D6 
constitutively traffics to and from the cell surface irrespective of chemokine 
binding (Galliera et al., 2004; Weber et al., 2004). The precise mechanism of D6 
internalisation remains to be fully understood, and conflicting findings exist in 
regards to its dependency on β−arrestins (Galliera et al., 2004; Weber et al., 
2004; McCulloch et al., 2008). Chemokines that are bound to D6 are internalised 
with the receptor and upon entry into the acidic early endosomal compartment 
dissociate from the receptor and are targeted for degradation, whereas the 
receptor is returned to the cell surface. Upon return to the cell surface, D6 can 
bind more ligand, and in doing so functions as a chemokine scavenger, with its 
continuous recycling facilitating the destruction of high levels of chemokine 
ligands, such as CCL2 (Fra et al., 2003; Hansell et al., 2006; Mantovani et al., 
2006; Graham, 2009). However, this feature is not restricted entirely to atypical 
chemokine receptors, as “classical” chemokine receptors possessing the DRYLAIV 
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sequence have also been reported to scavenge ligands (Hansell et al., 2006). 
Indeed, unchallenged mice lacking single “classical” chemokine receptors, such 
as CCR2 or CXCR2, have elevated levels of the ligands for these receptors, a 
phenomenon that is not seen in resting D6 deficient mice (Cardona et al., 2008). 
A more detailed discussion of D6 biology in vivo is included in section 1.6.2. 
Atypical Chemokine Receptor Chemokine Ligands 
D6 
CCL2, CCL3, hCCL3L1, CCL4, hCCL4L1, CCL5, 
hCCL7, hCCL8, CCL11, mCCL12, hCCL13, hCCL14, 
CCL17, CCL22, hCCL23, CCL24 
DARC 
hCCL2, hCCL5, hCCL7, hCCL11, hCCL13, hCCL14, 
hCCL17, hCXCL1, hCXCL2, hCXCL5, hCXCL6, 
hCXCL8, hCXCL11 
CXCR7 CXCL11, CXCL12 
CCX-CKR CCL19, CCL21, CCL25, hCXCL13 
mCCRL2 (hCRAM) CCL19, CCL5 
Table 1-2: Atypical chemokine receptors and their ligands. 
Chemokines preceded with h indicates that this chemokine binds to the receptor in humans, but not 
mice, whereas the prefix m designates chemokines that bind to the receptor in mice, but not 
humans. 
1.4 Homeostatic versus inflammatory chemokines, and 
their roles in the immune system 
In addition to grouping chemokines based on the arrangement of their conserved 
cysteine residues, chemokines can be broadly divided into two functional groups, 
homeostatic or inflammatory chemokines. Homeostatic chemokines are 
constitutively expressed, i.e. continuously produced, whereas expression of 
inflammatory chemokines is induced principally during times of infection or 
injury. Homeostatic chemokines include CCL19, CCL21, CXCL12 and CXCL13 and 
have a fundamental role in the organisation and maintenance of secondary 
lymphoid organs. CCL2, CCL3, CCL5 and CXCL1 are examples of inflammatory 
chemokines, which mediate activation and recruitment of effector cells to sites 
of infection and injury (Murphy et al., 2000; Le et al., 2004; Rot and von 
Andrian, 2004; Allen et al., 2007). The division of chemokines as constitutive 
homeostatic or inducible inflammatory has become less clear and some 
homeostatic chemokines, such as CCL21 are also inducible at peripheral sites 
(Serra et al., 2004). Furthermore, some inflammatory chemokines now clearly 
have homeostatic and developmental roles. CCR2 is required for Ly6Chi monocyte 
mobilisation from the BM both during homeostasis and following infection of the 
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host with Listeria monocytogenes (Serbina and Pamer, 2006). CCR2 has also been 
described to play a role in balancing bone mass, as animals deficient in CCR2 
have an increase in their bone mass. The increase in bone mass is associated 
with alterations in the development and bone resorptive potential of osteoclasts 
(Binder et al., 2009). Furthermore, CXCR2 has been reported to control 
neutrophil emigration from the BM during acute inflammation, but also controls 
the positioning and proliferation of oligodendrocyte progenitor cells in the 
developing spinal cord (Veenstra and Ransohoff, 2012). Nonetheless, the 
homeostatic/inflammatory designation is still a useful way of characterising 
chemokines and summarising their functional significance. 
1.4.1 Homeostatic chemokines 
Homeostatic chemokines regulate the development of primary and secondary 
lymphoid organs during embryogenesis. CXCL12 is considered to be the 
primordial chemokine (i.e. the first chemokine to evolve), as during 
embryogenesis it is involved in the organisation of the primary lymphoid organ, 
the BM. It is constitutively produced by BM stroma, and, through its interaction 
with its receptor CXCR4, it triggers B cell progenitor proliferation (D'Apuzzo et 
al., 1997) and directs haematopoietic precursors to the BM during embryogenesis 
(Aiuti et al., 1997). In the absence of CXCL12 or CXCR4, mice die perinatally, 
suffering from defects in B cell lymphopoiesis, myelopoiesis and cerebellar 
development (Ma et al., 1998). CXCL12 and CXCR4 are highly conserved during 
evolution, indicative of critical functions maintained in all organisms. For 
example, migration of primordial germ cells in zebrafish is CXCR4 dependent, as 
reduced CXCL12 results in a migrational defect (Raz and Reichman-Fried, 2006; 
Boldajipour et al., 2008). Interestingly, the atypical chemokine receptor CXCR7 
is crucial in directing the CXCR4-dependent migration of primordial germ cells. 
CXCR7 removes excess CXCL12 from undesirable locations, thereby aiding the 
generation and maintenance of a gradient of CXCL12. In the absence of CXCR7 
cells still respond to CXCL12, but do not exhibit directional migration 
(Boldajipour et al., 2008; Wang et al., 2011). Likewise in mice, CXCR7 regulates 
CXCR4 protein levels on interneurons by taking up CXCL12. CXCR7 regulates 
CXCL12 levels, and by doing so can regulate the level of responsive CXCR4 on 
interneurons, as excess CXCL12 leads to desensitisation of CXCR4 and its 
degradation (Sánchez-Alcañiz et al., 2011). In the absence of either of these 
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receptors, mice had defects in interneuron positioning (Wang et al., 2011). Most 
mice deficient in CXCR7 die at birth, as CXCR7 deficiency has been associated 
with abnormal cardiac development. Mice with a conditional deletion of CXCR7 
in endothelium presented with a similar phenotype as CXCR7 knock-out (KO) 
mice, illustrating that expression of the atypical chemokine receptor CXCR7 by 
endothelium cells is essential for normal cardiac development (Sierro et al., 
2007). 
Homeostatic chemokines, in particular CCR7 and CCR9, are involved in T cell 
development in the thymus. The thymus is a primary lymphoid organ that is 
surrounded by a capsule, underneath which lies the subcapsular zone, cortex, 
corticomedullary junction and medulla. Haematopoietic stem cell-derived 
precursors arrive in the thymus via blood vessels present at the corticomedullary 
junction (Nitta et al., 2008). Uehara et al. reported that CCR9 was crucial for T 
cell development, as repopulation of the thymus of lethally irradiated Rag mice 
(deficient in T and B cells) was less efficient with BM from CCR9 KO mice than 
WT (Uehara et al., 2002). However, CCR9 deficiency does not result in complete 
inhibition of precursor entry. It is the coordinated action of CCR7 and CCR9 that 
regulates entry of precursors into the thymus. In the absence of both these 
receptors there is a severe reduction in thymic precursors (Uehara et al., 2002; 
Liu et al., 2006; Krueger et al., 2010; Zlotoff et al., 2010). These precursors are 
double negative thymocytes that migrate outwards through the cortex to the 
subcapsular region of the thymus. CCR9, CCR7 and CXCR4 have also been 
reported to play a role in the migration of double negative thymocytes to the 
subcapsular region. CCR9 and CCR7 KO mice have decreased accumulation of 
double negative thymocytes near the subcapsular region (Misslitz et al., 2004; 
Förster et al., 2008; Nitta et al., 2008). During their migration, these cells 
mature into double positive CD4+CD8+ thymocytes and undergo pre-T cell 
receptor (TCR) mediated selection (Nitta et al., 2008; Rodewald, 2008). Self-
peptides are presented via major histocompatibility complex class II (MHCII) on 
thymic epithelial cells and thymic DCs. Cells are selected for survival or deletion 
based on the strength of the interaction between their TCR and the presented 
self-peptide. Weak interactions result in positive selection and cell survival, 
whereas a strong interaction leads to negative selection and deletion of cells by 
apoptosis. Clonal deletion of thymocytes with a strong TCR interaction to self-
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peptide is not the only outcome for thymocytes. Reactive T cells can survive, 
but are rendered anergic i.e. can not be stimulated to react to the self-peptide 
(Hogquist et al., 1994; Palmer, 2003; Nitta et al., 2008). Alternatively, 
thymocytes can be induced to differentiate into regulatory T cells (Tregs). Tregs 
can suppress autoreactivity of cells in the periphery (Workman et al., 2009). The 
autoimmune regulator (AIRE) gene is expressed by thymic epithelial cells in the 
medulla and is involved in the expression of tissue specific self-peptides. Mice 
deficient in AIRE have been shown to develop autoimmunity (Heino et al., 1999; 
Metzger and Anderson, 2011). Furthermore, AIRE regulates the accumulation of 
thymic DCs in the medulla. The migration of thymic DCs into the medulla is XCR1 
dependent and medullary thymic epithelial cells express the chemokine ligand 
XCL1. XCL1 deficient animals are defective in the accumulation of thymic DCs 
and in the generation of Tregs, and as a consequence are more susceptible to 
autoimmunity (Lei et al., 2011). 
Double positive thymocytes that were positively selected, migrate into the 
medulla and undergo further maturation into single positive cells, either CD4+ or 
CD8+ (Förster et al., 2008; Nitta et al., 2008). Maturation of single positive cells 
in the medulla is accompanied by an increase in responsiveness to the CCR7 
ligands, CCL19 and CCL21 expressed by thymic epithelial cells in the medulla. 
Fully mature CD4+ and CD8+ T cells express high levels of CCR7 (Ueno et al., 
2004; Davalos-Misslitz et al., 2007; Förster et al., 2008). The importance of CCR7 
for thymocyte migration in the medulla is demonstrated in CCR7 KO animals and 
mice containing the spontaneous paucity of LN T cells mutation (plt/plt). plt/plt 
mice lack CCL19 and CCL21 in lymphoid organs, but due to the existence of two 
CCL21 genes in mice, CCL21 production in non-lymphoid organs, such as the 
lung, is intact (Luther et al., 2000; Förster et al., 2008). Both CCR7 KO animals 
and plt/plt mice have decreased migration of thymocytes towards to the 
medulla. These mice also fail to negatively select thymocytes possessing TCRs 
reactive to self-peptides (Kwan and Killeen, 2004; Misslitz et al., 2004; Ueno et 
al., 2004; Witt and Robey, 2004; Kurobe et al., 2006), thus CCR7 KO animals 
have been shown to develop spontaneous autoimmunity and have exaggerated 
immune responses (Schneider et al., 2007; Förster et al., 2008). The egress of 
mature single positive thymocytes from the thymus is regulated by sphingosine-
1-phosphate receptor 1 (S1P1), which is upregulated in maturing single positive 
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thymocytes (Pappu et al., 2007; Zachariah and Cyster, 2009). Pappu et al. 
illustrated that targeted ablation of two kinases involved in the generation of 
S1P, the ligand for S1P1 causes significant reduction in thymocyte egress from 
the thymus (Pappu et al., 2007). 
The organisation of secondary lymphoid organs, such as LNs occurs via 
homeostatic chemokines that attract haematopoietic cells, such as lymphoid 
tissue inducer (LTi) cells to the site of future lymphoid organ development 
(Randall et al., 2008). The development of secondary lymphoid organs, such as 
LNs occurs through an interaction of a cell surface heterotrimer of lymphotoxin-
α1β2 (LTα1β2) positive LTi and lymphoid tissue initiator (LTin) cells with the 
LTα1β2 receptor (LTβR) positive lymphoid tissue organiser (LTo) cells (Ohl et al., 
2003a; Mebius and Kraal, 2005; Randall et al., 2008). The ligation of LTβR 
triggers the differentiation of LTo cells that form a stromal cell matrix that 
produces CCL19, CCL21 and CXCL13 and express cell adhesion molecules VCAM-1 
and ICAM-1. LTi cells express the integrin receptors for these cell adhesion 
molecules. These chemokines promote recruitment and clustering of LTi cells 
and the recruitment of mature lymphocytes to the developing lymphoid organ. In 
addition, homeostatic chemokines trigger expression of LTα1β2 on the surface of 
LTi cells and mature lymphocytes, thereby creating a positive feedback loop in 
which engagement of LTβR triggers release of homeostatic chemokines that 
recruit further LTα1β2 expressing cells (Ansel et al., 2000; Ansel and Cyster, 
2001; Cupedo and Mebius, 2003; Luther et al., 2003; Randall et al., 2008). 
The importance of CXCR5 and CCR7 ligands in the development of secondary 
lymphoid organs has been reported using mice lacking one or more of the 
ligands. Reports show that CXCL13 is the dominant chemokine ligand involved, as 
deletion of either CXCL13 or its receptor CXCR5 disrupts the formation of most 
peripheral LNs (PLNs) and Peyers’s patches (PPs) in intestine. In contrast, CCR7 
KO mice possess the majority of their PLNs (Ansel and Cyster, 2001; Ohl et al., 
2003b). LTi cells express both CXCR5 and CCR7, thus the deletion of CCR7 and 
the CXCR5 ligand, CXCL13, leads to a more severe phenotype, suggesting that 
these two receptors have overlapping roles in the development of LNs (Luther et 
al., 2003; Ohl et al., 2003b). Interestingly, mesenteric LNs (MLNs) are retained 
in CCR7/CXCL13 double KO mice, suggesting other chemokine receptors, such as 
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CXCR4 are involved in the recruitment of LTi cells during the development of 
MLNs (Luther et al., 2003). Furthermore, although still present, spleens in CCR7 
KO, CXCL13 KO and CCR7/CXCL13 double KO mice are disorganised, lacking 
clearly defined red and white pulp areas (Ohl et al., 2003a; 2003b). 
1.4.1.1 Structure and function of LNs 
In addition to regulating the development of secondary lymphoid organs, 
homeostatic chemokines also support the maintenance of these highly organised 
and structured lymphoid tissues by controlling the migration of lymphocytes and 
DCs within the distinct areas of the organs (Rossi and Zlotnik, 2000). 
LNs, as illustrated in Figure 1-4, are segregated into two principal areas: the 
cortex and the medulla. The cortex is further divided into an additional two 
areas, the T cell zone (paracortex) and the B cell zone, which consists of 
follicles and germinal centres. The medulla contains a network of lymphatic 
sinuses, called medullary sinuses which lymph drains into. Lymph enters LNs 
through the afferent lymphatic vessel and is channelled around the edge of LN in 
the subcapsular sinus, a hollow space below the fibrous capsule that surrounds 
the LN. Lymph also moves through trabecular sinuses towards medullary sinuses, 
located in the medulla of the LN (von Andrian and Mempel, 2003). LNs contain a 
fibroblastic reticular cell network, known as the conduit system. Fibroblastic 
reticular cells wrap around collagen fibres, and form channels that deliver lymph 
from the subcapsular sinus to T cell areas and direct to HEVs. The fibroblastic 
reticular cell network also acts as a filter of lymph, only allowing low molecular 
weight molecules, such as chemokines to enter the channels. The filtered lymph 
is transported via the conduit system to the HEVs, where lymph-borne 
chemokine can be transported into the lumen of HEVs and presented to attract 
blood-borne cells (Gretz et al., 2000; von Andrian and Mempel, 2003; 
Roozendaal et al., 2008). Lymph drains into the efferent lymphatic vessels and 
leaves the LN, providing an exit for lymphocytes. The majority of naïve 
lymphocytes enter the paracortex of LNs via HEVs. However, some memory T 
cells gain entry via the afferent lymphatics and the subcapsular sinus (von 
Andrian and Mempel, 2003).
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Figure 1-4: Simplified diagram of LN structure. 
LNs are surrounded by a fibrous capsule underneath which lymph flows in the subcapsular sinus 
and the trabecular sinuses. The trabecular sinuses extend through the cortex towards the medulla, 
where they connect with the medullary sinuses, which drain into the efferent lymphatic vessel. The 
cortex is divided into two sections, the T cell zone, known as paracortex and the B cell area 
consisting of primary follicles and germinal centres. HEVs allow flow of venous blood into the LN, 
delivering blood-circulating lymphocytes to the LN. Also illustrated in dark blue, is an example of 
the flow of filtered lymph from the subcapsular sinus to HEVs via the channels formed by the 
fibroblastic reticular cell network. Adapted from (von Andrian and Mempel, 2003). 
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Entry of the majority of lymphocytes from the blood into LNs is coordinated in a 
manner similar to that depicted in Figure 1-2. The chemokine-induced integrin 
activation for T and B cell migration through HEVs into LN is CCR7 dependent in 
resting LNs (von Andrian and Mempel, 2003; Miyasaka and Tanaka, 2004; Förster 
et al., 2008; Worbs and Förster, 2009). Binding of CCR7 to its ligand mediates 
leukocyte extravasation through the HEV into the paracortical area of the LN, 
where CCR7 ligands are constitutively expressed (von Andrian and Mempel, 2003; 
Miyasaka and Tanaka, 2004; Förster et al., 2008). 
The importance of CCR7 and its ligands in T cell migration has been illustrated 
using animals deficient in one or more of its ligands, or the receptor itself. LNs 
of plt/plt mice are smaller in size than wild-type (WT) animals and have a 
deficit in T cell numbers (Luther et al., 2000; Förster et al., 2008). Luther et al. 
demonstrated that HEVs express CCL21, but not CCL19, suggesting that CCL19 
was not involved in recruitment of leukocytes into LNs from the blood (Luther et 
al., 2000). In accordance with these results, mice specifically deficient in CCL19 
illustrated that CCL21 was sufficient for the organisation of T cell zones (Link et 
al., 2007). In contrast, Baekkevold et al. have reported that CCL19 protein can 
be transported from its site of production by LN stromal cells to the luminal side 
of HEVs and enables efficient T cell homing to LNs (Baekkevold et al., 2001). 
CCL19 also plays a non-redundant role in naïve T cell homeostasis that can not 
be compensated by CCL21 (Link et al., 2007). Naïve T cell homeostasis is highly 
dependent on the access of naïve T cells to LNs, as once in the T cell zone, naïve 
T cells receive survival signals provided by IL-7 produced by the fibroblastic 
reticular cell network. In vitro data also suggest that CCL19 is able to provide a 
survival signal to T cells, whereas CCL21 is not (Link et al., 2007). In addition to 
mediating efficient LN homing of T cells, CCR7 is required for T cell motility 
within LNs. In the absence of CCR7 signalling, either through deletion of CCR7 or 
its ligands, intranodal motility of CD4+ T cells is reduced. The transfer of WT 
CD4+ T cells and systemic administration of CCL21 restored motility of T cells in 
LNs of plt/plt mice (Worbs et al., 2007). 
The LNs of CCR7 KO animals are also deficient in T cells however, the B cell 
compartment of LNs in these mice is relatively unaffected by the absence of 
CCR7 (Förster et al., 1999; von Andrian and Mempel, 2003; Worbs et al., 2007). 
This indicates that although B cells can use CCR7 to migrate into LNs they are 
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not dependent on it, as it has been shown that CXCR4 can contribute to B cell LN 
homing. Okada et al. reported that transfer of CXCR4 deficient B cells into 
plt/plt mice resulted in reduced B cell homing to LNs. In contrast, although B 
cell homing to PPs was reduced in the absence of CXCR4 and CCR7 signalling it 
was not as severe as in the LNs. However, B cells deficient in CXCR5 also had a 
deficiency in homing to PPs, which was further reduced by the absence of CXCR4 
and CCR7 signalling. Therefore, B cell entry into PPs is dependent on CXCR4, 
CCR7 and CXCR5 (Okada et al., 2002). 
Entry of B cells into B cell follicles of LNs is mediated by CXCR5. CXCR5 ligand 
CXCL13 is expressed at high levels by stromal cells within the B cell follicles, 
named follicular DCs. Following activation, B cells downregulate CXCR5 and 
upregulate CCR7, which mediates their migration towards the T cell area. Also, 
a distinct T cell lineage, the follicular helper T cells, upon activation transiently 
downregulate CCR7 and upregulate CXCR5, mediating their mobilisation towards 
the B cell follicle (Fazilleau et al., 2009). B cells present Ag on MHCII to 
follicular helper T cells, which mediate Ag specific activation of B cells, driving 
their proliferation, affinity maturation and antibody class switching of 
plasmablasts (Cyster, 1999; von Andrian and Mempel, 2003; Worbs et al., 2007; 
Förster et al., 2008). Furthermore, B cells are activated by intact Ag presented 
to them by follicular DCs (von Andrian and Mempel, 2003). 
For all these processes to occur, naïve T cells need to be presented with an Ag 
peptide specific for their TCR. Ag presenting cells (APCs), in particular DCs, 
process and present Ag to T cells, mediating the initiation of the adaptive 
immune response, which is crucial in the defence against foreign pathogens (von 
Andrian and Mempel, 2003). Following activation of CD4+ T cells by engagement 
of their TCR with their specific Ag peptide presented in the context of MHCII, 
CD4+ T cells proliferate and differentiate into effector T helper (Th) cells, Th1, 
Th2, Th17, follicular Th cells or Tregs (Zhu et al., 2010). The differentiation of T 
cells into effector Th cells is accompanied by a change in chemokine receptor 
expression, which can facilitate their homing to inflamed sites. Although 
chemokine receptor expression can not fully be coordinated with an individual 
lineage, Th1 cells have been reported to have high expression of CXCR3 and 
CCR5. Th2 cells have high expression of CCR3, CCR4, and CCR8 and human Th17 
cells have high expression of CCR6 and CCR4 (Zhu and Paul, 2008). A proportion 
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of effector T cells also contributes to immunological memory. Memory T cells 
that persist after the resolution of inflammation or infection can broadly be 
divided into effector memory T cells or central memory T cells. Central memory 
T cells are CCR7+, whereas effector memory T cells are tissue resident, 
therefore express chemokine receptors other than CCR7 (Sallusto et al., 2004; 
Lanzavecchia and Sallusto, 2005). 
Migration of activated effector T cells to peripheral sites can be associated with 
the expression of specific receptors that allow constitutive homing to specific 
inflamed tissues. Upregulation of these receptors is related to the LN in which 
the T cells are activated. CD4+ T cells activated in MLNs upregulate the gut 
homing integrin α4β7 and the chemokine receptor CCR9, and are therefore 
highly responsive to CCL25, a chemokine ligand expressed by the epithelial cells 
of the small intestine (Campbell and Butcher, 2002). Upregulation of CCR9 and 
α4β7 is induced by DCs in the gut associated lymphoid tissue (GALT), and 
specifically the vitamin A metabolite retinoic acid, produced by the GALT DCs, 
enhances expression of the two gut homing molecules. The production of 
retinoic acid from vitamin A is reported to be crucial to imprint gut homing 
specificity, as vitamin A deficiency in mice results in the depletion of T cells 
from gut lamina propria (Iwata et al., 2004). In contrast, the biologically active 
form of vitamin D3 suppresses expression of the gut homing receptors, CCR9 and 
α4β7 by activated T cells, and induces expression of CCR10. CCR10 facilitates 
the recruitment of activated T cells to the skin in response to CCL27 secreted by 
keratinocytes (Sigmundsdottir et al., 2007). Furthermore, naïve CD4+ T cells 
activated in the subcutaneous LNs upregulate CCR4 and CCR10 and home to skin. 
In a model of delayed type hypersensitivity, T cells were still efficient in their 
migration to inflamed skin in the absence or following the blockage of one of 
these receptors. Inhibition of T cell migration to the skin was only achieved in 
mice with no functional CCR4 or CCR10 (Reiss et al., 2001).  
Ag reaches LNs by two routes. The first is by lymphatic drainage of peripheral 
tissues, which carries Ag to LNs where it can be taken up by an immature DC for 
Ag presentation. Alternatively, Ag is acquired and processed in peripheral tissues 
by immature DCs, the processed Ag is then carried to the draining LN by DCs. 
Entry of DCs into lymphatics from the tissues is CCR7 dependent. CCL21 is 
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produced by the lymphatic endothelial cells in peripheral tissues and coordinates 
DC migration into the lymphatics (Ohl et al., 2004). Delivery of DCs to the LN is 
also CCR7 dependent. DCs enter into the LN parenchyma by transmigrating 
though the floor of the subcapsular sinus in a CCR7 dependent manner. DCs 
deficient in CCR7 are retained in the subcapsular sinus (Braun et al., 2011). DC 
migration to the T cell zones is also CCR7 dependent, and as mentioned earlier is 
thought to be due to a combined effect of immobilised CCL21 and soluble 
CCL19/CCL21 (Schumann et al., 2010). Within the T cell zones, DCs can interact 
with naïve T cells. The interaction between incoming T cells and DCs bearing the 
Ag peptide specific for its TCR is impeded by competition by other T cells with 
irrelevant TCR specificity. To enhance the probability of the interaction 
occurring, naïve T cells within the paracortex undergo rapid migration in random 
directions (von Andrian and Mempel, 2003; Worbs et al., 2007; Förster et al., 
2008; Worbs and Förster, 2009). T cells that do not encounter their specific Ag 
peptide leave the LN via the efferent lymphatic. Exit of T and B cells from LNs is 
regulated by S1P and its receptor S1P1. S1P is expressed at higher levels in the 
blood and lymph than in the LN (Schwab and Cyster, 2007). The high levels of 
S1P in the blood means that S1P1 is desensitised, facilitating lymphocyte 
extravasation into tissues with low S1P levels, such as LNs. Within S1P low LNs, 
S1P1 is gradually resensitised and eventually is sufficiently active to drive 
departure of lymphocytes into the lymph. Activated T cells upregulate CD69, 
which downregulates S1P1 expression, stopping responsiveness to S1P and cells 
are retained in the LN. A S1P-degrading enzyme, S1P lyase, maintains the low 
levels of S1P within LNs, which upon inhibition leads to an increase in S1P levels 
in LNs and lymphocyte egress from the LN is blocked (Schwab et al., 2005). 
Lymphocyte egress can also be blocked by treatment with the S1P1 agonist, 
FTY720. In vitro studies have shown that binding of FTY720 to S1P1 inactivates 
it, by triggering its internalisation and subsequent degradation of the receptor 
(Schwab and Cyster, 2007). 
The role of DCs within the immune system shall be discussed in depth later in 
this Introduction in section 1.5. 
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1.4.1.2 Structure and function of the spleen 
The spleen, as illustrated in Figure 1-5 is divided into two main anatomically 
discrete areas, the red pulp and the white pulp, each with their own specific 
functions (Mebius and Kraal, 2005; Cesta, 2006). The red pulp is enriched with 
venous sinuses and macrophages, both of which facilitate the red pulp’s role as a 
blood filter and as a site for the removal of old erythrocytes. Macrophages 
destroy old or damaged erythrocytes, recycle released iron, and are also 
involved in the defence against blood-borne bacteria. After encountering 
bacteria, macrophages release molecules that inhibit iron uptake by the 
bacteria, thereby limiting their growth (Mebius and Kraal, 2005). 
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Figure 1-5: Simplified diagram of the structure of the spleen. 
The spleen is divided into the red pulp and the white pulp, all of which is surrounded by a fibrous 
capsule. The white pulp is the lymphoid region of the spleen, which consists of the T cell containing 
area, the periarteriolar lymphoid sheath (PALS) and B cell follicles. The white pulp is surrounded by 
the marginal zone, which is separated from the white pulp by the marginal sinus. Adapted from 
(Mebius and Kraal, 2005). 
Capsule 
Red pulp 
White pulp 
Splenic vein 
Splenic artery 
B 
B 
B 
PALS (T) 
Sinus-lining cells 
Marginal sinus 
Marginal  
Zone 
Chapter 1  48 
 
The white pulp is the lymphoid region of the spleen, and as such is of principal 
relevance to thesis. It has a similar structure in many ways to LNs. However, the 
main differences between the two secondary lymphoid organs lie in how 
lymphocytes and Ag enter each organ, and the presence of a region called the 
marginal zone (MZ). Ag delivery to LNs occurs via the lymphatics, whereas the 
blood carries Ag to the spleen where it is delivered through the MZ to the white 
pulp (Ohl et al., 2003a; Mebius and Kraal, 2005). The MZ is a specialised feature 
of the spleen, it surrounds the white pulp, but is separated from the white pulp 
by cell lined space known as the marginal sinus. The white pulp surrounds 
arterial vessels that enter the spleen and is composed of two areas, the T cell- 
containing periarteriolar lymphoid sheath (PALS) and the B cell follicles (Ohl et 
al., 2003a; Mebius and Kraal, 2005; Cesta, 2006; Britschgi et al., 2008). 
Lymphocyte entry into the white pulp via the MZ is integrin and chemokine- 
dependent. This process is thought to be mediated by a method similar to the 
transmigration of cells from the blood into underlying tissues, as depicted in 
Figure 1-2. A deficiency in CXCR5 or CCR7 reduces accumulation of B and T cells 
in the white pulp, respectively (Ohl et al., 2003a; Cyster, 2005; Mebius and 
Kraal, 2005). 
There are also MZ bridging channels, narrow channels that extend between the 
red pulp and the white pulp, and into the PALS. They provide a bridge through 
the MZ and assist in the migration of cells from the red pulp into the white pulp 
(Mitchell, 1973; Mebius and Kraal, 2005). The MZ bridging channels are rich in 
fibroblastic reticular cells, which form a network that guides T cell migration 
into the PALS. Bajenoff et al. proposed that this migration is likely to be CCR7 
dependent, as, similar to LN fibroblastic reticular cells, splenic fibroblastic 
reticular cells also produce CCL21. Furthermore, the introduction of WT T cells 
into WT and plt/plt mice illustrated that CCR7 ligands were required for T cell 
entry into PALS (Bajénoff et al., 2008). Blood-borne DCs enter the spleen via the 
MZ and the migration of DCs to the T cell zones of the spleen is also CCR7 
dependent, as plt/plt mice have decreased numbers of DCs in their splenic T 
cell zones (Gunn et al., 1999). However, a population of CXCR5+ DCs that are 
located near B cell follicles have also been described, which are dependent on 
CXCL13 for their presence, as very few CXCR5+ DCs are detected in the spleen of 
CXCL13 deficient mice (Yu et al., 2002). Interestingly, León et al. have shown 
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that these CXCR5+ DCs are able to drive development of Th2 cells outside of the 
T cell zone in response to the intestinal nematode, Heligmosomoides polygyrus 
(León et al., 2012). 
The spleen is also a key site for B cell maturation in mice. “Transitional” B cells 
from the BM enter the spleen and mature into either follicular B cells or MZ-B 
cells. Follicular B cells are the “classical” B cells that traffic around the body. 
MZ-B cells are long-lived resident cells of the MZ (Pillai et al., 2005; Pillai and 
Cariappa, 2009). Most B cells do not possess the appropriate adhesive properties 
that permit their retention in the MZ, but MZ-B cells express cannabinoid 
receptor 2, which positions and retains MZ-B cells in the MZ. Mice deficient in 
cannabinoid receptor 2 have decreased MZ-B cells within the MZ (Muppidi et al., 
2011). Their unique location within the MZ allows MZ-B cells to respond rapidly 
to blood-borne pathogens, producing antibodies and participating in the early 
response against blood-borne Ag. These innate-like cells provide a bridge 
between the innate and adaptive immune system (Lopes-Carvalho and Kearney, 
2004; Pillai et al., 2005; Pillai and Cariappa, 2009). MZ-B cells are limited to the 
MZ of the spleen, however other innate-like B cells, known as B1 B cells can be 
identified in body cavities (Martin and Kearney, 2000). 
Migration of follicular B cells to the B cell follicles is CXCR5 dependent, as naïve 
B cells respond to CXCL13 expression by stromal cells in B cell follicles. In the 
absence of CXCR5, mice have a defect in follicle and germinal centre formation 
(Förster et al., 1996). Within the B cell follicle, B cells are activated by binding 
of Ag to their Ag-specific B cell receptor. Similar to the LN, activated B cells 
upregulate CCR7 and migrate towards the edge of the B cell follicle towards the 
PALS. A third GPCR, EBI2 is involved in B cell migration to the outer areas of 
follicles and the MZ bridging channel, as in its absence EBI2 deficient B cells 
accumulate in the centre of B cell follicles and decreased numbers of B cells are 
found at the periphery of the follicle (Gatto et al., 2011). T cells activated by 
DCs presenting the Ag peptide specific for their TCR, downregulate CCR7 and 
upregulate CXCR5, which facilitates their migration to the edge of B cell 
follicles. Activated CD4+ Th cells stimulate isotype switching of B cells and their 
differentiation into Ag specific plasmablasts (Ohl et al., 2003a; Mebius and 
Kraal, 2005; Cesta, 2006). Plasmablasts downregulate both CXCR5 and CCR7, and 
upregulate CXCR4, leading to their migration into the CXCL12 expressing red 
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pulp. The presence of plasmablasts and the later differentiated plasma cells in 
the red pulp facilitates the rapid entry of antibodies into the bloodstream 
(Hargreaves et al., 2001; MacLennan et al., 2003; Mebius and Kraal, 2005). 
Finally, similar to the lymphocyte egress from LNs, S1P and its receptor S1P1 
regulate T cell emigration from the spleen into the bloodstream (Mebius and 
Kraal, 2005; Schwab and Cyster, 2007). 
1.4.2 Inflammatory chemokines and the innate immune system 
The adaptive immune response, although not clarified as such has already been 
discussed, as primarily it is an Ag specific response by T and B cells. The 
activation of T and B cells occurs within the secondary lymphoid organs, and 
their migration to, and within, these specialised structures is regulated by 
homeostatic chemokines. However, pathogen invasion usually occurs at 
peripheral sites away from these specialised lymphoid structures. Therefore, 
cells of the innate immune system act as an “alarm” system, alerting 
lymphocytes in secondary lymphoid organs to the presence of pathogen in the 
periphery. Pathogen invasion can stimulate the production of inflammatory 
chemokines by tissue resident DCs, macrophages, parenchymal and stromal 
cells. These inflammatory chemokines are typically ligands of the inflammatory 
chemokine receptors, CCR1, CCR3, CCR5, CXCR2, CXCR3 and CCR2 (Rot and von 
Andrian, 2004). CCR2 forms the main focus of this PhD and will be discussed in 
greater depth below. Inflammatory chemokines recruit cells of the innate 
immune system, such as DCs, monocytes, neutrophils and natural killer (NK) cells 
to the site of infection. The innate immune system does not recognise specific 
antigenic peptides like the adaptive immune system, but it recognises molecules 
on the surface of invading organisms called PAMPs. Innate effector cells 
recognise PAMPs and host-derived damage-associated molecular patterns by 
pattern recognition receptors (PRRs) (Rot and von Andrian, 2004; Sabroe et al., 
2008). Toll-like receptors (TLRs) are a family of PRRs that each recognise a 
specific PAMP or group of PAMPs. For example, TLR4 recognises, amongst other 
things, lipopolysaccharide (LPS) present in the cell wall of gram negative 
bacteria; TLR7 recognises single stranded RNA, a common feature of viruses, 
plus synthetic molecules such as imidazoquinolines; and TLR9 recognises 
bacterial unmethylated CpG oligodeoxynucleotide DNA (Edwards et al., 2003; 
Takeda et al., 2003). The innate immune system provides a rapid non-specific 
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response against the pathogen, and the subsequent adaptive immune response 
allows a targeted Ag specific response (Rot and von Andrian, 2004). 
One of the most important links between the innate and adaptive immune 
system are DCs, and the role they play in the immune system is now discussed. 
These cells form a focus of my studies described in Chapter 5. 
1.5 Dendritic cells and their role in the immune system 
Up to this point, I have presented an oversimplified role of DCs within the 
immune system, stating only their importance in driving T cell activation. 
However, the DC system and its functions are complex, consisting of many DC 
populations defined by differences in their function, mode of activation, and 
location. The first major division that can be made is between conventional DCs 
(cDCs) and plasmacytoid DCs (pDCs). cDCs, as their name implies, perform all 
tasks commonly assigned to DCs, such as sampling Ag in tissues, and processing 
and presenting Ag peptide to naïve T cells in secondary lymphoid organs. The 
context of this presentation determines the outcome for T cells, i.e. whether 
they become activated, tolerised or anergic (Ardavín, 2003; Shortman and Naik, 
2007; Tan and O'Neill, 2007). Activated pDCs are also thought to have Ag 
presenting function, but they are also professional type 1 interferon (IFN) 
producing cells (Asselin-Paturel et al., 2001; Tan and O'Neill, 2007). The 
functional properties of cDCs and pDCs will be discussed in greater depth below, 
but regardless of differences in their classification and roles, the development of 
both cDCs and pDCs is from common progenitors.  
As splenic cDCs and pDCs form a key focus of my thesis, I will next outline in 
detail what is known about the splenic DC system, including their development, 
subsets and functions. 
1.5.1 Development of dendritic cells 
cDCs were thought to be entirely of myeloid origin. However as Figure 1-6 
depicts, cDCs may also be of lymphoid origin (Ardavín et al., 1993; Ardavín, 
2003). Initially the distinction between cDCs of lymphoid and myeloid origin was 
thought to be in the expression of CD8α: lymphoid cDCs being CD8α+ and 
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myeloid cDCs CD8α-. However, although the resting splenic cDC compartment 
does indeed consist of CD8α+ and CD8α- cDCs, they can both be of lymphoid and 
myeloid origin (Vremec and Shortman, 1997; Martín et al., 2000; Manz et al., 
2001; Ardavín, 2003). Both cDCs and pDCs develop from haematopoietic stem 
cells that give rise to a multipotent progenitor, which in turn can give rise to 
both the common lymphoid progenitor (CLP) and common myeloid progenitor 
(CMP) (Figure 1-6). The CMP gives rise to the macrophage DC precursors (MDP) 
via the granulocyte–monocyte progenitor (GMP). Monocytes are progeny of MDPs, 
as are the common DC progenitors (CDP), which generate cDCs. (Naik et al., 
2007; Wu and Liu, 2007; Sathe and Shortman, 2008; Liu et al., 2009). CLPs are 
also thought to form cDCs, however most data indicating that CLPs are also a 
parent population of cDCs is produced in vitro (Ardavín et al., 1993; Traver et 
al., 2000; Manz et al., 2001; Wu et al., 2001; Shortman and Naik, 2007). Thus, it 
is thought that most splenic cDCs are derived from CMPs (Traver et al., 2000; Wu 
et al., 2001; Liu and Nussenzweig, 2010). 
There are few fully differentiated cDCs within the BM, as cDCs only complete 
their differentiation in the periphery. Thus, in the steady-state spleen, cDC 
precursors, known as pre-cDCs, can be found, that can give rise to both CD8α+ 
and CD8α- cDCs, but not pDCs (Naik et al., 2006; 2007; Shortman and Naik, 2007; 
Liu et al., 2009). Naik et al. conducted a detailed profiling of the surface 
phenotype of pre-cDCs that distinguished them from monocytes and fully 
developed cDCs, as they were found to be CD11cintMHCII-CD8α-Ly6C+CD11blo (Naik 
et al., 2006). Pre-cDCs are committed to CD8α+ or CD8α- cDC lineages via 
intermediary precursors that are CD24hi or CD24lo, respectively (Naik et al., 
2006; 2007; Shortman and Naik, 2007; Liu et al., 2009). These immature CD8α+ 
or CD8α- cDCs are capable of some proliferation in homeostasis (Liu et al., 2007; 
Shortman and Naik, 2007). However, it is not the proliferation of these cells that 
is responsible for maintaining cDC numbers in the spleen. It is in fact, the pre-
cDCs that achieve this feat (Kamath et al., 2000; Shortman and Naik, 2007). 
Splenic pre-cDCs are also responsive to the growth factor, fms-like tyrosine 
kinase-3 ligand (Flt3L), and in response to a decrease in splenic cDC numbers 
there is an increase in Flt3L in the blood, which triggers an increase in both the 
frequency and differentiation of pre-cDCs restoring splenic cDC populations 
(Hochweller et al., 2009). The Flt3L receptor, Flt3, is vital for DC development, 
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as Flt3 KO animals are deficient in pDCs and the majority of cDCs (McKenna et 
al., 2000). Both CLPs and CMPs are responsive to Flt3L as a proportion of each 
population expresses Flt3. Furthermore, Flt3L treatment of mice results in a 
dramatic expansion of cDCs and pDCs in secondary lymphoid organs (Mach et al., 
2000; D'Amico and Wu, 2003; Karsunky et al., 2003; Naik et al., 2005b; 2007). 
The developmental stages of pDCs are less well defined, but similar to cDCs they 
can be of both myeloid and lymphoid origin, with both CLPs and CMPs 
contributing to their development (Förster et al., 1999; von Andrian and 
Mempel, 2003; D'Amico and Wu, 2003; Worbs et al., 2007; Reizis, 2010). 
Traditionally, pDCs are thought to be fully differentiated before leaving the BM, 
so pDCs can be found in low numbers in the BM, blood and spleen (Omatsu et al., 
2005; Naik et al., 2005a). However, recent research suggests that there is also 
an intermediary precursor of pDCs that mainly exists in the BM, but is also found 
in low numbers in secondary lymphoid organs (Rossi and Zlotnik, 2000; Schlitzer 
et al., 2011; 2012). This precursor is proposed to be CCR9-, whereas fully 
differentiated pDCs are CCR9+. The CCR9- precursors, like pre-cDCs, are derived 
from CDPs, but are different from pre-cDCs as they express pDC markers, such as 
pDC Ag 1 (PDCA1) and SiglecH (Schlitzer et al., 2011; 2012). CCR9- precursors 
preferentially give rise to fully differentiated CCR9+ pDCs in the BM. CCR9- pDCs 
have a higher proliferative capacity than CCR9+ pDCs. In addition to their 
capacity to generate fully differentiated pDCs in the BM, CCR9- precursors 
present in the periphery can also give rise to cDCs, particularly the CD11b+CD8α- 
cDC population and to a lesser extent the CD8α+CD11b- cDC population (Schlitzer 
et al., 2011; 2012). This deviation from the pDC lineage is accompanied by the 
downregulation of transcription factors required for pDC differentiation, such as 
E2-2 and the E2-2 regulated transcription factors IRF8 and SpiB. Furthermore, 
there is a parallel upregulation of transcription factors, such as ID2 and PU.1 
which control cDC development (Cisse et al., 2008; Ghosh et al., 2010; Reizis et 
al., 2011a; Schlitzer et al., 2011; 2012). 
All of these populations are present in the steady-state spleen and it is only 
following injury or infection that pDCs, and cDCs, both CD8α+ and CD8α- cDCs 
are fully activated (Ardavín, 2003; Shortman and Naik, 2007). Furthermore, in a 
steady-state spleen Ly6Chi monocytes do not contribute to the splenic cDC 
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populations. However, in a challenged spleen or other tissue, Ly6Chi monocytes 
can differentiate into inflammatory DCs (Tam and Wick, 2004; Naik et al., 2006; 
Shortman and Naik, 2007). For example, following infection with Listeria 
monocytogenes, Ly6Chi monocytes differentiate into the inflammatory tumour 
necrosis factor alpha (TNFα) and inducible nitric oxide synthase (iNOS) producing 
DCs (TipDCs), identified as Ly6C+CD11b+CD11c+Mac3+ cells (Serbina and Pamer, 
2006). 
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Figure 1-6: Pathways of splenic DC development. 
In the BM a multipotent precursor cell can give rise to both the common lymphoid progenitor (CLP) 
and the common myeloid progenitor (CMP). CMPs differentiate to form the granulocyte-myeloid 
progenitor (GMP), from which the macrophage DC precursors (MDP) are formed. Following the 
downregulation of c-kit, MDPs become common DC progenitors (CDP). The CLP and the CDP 
generate fully differentiated pDCs that migrate into the blood and spleen. The CDP can also 
differentiate into a CCR9- DC precursor that in the BM can form fully differentiated pDCs. 
Alternatively, in the periphery CCR9- DC precursors generate CD11b+ and CD8α+ cDCs. Following 
infection or injury pDCs become activated. MDPs also differentiate into monocytes, which can give 
rise to inflammatory DCs, but not in the steady-state spleen, only following an inflammatory insult. 
In contrast to pDCs, cDCs are not fully differentiated on exit of BM, and a pre-cDC exists in the 
spleen. Pre-cDC population can be divided based on expression of CD24. CD24hi and CD24lo pre-
cDCs generate immature CD8α+ and CD11b+ cDCs, respectively. Following infection or injury the 
immature CD8α+ and CD11b+ cDCs become activated. Dashed lines indicate relationships that are 
still a source of controversy. Adapted from (Shortman and Naik, 2007; Schlitzer et al., 2012). 
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1.5.2 cDCs 
cDCs are resident cells that patrol peripheral tissue, and each tissue has specific 
cDC populations. Most cDCs in steady-state animals are immature, possessing a 
high capacity to sample their environment, internalise Ag and process it for 
presentation on MHC (Alvarez et al., 2008; Miloud et al., 2010). Immature cDCs 
express inflammatory chemokine receptors, such as CCR1, CCR2, CCR5 and 
CXCR1 (Sallusto et al., 1998; Sozzani et al., 1999; 2000). Upon an inflammatory 
insult, injury or infection, immature cDCs are recruited to the site by the 
recognition of inflammatory chemokine ligands for these receptors. Activation of 
TLRs by exposure to microbial stimuli or proinflammatory cytokines, such as IL-
1β and TNFα, results in maturation of cDCs (Allavena et al., 2000; Alvarez et al., 
2008). cDC maturation is accompanied by a decrease in their capacity to 
internalise Ag, and a parallel increase in their ability to present Ag. Mature cDCs 
upregulate production of the Ag peptide presentation complex, MHCII, whilst 
immature cDCs have low surface levels of MHCII (Cella et al., 1997; Sallusto and 
Lanzavecchia, 2002; Wilson et al., 2003). Immature splenic cDCs have a rapid 
turnover rate and their activation is associated with increased turnover and a 
shortened lifespan. This might act to limit the duration of Ag presentation and, 
as a consequence, the T cell mediated immune responses to that Ag (Kamath et 
al., 2000; 2002). Furthermore, cDC maturation results in a switch in the 
chemokine expression profile, with downregulation of inflammatory chemokine 
receptors and upregulation of CCR7 (Dieu et al., 1998; Sallusto et al., 1998; 
Sozzani et al., 1999; 2000; Alvarez et al., 2008). CCR7 leads to recruitment of 
mature/maturing cDCs to the draining LN. DCs enter LNs through the afferent 
lymphatics and accumulate in the subcapsular sinus (Weinlich et al., 1998; von 
Andrian and Mempel, 2003; Ohl et al., 2004; Alvarez et al., 2008; Wendland et 
al., 2011). As discussed above (section 1.4.1.1), the emigration of cDCs from the 
sinus to the T cell zones is CCR7 dependent, and plt/plt animals have a deficit 
of cDCs in the T cell zones with cDCs trapped in the subcapsular sinus (Gunn et 
al., 1999; Alvarez et al., 2008; Braun et al., 2011). 
The CCR7 dependent migration of cDCs from the periphery into LNs is an 
essential step in the development of peripheral tolerance (Worbs et al., 2006). 
Negative selection of self-reactive T cells in the thymus results in their deletion, 
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however not all cells specific for self-Ag are deleted and some escape into the 
periphery. cDCs are continuously exposed to self-Ag, such as apoptotic cells, 
which they can carry to LNs, and process and present to T cells. The activation 
of T cells specific for self-Ag could have deleterious effects, driving 
development of autoimmune diseases. Thus, cDCs are the driving force of 
peripheral tolerance, minimising the action of T cells specific for self-Ag by 
rendering them anergic or stimulating their differentiation into Tregs, thereby 
maintaining tolerance against self-Ags (Banchereau and Steinman, 1998; de St 
Groth, 2001; Lutz and Schuler, 2002; Steinman et al., 2003; Ohl et al., 2004). 
Nakano et al. have reported that not all cDCs are dependent on CCR7 for their 
migration to LNs, as although there was a significant reduction in the number of 
all cDC subsets in a resting LN of a plt/plt mouse there was no effect on the 
number inflammatory DCs, identified as CD11c+CD11b+Gr1+ (Nakano et al., 
2009). They reported that viral infection resulted in the accumulation of 
inflammatory DCs in LNs as a consequence of Ly6Chi monocyte migration directly 
from the blood to the LN (Nakano et al., 2009). The extravasation of Ly6Chi 
monocytes from the BM is highly CCR2 dependent (Serbina and Pamer, 2006) and 
consistent with these observations Nakano et al. observed a decrease in LN 
inflammatory DC accumulation in a CCR2 KO animal (Nakano et al., 2009). A 
similar decrease was not observed in CCL2 KO mice, indicating that CCL2 is not 
required for inflammatory DC accumulation (Nakano et al., 2009). Nakano et al. 
proposed that CCL8 is induced and that it is responsible for CCR2 dependent 
accumulation of inflammatory DCs, not CCL2 (Nakano et al., 2009). However, it 
is now known that CCL8 is not a CCR2 ligand in mice, but binds to CCR8 (Islam et 
al., 2011). A deficiency of either CCR2, or its ligands, CCL2 or CCL7, leads to a 
reduction in peripheral Ly6Chi monocyte numbers. However, retention of Ly6Chi 
monocytes in the BM was less pronounced in CCL2 KO mice, and low numbers of 
Ly6Chi monocytes are found in the periphery, which might explain the presence 
of inflammatory DCs in these animals (Tsou et al., 2007). Therefore, recruitment 
of inflammatory DCs to LNs is likely to be CCR2 independent, and the decrease 
in LN accumulation of inflammatory DCs might be due to decreased Ly6Chi 
monocytes in the blood of CCR2 deficient mice. 
cDCs within the T cell zones produce CCR7 ligands, which induce extension of 
dendrites on the mature cDC (Cyster, 1999; Yanagawa, 2002; Mebius and Kraal, 
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2005). Mature activated cDCs also produce thromboxane A2 that enhances 
random motility of T cells (von Andrian and Mempel, 2003; Kabashima et al., 
2003). Both of these processes increase the probability of an encounter between 
a cDC and a cognate T cell. The interaction of T cells with cDCs, as described 
earlier, occurs in the T cell zones of LNs and spleen (von Andrian and Mempel, 
2003; Mebius and Kraal, 2005). CCL21 is also found bound to the surface of LN 
cDCs. Chemokine-bearing cDCs mediate an initial chemokine-mediated tether 
between cDCs and T cells. This tether precedes synapse formation and does not 
support TCR signalling, but enhances the probability of an Ag dependent 
interaction between the tethered T cell and neighbouring cDCs presenting Ag 
specific for its TCR (Friedman et al., 2006). The Ag dependent contact between 
T cells and cDCs occurs via the immunological synapse, a specialised area 
containing adhesion molecules, MHCII and TCRs (Grakoui et al., 1999; Sallusto 
and Lanzavecchia, 2002). Activation and the full differentiation of naïve T cells 
requires three signals. Signal one is the recognition of MHCII presented Ag via 
the TCR. Signal two is provided by costimulatory molecules, such as CD80 and 
CD86. To support this process, maturing cDCs also upregulate costimulatory 
molecules and MHCII. Cytokines, such as IL-23 and IL-12 provide signal 3, 
determining the outcome of T cell activation, polarising T cells to an effector 
phenotype and influencing their homing properties. However, additional signals 
can be provided by molecules such as retinoic acid and Vitamin D3 (Hart, 1997; 
Banchereau et al., 2000; Sallusto and Lanzavecchia, 2002; Miloud et al., 2010). 
Activation of naïve T cells results in their proliferation in an IL-2 dependent 
manner and their differentiation into effector cells (Sallusto and Lanzavecchia, 
2002; Liao et al., 2011). Effector cells comprise CD4+ Th cells, cytolytic CD8+ T 
cells, Tregs or memory cells. It is these memory T cells that provide a rapid 
response to previously encountered Ag. They can respond to low doses of Ag 
even in the absence of costimulatory molecules and do not require Ag 
presentation by DCs (Sallusto and Lanzavecchia, 2002; Sallusto et al., 2004). 
Earlier in this Introduction, I described two routes for Ag delivery to LNs. The 
first, involves delivery of processed Ag from peripheral tissue by migratory 
mature cDCs. The second route of delivery is the lymphatic drainage of 
peripheral tissues, which carries Ag to LNs where it can be taken up by resident 
cDCs for Ag presentation. The majority of cDCs resident in secondary lymphoid 
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organs are reported to be immature and therefore possess a high capacity to 
capture Ag (Wilson et al., 2003). Resident cDCs can project extensions into the 
channels of the conduit system and pick up lymph-borne Ag (Roozendaal et al., 
2008). cDCs in the spleen are also exposed to systemic (blood-borne) Ag as well 
as local splenic Ag (von Andrian and Mempel, 2003; Mebius and Kraal, 2005). 
Thus, secondary lymphoid organ resident cDCs are most likely responsible for the 
development of an immune response against Ag delivered via lymph or blood to 
the lymphoid organs (Sixt et al., 2005). 
The spleen contains several subsets of cDCs that can be distinguished based on 
their expression of CD8α, CD11b and CD4. Splenic cDCs can be broadly divided 
into two groups: the CD8α+ cDCs, which are negative for CD11b, and CD11b+ 
cDCs that are negative for CD8α (Pulendran et al., 1997; Vremec and Shortman, 
1997; Leenen et al., 1998; Vremec et al., 2000; Wilson et al., 2003). The CD11b+ 
cDC population can be further subdivided into two subsets that are CD4+ or CD4-, 
both of which are located in the MZ of the spleen. Upon activation by 
inflammatory stimuli, such as LPS, they migrate into the T cell zone (Banchereau 
et al., 2000; Vremec et al., 2000; McLellan et al., 2002). The CD8α+ cDC subset 
are mainly located within the T cell zone regardless of their activation state 
(Wilson et al., 2003; Shortman and Heath, 2010). These two groups of cDCs 
differ in their expression of TLR, with CD8α+ cDCs possessing higher levels of 
expression of TLR3, and CD11b+ cDCs having higher expression of TLR5 and 7 
(Edwards et al., 2003). However, both subsets express TLR4, the receptor for 
LPS (Mazzoni and Segal, 2004) and following induction of systemic inflammation 
by LPS administration, both the CD8α+ and CD11b+ cDCs have increased turnover 
rates (Kamath et al., 2000) and die by apoptosis (Zanoni and Granucci, 2010). 
Experiments conducted by Liu et al. using parabiotic mice have provided data 
suggesting that blood-borne DC progenitors replenish splenic and LN DC network 
(Liu et al., 2007). Earlier I also discussed the role of the Flt3L responsive splenic 
pre-cDCs in restoring cDC numbers (Hochweller et al., 2009). 
CD8α+ and CD11b+ cDCs show several functional differences. CD8α+ cDCs are able 
to cross prime CD8+ T cells by presenting exogenous Ag on MHC class I, but are 
less efficient than CD11b+ cDCs at presenting Ag on MHCII (Haan et al., 2000; 
Shortman and Heath, 2010). The interaction of the cross-priming CD8α+ cDCs 
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with CD8+ T cells is mediated by the chemokine receptor XCR1 and its ligand 
XCL1. XCR1 reporter mice illustrated that XCR1 was exclusively expressed by 
CD8α+ cDCs, and CD8+ T cells produced XCL1, which stimulates XCR1 dependent 
chemotaxis of the CD8α+ cDCs. In the absence of XCL1, there was a decrease in 
the number of T cells reacting to Ag cross-presented by CD8α+ cDCs (Dorner et 
al., 2009). A population of splenic CD8α+ DCs have also been found to be positive 
for the expression of the C-type lectin langerin (Douillard et al., 2005; 
Kissenpfennig et al., 2005). Langerin is a marker of Langerhans cells, APCs which 
are found in the epidermis of skin (Kissenpfennig et al., 2005). Langerhans cells 
traffic to LNs via the dermal lymphatics in a CCR7 dependent manner (Gunn et 
al., 1999). Fluorescein isothiocyanate (FITC) painting of the epidermis of mice 
activates Langerhans cells resulting in an accumulation of FITC+ Langerhans cells 
in the LN. There are significantly fewer Langerhans cells in the LN of plt/plt 
mice (Gunn et al., 1999). Interestingly, following FITC painting Langerin+ cells in 
the spleen did not become FITC+. Similarly, a population of Langerin+ CD8α+ DCs 
has been reported in PLNs, which also do not become FITC+, but the “classical” 
Langerhans cells, identified as Langerin+CD8α- were FITC+ and their appearance 
in the PLNs was blocked by treatment with pertussis toxin. These results suggest 
that Langerhans cells within lymphoid organs might be segregated into two 
subpopulations: the blood-derived Langerin+CD8α+ DCs that do not migrate from 
the skin, and Langerin+CD8α- cells that migrate from the skin (Douillard et al., 
2005; Kissenpfennig et al., 2005). 
1.5.3 pDCs 
pDCs come under scrutiny in a major part of the Results section of my thesis so 
in this section I will describe the identification of pDCs and their subsets, 
followed by chemokine receptor expression by pDCs and the roles these 
receptors might play in pDC migration. I will then present an overview of the 
role of pDCs within the immune system. The majority of studies described in this 
section were performed in mice; when human data is described this distinction 
will be made clear. 
pDCs are rare cells (0.3-0.5% of lymphoid organs) that originate in the BM (Naik 
et al., 2005a; Reizis et al., 2011a). Although pDCs are classed as DCs they exhibit 
functional and morphological differences from cDCs. pDCs were originally 
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described as a minor subset of leukocytes, being found to have similar 
morphological properties to secretory lymphocytes (Asselin-Paturel et al., 2001; 
Bjorck, 2001; Nakano et al., 2001). In addition, their classification as 
plasmacytoid cells was due to similarities in morphology between pDCs and 
plasma B cells, and also by their expression of the B cell marker B220/CD45RA 
(Naik et al., 2005a; Reizis et al., 2011a). Furthermore, they were originally 
called plasmacytoid T cells due to their localisation within the T cell zones in 
human lymphoid tissue (Colonna et al., 2004; Liu, 2005). Likewise, murine 
splenic pDCs are mainly found within PALS, but can also be found in the red pulp 
(Asselin-Paturel et al., 2003; 2005; Umemoto et al., 2012). Murine pDCs have 
been shown to express low levels of MHCII and costimulatory molecules, in 
addition to low levels of CD11c, all molecules expressed at high levels on cDCs. 
pDCs are less efficient at T cell priming than cDCs, but can stimulate memory 
CD8+ T cells and effector Th1 cells (Colonna, 2003; Fonteneau et al., 2003). 
Furthermore, TLR7 and TLR9 activation of pDCs is reported to endow them with 
the ability to prime naïve T cells (Asselin-Paturel et al., 2001; Mouriès et al., 
2008; Villadangos and Young, 2008). Another difference between cDCs and pDCs 
is in the turnover rate of these cells: cDCs turn over rapidly, whereas pDCs turn 
over relatively slowly. Potentially the most obvious distinction between these 
two dendritic cell types is a functional difference, as pDCs possess the ability to 
produce high levels of type I IFNs (IFNα/β) quickly in response to viral infections 
via stimulation through TLR7 and TLR9 (Naik et al., 2005a; Reizis et al., 2011a). 
1.5.3.1 Subsets of pDCs 
In addition to the complexity of their classification, a further complication of 
pDCs is in their identification. There is no specific pDC marker, even though the 
most commonly used marker, PDCA1, also known as BST2 or tethrin, is often 
mistakenly thought of as one. PDCA1 is also expressed on plasma cells and during 
activation can also be found on several other cell types, including cDCs (Asselin-
Paturel et al., 2003; Blasius et al., 2006b). Thus, several cell surface markers 
are required to accurately identify pDCs. Typically used markers are B220, 
CD11c, MHCII, SiglecH, and Ly6C (Colonna et al., 2004; Reizis et al., 2011a). 
Flow cytometry illustrated that SiglecH was specifically expressed by pDCs in the 
BM, spleen, blood and LNs (Zhang et al., 2006; Blasius et al., 2006a). However, 
staining of tissues sections with anti-SiglecH illustrated that a subset of MZ 
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macrophages in the spleen and medullary macrophages in LNs also expressed 
SiglecH (Zhang et al., 2006). 
The lack of a pDC specific antibody has hampered investigations into pDC 
function in vivo, and as a consequence many studies establishing pDC function 
have been performed ex vivo. In the absence of a pDC specific antibody, pDCs 
can not be specifically ablated, as treatment with anti-PDCA1 or anti-CD11c 
results in the deletion of additional cell types. Mice deficient in PDCA1 have 
been generated, but in addition to the deletion of pDCs, plasma cell numbers 
are affected (Blasius et al., 2006b). Recently, a diphtheria toxin receptor (DTR)-
mediated conditional SiglecH KO has been generated (SiglecH-DTR). Following 
treatment with a single dose of diphtheria toxin, pDCs in the spleen, MLNs and 
BM of SiglecH-DTR mice were completely ablated, while there were no changes 
in the proportions of cDCs or other leukocytes. Tissue section staining illustrated 
that localisation of MZ macrophages was not affected in diphtheria toxin treated 
SiglecH-DTR mice (Takagi et al., 2011). 
Both PDCA1 and SiglecH have been described to modulate pDC function. PDCA1 
has been reported to limit viral spread and infection by preventing viral release 
from infected cells. Therefore, PDCA1 deficient animals were expected to have 
increased viral titres following infection, however they were shown to have 
decreased IFNα and decreased viral titres in lungs following intranasal infection 
with influenza B virus. There was an increase in the number of CD8+ virus 
specific T cells within the infected lungs of PDCA1 KO mice (Swiecki et al., 
2012). Interestingly, in addition to being located on the cell surface, PDCA1 is 
found in the Golgi apparatus and has been reported to regulate IFNα production. 
Binding of PDCA1 by anti-PDCA1 antibodies has been reported to cause a 
decrease in CpG induced IFNα production by splenic pDCs (Blasius et al., 2006b). 
Blasius et al. have also reported that incubation of purified splenic pDCs with 
anti-SiglecH antibodies caused a reduction in CpG induced IFNα secretion 
(Blasius et al., 2004). Furthermore, subcutaneous (s.c.) administration of CpG 
and SiglecH antibody resulted in a decrease in the level of IFNα present in the 
serum, with no effect on pDC numbers (Blasius et al., 2004). In sharp contrast, 
Zhang et al. reported no effect on IFNα production following addition of SiglecH 
antibody to BM derived pDCs (Zhang et al., 2006). 
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The use of SiglecH-DTR mice, which are actually deficient in SiglecH transcript 
and surface protein has revealed that in the absence of SiglecH, pDCs have 
altered developmental processes. They had higher levels of PDCA1 and CD11c, 
and produced more IFNα and IL12p40 than WT pDCs following treatment with 
CpG (Takagi et al., 2011). The absence of SiglecH and ablation of pDCs was 
shown to enhance Ag specific CD4+ T cell responses, as untreated SiglecH-DTR 
and pDC ablated animals had increased Ag specific division of OTII OVA specific T 
cells compared to WT animals. The increase in Ag specific division was 
accompanied by a parallel decrease in the ability of pDC-ablated animals to 
induce Treg generation (Takagi et al., 2011). SiglecH can also function as an 
endocytic receptor mediating Ag uptake. OVA conjugated to anti-SiglecH 
antibodies was internalised, processed and cross-presented on MHC class I to 
CD8+ T cells (Zhang et al., 2006). Takagi et al. also showed in vivo that a 
deficiency in pDCs or an absence of SiglecH led to a decrease in Ag specific 
division of OTI OVA specific CD8+ T cells, which was overcome by reconstitution 
with WT pDCs (Takagi et al., 2011). Collectively, these results illustrate that 
pDCs can mediate Ag specific T cell responses, and that SiglecH is involved in 
cross-presentation of Ag and regulates the generation of effector T cells and 
Tregs (Zhang et al., 2006; Takagi et al., 2011). 
Following the identification of pDCs using a combination of the above markers, 
several groups have recently described subsets of pDCs based on the expression 
of one or more surface proteins. It has also been proposed that the expression of 
these markers may indicate different stages of pDC development, rather than 
discrete subsets. The expression of these markers by putative immature and 
mature pDCs is summarised in Table 1-3. Kamogawa-Schifter et al. identified 
two subsets of pDCs based on the expression of a single marker, Ly49Q 
(Kamogawa-Schifter et al., 2005). Ly49Q is a type II C-type lectin and is a 
member of the Ly49 family of mouse NK receptors. However, it is not found on 
NK cells, NKT cells or T cell subsets, but is preferentially expressed on Gr1+ 
cells, including monocytes, neutrophils and pDCs (Omatsu et al., 2005; Toyama-
Sorimachi et al., 2004). Both Ly49Q+ and Ly49Q- pDCs have been identified in the 
BM. However, these cells were only classified as B220+CD11c+ before gating for 
Ly49Q. The B220+CD11c+ population can actually contain multiple cell types, 
such as NK-like cells and cDC progenitors. Nevertheless, both Ly49Q+ and Ly49Q- 
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populations produced high levels of IFNα in response to stimuli, indicating that 
they contained pDCs (Kamogawa-Schifter et al., 2005). Recent publications 
contradict the classification of two subsets of pDCs based on Ly49Q expression, 
and have identified Ly49Q as a marker of pDC maturation (Omatsu et al., 2005; 
Toma-Hirano et al., 2007). Toma-Hirano et al. and Omatsu et al. have both 
found that peripheral pDCs express Ly49Q, whereas Ly49Q- pDCs in the BM 
acquire expression of the marker before migrating to the periphery. Both groups 
conclude that Ly49Q- pDCs are an earlier developmental stage of pDCs that 
differentiate into the mature Ly49Q+ pDCs found in the spleen and LNs (Omatsu 
et al., 2005; Toma-Hirano et al., 2007). 
Surface Marker Immature Mature 
Ly49Q - + 
CD4 - + 
CD9 + - 
CCR9 - + 
Table 1-3: Proposed expression of surface markers by developmentally immature and 
mature pDCs. 
 
Another group has proposed that the developmental stages of pDCs can be 
defined by CD4 expression with CD4- pDCs maturing into CD4+ pDCs (O'Keeffe et 
al., 2002; Naik et al., 2005a). O’Keeffe et al. transferred purified CD4+ and CD4- 
pDCs from the spleen of a Ly5.2+ mouse into a normal, non-irradiated and non-
stimulated Ly5.1+ mouse and found that CD4- pDCs acquired expression of CD4 
(O'Keeffe et al., 2002). Similarly, Omatsu et al. found that there was a parallel 
acquisition of CD4 with Ly49Q expression by the mature pDC population (Omatsu 
et al., 2005). CpG induced activation of pDCs resulted in the downregulation of 
CD4 expression (O'Keeffe et al., 2002). Recent research has defined three 
subpopulations of pDCs based on expression of CD8α and CD8β: CD8α-β-,  
CD8α+β-, and CD8α+β+. The three subsets are mature unactivated pDCs, as 
defined by their expression of Ly49Q and the absence of activation markers. It 
was also shown that, in a model of allergic lung inflammation, CD8α+ populations 
had tolerogenic properties, both inducing generation of FoxP3+ Tregs and 
preventing the development of airway hyperreactivity (Lombardi et al., 2012). 
Lombardi et al. also demonstrated that activation of pDCs via TLR7 or TLR9 did 
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not alter their expression of CD8α or CD8β (Lombardi et al., 2012), which is in 
contrast to O’Keeffe et al. who showed that activation of pDCs was associated 
with upregulation of CD8α (O'Keeffe et al., 2002). Lastly, Björck et al. have 
described two developmental stages of pDCs based on the expression of CD9 
(Björck et al., 2011). CD9+ pDCs were purified from the BM and labelled with 5-
Carboxyfluorescein diacetate succinimidyl ester (CFSE) and injected into a non-
irradiated and non-stimulated recipient and after 4 days were found to lose CD9 
expression. The majority of BM pDCs were CD9+ and following their migration 
and differentiation into developmentally mature pDCs in the periphery lost CD9 
expression (Björck et al., 2011). The CD9+ subset was CD4- and the CD9- subset 
was CD4+ (Björck et al., 2011). This supports the conclusion drawn from the work 
by the O’Keefe group, as they determined the CD4- subset to be a precursor of 
CD4+ pDCs (O'Keeffe et al., 2002).  
When describing the developmental stages of pDCs, all groups looked at the IFNα 
producing capabilities of these cells either by enzyme-linked immunosorbent 
assay (ELISA) or by monitoring intracellular IFNα. O’Keeffe et al. measured IFNα 
by ELISA following stimulation of pDCs with CpG for 14 hours (hrs) (O'Keeffe et 
al., 2002). Omatsu et al. (Omatsu et al., 2005) and Björck et al. (Björck et al., 
2011) monitored intracellular IFNα levels following 5 or 9 hrs stimulation with 
CpG, respectively. All groups found that the two subsets had the ability to 
produce IFNα in response to bacterial CpG stimulation (O'Keeffe et al., 2002; 
Omatsu et al., 2005; Toma-Hirano et al., 2007), except Björck et al. who showed 
that the CD9- pDCs only produced minimal levels of IFNα (Björck et al., 2011). 
Interestingly, most groups showed that the developmentally more “immature” 
pDC subset, CD4- or CD9+, are the cells responsible for producing the majority of 
IFNα in response to Staphylococcus aureus extract or influenza virus, 
respectively (Björck et al., 2011); O'Keeffe et al., 2002). This would indicate 
that the developmentally immature pDCs are responsible for the majority of 
IFNα production in response to viral infections and that mature (CD4+CD9-) pDCs 
produce minimal levels of IFNα (O'Keeffe et al., 2002; Björck et al., 2011). It has 
also been proposed that these mature peripheral pDCs promote immune 
tolerance (Björck et al., 2011). However, research using the Ly49Q marker to 
determine maturation has, in fact, suggested that the reverse is true. The 
developmentally immature Ly49Q- pDCs that differentiate to acquire the 
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maturation marker Ly49Q, actually produce less IFNα/β and inflammatory 
cytokines (IL-6 and IL-12) than the mature Ly49Q+ pDCs (Omatsu et al., 2005; 
Toma-Hirano et al., 2007). Thus, there remain some contradictions over the 
function of developmentally mature and immature pDCs. 
In brief, identification of pDCs requires a range of cell surface markers (Colonna 
et al., 2004; Reizis et al., 2011a). Gating strategies typically use a combination 
of pDC “specific” markers, such as PDCA1 (Asselin-Paturel et al., 2003; Blasius et 
al., 2006b) and SiglecH (Zhang et al., 2006; Blasius et al., 2006a), and markers 
expressed by other cell types, such as B220, CD11c and Ly6C (Colonna et al., 
2004; Reizis et al., 2011a). Furthermore, developmentally mature pDCs can 
theoretically be distinguished from immature pDCs by differences in expression 
of several markers (Table 1-3). Mature pDCs are proposed to be Ly49Q+, CD4+, 
CD9-, CD8α+ and CCR9+, whereas immature pDCs are Ly49Q-, CD4-, CD9+ and 
CCR9- (O'Keeffe et al., 2002; Omatsu et al., 2005; Björck et al., 2011; Lombardi 
et al., 2012). This division might be oversimplified, as no study has examined the 
expression of all five markers on splenic pDCs. The majority of research has 
illustrated that both immature and mature pDCs can produce IFNα, but there is 
debate over which pDC developmental stage has the superior ability to produce 
IFNα (O'Keeffe et al., 2002; Omatsu et al., 2005; Björck et al., 2011). 
1.5.3.2 Chemokine receptor expression 
Despite the current controversy regarding the identification and function of the 
maturation states of pDCs, they have been assigned several key roles in vivo. In 
addition, several lines of evidence suggest that pDC subset location and function 
is critically dependent on chemokine receptor expression. pDCs have been shown 
to express a variety of chemokine receptors, both inflammatory (CCR2, CCR5 
and CXCR3) and homeostatic (CCR9, CXCR4 and CCR7) (Wendland et al., 2007; 
Randolph et al., 2008; Seth et al., 2011). Several groups have investigated the 
role of many of these chemokine receptors in pDC migration. For example, CCR9 
is responsible for the migration of pDCs into the intestine, in both homeostatic 
and inflammatory conditions. pDCs are largely absent from the intestine of an 
animal deficient in CCR9, but pDC numbers in secondary lymphoid organs are 
unaffected (Wendland et al., 2007). In the BM, Björck et al. have shown that the 
two developmental pDC stages, the CD9+ and CD9-, are also CCR9- and CCR9+, 
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respectively (Björck et al., 2011). CD9-CCR9+ pDCs were reported to be mature 
peripheral pDCs that secrete low levels of IFNα in response to viral infection. It 
also appears that it is the precursor CCR9- population of pDCs that is responsible 
for the secretion of proinflammatory cytokines, such as TNFα and IL-6 (Björck et 
al., 2011). In support of these observations, Schlitzer et al. have recently 
identified a pDC precursor in the BM and in secondary lymphoid organs that is 
CCR9- (Schlitzer et al., 2011). Upon CpG stimulation, the precursor CCR9- pDCs 
secreted higher levels of IFNα, IL-12 and IL-6 than CCR9+ pDCs (Schlitzer et al., 
2011). Hadeiba et al. also report that the majority of peripheral pDCs are CCR9+ 
(Hadeiba et al., 2008). This group found that CCR9 was rapidly downregulated in 
response to activation by TLR7 or TLR9 ligands, while co-stimulatory molecules 
and MHCII were upregulated. Interestingly, it was found that both the CCR9+ and 
CCR9- populations could both produce IFNα in similar quantities in response to 
CpG (Hadeiba et al., 2008). However, a consistency between the two groups was 
in the description of CCR9+ pDCs being responsible for the tolerogenic properties 
associated with pDCs (Hadeiba et al., 2008; Björck et al., 2011; Schlitzer et al., 
2011). The tolerogenic role of pDCs is though to occur due to their induction of 
Tregs that secrete the anti-inflammatory cytokine, IL-10 (Colonna et al., 2004; 
Ito et al., 2007; Baba et al., 2009; Matta et al., 2010). Hadeiba et al. 
demonstrated that CCR9+ pDCs suppressed the frequency of IL-17 producing 
effector T cells, thereby decreasing the clinical severity of allogeneic graft 
versus host disease. CCR9+ pDCs induced the development of FoxP3+ Tregs cells, 
which also contributed to the reduction in disease severity (Hadeiba et al., 
2008). 
Other chemokine receptors have also been ascribed roles in pDC migration. Until 
very recently, CCR7 had only been shown to mediate migration of pDCs in in 
vitro chemotaxis assays, but it has now been shown to facilitate pDC 
extravasation into LNs though HEVs (Seth et al., 2011). Originally, this role was 
thought to be accomplished by CCR5, which was one of the few identified 
receptors that could mediate a chemotactic response resulting in the 
mobilisation of pDCs to an inflamed LN vessel (Colonna et al., 2004; Randolph et 
al., 2008; Sozzani et al., 2010; Seth et al., 2011). However, Seth et al. showed 
that although CCR7 was present in minute levels on naïve cells, it was highly 
upregulated on pDCs following their activation with TLR ligands (Seth et al., 
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2011). Interestingly, CCR7 KO animals, regardless of their activation status, 
display reduced LN pDC numbers due to impairment in the mobilisation of CCR7 
deficient pDCs. Conversely, BM and splenic pDC numbers were not affected by 
the absence of CCR7. This would indicate that, similar to naïve T cells, pDCs 
may also demonstrate increased integrin affinity in response to CCR7 signalling, 
which facilitates effective adhesion and migration across HEVs (Seth et al., 
2011). Results produced in our lab by Elinor Anderson also show that mice 
deficient in CCX-CKR, the atypical chemokine receptor for CCL19, CCL21 and 
CCL25, have a deficit in pDC numbers restricted to their MLNs (Anderson, 2011). 
pDCs have been shown to constitutively migrate into the splenic white pulp using 
a combination of CCR7 and CXCR4 to traverse MZ bridging channels (Umemoto et 
al., 2012). Another inflammatory chemokine receptor reported to mediate pDC 
migration in vivo is CXCR3 which has been shown to mediate murine pDC 
migration across HEVs during times of inflammation (Yoneyama et al., 2004). In 
addition, intravenous (i.v.) administration of CpG leads to the migration of some 
pDCs into the MZ, and the formation of pDCs clusters in both the MZ and T cell 
zones of the spleen. The initial migration and clustering of pDCs was shown to be 
dependent on CXCR3 and CXCR4, and at later time points was entirely CCR7 
dependent (Asselin-Paturel et al., 2005). 
In contrast to the previously discussed chemokine receptors, CCR2 has yet to be 
designated an in vivo role in pDC migration. Investigations using human pDCs 
have suggested that CCR2 is non-functioning in in vitro migration assays (Colonna 
et al., 2004). Interestingly, it has been reported that although most murine BM 
pDCs express CCR5 and CXCR3, only ~25% express CCR2 (according to staining 
with anti-CCR2 antibody MC-21) (Wendland et al., 2007), indicating that CCR2 
might have a role on a specific subset of pDCs. However, Wendland et al. also 
demonstrated that a significantly higher proportion of Flt3L expanded splenic 
pDCs expressed CCR2 compared to BM pDCs from an untreated animal (Wendland 
et al., 2007). Baba et al. have shown that the absence of CCR2 or CCR5 does not 
affect thymic pDCs numbers (Baba et al., 2009). However, recruitment of pDCs 
to sites of imiquimod induced skin inflammation has been reported to be 
dependent on the CCR2 ligand, CCL2 (Drobits et al., 2012). 
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1.5.3.3 pDC function 
pDCs have been described to have a variety of functions, with the majority of 
their functions reliant on their ability to produce high levels of IFNα/β following 
TLR7 or TLR9 activation (Gibson et al., 2002; Colonna et al., 2004; Fuchsberger 
et al., 2005). TLR7 and TLR9 are expressed intracellularly and recognise single 
stranded viral RNA and DNA that is transported to the endosomal compartments 
upon infection of a cell with virus (Edwards et al., 2003; Colonna et al., 2004; 
Fuchsberger et al., 2005). IFNα has well-characterised, direct anti-viral effects, 
including inhibition of viral replication and upregulation of IFN-stimulated genes, 
such as ribonuclease L, which also combat viral replication. Thus, pDCs have a 
vital role in immune defence against viral infections (Borrow et al., 2010). In 
addition, they have been described to function in tissue repair following acute 
injury (Colonna et al., 2004; Smit et al., 2006; Gilliet et al., 2008; Gregorio et 
al., 2010; Cervantes-Barragan et al., 2012). For example, although pDCs can be 
found in the majority of secondary lymphoid organs in low numbers, they are 
actually absent from most peripheral tissues, including normal skin. However, 
following injury to the skin, pDCs are rapidly recruited to the injury site (Gilliet 
et al., 2008; Gilliet and Lande, 2008; Gregorio et al., 2010). Human pDCs have 
been shown to respond to CXCR3 ligands, and production of CXCR3 ligands is 
induced by skin injury. Therefore, it has been proposed that CXCR3 might play a 
role in pDC recruitment to sites of inflammation (Vanbervliet et al., 2003; 
Gregorio et al., 2010). Chemerin, the ligand for chemokine-like receptor 1, has 
also been assigned a role in pDC recruitment to inflamed skin. Chemerin is 
constitutively produced in an inactive form by keratinocytes and endothelial 
cells in healthy skin. It is only following its activation by C-terminal cleavage by 
serine proteases that chemerin can stimulate pDC recruitment to inflamed skin. 
It has been hypothesised that skin injury might stimulate protease release from 
damaged keratinocytes (Vermi et al., 2005; Gregorio et al., 2010). 
Gregorio et al. have demonstrated, using a tape strip model of skin injury, that 
the infiltration of pDCs is rapid, occurring within 24 hrs after injury. This was 
transient, as pDC numbers were dramatically reduced within 48 hrs, and 
returned to the low levels found in healthy skin (Gregorio et al., 2010). The 
infiltrated pDCs produce high levels of IFNα/β, in response to TLR7 and TLR9 
stimulation, and contribute to wound healing. Interference with the IFNα/β 
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pathway, either through inhibition of IFNα/β receptor signalling or in mice 
lacking the receptor for these cytokines, led to an impairment in wound healing 
due to a delay in wound re-epithelisation (Gregorio et al., 2010; Guiducci et al., 
2010). Furthermore, the inflammatory response was profoundly affected in the 
absence of the IFNα/β receptor. There was a deficiency in IL-6, IL-17 and IL-22 
expression in injured skin, thereby demonstrating the pivotal role of IFNα/β 
produced by infiltrating pDCs in early inflammatory responses (Gregorio et al., 
2010; Guiducci et al., 2010). 
Interestingly, in this model of skin injury, the groups concluded that the stimulus 
for pDC activation via TLR7 and TLR9 was actually host derived nucleic acids 
(Gilliet and Lande, 2008; Gregorio et al., 2010; Guiducci et al., 2010). This was a 
consequence of the induction of a cathelicidin peptide, which forms a complex 
with the self RNA and DNA released upon cell damage and transports them to the 
endosomes containing TLR7 and TLR9. However, although cathelicidin was 
sufficient to promote IFNα/β, it was not essential (Gilliet and Lande, 2008; 
Gregorio et al., 2010; Guiducci et al., 2010). The chronic activation of pDCs by 
nucleic acids can lead to the development of autoimmune diseases of the skin. 
For example, the thickening of the epidermal layer, characteristically found in 
psoriatic lesions, is thought to occur as a consequence of IFNα/β production 
from chronically activated pDCs leading to the expansion of autoimmune T cells 
(Anandarajah and Ritchlin, 2004). In summary it is clear that IFN-producing 
pDCs, whether characterised as mature or immature, have a major role in the 
induction of skin inflammation. Somewhat paradoxically, these same cells may 
have a major role in the resolution of inflammation, as they can substantially aid 
wound healing processes. Both these contrasting roles are likely dependent on 
continuous recruitment of pDCs with IFN-producing potential from the BM into 
the blood (Anandarajah and Ritchlin, 2004; Gilliet and Lande, 2008; Gregorio et 
al., 2010; Guiducci et al., 2010). 
The chronic activation of pDCs has also been associated with other autoimmune 
diseases, in particular systemic lupus erythematosus (SLE). A dominant feature 
of SLE is the formation of immune complexes that are deposited in different 
parts of the body. Immune complexes are mainly formed by an interaction of 
autoantibodies with self-nucleic acids that are released from dying cells. 
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Autoantibodies are produced from autoreactive B cells that become activated as 
a consequence of a breakdown in tolerance to nuclear self-Ags. The deposition 
of the immune complexes triggers immune reactions leading to inflammation 
and detrimental tissue damage, particularly in the kidneys (Banchereau and 
Pascual, 2006; Pascual et al., 2006; Mangini et al., 2007; Rönnblom and Pascual, 
2008; Santiago-Raber et al., 2009). pDCs are thought to play a pivotal role in the 
development of SLE, due to their recognition of self-nucleic acids via TLR7/9. 
This can lead to their chronic activation of pDCs and secretion of copious 
amounts of IFNα/β. IFNα/β has several fundamental roles in the initiation and 
exacerbation of the disease (Banchereau and Pascual, 2006; Pascual et al., 2006; 
Mangini et al., 2007; Rönnblom and Pascual, 2008; Santiago-Raber et al., 2009). 
Firstly, it has DC inducing properties, in that it triggers the unregulated 
differentiation of monocytes into cDCs. These cDCs capture autoAg and present 
it to CD4+ and CD8+ T cells, thereby promoting the loss of tolerance and the 
development of autoimmunity (Banchereau and Pascual, 2006; Pascual et al., 
2006; Mangini et al., 2007). Furthermore, IFNα/β are thought to have direct and 
indirect actions on B cell function. Foremost, the development of autoreactive T 
cells via the effects of IFNα/β helps to promote the development of autoreactive 
B cells into plasma cells. IFNα/β can act directly on these plasma cells, 
promoting the production of autoantibodies and leading to the generation of 
immune complexes (Banchereau and Pascual, 2006; Pascual et al., 2006; Mangini 
et al., 2007). 
Crucially, it is important to understand that although pDCs may contribute to the 
generation of autoimmune diseases, their immunosuppressive properties may 
balance some of these effects. For example, pDC induction of Tregs is beneficial 
in reducing the occurrence of autoreactive T cells. However, this property may 
contribute to pathogenesis in some cases. Indeed, pDCs are known for their 
ability to induce tolerance to tumour cells, thereby aiding tumour generation 
and growth (Wei et al., 2005; Sisirak et al., 2012). In spite of this, they can also 
facilitate protective responses against tumour cells (Matta et al., 2010). The 
deciding factor in this balance between tolerance and protection against 
tumours is thought to be the activation state of pDCs. Resting pDCs are thought 
to induce tumour tolerance via their induction of Tregs, whereas TLR7/9 
activated pDCs can induce tumour regression (Colonna et al., 2004; McKenna et 
Chapter 1  72 
 
al., 2005; Swiecki and Colonna, 2010). Topical treatment of mice with an 
imiquimod containing cream, Aldara, leads to a TLR7 and IFNα/β dependent 
regression of tumours. Tumour regression was coordinated with an increase in 
pDC numbers, which expressed CD8α. There was also an increase in the number 
of NK cells and CD8+ T cells within the tumour, however the absence of either of 
these populations had no effect on tumour regression, whereas depletion of 
pDCs enhanced tumour growth. The cytotoxicity of pDCs corresponded with their 
expression of CD8α, as TLR7 activation of pDCs by imiquimod treatment led to 
upregulation of the cytolytic molecules, TNF-related apoptosis-inducing ligand 
(TRAIL) and granzyme B. Thus, imiquimod treatment leads to tumour regression 
as a direct consequence of TLR7 mediated activation of pDCs, with NK cells and 
T cells having minimal roles (Palamara et al., 2004; Drobits et al., 2012). In 
contrast, TLR9 mediated activation of pDCs has been shown to cause tumour 
regression in a CD8+ T cell- and NK cell-dependent fashion (Liu et al., 2008). 
However, Sorrentino et al. have described a role of TLR9 activated pDCs in 
generating tolerance to tumours (Sorrentino et al., 2010). This apparent 
discrepancy might be explained by differences in the tumour model used in 
these studies; tumour tolerance was described using a lung carcinoma model, 
whereas tumour regression was illustrated in a model of melanoma. 
Furthermore, TLR9 activation was induced by two different classes of CpG: 
tolerance was induced using CpG type B (CpG-B) and regression was induced 
using CpG type A (CpG-A) (Liu et al., 2008; Sorrentino et al., 2010). There are 
three classes of CpGs, type A, B and C. CpG-A induces potent IFNα/β production 
by pDCs; CpG-B induces pDC activation, in terms of expression of costimulatory 
molecules and MHCII; and CpG type C (CpG-C) induces a combination of the two 
effects (Krug et al., 2001a; Kerkmann et al., 2003). Thus, differences in the role 
of pDCs in tumour defence or tolerance might be explained by alterations in the 
precise nature of the activation of pDCs. 
I have highlighted some of the protective and inductive roles for pDCs in a 
variety of scenarios, but their most imperative role is in the defence against 
viral pathogens, acting as a vital link between the innate and adaptive immune 
systems (Swiecki and Colonna, 2010). Production of IFNα/β by activated pDCs 
promotes cytotoxicity in NK cells and CD8+ T cell and stimulates their production 
of the proinflammatory cytokine IFNγ, aiding in defence against viruses (Colonna 
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et al., 2004; Guillerey et al., 2012). Furthermore, IFNα/β can regulate the 
production of the Th1 inducing cytokine IL-12, thereby modulating polarisation 
of naïve CD4+ T cells. Low levels of IFNα/β lead to IL-12 production by both cDCs 
and pDCs, polarising naïve CD4+ T cells to a Th1 phenotype, although high levels 
of IFNα/β inhibit IL-12 production by cDCs (Asselin-Paturel et al., 2001; Colonna 
et al., 2004). Activated pDCs also produce the proinflammatory cytokine IL-6, 
which stimulates the differentiation of B cells into antibody-producing plasma 
cells (Jego et al., 2003; Colonna et al., 2004). In addition, as already discussed, 
pDCs can induce development of Tregs, which can lead to tolerance against 
tumours (Colonna et al., 2004; McKenna et al., 2005; Matta et al., 2010; 
Sorrentino et al., 2010; Swiecki and Colonna, 2010). However, pDC induced Treg 
generation has also been shown to dampen autoimmune T cell responses, leading 
to protection against the development of experimental autoimmune 
encephalomyelitis (EAE) (Irla et al., 2010). EAE was induced in mice with a pDC 
specific deficiency in MHCII expression by immunisation with the 
encephalitogenic myelin oligodendrocyte glycoprotein (35-55) peptide, in 
combination with Complete Freund’s adjuvant (CFA). In the absence of MHCII 
expression by pDCs, mice had impaired expansion of Ag-specific Tregs, which 
was associated with exacerbation of EAE in these animals (Irla et al., 2010). 
In summary, the varying functions of pDCs are largely dependent on their 
activation by TLR7/9, and subsequent IFNα production (Gibson et al., 2002; 
Colonna et al., 2004; Fuchsberger et al., 2005). IFNα has direct anti-viral effects 
and therefore functions as part of the innate immune system. Furthermore, IFNα 
provides a link between the innate and adaptive immune system, promoting 
cytotoxicity in NK cells and CD8+ T cells, thereby generating an effective 
immune response against viral pathogens (Colonna et al., 2004; Guillerey et al., 
2012). However, activation of pDCs is not always beneficial, as their chronic 
activation can be detrimental and has been associated with the development of 
pathologies, such as SLE (Banchereau and Pascual, 2006; Pascual et al., 2006; 
Mangini et al., 2007) and psoriasis (Anandarajah and Ritchlin, 2004). In addition, 
pDCs have been described to possess conflicting roles in tumour generation. 
Activated pDCs, in most cases, induce tumour regression, whereas resting pDCs 
are thought to induce tolerance to tumour cells, promoting tumour growth 
(Colonna et al., 2004; McKenna et al., 2005; Swiecki and Colonna, 2010). 
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Therefore, in addition to generating an effective inflammatory response against 
pathogenic organisms and tumours, pDCs may also play a role in the 
maintenance of peripheral tolerance to harmless self-Ag. For instance, mature 
CCR9+ pDCs have been described to possess tolerogenic properties, which 
facilitate the induction of Tregs (Hadeiba et al., 2008; Björck et al., 2011; 
Schlitzer et al., 2011).  
1.6 Current understanding of CCL2 receptor expression 
and function 
The expression and function of the two CCL2 receptors, CCR2 and D6 are a key 
focus point in my thesis. Therefore, in this section I will provide an overview of 
the current understanding of the roles of CCR2 and D6 in the immune system. 
1.6.1 CCR2 
Expression of CCR2 has been reported on numerous cell types, including Ly6Chi 
monocytes (Serbina and Pamer, 2006), cDCs (Lewis et al., 2011) and pDCs 
(Wendland et al., 2007). In addition, other cell populations, such as NK cells 
(Saederup et al., 2010), neutrophils (Maus et al., 2003) and T cells (Mack et al., 
2001) have been reported to express CCR2, however this is a source of 
controversy. The role of CCR2 differs depending on the cell, organ, or 
inflammatory environment. A cell system that has been extensively studied, in 
regards to its expression and the role of CCR2, is the phagocytic system. The 
phagocytic system of cells includes neutrophils, monocytes, DCs and 
macrophages. 
1.6.1.1 CCR2 and neutrophils 
Neutrophils and monocytes both arise from the same precursor in the BM, the 
GMP, however they both exhibit differential cell division properties, as mature 
neutrophils take longer to generate than monocytes (Gordon and Taylor, 2005; 
Sugimoto et al., 2006; Gabrilovich et al., 2012). GMPs are CCR2+ (Si et al., 
2010), but there is controversy surrounding the expression of CCR2 by 
neutrophils. Souto et al. showed that neutrophils in steady-state mice were 
CCR2-, but that these cells upregulated CCR2 during chronic inflammation and 
that this was crucial for tissue infiltration in a model of sepsis (Souto et al., 
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2011). Similarly migration of neutrophils into postischaemic tissue has also been 
reported to be CCR2 dependent (Reichel et al., 2006). In contrast, Maus et al. 
reported that neutrophils do not express CCR2, and LPS-induced neutrophil 
migration was CCR2 independent. However, neutrophil accumulation within 
pulmonary tissue in response to LPS was increased in the presence of CCL2. 
Furthermore, absence of CCR2 led to decreased neutrophil accumulation. This 
decrease in accumulation was coincident with a CCR2 dependent decrease in 
monocyte mobilisation into pulmonary tissue, and the presence of monocytes led 
to accelerated and amplified accumulation of neutrophils. Thus, accumulation of 
neutrophils in inflamed lung tissue was proposed to be mediated by the CCR2 
dependent recruitment of monocytes (Maus et al., 2003). 
1.6.1.2 CCR2 and monocytes 
There are two subsets of monocytes that can be separated by their expression of 
the surface marker Ly6C. Ly6Chi monocytes express low levels of the chemokine 
receptor CX3CR1 and high levels of CCR2. The second subset of monocytes, 
Ly6Clo, expresses much lower levels of Ly6C, high levels of the CX3CR1, and 
lower levels of CCR2. There is a third subset of monocytes that are classed as 
Ly6Cinter, due to their intermediate expression of this marker (Sunderkötter et 
al., 2004; Serbina and Pamer, 2006; Tacke and Randolph, 2006). The Ly6Cinter 
monocytes are thought to have an intermediate phenotype, i.e. between that of 
Ly6Chi and Ly6Clo monocytes. They are produced from Ly6Chi monocytes, by the 
downregulation of CCR2 and Ly6C after inflammation has been resolved, and 
these cells are thought to mature into Ly6Clo monocytes. Ly6Clo monocytes have 
a longer half life than Ly6Chi monocytes and can be found in both resting and 
inflamed tissues (Geissmann et al., 2003; Auffray et al., 2009b). Using mice with 
a targeted replacement of CX3CR1 by a green fluorescent protein (GFP) reporter 
(Jung et al., 2000), CX3CR1hiLy6Clo monocytes have been shown to patrol blood 
vessels in resting animals by crawling on the luminal side of the endothelium 
(Auffray et al., 2007; 2009b). In contrast, Ly6Chi monocytes are recruited from 
the BM and into tissues in response to inflammation or infection in a highly CCR2 
dependent manner, and are thus classified as inflammatory monocytes. CCR2 is 
usually considered as an inflammatory chemokine receptor, although the 
dependence of Ly6Chi monocytes on CCR2 for their egress from the BM during 
homeostasis demonstrates that CCR2 also has key homeostatic roles 
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(Sunderkötter et al., 2004; Serbina and Pamer, 2006; Tacke and Randolph, 
2006). 
The BM has always been assumed to be the main source of monocytes during 
inflammation. However, very recently Swirski et al has presented evidence of a 
splenic Ly6Chi monocyte reservoir. This reservoir consists of clusters of 
monocytes in the cords of the subcapsular red pulp. However, CCR2 does not 
appear to be so critical for the mobilisation of these cells during inflammation. 
Swirski and coworkers demonstrated that in response to myocardial infarction 
there was a loss of monocytes from the spleen, gain in blood and no change in 
BM. The same was true in WT and CCR2 KO mice, indicating CCR2 independent 
migration from the spleen. Thus, CCR2 is required for monocyte mobilisation 
from the BM, but not the spleen (Swirski et al., 2009). The migration of 
monocytes into inflamed LNs has also been reported to be dependent on CCL2. 
Skin inflammation results in the production of CCL2, which drains into LNs via 
the lymphatics. HEVs have been reported to present CCL2 on their luminal side, 
which mediates extravasation of blood-borne monocytes into LNs. The number of 
monocytes in the draining LN of a CCL2 KO animal was significantly lower, but 
could be rescued by the administration of CCL2 (Palframan et al., 2001). 
CCR2+ monocytes have been shown to have important roles in many disease 
models, particularly in defence against pathogens. CCR2 KO mice have enhanced 
susceptibility to the intracellular pathogen Listeria monocytogenes. This is due 
to the lack of TipDCs in the spleen. Ly6Chi monocytes give rise to these 
inflammatory DCs, thus retention of Ly6Chi monocytes in the BM of CCR2 KO mice 
leaves them susceptible to this infection (Serbina and Pamer, 2006; Serbina et 
al., 2008). Furthermore, the CCR2-dependent recruitment of Ly6Chi monocytes is 
involved in the defence against viral pathogens, such as murine cytomegalovirus 
(MCMV) infection. The induction of IFNα/β production by pDCs was shown to be 
crucial for the CCR2 dependent release of monocytes from the BM in response to 
MCMV infection. IFNα/β stimulated production of CCR2 ligands by F4/80+ cells in 
the BM, and, in the absence of CCR2, monocytes were retained in the BM and 
unable to mount a protective response in the infected liver (Hokeness et al., 
2005; Crane et al., 2009). 
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1.6.1.3 CCR2 in cDC biology 
Chiu et al. have reported that CCR2 is important for the maturation of cDCs. 
They induced localised immune responses in the lungs of mice by challenging 
them with beads coated with Mycobacterium bovis protein Ag or Schistosoma 
mansoni egg Ag and found that in the absence of CCR2, cDCs in the lungs of Ag 
challenged mice had significantly decreased MHCII and CD40 expression (Chiu et 
al., 2004). BM derived DCs from CCR2 KO mice were also shown to have reduced 
expression of the costimulatory molecules, CD80 and CD86 compared to WT 
counterparts (Fiorina et al., 2008; Jimenez et al., 2010). However, differences 
in the cellularity of the BM of WT and CCR2 KO mice e.g. numbers of Ly6Chi 
monocytes (Serbina and Pamer, 2006) are likely to have influenced this result 
because the cellular composition of the BM derived DC cultures would have been 
different from the start. However, Fiorina et al. also showed that cDCs from the 
spleen of CCR2 KO animals also have reduced expression of CD80, but not CD86 
(Fiorina et al., 2008). CCR2 dependent maturation has been hypothesised to act 
through the transcription factor NF-κB because the inhibition of NF-κB blocks 
cDC maturation and the expression of costimulatory molecules. Jimenez et al. 
proposed a model were the interaction of CCR2 with its ligand, CCL2, induces 
the activation of NF-κB, thereby influencing cDC maturation (Jimenez et al., 
2010). 
CCR2 is involved in the migration of cDCs to inflammatory sites rather than their 
migration into LNs, which is CCR7 dependent (Sallusto et al., 1998). In contrast, 
CCR2 has been reported to participate in Langerhans cell migration from 
inflamed skin to the draining LN. The density of Langerhans cells in the skin of 
CCR2 KO mice was normal, but the migration of Langerhans cells to the draining 
LN was diminished in the absence of CCR2 (Sato et al., 2000). Langerhans cells in 
resting animals are generated and maintained locally by precursors in the 
epidermis. However, following their depletion by localised skin inflammation, 
inflammatory Ly6Chi monocytes can replenish the population of Langerhans cell 
precursors (Ginhoux et al., 2006; Shortman and Naik, 2007). However, it has also 
been reported that the migration of Langerhans cells from the skin to the 
draining LNs is not actually CCR2 dependent, but in fact activation of NF-κB by 
CCR2 signalling pathways leads to local production of the CCR7 ligand, CCL19 
(Jimenez et al., 2010). Thus, CCR2 deficiency not only leads to cDC maturation 
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defects, but is also associated with decrease CCL19 production, and thus CCR7-
dependent migration of Langerhans cells. 
1.6.1.4 CCR2 and lymphocytes 
The absence of CCR2 results in several other phenotypes. For example, CCR2 KO 
mice have impaired cytokine responses after bacterial infection, exhibiting a 
deficit in IL-12 production. This deficit has been observed in LN cells, 
splenocytes and BM derived DCs following LPS stimulation, and is attributed to 
decreased production of this cytokine by cDCs (Boring et al., 1997; Peters et al., 
2000; Jimenez et al., 2010). IL-12 is required for polarisation of T cell responses 
to a Th1 phenotype, resulting in the production of T cells capable of releasing 
the proinflammatory cytokine IFNγ. Thus, in addition to IL-12, CCR2 KO animals 
produce significantly less IFNγ than WT mice. However, there is no reported 
difference in the levels of Th2 cytokines detected indicating that CCR2 is only 
needed for a successful Th1 response (Boring et al., 1997; Peters et al., 2000; 
Chiu et al., 2004). The deficit in Th1 responses by CCR2 KOs has been reported 
to be as a consequence of the absence of IL-12 producing inflammatory DCs in 
CCR2 deficient animals (Nakano et al., 2009). As discussed earlier in section 
1.5.2, inflammatory DCs are derived from Ly6Chi monocytes. In the absence of 
CCR2, Ly6Chi monocytes are retained in the BM leading to a subsequent decrease 
in the accumulation of inflammatory DCs in LNs (Serbina et al., 2008; Nakano et 
al., 2009). The accumulation of inflammatory DCs in inflamed LNs and Th1 
responses were not affected by the absence of CCL2 (Nakano et al., 2009). CCL2 
deficient animals also retain Ly6Chi monocytes in the BM, but it is less 
pronounced than in CCR2 KO animals (Tsou et al., 2007). Therefore, low 
numbers of Ly6Chi monocytes might still be present in the periphery of CCL2 
deficient animals, and as a consequence appropriate numbers of inflammatory 
DCs might be expected to be found in inflamed LNs. 
The polarisation of T cells to an effector phenotype can be influenced by the 
presence of inflammatory chemokines at the time of their activation. The 
presence of CCL3 induces effector Th1 cells, whereas CCL2 induces Th2 cells 
(Luther and Cyster, 2001; Rot and von Andrian, 2004). Therefore, in the absence 
of CCL2 the Th2 response is diminished and mice are susceptible to infection by 
a range of pathogens (Boring et al., 1997; deSchoolmeester et al., 2003). For 
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example, the expulsion of helminth nematodes, such Trichuris muris is highly 
dependent on Th2 polarised immune responses. In the absence of CCL2, worms 
were not expelled (deSchoolmeester et al., 2003). 
Interestingly, although CCR2 can affect T cell activity, there is some controversy 
over the expression of CCR2 by naïve T cells. Although CCR2 mRNA has been 
found in naïve T cells, there are conflicting results about surface protein 
expression. Mack et al., using an anti-CCR2 antibody MC-21, found that both 
naïve CD8+ and CD4+ T cells expressed CCR2 (Mack et al., 2001). In contrast, the 
use of the CCR2-red fluorescent protein (RFP) reporter mice illustrated that 
although T cells possessed CCR2 at the transcript level, no CCR2 was detected on 
their surface (Saederup et al., 2010). Activated T cells have been shown to 
express CCR2, both at the transcript level and antibody mediated detection of 
surface CCR2 (Nansen et al., 2000; Mack et al., 2001; Peters et al., 2004). 
Inngjerdingen et al. have also presented a clear example of CCR2 expression 
being upregulated by cell activation. CCR2 expression was higher on activated 
human NK cells, than on nonactivated (Inngjerdingen et al., 2001). They also 
showed that CCR2, even though at lower levels on nonactivated NK cells, was 
still active, demonstrated by chemotaxis of these cells in response to CCL2, 
although the response was less robust than activated cells (Inngjerdingen et al., 
2001). CCR2-RFP reporter mice illustrated that although murine NK cells were 
positive for RFP, they were reported not to possess surface CCR2 based on 
staining with anti-CCR2 MC-21 antibody (Saederup et al., 2010). However, CCL2 
has been shown to mediate NK cell recruitment in vivo. Morrison et al. have 
reported that neutralisation of CCL2 leads to a decrease in NK cell recruitment 
to fungal infected lungs (Morrison et al., 2003). Thus, activation of NK cells and 
T cells might be associated with their upregulation of CCR2. In contrast, B cells 
have been reported to downregulate CCR2 expression following maturation, as 
measured by monitoring CCR2 mRNA. Activation of CCR2 on immature B cell did 
not mediate their recruitment to inflamed areas, but actually antagonised 
immature B cell migration to B cell follicles (Flaishon et al., 2004). 
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1.6.1.5 CCR2 and disease 
CCR2 has been described to function on a variety of cell types, both myeloid and 
lymphoid, therefore it is not surprising in addition to its roles in the defence 
against bacterial and viral pathogens, CCR2 has been described to function in a 
variety of immunopathologies. In particular monocyte migration has been shown 
to be involved in the development of atherosclerosis, as CCR2 and CX3CR1 
mediated migration of Ly6Chi and Ly6Clow monocytes respectively, leads to the 
development of macrophage derived foam cells (Lucas and Greaves, 2001; Tacke 
et al., 2007). The CCR2 dependent recruitment of monocytes to the central 
nervous system is crucial for the development of EAE, as CCR2 KO animals are 
resistant to EAE development (Gaupp et al., 2003; Mildner et al., 2009; Prinz 
and Priller, 2010). CCR2 has also been described to have both protective and 
disease-promoting effects on the development and progression of collagen-
induced arthritis (CIA). During the initiation phase of CIA, blockade of CCR2 
using the anti-CCR2 antibody MC-21 led to a decreased clinical score, as CCR2 
influences the Ag specific activation of T cells (Brühl et al., 2004), which might 
be associated with the earlier discussed CCR2 KO inflammatory DC deficit 
(Nakano et al., 2009). In contrast, during the progressive stage of the disease, 
blockade of CCR2 enhances clinical score, which correlates with a decrease in 
the number of Tregs. This decrease was specifically limited to a CCR2+ 
subpopulation of Tregs, which suppressed activation of other T cells and B cells 
(Brühl et al., 2004). 
The pivotal role CCR2 and its ligands play in monocyte mobilisation, and the role 
that these cells play in numerous diseases have highlighted CCR2 and CCL2 as 
potential therapeutic targets. Merck developed a CCR2 inhibitor, MK-0812, which 
has entered into clinical trials for rheumatoid arthritis and multiple sclerosis. 
However, in a phase II clinical rheumatoid arthritis trial, MK-0812 treated 
patients failed to show any significant improvements compared to the placebo 
group (Horuk, 2009). Vergunst et al. also reported no clinical improvement of 
rheumatoid arthritis following treatment with a CCR2 blocking antibody 
(MLN1202) (Vergunst et al., 2008). Likewise, infusions of human anti-CCL2 
antibody (ABN912) did not result in clinical improvement of rheumatoid arthritis 
(Haringman et al., 2006). ChemoCentryx also developed a CCR2 antagonist, 
CCX140, which is being tested in numerous inflammatory and metabolic 
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diseases. A phase II clinical trial in patients with Type 2 diabetes mellitus has 
been completed and indicated CCX410 treatment results in a decrease in fasting 
plasma glucose levels (Xia and Sui, 2009). 
In summary, CCR2 expression appears to be mainly limited to cells of the innate 
immune system and their BM precursors, particularly Ly6Chi monocytes (Sallusto 
et al., 1998; Serbina and Pamer, 2006). However, low levels of CCR2 have been 
detected on some lymphocyte populations (Mack et al., 2001). The absence of 
CCR2 has a profound effect on Ly6Chi monocytes. Ly6Chi monocytes are highly 
dependent on CCR2 for their emigration from the BM during homeostasis and 
inflammation. The deficit in peripheral Ly6Chi monocytes in CCR2 KO animals 
leaves them susceptible to infection Listeria monocytogenes, due to a decrease 
in inflammatory monocyte derived TipDCs (Serbina and Pamer, 2006). The 
absence of CCR2 is not always detrimental, as the absence of peripheral Ly6Chi 
monocytes in CCR2 KO mice renders them resistant to EAE development (Gaupp 
et al., 2003; Mildner et al., 2009; Prinz and Priller, 2010). CCR2, amongst over 
inflammatory chemokine receptors, has been reported to facilitate the 
migration of cDCs to sites of inflammation. Following their maturation cDCs 
downregulate CCR2 and upregulate CCR7 (Sallusto et al., 1998). Interestingly, 
CCR2 deficiency reportedly affects the maturation state of cDCs, as CCR2 
signalling led to NF-κB induced cDC maturation (Jimenez et al., 2010). 
Collectively, these data suggest that regardless of its classification as an 
inflammatory chemokine receptor, CCR2 plays vital roles both in homeostasis 
and inflammation. 
1.6.2 D6 
Most information about cell-type specific expression of D6 has been generated in 
human samples using an anti-human D6 antibody. First assessment of D6 
expression came from Northern blotting, which showed placenta to be by far the 
site of highest D6 expression in humans (Nibbs et al., 1997b). Nibbs et al. have 
also reported D6 expression by lymphatic endothelium in human skin, gut and LN 
afferent lymphatics, but D6 was absent from lymphatics in other organs (Nibbs 
et al., 2001). D6 has also been shown to be expressed by human trophoblasts 
(Martinez de la Torre et al., 2007; Madigan et al., 2010), hepatocytes and some 
leukocytes populations, such as mast cells, and macrophages (Hansell et al., 
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2011a). D6 has also been detected on human blood pDCs, B cells and cDCs 
(McKimmie et al., 2008). The absence of a reliable anti-murine D6 antibody 
means that there is limited information available about D6 expression by mouse 
leukocytes. However, the use of a chemokine internalisation assay facilitated 
the detection of D6 activity on murine innate-like B cells, including B cells in the 
colon (Bordon et al., 2009), splenic MZ-B cells and B1 B cells in various tissues 
(Hansell et al., 2011b). 
As discussed earlier, D6 is considered to be an atypical chemokine receptor, due 
to its inability to signal using the “classical” signalling pathways and its ability to 
scavenge large amounts of ligands without becoming desensitised. The proposed 
function of D6 in regulating inflammatory chemokine levels and as a 
consequence modulating in vivo inflammatory responses was established by 
studies investigating the affect of D6 deletion in the progression and resolution 
of a number of models of inflammation (Fra et al., 2003; Bonecchi et al., 2004; 
Hansell et al., 2011b). Lee et al. have proposed that it is not the D6 dependent 
regulation of inflammatory chemokine levels at peripheral sites of inflammation, 
but its ability to regulate the level of inflammatory chemokines on the lymphatic 
surfaces that might explain the inability of D6 deficient animals to resolve 
inflammatory responses (Lee et al., 2011). D6 was reported to regulate 
accumulation of inflammatory leukocytes at sites of peripheral inflammation and 
in the draining LNs by clearing inflammatory chemokines from lymphatic 
surfaces. In the absence of D6, lymphatic endothelial cells present inflammatory 
chemokines, which leads to an accumulation of cells in the draining LNs and 
lymphatic congestion. Lymphatic congestion leads to impaired migration of cells, 
including APCs from peripheral sites of inflammation, therefore hindering the 
development of an effective immune response (Lee et al., 2011). Recently D6 
has also been suggested to indirectly modulate the function of other chemokine 
receptors expressed by D6+ cells. The CXCR5 dependent migration of innate-like 
B1 B cells to CXCL13 was enhanced in the absence of D6 (Hansell et al., 2011b). 
Aberrant inflammatory responses in the absence of D6 have been observed in 
two different models of cutaneous skin inflammation. In one study skin 
inflammation was induced by the s.c. injection of CFA, which leads to the 
development of cutaneous lesions. A significantly greater proportion of D6 KO 
animals developed lesions that were graded as moderate to severe than WT 
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animals. D6 KO animals also had a significant increase in necrotic tissue at the 
injection site, and the draining LNs of D6 KOs had increased cellularity and levels 
of inflammatory chemokines compared to WT (Martinez de la Torre et al., 2007). 
More convincingly, Jamieson et al. induced cutaneous skin inflammation by 
repeated topical application of a phorbol ester irritant, TPA. TPA application 
caused production of TNFα that induced production of inflammatory chemokines 
that drive leukocyte infiltration. D6 KO animals were found to have significantly 
higher levels of inflammatory chemokines, supporting the role of D6 in the 
clearance of inflammatory chemokines. Repeated application of TPA to WT 
animals induced moderate inflammation that was rapidly resolved. In contrast, 
D6 deficient animals had a prolonged and exaggerated response developing a 
psoriatic like pathology (Jamieson et al., 2005).  
Nibbs et al. demonstrated that D6 deficient mice were more susceptible to the 
development of papillomas in a chemical carcinogen model of tumourigenesis 
(Nibbs et al., 2007). Furthermore, deletion of D6 was sufficient to render 
previously resistant mouse strains susceptible to papilloma formation. Mouse 
strains that are susceptible to papilloma formation were shown to have 
increased tumour burdens in the absence of D6 (Nibbs et al., 2007). In addition, 
transgenic overexpression of D6 in keratinocytes in the epidermis of transgenic 
mice altered their susceptibility to papilloma formation; susceptible mouse 
strains were more resistant to papilloma formation. Furthermore, TPA induced 
inflammation was more rapidly resolved in transgenic animals overexpressing D6. 
This study suggested that increased inflammatory chemokine levels and delayed 
resolution of TPA-induced inflammation in D6 KO animals were associated with 
their enhanced susceptibility to tumour development (Nibbs et al., 2007). 
The progression of several other diseases has been found to be altered in D6 
deficient animals, such as allergic lung inflammation (Whitehead et al., 2006), 
and Mycobacterium tuberculosis infection (Di Liberto et al., 2008). D6 deficient 
animals had increased disease severity in each of these models (Whitehead et 
al., 2006; Di Liberto et al., 2008). In a murine model of myocardial infarction, 
deletion of D6 resulted in adverse cardiac remodelling (Cochain et al., 2012). 
The aberrant response in each of these diseases could be linked to elevated 
inflammatory chemokine levels and increased infiltration of inflammatory cells 
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(Whitehead et al., 2006; Di Liberto et al., 2008; Cochain et al., 2012). Likewise, 
D6 deficiency and the associated increase in inflammatory chemokines and 
inflammatory infiltrate has been suggested to cause increased rate of foetal loss 
during inflammation (Martinez de la Torre et al., 2007). D6 has also been 
reported to inhibit resorption of embryos transferred into allogeneic recipients 
(Madigan et al., 2010). Therefore, expression of D6 by trophoblasts in the 
placenta might have key roles in foetal survival during inflammation (Martinez 
de la Torre et al., 2007; Madigan et al., 2010). 
There are conflicting reports of the role of D6 in dextran sodium sulphate (DSS)-
induced model of colitis. Our group found that D6 deficient mice had reduced 
disease severity (Bordon et al., 2009), whereas Vetrano et al. reported that D6 
deficient animals presented with increased disease severity (Vetrano et al., 
2010). A further contradiction between the two studies was that Vetrano et al. 
illustrated that D6 KOs had increased production of inflammatory chemokines 
and leukocyte recruitment to inflamed mucosa (Vetrano et al., 2010), while 
Bordon et al. showed no difference in inflammatory chemokine production by 
WT and D6 KO (Bordon et al., 2009). Furthermore, Bordon et al. found that D6 
deficient inflamed colons had elevated numbers of IL-17A secreting γδ T cells 
compared to WT animals, with a corresponding increase in IL-17A levels. The 
decreased susceptibility was linked to the increase IL-17A levels, as blockade of 
IL-17A increased disease severity in D6 KOs (Bordon et al., 2009). A consistency 
between the two groups is that both showed that D6 mRNA was upregulated in 
inflamed colons (Bordon et al., 2009; Vetrano et al., 2010). The discrepancies in 
these two studies might be explained by differences in the setup of the disease 
models. Both groups scored animals for 8 days after the start of DSS 
administration. However, Bordon et al. induced colitis with a lower dose of DSS 
over a shorter time-scale than Vetrano and co-workers (Bordon et al., 2009; 
Vetrano et al., 2010). Vetrano et al. added 3% DSS to the drinking water of 
animals for 7 days (Vetrano et al., 2010), whereas Bordon et al. added 2% DSS to 
their drinking water for 5 days, followed by 3 days with normal drinking water 
(Bordon et al., 2009). The DSS model of colitis is also markedly affected by local 
animal housing conditions, most likely because it affects the intestinal 
microflora of the animals. The contradictions within these studies mean that the 
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exact requirement for D6 in DSS-induced colitis is unclear and requires more 
investigation. 
Savino et al. reported an increase in the number of Ly6Chi monocytes that 
accumulate in the spleen of D6 deficient animals following inflammation. 
Subcutaneous administration of the inflammatory agent CFA led to an 
accumulation of Ly6Chi monocytes in the spleens of D6 KO animals greater than 
that observed in WT animals. Furthermore, Savino et al. illustrated that the 
accumulation of Ly6Chi monocytes in the spleen of D6 KO animals was CCR2 
dependent. D6 KO animals were irradiated and reconstituted with BM from WT, 
D6 KO or CCR2 KO animals prior to CFA treatment. The accumulation of Ly6Chi 
monocytes was observed in animals reconstituted with BM from WT and D6 KO 
animals, but not CCR2 KO animals (Savino et al., 2012). Ly6Chi monocytes from 
D6 KO animals were reported to have enhanced immunosuppressive activity, as 
measured by decreased disease severity in a model of graft versus host disease 
and decreased proliferation of CD8+ T cells upon culture in vitro with monocytes 
from D6 KO animals compared to WT (Savino et al., 2012). 
It has been proposed that in addition to the atypical chemokine receptor D6, 
which can scavenge CCL2, CCR2 also possesses some scavenging function, as it 
too can be rapidly recycled back to the plasma membrane and maintain high 
responsiveness to ligands (Volpe et al., 2012). The absence of CCR2 leads to 
sustained high CCL2 levels at sites of inflammation (Tylaska et al., 2002; Maus et 
al., 2005). In WT animals the levels of CCL2 gradually decrease over the course 
of inflammation, whereas in CCR2 KO animals the levels actually increase 
(Tylaska et al., 2002). Thus, CCR2 dependent recruitment of monocytes may 
limit further recruitment of monocytes by sequestering CCL2 and returning the 
inflamed tissue to steady-state (Maus et al., 2005). 
In summary, the majority of D6 expression data has been produced by analysing 
human tissues. Studies in the murine system have been hampered by the lack of 
a reliable anti-D6 antibody. However, recently using a chemokine internalisation 
assay, D6 receptor activity has been detected on murine innate-like B cells, 
including B cells in the colon, MZ-B cells and B1 B cells (Bordon et al., 2009; 
Hansell et al., 2011b). D6 is a promiscuous receptor that binds many 
inflammatory CC chemokines. Several groups have proposed that D6 serves as a 
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scavenger for inflammatory chemokines and as a consequence modulates 
inflammatory responses (Fra et al., 2003; Hansell et al., 2006; Mantovani et al., 
2006; Graham, 2009). Consistent with this hypothesis, D6 deletion is associated 
with aberrant inflammatory responses (Jamieson et al., 2005; Whitehead et al., 
2006; Di Liberto et al., 2008; Cochain et al., 2012). Therefore, D6 appears to be 
important for the resolution of inflammation. 
1.7 Thesis Aims 
Two CCL2 receptors, CCR2 and D6, have been implicated in the progression and 
regulation of several diseases through their ability to control leukocyte 
migration. With my group’s interest in chemokine regulation, at the outset of 
the project I was initially interested in examining how CCR2 contributes to the 
regulation of its ligands through chemokine scavenging, and the mechanisms that 
are responsible for this form of feedback control during inflammation. When 
considering the regulation of CCR2 ligands, it is important to consider the 
activity of D6 alongside those of CCR2 because this molecule, as discussed in the 
previous sections, binds many of the CCR2 ligands and is proposed to act as a 
‘professional’ chemokine scavenger. The relative contribution of CCR2 and D6 to 
chemokine regulation was considered an important aim. We specifically wanted 
to conduct these experiments using homogenous populations of primary 
leukocytes purified from mice because (i) it was considered more physiological 
than using transfected cell systems; (ii) leukocytes are easy to isolate in bulk 
with high purity; and (iii) it would allow us to use equivalent cell preparations 
from animals lacking CCR2 or D6 to identify the receptor(s) responsible for 
scavenging. To facilitate this work, therefore, we first needed to confidently 
identify suitable cell preparations expressing and possibly co-expressing CCR2 
and D6. However, primarily due to the lack of antibodies specific for mouse D6, 
there was limited understanding at the time of which cells express D6 and 
whether this atypical chemokine receptor could be co-expressed with CCR2. 
CCR2 had been more widely investigated and the impact of CCR2 deficiency on 
steady state and inflammation-driven leukocyte trafficking had been extensively 
reported. CCR2 protein expression in the mouse had been primarily assessed 
using a rat anti-mouse CCR2 antibody produced by Mack and colleagues (Mack et 
al., 2001), although commercial sources of anti-CCR2 antibodies were also 
available. Rat monoclonal antibodies often cross-react non-specifically with 
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mouse cells, and careful control experiments are required, but surprisingly, 
CCR2 deficient cells had rarely been used as controls in published studies using 
this antibody. Moreover, there were contradictions and inconsistencies in the 
anti-CCR2 flow cytometry data in literature, and between flow cytometry data 
and transcript analysis of CCR2 expression. This has led to uncertainty about 
whether certain cell types, such as neutrophils, can express CCR2 and this could 
clearly affect the interpretation of results generated using CCR2 deficient mice. 
Thus, at the beginning of the project, we felt that not only was our 
understanding of D6 expression by mouse leukocytes somewhat limited, but also 
that a comprehensive flow cytometric characterisation of CCR2 expression by 
mouse leukocytes was required. Therefore, I initially aimed to: 
1) Use available anti-mouse CCR2 antibodies, alongside other chemokine 
receptor detection techniques under development in the group, to 
provide a hitherto unavailable, carefully controlled, and robust 
description of the expression of D6 and CCR2 by mouse leukocytes. 
The data generated from these experiments, and the techniques developed to 
generate these data (all of which are reported in Chapter 3), altered the 
direction of my project away from its original focus on chemokine scavenging 
and allowed me to set the following subsequent aims: 
2) To explore whether the novel receptor detection techniques I developed 
can be used to examine receptor specificity and to detect CCL2 receptors 
on leukocytes from other mammalian species (Chapter 3); 
3) To define the impact of CCR2 deletion on the cellularity of lymphoid 
organs before and during systemic LPS challenge (Chapters 3 & 4); 
4) To reveal the dynamics of CCL2 receptor regulation in response to 
transient systemic inflammation (Chapter 4); 
5) To define the function of CCR2 on pDCs and examine whether differential 
expression of CCR2 defines two functionally distinct pDC subsets (Chapter 
5).
Chapter 2 – Materials and Methods 
2.1 Mice 
WT, D6 KO, CX3CXR1GFP/+, CD200R1 KO, CCR2 KO, OTII and OTI TCR transgenic 
mice, all on a C57BL/6 background, were bred at the Central Research Facility, 
University of Glasgow. Alternatively, WT animals on a C57BL/6 background were 
obtained from Harlan UK (Bicester, Oxon). The generation of CCR2 KOs (Boring 
et al., 1997), D6 KOs (Jamieson et al., 2005), CX3CXR1GFP/+ (Jung et al., 2000), 
CD200R1 KO (Boudakov et al., 2007), OTII (Murphy et al., 1990) and OTI 
(Hogquist et al., 1994) mice has been described. OTI and OTII animals possess 
CD8 or CD4 T cells with TCR specific for OVA peptides, respectively. OTI mice 
have CD8 TCR specific for OVA peptide 257-264 and OTII animals have CD4 TCR 
specific for OVA peptide 323-339, both of which need to be complexed to MHCI 
or MHCII, respectively. In all experiments, age-matched male littermate cohorts 
at 8–12 weeks of age were used. All mice were housed under specific pathogen-
free conditions in the animal facility at the Central Research Facility, University 
of Glasgow, UK. OTI mice were maintained in filter-top cages. All procedures 
were performed in accordance with United Kingdom Home Office regulations, 
and under the auspices of Project and Personal Licences. 
2.2 Maintenance of Flt3L producing cell lines: Flt3L 
generation and isolation 
CHO-Flt3L cells (a kind gift from the Simon Milling Laboratory, University of 
Glasgow, UK) and B16FL (kindly provided by Oliver Pabst, Medizinischen 
Hochschule Hannover, Germany) are two cell lines engineered to stably produce 
murine Flt3L. Both CHO-Flt3L cells (Naik et al., 2010) and B16FL (a murine 
melanoma tumour cell line) (Mach et al., 2000) were maintained in T75 flasks in 
RPMI 1640 supplemented with 10 U/ml penicillin/streptomycin, 0.2 mM L-
glutamine, 10% Foetal Calf Serum, and 26.3 nM β- Mercaptoethanol (β-ME) (all 
purchased from Invitrogen, Paisley, UK). Cells were harvested at 70-80% 
confluency twice a week and cell culture conditioned media (CM) containing 
Flt3L was harvested from cultures when cells reached confluency, typically 
every 3 days. CM was filtered using a 0.2 µm pore filter and syringe. 
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2.3 Measurement of Flt3L by ELISA 
The amount of Flt3L in CMs was determined by ELISA according to the 
manufacturer’s instructions (R&D Systems, Abingdon, UK). In brief, following the 
addition of assay diluent to each well, samples, controls or standards were 
added to wells and incubated for 2 hours (hrs) at room temperature (RT). After 
washing with the supplied wash buffer, Mouse Flt3L conjugate was added to 
each well and incubated at RT for 2 hrs. Plates were then washed and the 
substrate solution was added to each well and incubated for 30 minutes (mins) 
at RT before stop solution was applied. The optical density of each well at 450 
nm was determined using a Sunrise microplate reader (Tecan, Reading, UK) and 
sample Flt3L concentrations calculated from the standard curve obtained. 
2.4 LPS administration in vivo 
Age-matched animals were treated intravenously (i.v.) with either 100 µl sterile 
PBS (Invitrogen) or 15 µg LPS E. coli (serotype 0111.B4; Sigma Aldrich, Dorset, 
UK) in 100 µl sterile PBS, 24, 48 or 72 hrs before tissues were harvested. 
Alternatively, 3 hrs prior to the i.v. injection of PBS or LPS, mice were injected 
intraperitoneally (i.p.) with either 100 µl sterile PBS or 0.3 mg/kg CXCR2 
antagonist, SB225002 (Cambridge Bioscience, Cambridge, UK). 
2.5 Flt3L mediated expansion of DCs in vivo 
In vivo expansion of pDCs was achieved by the administration of 10 µg human 
recombinant Flt3L (rhFlt3L) (kindly provided by the Simon Milling Laboratory, 
University of Glasgow, UK) in 100 µl sterile PBS i.p. for 9 consecutive days. Mice 
were sacrificed on the 10th day. Alternatively, pDCs were expanded using murine 
Flt3L produced by B16FL cells. Mice were s.c. transplanted with ~2x106 B16FL 
cells and tumour growth was monitored over a period of 10-14 days until 
sacrifice. 
2.6 Imiquimod administration in vivo 
The dorsal skin of age-matched animals was topically treated once daily with 
either ~10-12 µl of AldaraTM 5% imiquimod cream (Meda AB, Takeley, UK) or 
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control aqueous cream B.P. (Boots, Nottingham, UK) for 7 days before tissues 
were harvested on the 8th day. 
2.7 Preparation of single cell suspensions from lymphoid 
organs 
Spleens and LNs were collected, cut into approximately 5 mm3 pieces and 
digested with 0.1 mg/ml Collagenase D (Roche, Burgess Hill, UK) in Hank’s 
balanced salt solution medium (HBSS) (Invitrogen) for 45 mins at 37°C in a cell 
shaker. The use of the term peripheral LNs (PLNs) is in reference to a pooled 
collection of the cervical, axillary, brachial, inguinal and popliteal LNs. The BM 
was prepared by harvesting femurs and flushing the BM from the bones with 
complete RPMI (RPMI 1640 supplemented with 10 U/ml penicillin/streptomycin, 
0.2 mM L-glutamine, and 10% Foetal Calf Serum (FCS) [all Invitrogen]) using a 
syringe and a 26-gauge needle. Single cell suspensions were prepared in 
complete RPMI by the gentle mechanical disruption of tissues and passing 
through a 40 µm nylon mesh (Cadisch, London, UK). Cells were subsequently 
washed by centrifugation at 400xg for 5 mins at 4°C and resuspended in 
complete medium. Red blood cell lysis was performed on both spleen and BM 
samples using Red Blood Cell Lysis Buffer (Sigma Aldrich) for 1 min at RT 
followed by washing with complete RPMI for 5 mins at 4°C. Cells were 
resuspended in complete medium and viable cell counts were performed using a 
Neubauer haemocytometer and phase contrast microscope. Cell suspensions 
were kept on ice until required. 
2.8  Preparation of single cell suspensions from murine 
blood 
Blood was harvested from animals by terminal cardiac puncture using a 1 ml 
syringe and a 25-gauge needle, which prior to collection had been flushed with 
0.5 M ethylenediaminetetraacetic acid (EDTA) pH8.0 dissolved in distilled H2O 
(kind gift from Chris Hansell, University of Glasgow, UK). The amount of blood 
retrieved was recorded. Red blood cell lysis was performed using ammonium 
chloride (Stemcell Technologies, Manchester, UK) at a ratio of 9:1 ammonium 
chloride to blood. The cells in ammonium chloride were vortexed and incubated 
on ice for 10 mins. Cells were then washed twice by centrifugation at 400xg with 
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complete RPMI for 5 mins at 4°C. Cells were resuspended in complete medium 
and viable cell counts were performed using a Neubauer haemocytometer and 
phase contrast microscope. Cell suspensions were kept on ice until required. 
2.9 Preparation of single cell suspension from human 
peripheral blood 
50 ml of blood was collected from healthy donors. 4 ml of Histopaque (Sigma 
Aldrich) was added to a 15 ml Falcon Tube (BD Biosciences, Oxford, UK). 10 ml 
of blood was gently layered on top of the Histopaque. The solution was 
centrifuged for 20 mins at 2100 RPM at RT with the acceleration and break set to 
the lowest setting. The lymphocyte layer was harvested and washed three times 
in complete RPMI by centrifugation at 400xg for 5 mins at 4°C. Cells were 
resuspended in complete medium and viable cell counts were performed using a 
Neubauer haemocytometer and phase contrast microscope. Cell suspensions 
were kept on ice until required. 
2.10 Preparation of single cell suspensions from murine 
skin 
Murine dorsal skin was excised and cut into small ~5 mm3 pieces and digested 
using 0.1 mg/ml Collagenase D (Roche) in HBSS (Invitrogen) for 1.5 hrs at 37°C in 
a cell shaker. After the incubation, 0.2% (w/v) Dispase (Invitrogen) was added 
and cells were incubated for a further 20 mins at 37°C in a cell shaker. Following 
digestion of the skin, a single cell suspension was prepared by passing pieces of 
skin through a 70 µm nylon mesh (Cadisch). Cells were subsequently washed 
twice in complete medium by centrifugation for 5 mins at 4°C and resuspended 
in complete medium.  
2.11 Generation of BM-derived DCs 
BM was harvested as described in section 2.7, and used for the differentiation of 
BM-derived pDCs (BM-pDCs). 2x106 BM cells per ml were incubated at 37°C in 5% 
CO2 and cultured for 7 to 10 days in RPMI 1640 medium supplemented with 10% 
FCS, penicillin/streptomycin, 4 mM L-Glutamine, and 26.3 nM β-ME. Medium was 
conditioned with 1-100 ng/ml Flt3L, either rhFlt3L, or CM from the CHO-Flt3L 
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cell line or the B16FL tumour cell line. Medium was replaced every 2-3 days. BM-
DCs were harvested by gentle washing of the plates. 
2.12 Flow cytometry 
Cells were washed by centrifugation at 400xg at 4°C for 5 mins in ice cold FACS 
buffer (1X PBS, 1% FCS, 0.02% NaNH3 and 5 mM EDTA), suspended at 1-2 x106 
cells per well in a 96-well round bottomed plate (Corning Limited, New York, 
USA). Cells were treated with Fc block (Anti-CD16/CD32) (BD Biosciences) 
diluted 1:100 in FACS buffer at 4°C for 15 mins prior to antibody staining. 
Treatment with Fc Block is used to minimise non-specific binding. Cells were 
washed by centrifugation at 400xg at 4°C for 5 mins, supernatant (SN) was 
removed and cells were stained for 15 mins with fluorescein isothiocyanate 
(FITC), phycoerythrin (PE), allophycocyanin (APC), efluor450 (e450), pacific blue 
(PB), Horizon V450 (V450), peridinin chlorophyll protein complex (PerCP), 
AlexaFluor647 (AF647), PE-Cy7 conjugate, PE-Cy5 conjugate, APC–Cy7 conjugate, 
alexafluor700 (AF700) or biotin-conjugated antibodies specific for selected cell 
markers (antibodies targeted against cell markers; murine Table 2-1; rat Table 
2-2 and human Table 2-3). Antibodies were purchased from BD Biosciences; 
eBioscience (Hatfield, UK); Miltenyi-Biotec (Surrey, UK); R&D Systems; MBL 
(Woburn, USA); Novus Biologicals (Cambridge, UK); Epitomics (Burlingame, USA); 
Biolegend (Cambridge, UK) or AbD Serotec (Kidlington, UK), as indicated. Some 
of the anti-rat antibodies were generated in house and were kindly provided by 
the Simon Milling laboratory (University of Glasgow, UK). Biotin-conjugated 
antibodies were detected by the addition of one of a variety of streptavidin 
antibodies conjugated with a fluorescent dye (BD Biosciences). All FACS 
antibodies were used at 1:200, unless stated otherwise, in FACS buffer. All 
incubations were performed in 50 µl of FACS buffer at 4°C in the dark. After 15 
mins at 4°C, with appropriate stains, the cells were washed twice with FACS 
buffer. Dead cell exclusion was performed in the majority of experiments using 
the cell viability dye ViaProbe (BD Biosciences). 10 µl of ViaProbe in 100 µl of 
FACS buffer was added to each well and incubated for 10 mins. Following 
ViaProbe staining of dead cells, an additional 100-200 µl FACS buffer was added. 
Alternatively, fixable viability dyes (eBiosciences) were used prior to the 
antibody staining steps, according to manufacturer’s instructions. Concisely, 
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cells were washed twice in PBS, resuspended at 1-10x106 cells per ml in PBS and 
1 µl of fixable viability dye per ml was added. The cells were vortexed 
immediately and incubated for 30 mins at 4°C. Cells were washed in FACS buffer 
and stained according to the above protocol. 
Stained cell preparations were acquired using either a Miltenyi MACSQuant or BD 
LSRII. Unstained cells and cells stained with only one fluorescent antibody were 
used to establish acquisition parameters. Retrieved data was analysed using 
FlowJo software (Treestar inc., OR, USA). To aid analysis, fluorescent minus one 
(FMOs) samples were prepared, these cells were stained with all antibodies bar 
one, which was substituted with an appropriate isotype. This technique allows 
for confident determination of true populations of stained cells. 
2.13 Conjugation of a fluorescent PE-Cy7 tandem dye to 
IL-17RB antibody 
The Lightning-LinkTM PE-Cy7 Tandem Conjugation kit (Innova Biosciences, 
Cambridge, UK) was used according to manufacturer’s instructions to attach a 
PE-Cy7 fluorescent tandem dye to the anti-murine IL-17RB antibody supplied by 
Andrew McKenzie (University of Cambridge, UK). 1 µl of the supplied LL-modifier 
reagent was added to 10 µg/10 µl antibody and mixed gently. The 11 µl of 
antibody/LL-modifier mix was added to a vial of Lightning-LinkTM mix and 
resuspended gently by pipetting the mixture up and down. The mixture was left 
for 3 hrs in the dark at RT. Following completion of the incubation period, 1 µl 
of the supplied LL-Quencher FD reagent was added, and subsequent to a 30 min 
incubation period the antibody was used according to staining protocol described 
in section 2-12. 
2.14  Staining of CCR2 using MC-21 antibody 
Cells were washed by centrifugation at 400xg at 4°C for 5 mins in ice cold FACS 
buffer, resuspended at 1-2x106  cells per well in a 96-well round bottomed plate. 
Following further centrifugation cells were incubated in 10% heat-inactivated 
mouse serum (kindly provided by Chris Hansell, University of Glasgow, UK) in PBS 
for 1 hr at 4°C. Cells were then washed three times in FACS buffer. The cells 
were then stained with 2.5, 5 or 10 µg/ml MC-21 anti-CCR2 (a kind gift from the 
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Matthias Mack Laboratory, Regensburg, Germany) or the appropriate isotype (Rat 
IgG2bκ) for 1 hr at 4°C. Subsequent to a further three wash steps, cells were 
stained with biotinylated polyclonal anti-rat IgG (1:100) (BD Biosciences) for 30 
mins at 4°C. Cells were then washed another three times and stained with the 
streptavidin-APC for 15 mins at 4°C. Lastly, cells were washed three more times 
and then stained for other surface markers as indicated in section 2-12. 
2.15 Fluorescently labelled chemokines 
Almac (Craigavon, UK) chemically synthesise endotoxin free human chemokines 
labelled with AF647. Chemical synthesis of chemokines ensures high purity 
products with precise aa sequences. CCL2 and CCL5 selectively labelled at or 
near their C-terminus with a single AF647 molecule were used in this project. 
CCL2AF647: QPDAINAPVT CCYNFTNRKI SVQRLASYRR ITSSKCPKEA VIFKTIVAKE 
ICADPKQKWV QDSMDHLDKQ TQTPK(AF647)T-OH 
CCL5AF647: SPYSSDTTPC CFAYIARPLP RAHIKEYFYT SGKCSNPAVV FVTRKNRQVC 
ANPEKKWVRE YINSLEK(AF647)S 
In the case of each chemokine AF647 was incorporated at the indicated position 
at a molar ratio of dye:chemokine of 1:1. Targeted labelling of chemokines at 
their C-terminus leaves the N-terminus, which is important for the biological 
function of chemokines, unmodified. 
2.16 Chemokine uptake assay 
Cells (1-2x106 cells/ 50 µl) in binding buffer (complete RPMI with 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesylfonic acid (HEPES) pH7.2 [Invitrogen]) were 
incubated in a 96-well polypropylene plate (NUNC, Fisher Scientific, 
Leicestershire, UK) with 25 nM CCL2AF647 or CCL5AF647 with or without competition 
at 37°C for 60 mins in the dark. Competition, unless indicated otherwise, refers 
to the addition of 10~fold molar excess of unlabelled chemokine ligand 
(PeproTech, London, UK) to the binding buffer. Alternatively, prior to incubation 
with CCL2AF647, cells were incubated for 30 mins with 0-250 nM of unlabelled 
chemokine ligand. Cells were washed in binding buffer by centrifugation at 
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400xg for 5 mins at 4°C, and incubated in binding buffer containing 25 nM 
CCL2AF647 for 60 mins at 37°C. Subsequent to the 60 min incubation period with 
CCL2AF647, cells were washed and stained for surface markers as indicated in 
section 2-12.  
2.17 FACS purification of pDCs and cDCs 
pDCs and cDCs from the spleen of B16FL treated tumour bearing WT animals 
were purified using a BD FACS Aria. Following preparation of a single cell 
suspension as described above, cells were either immediately Fc Blocked and 
stained for pDCs, or this was delayed until after the chemokine uptake assay was 
performed. The pDCs were gated as live, B220+CD11c+Ly6C+CD11b-SiglecH+ and 
cells were sorted as total pDCs. Alternatively, pDCs were divided into two 
subsets, CCL2hi and CCL2lo and each subset sorted. B220-CD11c+ cells were sorted 
and classified as cDCs. Subsequent to sorting the purity of the sorted cells was 
tested and was routinely >95%. 
2.18 RNA preparation 
Following purification, cells were centrifuged at 400xg for 5 mins at 4°C and the 
SN completely removed. Samples were resuspended in 350 µl RLT buffer 
provided in the RNeasy Mini Kit (Qiagen, Crawley, UK). The cell lysates were 
homogenised by passing 5-10 times through a 20-gauge needle attached to a 1 ml 
syringe. The homogenised cell lysates were then stored at -80ºC. RNA was 
isolated the following day according to the RNeasy Mini Kit instruction manual. 
The optional on-column DNase digestion step was performed using the RNase-
Free DNase Set (Qiagen). Each sample was stored at -80ºC until used. 
2.19 Synthesis of complementary DNA (cDNA) from RNA 
cDNA was reverse-transcribed from 200 ng of RNA using the AffinityScriptTM 
Multiple Temperature cDNA Synthesis Kit (Agilent Technologies Limited, 
Wokingham, UK), according to manufacturer’s instructions. Concisely, 200 ng 
RNA was added to 0.5 µg oligo (dT) primer and the total volume adjusted to 15.7 
µl in RNase-free water. Samples were incubated at 65°C for 5 min, then 21°C for 
10 mins. When the reaction had been cooled to RT, the final volume of the 
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reaction was adjusted to 20 µl by the addition of 4.3 µl of a cocktail containing 
1X AffinityScript RT Buffer, 2 mM dNTP mix, 20 U RNase Block Ribonuclease 
Inhibitor and 1 µl of AffinityScript Multiple Temperature RT. In controls, 
AffinityScript Multiple Temperature RT was replaced by 1 µl of RNase-free 
water. Samples were incubated for 5 mins at 42°C, followed by 1 hr incubation 
at 55°C and then 70°C for 15 mins. Samples were stored at -20°C until they were 
used for Quantitative Polymerase Chain Reaction (QPCR). 
2.20 Microarray 
RNA extracted from sorted total pDCs, CCL2hi and CCL2lo pDCs was sent to the 
Glasgow University Polyomics Facility. The facility determined the RNA 
concentration using a Thermo Fisher Nanodrop 1000TM Spectrophotometer 
(Thermo Fisher Scientific, Loughborough, UK). The facility used the RNA 6000 
Nano kit (Agilent Technologies Limited) to determine the RNA integrity using an 
Agilent Bioanalyzer 2100 (Agilent Technologies Limited). The RNA samples were 
loaded and run on a Gene 1.0 ST array (Affymetrix, High Wycombe, UK), which 
analysed ~28,000 genes within the mouse genome, including exons. Analysis of 
the ensuing results was performed using software from Partek Genomic Suite 
(Partek Incorporated, Saint Louis, USA) and heat-maps were generated using 
GeneSpring version 12.0 (Agilent Technologies Limited). 
2.21 QPCR 
Equal amounts of cDNA were added to a 384-well MicroAmp® Fast Optical 
Reaction Plate (Applied Biosystems, Paisley, UK) in triplicate per biological 
sample. The final total of each well was adjusted to 10 µl with 1X TaqMan® 
Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems), 0.5 µl of 
20X appropriate probe (Applied Biosystems) (see Table 2-4 for list of probes) and 
RNase-free water. All assays contain sequence-specific unlabelled primers plus a 
TaqMan® probe labelled with a fluorescent FAMTM dye. Plates were loaded into a 
7900HT Fast Real-Time PCR System machine (Applied Biosystems) and incubated 
for 10 mins at 95°C followed by 40 cycles of 15 secs at 95°C, and 1 min at 60°C. 
Relative quantity (RQ) values were determined for each sample using RQ 
Manager software (Applied Biosystems). 
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2.22 Co-culture of pDCs with naïve OTI or OTII T cells 
cDCs, or pDCs, either CCL2hi, CCL2lo or total pDCs, purified from the spleens of 
B16FL tumour bearing mice, were incubated in complete RPMI supplemented 
with 50 µM β-ME, plus varying amounts of total OVA protein (Calbiochem, 
Nottingham, UK) for 3 hrs at 37ºC with or without 1 µg/ml R848 (kind gift from 
the Simon Milling laboratory, University of Glasgow, UK). Following the 
incubation period, cells were washed twice in media by centrifugation at 400xg 
for 5 mins at 4°C. Naïve T cells from the LNs and spleen of OTI or OTII mice were 
sorted using a BD FACS Aria, as CD8α+CD62L+ or CD4+CD62L+ T cells, respectively. 
Purified T cells were spun at 400xg for 5 mins at 4°C, washed in PBS, and 
resuspended at 10x106 cells per ml in PBS. 1 µl of 5 mM stock CFSE (eBioscience) 
was added per ml of cells, and cells were incubated in the dark for 3-4 mins at 
37ºC. Upon completion of incubation period, cells were washed in PBS and 
resuspended at 1x106 cells per ml. 100 µl of the T cell suspension was added to 
either cDC or pDC containing wells. In some experiments 1, 12.5 or 25 nM mCCL2 
(PeproTech) was added to the culture media. Cells were incubated for 3 days, 
before restaining according to section 2-12. Data were acquired on a BD LSRII. 
2.23 Migration assays 
Total pDCs, purified from the spleens of B16FL treated mice, were resuspended 
at 1x106 cells per ml in chemotaxis buffer (RPMI supplemented with 0.5% bovine 
serum albumin [Sigma Aldrich] and 25 mM HEPES, pH7.2 [Invitrogen]). 600 µl of 
chemotaxis buffer was added to the middle 12 wells of a 24 Transwell plate 
following the removal of the provided 5.0 µm pore polycarbonate membrane 
insert (Corning Limited). Plates were incubated at 37ºC for 10 mins. The wells 
were then spiked with 0-50 nM unlabelled murine CCL2 (PeproTech) diluted in 
chemotaxis buffer. Following, the gentle lowering of the filters into the media 
filled wells, the plate was once again incubated at 37ºC for 10 mins, to allow 
some chemokine to adhere to the filter. 100 µl of the cell suspension (1x105 
cells) was added to the upper well and the plate was returned to the 37ºC 
incubator for 3 hrs. The cells were then retrieved from the lower well and 
stained according to section 2-12. Cells were resuspended in 200 µl FACS buffer 
and data were acquired from a set volume of sample on a Miltenyi MACSQuant. 
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2.24 Ex vivo stimulation of sorted pDCs to measure 
maturation of pDCs 
CCL2hi and CCL2lo pDCs, purified from the spleens of B16FL tumour bearing mice, 
were resuspended at 1x106 per ml in complete RPMI supplemented with 50 µM β-
ME. 1x105 cells were added to each well and incubated with 5 µg/ml CpG-C 
(Source BioScience LifeSciences, Nottingham, UK) with 0, 0.1 or 1 µg/ml 
recombinant murine IL-13 (R&D Systems) for 18 hrs at 37ºC. Subsequent to the 
completion of the incubation period, cells were centrifuged at 400xg for 5 mins 
at 4ºC. Cells were then restained according to section 2-12 and data were 
acquired on a BD LSRII. 
2.25 Ex vivo stimulation of IFNα  production by sorted 
pDCs  
CCL2hi and CCL2lo pDCs, purified from the spleens of mice carrying B16FL 
tumours, were resuspended at 1x106 per ml in complete RPMI supplemented with 
50 µM β-ME. 1x105 cells were added to each well and incubated with either 
media alone, 10 µg/ml CpG-A (Source BioScience LifeSciences), or 10 µg/ml 
R848 for 8 hrs at 37ºC. Subsequent to the completion of the incubation period, 
cells were centrifuged at 400xg for 5 mins at 4ºC. Following of which SN was 
harvested and frozen at -80ºC until required. Cells were also harvested and RNA 
extracted as described in section 2-17. 
2.26  Measurement of IFNα  production by ELISA 
The amount IFNα in the SN from section 2-24 was determined by ELISA according 
to the manufacturer’s instructions (PBL Interferon Source, New Jersey, USA). 
Following the preparation of samples, controls or standards diluted in sample 
buffer (PBL Interferon Source) they were added to each well, and incubated for 
1 hr at RT with shaking 450 RPM. The plate was then transferred to 4ºC and 
incubated for 20-24 hrs. After washing four times with the supplied wash buffer 
(PBL Interferon Source), horseradish peroxidase solution (PBL Interferon Source) 
was added to each well and incubated at RT for 2 hrs with shaking 450 RPM. 
Plates were then washed four times and the substrate solution (PBL Interferon 
Source) was added to each well and incubated for 15 mins at RT before stop 
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solution (PBL Interferon Source) was applied. The optical density of each well 
was determined within 5 mins of stop solution being added at 450 nm using a 
Sunrise microplate reader (Tecan) and sample IFNα concentrations calculated 
from the standard curve obtained. 
2.27 Cytospin preparation and staining 
5x104 CCL2hi or CCL2lo pDCs, purified from the spleens of B16FL treated mice, 
were centrifuged at 400xg for 5 mins at 4ºC and resuspended in 70 µl PBS. 
Alternatively, cells were stimulated with CpG-C according to section 2-23. Upon 
assembling of the poly-L-lysine slide (VWR, Lutterworth, UK), filter card (Thermo 
Fisher Scientific) and funnel in the clip, cells were pipetted into the funnel. The 
cells were centrifuged for 6 mins at 450 RPM at RT. Slides were allowed to dry 
and stained using Rapid Romanowsky staining kit (Raymond A Lamb Limited, 
Eastbourne, UK), according to manufacturer’s instructions. In brief, slides were 
immersed in fixative solution (contains Thiazine dye in methanol) for 30 secs and 
transferred without rinsing or drying to solution B (contains Eosin Y) for 15-30 
secs. The slide was slowly agitated whilst in solution B, by gently immersing and 
withdrawing the slide. Again without washing or rinsing, this staining procedure 
was repeated with solution C (contains Methylene Blue). Slides were washed in 
distilled H2O and allowed to dry. Slides were then mounted using DPX mountant 
for microscopy (VWR) and examined under an Olympus BX41 microscope and 
CellB Software (Olympus, Essex, UK). 
2.28 Statistical analyses 
Results are shown as means ± 1 standard deviation (SD) unless otherwise stated. 
Normal distribution was tested where appropriate using the D’Agostino and 
Pearson omnibus normality test. Groups were compared using a Student’s 
unpaired two-tailed t test, one-way ANOVA with Tukey post-test, two-way 
ANOVA with Bonferroni post-test or Mann-Whitney test. Values of p<0.05 were 
considered to be statistically significant. 
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Antigen Clone Isotype Supplier Dilution 
Ly6C AL-21 RatIgM κ BD Biosciences 1:200 
I-A/I-E M5/114.15.2 RatIgG2b κ eBioscience 1:500 
Gr1 RB6-8C RatIgG2b κ eBioscience 1:200 
CD86 GL1 RatIgG2a κ eBioscience 1:200 
CD3 17A2 RatIgG2b κ eBioscience 1:200 
CD11b M1/70 RatIgG2b κ BD Biosciences 1:200 
CD4 GK1.5 RatIgG2b κ eBioscience 1:200 
PDCA1 JF05-12C.4.1 RatIgG2b κ Miltenyi-Biotec 1:11 
CD49b DX5 RatIgM κ eBioscience 1:200 
CD11c N418 Armenian Hamster IgG eBioscience 1:200 
F4/80 BM8 RatIgG2a κ eBioscience 1:200 
γδ eBioGL3 Armenian Hamster IgG eBioscience 1:200 
CD8α 53-6.7 RatIgG2a κ eBioscience 1:200 
B220 RA3-6B2 RatIgG2a κ eBioscience 1:250 
CD115 AFS98 RatIgG2a κ eBioscience 1:200 
SiglecH eBio440c RatIgG2b κ eBioscience 1:200 
CCR9 242503 RatIgG2b κ R&D Systems 1:50 
CD62L MEL-14 RatIgG2a κ eBioscience 1:200 
LPAM-1 DATK32 RatIgG2a κ eBioscience 1:200 
OX40L RM134L RatIgG2b κ eBioscience 1:200 
CD9 eBioKMC8 RatIgG2a κ eBioscience 1:200 
CCR7 4B12 RatIgG2a κ eBioscience 1:200 
CD69 H1.2F3 Armenian Hamster IgG eBioscience 1:200 
IL-17RB D9.2 MouseIgG1 κ Andrew McKenzie 1:200 
Ly49Q 2E6 RatIgG2a κ MBL 1:200 
CCR2  Polyclonal Novus Bio. 1:10 
CCR2 E68 Rabbit Monoclonal IgG Epitomics 1:10 
CCR2 MC-21 RatIgG2b κ Matthias Mack 1:100 
CD19 eBio1D3 RatIgG2a κ eBioscience 1:200 
CD107b M3/84 RatIgG1 κ eBioscience 1:100 
NK1.1 PK136 MouseIgG2a κ eBioscience 1:200 
CD25 7D4 RatIgM κ BD Biosciences 1:200 
CD200R1 OX-90 RatIgG2a κ AbD Serotec 1:100 
CD312a1 13MOKA RatIgG2a κ eBioscience 1:100 
ICOS-L HK5.3 RatIgG2a κ eBioscience 1:200 
CD45 30-F11 RatIgG2b κ eBioscience 1:200 
Table 2-1: Antibodies and isotypes for flow cytometry of murine cells.
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Antigen Clone Supplier Dilution 
MHCII OX-6 BD Biosciences 1:400 
CD4 OX-35 BD Biosciences 1:400 
CD45R His24 BD Biosciences 1:200 
CD11b OX-42 BD Biosciences 1:200 
CD43 W3/13 In house 1:200 
CD45RA OX-33 Biolegend 1:200 
Igκ OX-12 Biolegend 1:200 
CD45RC OX-22 In house 1:200 
TCRαβ R73 In house 1:200 
Igλ MRL-61 Biolegend 1:200 
Table 2-2: Antibodies and isotypes for flow cytometry of rat cells. 
Antigen Clone Supplier Dilution 
CD14 M5E2 Biolegend 1:20 
CD3 UCHT1 Biolegend 1:100 
CD56 MEM-188 Biolegend 1:25 
CD15 W6D3 Biolegend 1:25 
CD19 HIB19 Biolegend 1:100 
CD123 6H6 Biolegend 1:20 
CD304 BDCA-4 Miltenyi Biotech 1:20 
MHCII L243 Biolegend 1:40 
Table 2-3: Antibodies and isotypes for flow cytometry of human cells. 
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Target Gene Abbreviation Assay ID 
cysteinyl leukotriene receptor 1 Cysltr1 Mm00445433_m1 
G protein-coupled receptor 174 Gpr174 Mm01238430_m1 
Eph receptor B2 Ephb2 Mm01181021_m1 
chemokine (C-C motif) receptor 2 Ccr2 Mm00438270_m1 
PHD finger protein 17 Phf17 Mm00552321_m1 
guanylate binding protein 4 Gbp4 Mm00657752_m1 
cytochrome c oxidase, subunit VI a, 
polypeptide 2 Cox6a2 Mm00438295_g1 
retinoic acid receptor, gamma Rarg Mm00441091_m1 
mitogen-activated protein kinase 
kinase kinase 14 Map3k14 Mm00444166_m1 
interferon regulatory factor 7 IRF7 Mm00516788_m1 
glyceraldehyde 3-phosphate 
dehydrogenase GAPDH 4352932E 
Table 2-4: Probes used in QPCR. 
Chapter 3 – Using fluorescent CCL2 to detect CCL2 
receptors 
3.1 Currently available methods to detect CCR2 
In the Introduction, I discussed the role that chemokines and their receptors play 
in homeostasis and inflammation. I provided details about the known roles of 
CCR2 in diseases, such as atherosclerosis (Lucas and Greaves, 2001; Tacke et al., 
2007), CIA (Brühl et al., 2004) and EAE (Gaupp et al., 2003; Mildner et al., 2009; 
Prinz and Priller, 2010). In many cases the role of CCR2 was identified by using 
animals deficient in the receptor, with a lack of CCR2 causing disease to be 
either abrogated or augmented. In addition, observed alterations in cell 
frequencies in analysed tissues of CCR2 KOs provided information about the 
dependency of specific cell populations on CCR2 for their migration. However, in 
the case of many murine chemokine receptors, including CCR2 and D6, there is 
limited information available about their expression, mainly due to poor 
sensitivity of available reagents. The original aim of this project was to 
determine how CCR2 and D6 contribute to the regulation of their ligands through 
chemokine scavenging. To achieve this aim, a comprehensive flow cytometric 
characterisation of CCR2 and D6 expression by mouse leukocytes was required. 
Methods that are currently available to detect CCR2, in addition to other 
chemokine receptors, are limited to either antibodies targeted against the 
receptor, RT-PCR or knock-in reporter mice. Two CCR2 reporter mice have been 
generated. Serbina et al. generated a CCR2-GFP reporter mouse using bacterial 
artificial chromosomes carrying the gene encoding enhanced GFP under the 
control of the CCR2 promoter (Serbina et al., 2009). The CCR2-RFP reporter 
mice were generated by Saederup et al. and have the first 279 base pairs of the 
amino terminus of the CCR2 opening reading frame replaced with an expression 
cassette containing cDNA encoding RFP (Saederup et al., 2010). These methods 
all suffer from limitations. RT-PCR only provides information about receptor 
transcript levels, and although RT-PCR on a single cell basis is possible, it is 
technically challenging and difficult to use to look at large mixed populations of 
cells. Moreover, the transcript level does not necessarily reflect the level of 
functional protein. Reporter mice provide further scope for the analysis of CCR2 
expression as they facilitate analysis of CCR2 expression by individual cells using 
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flow cytometry and tissue sections. However, the GFP/RFP levels merely reflect 
CCR2 transcript levels - positivity for GFP/RFP does not necessarily indicate 
expression of CCR2 protein. Indeed, some RFP+ cells were not found to express 
CCR2 at the cell surface (Saederup et al., 2010). This is one of several caveats 
that need to be considered when thinking about the validity of knock-in reporter 
mice. Therefore, a method of protein detection is preferable in many cases. 
Anti-CCR2 antibodies also facilitate the analysis of CCR2 expression by single 
cells using flow cytometry. Furthermore, at the beginning of this project the 
CCR2-RFP reporter mice had yet to be generated and thus were not available to 
the scientific community. Consequently, as the only remaining option, our focus 
turned to the use of antibodies to specifically detect CCR2. It was known at the 
time of initiating our study that antibodies targeted against chemokine receptors 
have proven in many cases to be unreliable. Most antibodies targeted against 
murine chemokine receptors are less efficient than the human equivalents, with 
some antibodies failing to detect the receptor of interest or having low 
sensitivity for their target (Hansell et al., 2011b). This is in part due to the fact 
that mice are the usual animals of choice for inoculation with immunogen to 
generate monoclonal antibodies targeted against chemokine receptors. In 
addition, many antibodies are not generated against the entire protein, but a 
selective peptide, which may be obscured when the protein is in its native, 
folded conformation. Furthermore, chemokine receptors are subject to post-
translational modifications, which alter the binding affinity and functions of the 
receptor, which could interfere with antibody binding. For example, the N-
terminus of chemokine receptors is thought to be decorated by glycosylation, 
and tyrosine residues are often sulphated (Preobrazhensky et al., 2000; 
Gutiérrez et al., 2004). This phenomenon may be cell-type specific resulting in 
the antibody recognising the receptor better on one cell-type than another. 
Regardless of these constraints I tested a range of available anti-mouse CCR2 
antibodies and, crucially, included CCR2 KO mice as negative controls. In 
addition, I used a novel chemokine receptor detection technique that has been 
optimised in our lab that uses fluorescently labelled chemokine to detect cells 
bearing CCR2 and/or D6. The data from these experiments, which are described 
below, altered the direction of my project from the original focus on chemokine 
scavenging, and my subsequent aims were to explore the regulation, specificity 
and function of CCL2 receptors on the identified cell populations. 
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3.1.1 Examination of murine CCR2 detection by flow cytometry 
using commercially available anti-mouse CCR2 antibodies 
I first assessed the ability of two commercially available anti-CCR2 antibodies to 
detect murine surface CCR2 protein, one monoclonal and the second polyclonal. 
The monoclonal antibody from Epitomics was generated in rabbits and a 
synthetic peptide corresponding to the N-terminal residues of human CCR2 was 
used as the immunogen. It was stated to have immunoreactivity to both human 
and murine CCR2. The polyclonal antibody from Novus Biologicals was generated 
in goats and a synthetic peptide (SHSLFTRSIQELDEGATTPYDYDDGEPC), which 
corresponds to the N-terminal residues of murine CCR2, was used as the 
immunogen. The BM is a rich source of CCR2+ cells, particularly Ly6Chi 
monocytes, which are known to be highly dependent on CCR2 for their 
emigration from the BM. CCR2 KO animals have a deficit in peripheral Ly6Chi 
monocytes due to their retention within the BM in the absence of CCR2 (Serbina 
and Pamer, 2006; Tsou et al., 2007). Therefore, due to the large number of 
CCR2+ cells within the BM, both antibodies were tested at a range of 
concentrations and incubation times on BM cells. However, both failed to detect 
CCR2 in WT BM when compared to background level in CCR2 KO BM (Figure 3-1). 
3.1.2 Analysis of CCR2 detection by flow cytometry using a 
widely-used rat anti-mouse CCR2 monoclonal antibody,  
MC-21 
Following the failure of the two commercial antibodies to detect murine CCR2, I 
tested the most commonly used anti-mouse CCR2 antibody (clone MC-21) 
generated in the laboratory of Matthias Mack (Mack et al., 2001). The MC-21 
antibody is considered to be the gold standard for CCR2 detection in mice, with 
many published conclusions being based on the results generated with this 
antibody (Maus et al., 2002; Peters et al., 2004; Saederup et al., 2010). Unlike 
the commercially available antibodies, MC-21 is a rat antibody targeted against 
murine CCR2 protein. The antibody is a monoclonal antibody, which means it 
only recognises a single epitope on murine CCR2. The coding region of murine 
CCR2 was amplified and inserted into a vector that was used to transfect CHO 
cells, which were then used to immunise rats (Mack et al., 2001). The staining 
method reported in the original paper was followed, with the reported 
concentration 5 µg/ml (1:100), plus two further concentrations, 10 µg/ml (1:50) 
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or 2.5 µg/ml (1:200) being used. WT cells were also analysed with the isotype 
control antibody used in previous studies using MC-21, RatIgG2bκ (Mack et al., 
2001). The isotype control antibody was also used at 2.5 µg/ml, 5 µg/ml or 10 
µg/ml. MC-21 mediated CCR2 detection was assessed in the spleen, BM and 
blood of WT mice by flow cytometry. Importantly, cells from CCR2 KO mice 
stained with MC-21 were used as controls (Figure 3-2). Following gating of cells 
based on their size and granularity properties using forward scatter (FSC) and 
side scatter (SSC), live cells were gated on the basis of being ViaProbe negative 
and the relative anti-CCR2 immunoreactivity detected by MC-21 was determined 
on WT and CCR2 KO cells. In the three tested tissues and with all concentrations 
of MC-21, total live WT cells appeared to have specific CCR2 immunoreactivity 
when compared to WT cells stained with the isotype control used at the same 
concentration as MC-21. However, MC-21 stained CCR2 KO cells had similar 
immunoreactivity to WT cells in all tissues tested, except in the blood when a 
1:100 dilution of MC-21 was used and BM when a 1:200 dilution was used. 
Nevertheless, when comparing flow cytometry plots of MC-21 immunoreactivity 
on WT and CCR2 KO there were some noticeable differences (Figure 3-3). Live 
cells were divided into six populations based on their expression of Ly6C and MC-
21 immunoreactivity. The relative frequency of each of these populations was 
determined in the spleen (Figure 3-3B), BM (Figure 3-3C) and blood (Figure 3-3D) 
of WT and CCR2 KO animals, in addition to WT isotype control samples. The 
majority of cells possessing high MC-21 immunoreactivity also expressed high 
levels of Ly6C, and consistent with published observations (Serbina and Pamer, 
2006), these cells were absent in the periphery of CCR2 KO animals. As discussed 
in the Introduction, Ly6Chi monocytes are highly dependent on CCR2 for their 
mobilisation from the BM (Sunderkötter et al., 2004; Serbina and Pamer, 2006; 
Tacke and Randolph, 2006), thus it is likely that MC-21 is detecting CCR2 on 
monocytes in the BM of WT animals. In contrast, in the spleen and blood the 
observed decrease in CCR2 detection might be explained by a loss of CCR2 
protein and/or the loss of Ly6Chi monocytes from CCR2 KO animals. In the 
majority of cell populations, the isotype control gave fewer positive cells when 
compared to both WT and CCR2 KO samples. There were, however, few 
statistical differences between WT and CCR2 KO MC-21 stained samples. In fact, 
in some populations, such as the spleen Ly6C-MC-21/Isolo (Figure 3-3A) and BM 
Ly6C+MC-21/Isolo (Figure 3-3B) there was a higher proportion of cells with MC-21 
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immunoreactivity present in CCR2 KO samples than WT or isotype control. This 
suggests that MC-21 is subject to non-specific binding (i.e. binding to something 
other than CCR2). Therefore, despite providing some detection of CCR2, these 
results indicate that MC-21 has a high level of non-specific background staining, 
demonstrating the importance of using CCR2 KOs as controls. 
3.1.3 Profiling CCR2 expression in murine lymphoid organs and 
blood using MC-21 
I next investigated which cells might be responsible for the limited CCR2 specific 
staining noted in Figure 3-3. To determine relative background level of staining 
on different cell types in the spleen (Figure 3-4A), BM (Figure 3-4C) and blood 
(Figure 3-4E), I compared the level of CCR2 detection with 5 µg/ml MC-21 on WT 
and CCR2 KO cells to staining of WT cells with the isotype. Comparison of MC-21 
stained WT cells to isotype control WT samples in histogram overlays of each 
splenic cell population indicated that all WT cells, excluding neutrophils, 
possessed MC-21 immunoreactivity (Figure 3-4A). In contrast, in the BM (Figure 
3-4C) and blood (Figure 3-4E) comparison of histogram overlays of MC-21 stained 
WT cells to isotype control WT samples indicated that Ly6Chi monocytes and 
neutrophils both possessed MC-21 immunoreactivity. However, comparison of 
MC-21 stained WT to CCR2 KO samples, indicated that only Ly6Chi monocytes in 
each tissue had an appreciable level of MC-21 immunoreactivity specific for 
CCR2, although low levels of CCR2-specific MC-21 immunoreactivity were 
detected on splenic pDCs, CD11b+ cDCs and perhaps NK cells. The high 
background level of staining with MC-21 became even more apparent when the 
number of MC-21+ cells within each population in WT and CCR2 KO samples was 
quantified. Quantification of the results, considering anything above the isotype 
stained WT cells to be positive, illustrated that there were no statistical 
differences in the proportions of MC-21+ cells detected in any splenic cell 
population of WT and CCR2 KO animals (Figure 3-4B). Trends in the data 
suggested decreased MC-21 immunoreactivity in Ly6Chi monocytes of CCR2 KO 
animals compared to WT, which was significant in the BM (Figure 3-4D) and 
blood (Figure 3-4F), but not in the spleen. Furthermore, in each tissue no 
statistical differences were found in the proportion of MC-21+ neutrophils 
detected in WT and CCR2 KO samples. 
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Collectively, these results indicate that the tested commercially available anti-
mouse CCR2 antibodies were unable to detect CCR2. Furthermore, in my hands, 
the commonly used MC-21 was also limited in its ability to detect CCR2. It did, 
however, detect some CCR2, but it was predominantly restricted to Ly6Chi 
monocytes. The large shift in signal detected in WT animals over the background 
isotype level indicated high levels of CCR2. However, in the majority of cell 
populations a large proportion of this signal was not in fact true CCR2 detection, 
as it was also present in stained CCR2 KO samples. Thus, accurate CCR2 
detection using MC-21 can only be achieved by comparing staining in WT and 
CCR2 KO animals, and the isotype staining in the case of MC-21 is not a 
particularly useful control. 
3.2 Development of a sensitive method to detect CCR2 
The commercial antibodies that I tested were unable to detect CCR2 and, 
although MC-21 did detect CCR2, it provided poor distinction of CCR2+ cells in all 
cell populations except Ly6Chi monocytes. Furthermore, MC-21 should be used 
with caution, as without the appropriate CCR2 KO controls, false positives might 
be generated. Typically an isotype control would be used to establish what anti-
CCR2 reactivity is specific. However, in many cases this staining would still be 
present in CCR2 KO cells. It is for this reason a new assay needed to be 
developed that would allow reliable identification of CCR2-, CCR2lo and CCR2hi 
cells. Our lab has optimised a novel approach using fluorescently labelled 
chemokines to detect cells bearing chemokine receptors (Figure 3-5). In brief, a 
single cell suspension is incubated with fluorescent chemokine for 1 hr at 37°C, 
with or without an unlabelled competitor chemokine ligand, and following 
immuno-staining for cell surface markers, cells are analysed by flow cytometry. 
This method does not measure binding of fluorescent chemokine to surface 
chemokine receptor, but actually provides information about the ‘activity’ of 
the receptor, as fluorescent chemokine must bind and be internalised by the 
receptor to be detectable in subsequent flow cytometry. Receptor 
internalisation is generally seen as a key part of the signalling cascade of these 
molecules, so ligand internalisation probably indicates when the receptor is 
competent for signalling. Using CCL2AF647 or CCL22AF647, this method has been 
used to detect cells expressing the atypical chemokine receptor D6. In these 
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experiments, much CCL2AF647 uptake was D6-independent (Bordon et al., 2009; 
Hansell et al., 2011b). 
Since both CCR2 and D6 can bind CCL2, suitable controls need to be included to 
discriminate between CCR2 and D6 dependent uptake of CCL2AF647 (Figure 3-5). 
Comparison of CCL2AF647 uptake by WT and CCR2 KO should identify cells capable 
of CCR2 dependent uptake of CCL2AF647. Similarly, D6 KO animals can be used to 
define D6-specific uptake. However, to discriminate between CCR2 and D6 
dependent uptake and non-specific uptake by WT or CCR2 KO cells, competition 
of CCL2AF647 uptake with unlabelled murine CCL22 (mCCL22), a D6 specific ligand 
is used. Any observed decrease in CCL2AF647 uptake in the presence of mCCL22 is 
indicative of D6 activity, as D6 is the only known receptor to bind both CCL2 and 
CCL22. As confirmation that any decrease in CCL2AF647 uptake as a consequence 
of competition with mCCL22 was truly D6 dependent, and was not simply due to 
the addition of unlabelled chemokine, competition with a non-D6 ligand, such as 
mCCL19 is included. The lab had previously conducted some profiling of D6 
activity, which indicated that in resting mice D6 activity was predominantly 
restricted to innate-like B cells i.e. MZ-B cells and B1 B cells (Hansell et al., 
2011b). Thus, in the first experiments, CCL2AF647 uptake was plotted against 
CD19, a lineage specific marker of B cells (Figure 3-6). By comparing uptake in 
WT and CCR2 KO animals, it was clear that the vast majority of CCR2 dependent 
uptake was limited to CD19- cells. However, there was a small population of 
CD19lo cells that possessed CCR2 dependent uptake of CCL2AF647, highlighted in 
Figure 3-6A by the yellow box. The detection of CCR2 dependent uptake by 
CD19lo cells was not entirely unexpected, as CCR2 has previously been shown to 
be expressed by immature B cells (Flaishon et al., 2004) and plasma cells 
(Delogu et al., 2006). It was likely that the observed uptake was by plasmablasts 
or plasma cells, as maturation of B cells into plasma cells is accompanied by a 
downregulation of CD19 (Cascalho et al., 2000) and the cells were CD19lo. 
Surprisingly, both the CD19+ and CD19- populations in CCR2 KO mice possessed 
significant levels of D6 dependent uptake, as indicated by competition with 
mCCL22 (Figure 3-6B). Thus, D6 activity is not restricted to B cells as first 
thought from WT/D6 KO comparisons (Hansell et al., 2011b), however D6 
dependent uptake may have been hard to detect in these experiments due to 
the high levels of CCR2 dependent uptake of CCL2AF647. In contrast, competition 
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with mCCL19, a ligand that does not bind CCR2 or D6 did not cause a significant 
reduction in CCL2AF647 uptake in the CCR2 KO by either CD19+ or CD19- cells 
(Figure 3-6B). This illustrates that the large majority of uptake remaining in 
CCR2 KO samples, is truly D6 dependent and is not as a consequence of non-
specific inhibition of CCL2AF647 uptake by the presence of an excess of unlabelled 
chemokine. 
The CCL2AF647 assay relies on the ability of either CCR2 or D6 to internalise 
CCL2AF647. Therefore, the assay can only detect active receptor, and provides 
information about the ‘activity’ of the receptor. However, it may be argued that 
using a method to detect only active chemokine receptor is restrictive, in that 
‘inactive’ receptors would not be identified using this method. In theory, with a 
simple modification to the assay (incubation at 4°C) it could also be used to 
measure surface levels of CCR2, irrespective of the ability of CCR2 to internalise 
or its activity on these cells. Another member of the lab, Chris Hansell (personal 
communication) has performed the assay incubating cells with CCL2AF647 at 4°C 
instead of 37°C to prevent receptor internalisation (Hurson, 2011). This allows 
measurement of binding of CCL2AF647 to surface receptors. However, the 
fluorescence detected by flow cytometry is much lower than with incubations at 
37°C and receptor detection is very poor. Therefore, throughout this thesis, 
incubations were performed at 37°C and for this reason CCR2 and D6 detection is 
referred to in terms of ‘activity’ rather than expression or binding. 
3.2.1 CCL2AF647 uptake assay can sensitively detect mouse CCR2 
activity in cells from several lymphoid organs and the blood 
The internalisation assay was next used to characterise CCR2 dependent uptake 
of CCL2AF647 in the spleen (top row), BM (middle row) and blood (bottom row) 
(Figure 3-7). Use of the MC-21 anti-CCR2 antibody indicated that CCR2 
expression was predominantly limited to Ly6Chi monocytes, thus here I plotted 
Ly6C against CCL2AF647 uptake, which would facilitate the examination of 
CCL2AF647 uptake by both Ly6C+ and Ly6C- cells. In comparison to data generated 
with MC-21 (Figure 3-3), there were much larger flow cytometry shifts when 
using CCL2AF647, indicating that the CCL2AF647 assay had improved sensitivity 
compared to anti-murine CCR2 antibodies. Live cells were divided into 5 
populations based on Ly6C expression and CCL2AF647 uptake. The majority of 
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CCR2 dependent activity was by Ly6C+ cells, however some cells within the Ly6C- 
fraction also exhibited CCR2 dependent uptake. Of note is the Ly6ChiCCL2AF647-hi 
population present in all WT tissues, but absent in CCR2 KO, as there was a 
significant reduction in the number of live cells detected in this gate (Figure 3-
7B-D). Ly6C+ cells from the spleen and BM of CCR2 KOs also had some D6 
dependent uptake, as remaining uptake in the BM Ly6C+CCL2+ population and 
splenic Ly6C+CCL2lo was sensitive to the addition of mCCL22. However, the 
majority of D6 dependent uptake was restricted to Ly6C- cells. These results 
indicate that the prevalent receptor responsible for CCL2AF647 uptake in all three 
tissues is CCR2, with D6 responsible for a minor proportion of uptake. D6 appears 
to have a greater role in the spleen, which corresponds with D6 being a marker 
of MZ-B cells and B1 B cells. MZ-B cells are restricted to the spleen and B1 B 
cells are more abundant in this organ than in BM or blood (Hansell et al., 2011b). 
A deficiency in CCR2 clearly led to a major reduction in CCL2AF647 uptake, and 
competition with mCCL22 resulted in maximum reduction of CCL2AF647 uptake in 
the spleen. However, in the BM and blood there was a population of Ly6C+ cells 
that were still positive for CCL2AF647 uptake in CCR2 KO even in the presence of 
excess mCCL22 (Figure 3-7). These cells appeared to have CCR2 and D6 
independent uptake of CCL2AF647. It was hypothesised that these cells may 
express another receptor that can uptake CCL2AF647. To investigate this 
possibility, CCL2AF647 uptake by BM cells was competed with a range of CC 
chemokine ligands, including mCCL2 and other mouse inflammatory chemokines 
(Figure 3-8). CCL2AF647 is based on human CCL2, so the use of mCCL2 would 
assess whether uptake is by a mouse CCL2 receptor. The majority of these 
ligands are D6 ligands, except mCCL7, mCCL8, mCCL19 and mCCL21. mCCL7 and 
mCCL8 were originally thought to be ligands of D6 (Graham, 2009). However 
recent work by Hansell et al. demonstrated that mCCL7 and mCCL8 are not D6 
ligands, as they were both unable to block D6 dependent uptake of CCL2AF647 by 
B1 B cells (Hansell et al., 2011b). All D6 ligands used were able to marginally 
reduce CCL2AF647 uptake by BM cells compared to non-D6 ligands, but no tested 
ligand was able to completely compete the CCR2 and D6 independent uptake. 
Thus, these cells have some D6 activity, but remaining uptake is not due to a 
mouse CCL2 receptor, or other mouse receptors, such as CCR1, CCR2, CCR4, 
CCR5, CCR7 and CCR8 (Islam et al., 2011). The cells might therefore be 
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exhibiting a form of non-specific uptake of CCL2AF647, perhaps pinocytosis, or be 
internalising CCL2AF647 via another unidentified receptor. 
3.3 Identification of cells carrying CCL2 receptor activity 
in mouse lymphoid tissue and blood 
Most information on CCR2 expression has been provided using MC-21. Since the 
CCL2AF647 assay appears to give improved sensitivity of CCR2 detection compared 
to MC-21, earlier profiling experiments using this antibody may have led to an 
unintentional disregard of some CCR2lo cell populations. Also, as discussed 
earlier, the use of this antibody with the isotype alone and no CCR2 KO control 
can lead to the generation of false positive CCR2+ populations. Consequently, 
having begun to establish the CCL2AF647 uptake assay as a sensitive and reliable 
way to detect CCR2 activity, I performed a detailed profiling of CCR2 expressing 
cells in lymphoid organs and blood. Furthermore, as a by-product of the assay 
design, I anticipated that I would also generate data on the activity of D6 on the 
same cell populations analysed for CCR2. This could prove to be advantageous as 
perhaps, similar to CXCR7 and CXCR4, D6 and CCR2 might have roles in 
regulating one another when co-expressed on the same cell (Hartmann et al., 
2008; Salanga et al., 2009). Moreover, my data described so far has already 
indicated that D6 activity is not restricted to innate-like B cells, at least in the 
context of CCR2 deficiency. 
3.3.1 CCR2 activity in the spleen is predominantly restricted to 
cells of the innate immune system 
The spleen contains several lymphoid and myeloid cell subsets. By comparing 
internalisation of CCL2AF647 in WT and CCR2 KO with or without mCCL22 
competition, I established the receptor responsible for CCL2AF647 uptake by a 
variety of splenic lymphocytic (Figure 3-9), myeloid (Figure 3-10) and DC 
populations (Figure 3-11). These cells were all identified on the basis of their 
expression of various standard markers, according to the literature. In most 
cases, a range of markers are required to definitely identify cell populations, as 
although some markers are considered to identify distinct lineages, there is 
some overlap. Macrophages were identified using the myeloid cell markers F4/80 
and CD11b (Lloyd et al., 2008). pDCs were identified using CD11b and a 
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combination of other markers: B220, CD11c and Ly6C (Asselin-Paturel et al., 
2003). CD11c is typically considered to be a DC marker, however other cell 
types, such as macrophages, germinal centre B cells and granulocytes, also 
express CD11c (Hume, 2008). Thus, cDCs were identified as CD11chi MHCIIhi cells 
(Ghosh et al., 2010) and to avoid potential contamination of the cDC populations 
the majority of lymphocytes were excluded from the analysis. A combination of 
antibodies used to identify T cells (anti-CD3), B cells (anti-CD19) and NK cells 
(anti-NK1.1) were all conjugated to a similar fluorophore as the viability dye, 
which facilitated the removal of these cells from the analysis at the time of 
live/dead cell gating. The two subsets of cDCs were delineated using CD11b and 
CD8α (Vremec and Shortman, 1997; Wilson and O'Neill, 2003). NK cells were 
identified using anti-CD49b (clone DX5), which, unlike the NK1.1 cell marker 
recognises NK cells in all mouse strains (Arase et al., 2001). 
First, I examined the activity of the CCL2 receptors, CCR2 and D6 on a number of 
splenic lymphocyte populations (Figure 3-9). In contrast to MC-21 staining, WT 
NK cells were found to have significant levels of CCR2 mediated uptake of 
CCL2AF647 (Figure 3-9A). WT T cells, both γδ+ T cells (Figure 3-9B) and TCR αβ+ T 
cells, CD4+ and CD8α+ (Figure 3-9C), had low levels of CCR2 activity. B cells, as 
expected were the only lymphocyte population that were found to have D6 
dependent uptake with approximately 14% of CCR2 KO cells taking up CCL2AF647 
(Figure 3-9D). With a more detailed gating strategy to delineate MZ-B cells from 
within the total B cell gate, it was found that approximately 68% of CCR2 KO MZ-
B cells possess D6 activity. These results support published observations stating 
that within the spleen MZ-B cells are the principal cells with D6 dependent 
CCL2AF647 uptake (Hansell et al., 2011b). The remaining CD21- B cell population 
(Figure 3-9D) did, however still possess significant levels of D6 specific uptake in 
CCR2 KOs, which might be explained by the previously identified D6+ B1 B cells 
(Hansell et al., 2011b). 
Next, I focused on myeloid cells (Figure 3-10). Ly6Chi monocytes, identified as 
Ly6ChiCD11b+Gr1lo (Sunderkötter et al., 2004; Serbina and Pamer, 2006), were 
found to have high CCR2 activity in WT animals, having the highest proportion of 
CCL2+ cells (~85%) of all cell populations tested. Furthermore, competition with 
mCCL22 had no effect on CCL2AF647 uptake by CCR2 KO cells, indicating an 
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absence of D6 on Ly6Chi monocytes (Figure 3-10A). Macrophages had low, but 
significant levels of CCR2 activity in WT animals, and also D6 dependent uptake 
in CCR2 KO samples (Figure 3-10B). Some populations clearly lack CCR2 or D6 
activity, for example neutrophils, identified as Ly6C+Gr1hiCD11b+ (Panopoulos et 
al., 2006; Daley et al., 2008), because WT neutrophils did not internalise more 
CCL2AF647 than CCR2 KO neutrophils in the presence or absence of mCCL22 
(Figure 3-10A). 
The final splenic cell populations to be examined for CCR2 and D6 activity were 
DCs (Figure 3-11). In contrast to MC-21 staining, CD11b+ cDCs (Figure 3-11A), 
CD8α+ cDCs (Figure 3-11B) and pDCs (Figure 3-11B) from WT animals were found 
to have significant levels of CCR2 mediated uptake of CCL2AF647. Approximately 
46% of pDCs were found to have strong CCR2 activity, and were also found to 
have significant levels of D6 activity, as mCCL22 resulted in a further reduction 
of CCL2AF647 by CCR2 KO cells. There was no evidence of D6 activity on either of 
the CCR2 KO cDC populations. The gated CD11c+MHCII- population of cells in 
Figure 3-11A also possessed significant levels of CCR2 activity. The identity of 
this population is uncertain, but initial investigations suggest that the population 
contains a mix of several cell types. These observations shall be discussed in 
more detail in the Discussion. 
In accordance with earlier results the vast majority of cell populations 
internalised CCL2AF647 in a CCR2 mediated fashion, with only a few cell 
populations in the spleen of CCR2 KOs having any evidence of low D6 activity i.e. 
macrophages (Figure 3-10) and pDCs (Figure 3-11). The majority of splenic CCR2 
dependent uptake was by myeloid cells and DCs, with limited uptake by 
lymphoid cells except NK cells. As illustrated in the Introduction, CCR2 has been 
described to have roles in the mobilisation of numerous cell populations, 
including CD11b+ cDCs (Osterholzer et al., 2009), NK cells (Morrison et al., 2003) 
and monocytes (Serbina and Pamer, 2006). Conversely, a functional role of CCR2 
on pDCs, to my knowledge, has yet to be elucidated and it was striking that 
these cells could be clearly divided into CCL2hi and CCL2lo subsets. Moreover, the 
apparent presence of D6 activity on these cells was also unexpected. 
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3.3.2 Monocytes, CD11c+ cells and pDCs possess CCR2 activity 
in the BM 
A somewhat less detailed profiling of CCR2 activity was also conducted in the BM 
(Figure 3-12). Monocytes and neutrophils were gated based on their expression 
of Ly6C, CD11b, Gr1 and CD115. Ly6C+CD11b+ cells were examined for Gr1 and 
CD115 expression (Figure 3-12A). Mature neutrophils express high levels of Gr1 
and are CD115-, whereas monocytes are Gr1loCD115+ (Sunderkötter et al., 2004; 
Serbina and Pamer, 2006; Rose et al., 2011). Once more, Ly6Chi monocytes were 
found to have the highest CCR2 activity of all cell types analysed, with ~98% of 
WT cells being very positive for CCR2 dependent CCL2AF647 uptake. In contrast to 
splenic Ly6Chi monocytes, CCR2 KO BM Ly6Chi monocytes possessed weak but 
significant levels of D6 activity. Neutrophils were predominantly negative for 
CCR2 activity. However, there was a small population of neutrophils that were 
CCL2+, which might be explained by a small contamination with Ly6Chi 
monocytes or cell doublets. There was also a population of Ly6C+CD11b+ cells 
that were Gr1hiCD115+, highlighted by the green box in Figure 3-12A. Analysis of 
the physical properties of the Gr1hiCD115+ cells (shown at the top of Figure 3-12A 
in green) illustrated that the cells were very large, being larger than both 
monocytes and neutrophils, suggesting that these ‘cells’ might be cell doublets.  
A further 3 populations of cells, Populations A, B and C were identified in the BM 
by their expression of CD11b, Gr1, CD115 and Ly6C (Figure 3-12A). All 3 
populations were Gr1loCD11b+, but differed in their expression of Ly6C and 
CD115. Population A was Gr1loCD11b+CD115+Ly6Clo. The expression of CD115 and 
the physical properties of these cells (shown in light blue at the top of Figure 3-
12A) suggested that they are of monocytic origin. Furthermore, Population A 
cells were very positive for CCR2 uptake, and CCR2 KO Population A possessed 
significant levels of D6 activity. Populations B and C were both 
Gr1loCD11b+CD115- differing only in their expression of Ly6C. Population B was 
Ly6C+, whereas Population C was Ly6Clo. Populations B and C also had unique 
physical properties that could be used to segregate the two populations. 
Population B (shown in yellow at the top of Figure 3-12A) were found to have 
similar properties to monocytes, as they were larger than lymphocyte 
populations. The physical properties of Population C (shown in purple at the top 
of Figure 3-12A) indicated that these are very large granular cells. Populations B 
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and C did not possess significant levels of CCR2 or D6 activity, but both 
populations from WT animals did internalise very low levels of CCL2AF647 in a 
CCR2 dependent manner. The identity of Populations A, B and C shall be 
discussed in more detail in the Discussion. 
The assay also illustrated that BM B cells, delineated as B220+CD11c- cells, were 
largely negative for CCR2 and D6 dependent uptake of CCL2AF647 (Figure 3-12B). 
Similar to splenic pDCs, WT BM pDCs were found to have significant levels of 
CCR2 mediated uptake of CCL2AF647 and showed CCL2hi and CCL2lo subsets, and 
CCR2 KO pDCs also possessed significant levels of D6 activity (Figure 3-12B). 
However, the level of D6 activity on BM pDCs appeared to be substantially higher 
than that found on splenic pDCs (Figure 3-11B). CD11c+ cells also had significant 
CCR2 and D6 activity. CD11c is expressed by a range of cells including DCs, 
macrophages, B cells and granulocytes (Hume, 2008). I therefore, chose not to 
name the CD11c+ population cDCs as it may contain others cell types too and 
insufficient markers were present to allow them to be more definitively 
assigned. 
3.3.3 CCR2 activity is predominantly restricted to monocytes, 
CD11c+ cells and pDCs in the blood 
I next assessed the cells that were responsible for CCR2 mediated uptake of 
CCL2AF647 in the blood (Figure 3-13). As with the spleen and BM, Ly6Chi 
monocytes were the cells highest for CCR2 activity, with ~95% of WT cells 
showing CCR2 dependent CCL2AF647 uptake (Figure 3-13A). Similar to neutrophils 
in all other tissues tested, blood neutrophils were predominantly CCR2-. The 
blood also contained the Ly6C+CD11b+CD115+Gr1hi population of cells (Figure 3-
13A) that were previously identified in the BM (Figure 3-12A). The physical 
properties of these cells, shown at the top of Figure 3-13 in green, also indicated 
that they too might be doublets. Furthermore, as with BM samples, the blood 
contained the three cell populations of uncertain identity, Populations A, B and 
C (Figure 3-13A). Population A had significant levels of CCR2 activity, however in 
contrast to Population A in the BM, the population was much more 
heterogeneous and possessed no detectable D6 activity in the absence of CCR2. 
The percentage of CCL2+ cells within Population A (50%) was also dramatically 
lower than that observed in the BM (85%). In stark contrast to Population B in 
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the BM, the blood WT Population B had significant levels of CCR2 activity, 
comparable to that of Ly6Chi monocytes. Population C in both the BM and blood 
did not possess significant levels of CCR2 or D6 activity, but a small proportion of 
cells internalised very low levels of CCL2AF647 in a CCR2 dependent manner. The 
physical properties of each of these cell populations in the blood were consistent 
with the previous observations in the BM (Figure 3-12A) e.g. Populations A and B 
were of similar size to monocytes, whilst Population C were large and 
granulocytic in appearance (Figure 3-13A). As mentioned above, these three 
populations of cells will be discussed in more detail in the Discussion. 
Similar to data generated in the BM, B cells in the blood were largely negative 
for CCR2 and D6 dependent uptake of CCL2AF647, while WT B220-CD11c+ cells 
possessed significant levels of CCR2 activity (Figure 3-13B). However, there was 
no significant D6 activity detected in B220-CD11c+ cells of CCR2 KOs, although 
histogram overlays suggested that mCCL22 did have a minor effect on CCL2AF647 
uptake. pDCs in the blood also possessed D6 and significant CCR2 activity, with 
clear CCL2hi and CCL2lo subsets identifiable (Figure 3-13B). The level of pDC D6 
activity was comparable to that in the BM and was higher than the levels 
detected in splenic pDCs. 
3.3.4 CCR2+ cells are rare in resting PLNs 
CCR2 activity was next profiled on lymphocyte and myeloid cell subsets in the 
PLNs of WT animals, using CCR2 KO animals as controls (Figure 3-14). Similar to 
the spleen, γδ+ T cells in the PLNs had low, but significant levels of CCR2 activity 
(Figure 3-14A). In contrast to the spleen, T cells (CD3+) were negative for CCR2 
activity (Figure 3-14A) and B cells from CCR2 KO animals were negative for D6 
activity (Figure 3-14B). This apparent lack of D6 activity can be explained by the 
low abundance of D6 expressing B1 B cells and the absence of MZ-B cells in the 
LNs (Hansell et al., 2011b). cDCs gated as CD11c+ were further divided into two 
populations based on their level of MHCII expression (Cella et al., 1997; Wilson 
et al., 2003) (Figure 3-14C). MHCIIhi cells, defined as migratory cDCs, were 
negative for both CCR2 and D6, whereas a subset of resident cDCs defined by 
their low MHCII expression showed CCR2 dependent uptake of CCL2AF647. pDCs 
are also CD11c+ and MHCIIlo, and are likely to be included in the resident cDC 
gate, and therefore may account for some, if not all, of the CCR2 dependent 
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uptake. The CCR2 activity of PLN pDCs will be examined in more detail in 
Chapter 5. In contrast to all other tissues, no D6 activity was detected on any 
population in resting PLNs. 
3.4 Effect of CCR2 deletion on the cellular composition of 
lymphoid organs and the blood 
CCR2 plays a pivotal role in the migration of several cell types during 
inflammation, including cell populations that I have identified as having CCR2 
activity, such as NK cells (Morrison et al., 2003), cDCs (Osterholzer et al., 2005) 
and Ly6Chi monocytes (Serbina and Pamer, 2006). Ly6Chi monocytes have also 
been shown to be highly dependent on CCR2 for their emigration from the BM 
into the blood during homeostasis, as a lack of CCR2 leads to the retention of 
Ly6Chi monocytes in the BM (Geissmann et al., 2003; Serbina and Pamer, 2006). 
Therefore, I next sought to determine if CCR2 deletion affected the cellularity 
of secondary lymphoid organs, blood and BM, as perhaps akin to Ly6Chi 
monocytes, other CCR2+ populations require CCR2 for their mobilisation into 
blood and seeding of secondary lymphoid organs during homeostasis (Figure 3-
15). 
Consistent with published observations (Serbina and Pamer, 2006), there was a 
significant deficit in peripheral monocytes in the spleen and blood of the CCR2 
KO mice, which coincided with a significant increase in monocytes in the BM of 
CCR2 KOs (Figure 3-15). There were no apparent effects of CCR2 deletion on the 
frequency of any other identified cell populations in the spleen or BM (Figure 3-
15A and B). The absence of CCR2 affected the frequency of blood Population B, 
as there was a significant reduction in the CCR2 KOs (Figure 3-15C). However, 
there was no corresponding increase in the BM of CCR2 KOs (Figure 3-15B). No 
cell population in the blood, other than Ly6Chi monocytes and Population B, was 
affected by a deficit in CCR2 (Figure 3-15C). The frequency of migratory cDCs, 
resident cDCs and γδ+ T cells present in PLNs were not affected by the absence 
of CCR2. However, there was an increase in B cell frequency in the PLNs of CCR2 
KOs, and a decrease in the frequency of T cells (Figure 3-15D). 
In summary, I have definitively identified numerous cell populations within the 
secondary lymphoid organs, BM and blood that possess CCR2 activity. CCR2 
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activity was mainly limited to myeloid cells and DCs, both cDCs and pDCs. I was 
able to define two populations of pDCs with respect to CCR2 activity, and there 
was clear evidence of D6 activity in CCR2 KO pDCs. There was also variation in 
CCL2 receptor activity between pDCs from different anatomical locations. 
Furthermore, two populations of cells identified in the blood, Populations A and 
B were found to have high levels of CCR2 activity. Interestingly, although these 
populations were also identified in the BM, only Population A possessed CCR2 
activity in the BM. In each tissue, CCR2 was the receptor responsible for the 
majority of CCL2AF647 uptake. In addition, in all tissues except PLNs, significant 
levels of D6 activity were also detected on a few cell populations, such as MZ-B 
cells and pDCs in CCR2 KOs. The frequency of all but a few CCR2+ populations 
were relatively unaffected by deletion of CCR2. The frequency of Ly6Chi 
monocytes was profoundly affected in the BM, spleen and blood of CCR2 KOs. 
Furthermore, the frequency of Population B in the blood was significantly 
reduced in the absence of CCR2. Lastly, T cell frequency was significantly 
reduced whilst B cell frequency was significantly increased in the PLNs of CCR2 
KOs. The reason for this alteration in lymphocyte subsets is not clear and was 
not investigated further. 
3.5 CCL2AF647 uptake assay detects CCL2 receptors in rat 
and human 
Having demonstrated that the CCL2AF647 uptake assay could be used to reliably 
and sensitively detect CCR2 and D6 activity on cells from murine spleen, BM, 
PLNs and blood, I assessed whether the uptake assay would work to detect CCL2 
receptors in other species. The ability of the reagents I used to work across 
species would present a further advantage of the assay over antibodies, which 
are often species restricted in terms of reactivity. As stated earlier, the 
fluorescent CCL2 used in the assay is human CCL2, yet it can be used to detect 
CCR2 and D6 activity of murine cells. This is due to the fact that chemokines 
have highly conserved primary and tertiary structures (Allen et al., 2007). Thus, 
human and murine CCL2 are structurally very similar, providing a likely 
explanation for the cross-reactivity of human CCL2AF647 with murine CCR2 and 
D6. This is very common with chemokines, and chemokines from one species can 
usually bind and activate receptors from another species. To determine if 
CCL2AF647 could be used to detect CCL2 receptors in species other than the 
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mouse, I tested the assay using single cell suspensions of both rat spleen (Figure 
3-16A) and human peripheral blood (Figure 3-16B). Similar to the chemokine 
ligands, chemokine receptors are also highly conserved between species (Murphy 
et al., 2000), and although CCR2 and D6 genes are present within the rat 
genome there is little known about their expression or chemokine binding 
profiles in the rat. Therefore, I do not refer to CCL2AF647 uptake by rat 
splenocytes in terms of CCR2 or D6, but as CCL2 receptors. However, I used 
competition with mCCL22 to try and identify D6 activity on rat splenocytes, and 
rat CCL2 (rCCL2) was used to demonstrate that uptake was receptor-mediated 
rather than non-specific uptake. It is not known whether mCCL22 is active on rat 
CCL2 binding receptors, however no rat CCL22 was available for purchase. 
First, I characterised uptake of CCL2AF647 by four rat splenic populations: CD4+ 
cDCs, pDCs, neutrophils and monocytes (Figure 3-16A). Earlier I discussed the 
use of CD11c as a marker for DCs, but stated that other cells also express it 
(Hume, 2008). However, its use, in combination with a number of other markers, 
is key in the identification of DCs in mice. The identification of DCs within the 
rat is hindered by the lack of a functioning anti-CD11c antibody or an equivalent 
lineage marker. Thus, complex gating strategies that rely on the exclusion of the 
majority of lymphocyte populations are employed to identify DC subsets in this 
species (Hubert et al., 2006). To identify monocyte and neutrophil populations I 
employed gating strategies similar to those that have been described elsewhere 
(Yrlid et al., 2006). 
Similar to the mouse, the majority of rat neutrophils did not internalise CCL2AF647 
(Figure 3-16A). However, there was a small population of neutrophils with CCL2 
receptor activity. I think these are likely to be contaminating monocytes, as 
their CCL2AF647 uptake profile appears similar to that of monocytes. In the other 
three populations (pDCs, monocytes and CD4+ cDCs), much of the uptake was 
competable with rCCL2, indicating uptake by a rat receptor capable of binding 
rat CCL2. Addition of mCCL22 had no effect on the ability of the cells to 
internalise CCL2AF647, indicating that mCCL22 may not be active on rat D6 or that 
rat D6 is not expressed in the cells examined. pDCs and monocytes were found 
to have high levels of receptor mediated CCL2AF647 internalisation, while only a 
small number of CD4+ cDCs had low levels. In contrast to murine pDCs, all rat 
pDCs appeared to be CCL2+. CD43- monocytes are considered to be the rat 
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equivalent of the murine Ly6Chi monocytes, possessing high levels of CCR2 (Yrlid 
et al., 2006). However, in contrast to murine monocytes, I found a proportion of 
rat monocytes that did not possess CCL2 receptor activity (Figure 3-16A). 
The assay was also tested on human peripheral blood leukocytes (Figure 3-16B). 
Uptake was competed with an excess of hCCL2 or hCCL22, as human D6 is known 
to bind both hCCL2 and hCCL22, whilst human CCR2 binds hCCL2 but not hCCL22 
(Bonecchi et al., 2004). Monocytes and pDCs were found to have high levels of 
CCR2, demonstrated by inhibition of CCL2AF647 uptake with hCCL2 with no 
corresponding decrease with competition with hCCL22. As in mice, but in 
contrast to rats, there was heterogeneity amongst human pDCs with respect to 
CCR2 activity. In stark contrast to mouse splenic NK cells, very few human 
peripheral blood NK cells showed evidence of CCR2 activity. B cells had no CCR2 
mediated uptake of CCL2AF647. The presence of hCCL22 did not modulate 
CCL2AF647 uptake, indicating that there is unlikely to be any active D6 present on 
any of these cells. 
Collectively these results indicate that a single reagent, CCL2AF647, works in 
three mammalian species. Work conducted by Amanda Guth (Colorado State 
University, USA) also suggests that the assay works with cells isolated from dogs 
(personal communication). Therefore, I propose that the CCL2AF647 assay might 
work in all mammalian species. This presents a distinct advantage of the assay 
over antibody mediated detection, as reliable anti-CCR2 antibodies are not 
available in many mammalian species, and, as I have shown, the available anti-
mouse CCR2 antibodies are of limited sensitivity and reliability. 
3.6 Using CCL2AF647 uptake assay to determine CCR2 
receptor specificity 
In the process of establishing CCL2AF647 as a reliable detection method of CCR2, I 
have shown the assay to be capable of detecting both high and low levels of 
CCR2 on a range of cells in different tissues. I next set out to assess the ability 
of the assay to monitor receptor specificity, by assessing CCR2 mediated 
CCL2AF647 uptake in the presence of unlabelled ligands. By pre-incubating cells 
with unlabelled CCR2 ligands, or by competing CCL2AF647 uptake with unlabelled 
Chapter 3  122 
 
CCR2 ligands, I was able to characterise CCR2 specificity and the impact of prior 
exposure of CCR2 ligands on subsequent CCR2 activity. 
3.6.1 Monitoring murine CCR2 activity in the presence of a 
competitor ligand 
Having consistently shown the inhibition of D6 dependent CCL2AF647 uptake by co-
incubation with an excess of unlabelled mCCL22, I assessed the effect of co-
incubating unlabelled CCR2 ligands on CCR2 activity in the CCL2AF647 uptake 
assay. Mouse CCL8 was originally considered to be a CCR2 ligand, but it is now 
known to be a CCR8 ligand rather than binding CCR2 (Hansell et al., 2011b; Islam 
et al., 2011), so it was not included in my experiments. CCL3 was included as a 
negative control, as similar to CCL22, it is also a D6 ligand and should have 
little, if any, CCR2 binding activity. Splenocytes from WT mice were incubated 
with CCL2AF647 in the presence or absence of 25 nM unlabelled mCCL2, mCCL3, 
mCCL7 or mCCL12, and CCL2AF647 uptake was assessed (Figure 3-17A). CCR2 
deficient splenocytes incubated with CCL2AF647 without a competitor chemokine 
were included as a negative control. Each competitor ligand generated a unique 
profile in terms of uninhibited CCL2AF647 uptake. CCL2AF647 uptake was blocked in 
the presence of unlabelled mCCL2 and within the Ly6C- population was actually 
more effective than CCR2 deletion because it inhibited uptake by MZ-B cells. 
Similarly, although mCCL3 had little effect on CCL2AF647 uptake by Ly6C+ cells it 
did cause a reduction in CCL2AF647 uptake by Ly6C- cells. Competition with 
mCCL7 and mCCL12 caused a reduction in CCL2AF647 uptake by Ly6Chi cells, but 
had differential effects on Ly6C- cells. This is consistent with mCCL12 being a 
ligand of D6, whilst mCCL7 is not (Hansell et al., 2011b). 
In the earlier profiling experiments, Ly6Chi monocytes were consistently found to 
have the highest CCR2 activity. Therefore, I measured CCR2 activity on splenic 
Ly6Chi monocytes in response to co-incubation with varying concentrations of 
several unlabelled murine CCR2 ligands (Figure 3-17B). Within the same sample I 
was able to measure CCR2 activity of splenic Ly6C-CD11b+ cells (Figure 3-17C). 
Representative histograms of CCL2AF647 uptake in CCR2 KO and WT monocytes, in 
the presence of increasing concentrations of mCCL2, mCCL7 or mCCL12, 
illustrate that as the concentration of the competitor ligands increases, there is 
a parallel decrease in CCL2AF647 uptake. mCCL3 had minimal effects on CCR2 
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mediated uptake of CCL2AF647 as expected. At higher concentrations of the 
competitor ligands, mCCL2 appeared to cause the greatest inhibition of CCL2AF647 
uptake. However, on quantification, there were no significant differences 
between mCCL2, mCCL7 and mCCL12 in their ability to inhibit CCL2AF647 uptake, 
but mCCL3 was significantly inferior at all tested concentrations than mCCL2. 
Furthermore, at the highest concentration of competitor ligands (25 nM), 
CCL2AF647 uptake was comparable to that in the CCR2 KO, particularly in the case 
of mCCL2. These results demonstrate that the three ligands are equal in their 
capacity to compete CCR2 dependent CCL2AF647 uptake by Ly6Chi monocytes. In 
contrast, although mCCL2 showed a dose response curve for inhibition of 
CCL2AF647 uptake by Ly6C-CD11b+ cells, mCCL7 and mCCL12 were less effective. 
3.6.2 Establishing the effect of chemokine exposure on murine 
CCR2 activity 
Having demonstrated the ability of the assay to confirm the specificity of murine 
CCR2, I next assessed whether prior exposure of CCR2 to unlabelled ligands 
affected its activity. The underlying principle to this experiment extends from 
another aspect of chemokine receptor dynamics, known as desensitisation. 
Chemokine receptor desensitisation, as discussed in the Introduction, is a 
process by which a receptor becomes refractory to further stimulation by a 
chemokine ligand after an initial exposure to chemokine. Thus, on exposure to 
ligand, the chemokine receptor can become unresponsive to further chemokine 
ligands. Splenocytes from WT mice were pre-incubated with varying 
concentrations of unlabelled CCR2 ligands, or the negative control mCCL3, prior 
to exposure to CCL2AF647 (Figure 3-18). CCR2 deficient splenocytes without prior 
exposure to unlabelled CCR2 ligands, but incubated with CCL2AF647 were used as 
a negative control. Similar to the co-incubation data, each unlabelled chemokine 
generated unique profiles of uncompeted CCL2AF647 uptake (Figure 3-18A). 
Representative histograms of CCL2AF647 uptake in Ly6Chi monocytes following 
exposure to unlabelled mCCL2, mCCL7 or mCCL12, indicate that as the 
concentration of ligand increases, CCL2AF647 uptake decreases (Figure 3-18B). 
Pre-incubation with mCCL3 had no effect on CCR2 mediated uptake of CCL2AF647. 
By comparing the effect of each ligand on CCL2AF647 uptake, mCCL2 was found to 
be the most effective at inhibiting uptake at the majority of concentrations 
tested, causing a significant decrease in uptake when compared to mCCL3, 
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mCCL7 and mCCL12. Also, at the highest concentration tested, mCCL2 inhibited 
uptake to levels similar to the background levels observed in the CCR2 KO. 
mCCL7 and mCCL12 although not as effective as mCCL2 appeared to have similar 
profiles to each other. This result was more striking in Ly6C-CD11b+ cells, as 
mCCL7 and mCCL12 were unable to inhibit CCL2AF647 uptake at all 
concentrations, except the highest concentration (250 nM) were minimal 
inhibition was achieved (Figure 3-18C). 
Taken these results together they detail a sensitive technique that is capable of 
monitoring downregulation of receptor activity, as a consequence of receptor 
desensitisation. They give preliminary insights into the responsiveness of CCR2, 
as competition of CCL2AF647 binding to CCR2 required only low concentrations of 
unlabelled ligand, whereas over ten-fold higher concentrations of unlabelled 
ligand were required to fully desensitise CCR2. In addition, these results suggest 
that although each ligand can inhibit CCL2AF647 uptake, they differ in their 
capacity to desensitise CCR2. Furthermore, these results also suggest that the 
interaction of CCR2 with its ligands are cell-type specific, as although mCCL7 
and mCCL12 were able to desensitise CCR2 on Ly6Chi monocytes, they were 
unable to do so on Ly6C-CD11b+ cells. 
3.7 Summary 
In this chapter, I have detailed how several anti-mouse CCR2 antibodies are 
either incapable of detecting CCR2, or can only facilitate the detection of high 
levels of CCR2. With MC-21, careful controls are essential, with cells from CCR2 
KO mice serving as a better control than isotype control antibodies. I described 
the use of a novel sensitive assay to detect CCR2 and demonstrate some of the 
advantages of the assay over currently available methods. Firstly, with 
appropriate controls it can be used to detect both CCR2 and D6. Furthermore, 
other members of the group have used this assay with other fluorescently 
labelled chemokines to detect other chemokine receptor activity on cells, in 
single cell suspensions from other tissues, including the gut and lung. These 
tissues, particularly the gut, have provided further challenges when using 
antibodies, as they have an even greater background signal, yet the chemokine 
assays can be used to profile receptor activity (Bordon et al., 2009; Hansell et 
al., 2011b). The assay can also be used to detect receptor activity in multiple 
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species, providing yet another advantage over the use of antibodies, particularly 
in the rat were antibody reagents are scarce. In addition, the assay has also 
facilitated the monitoring of CCR2 receptor specificity, and the receptiveness of 
CCR2 to desensitisation with unlabelled chemokines. 
These results present a detailed profiling of CCR2 activity on leukocytes in some 
of the major murine lymphoid organs. In all organs tested, CCR2 was the major 
receptor mediating CCL2AF647 uptake, with D6 playing a minor role. The cell 
populations that were found to be responsible for the majority of CCR2 
dependent uptake were of either a myeloid cell origin or DCs, with monocytes 
always being the population with highest CCR2 activity. Furthermore, I identified 
three Gr1loCD11b+ populations, present in the blood and BM, that I named 
Population A, B and C. These populations differed in their expression of Ly6C 
and CD115. Population A was the only one of the three populations to express 
CD115 and possessed significant levels of CCR2 activity in the BM and blood. In 
contrast, Populations B and C were CD115- and no CCR2 activity was evident on 
either population in the BM. However, Population B in the blood possessed 
significant CCR2 activity. The identity of these populations is uncertain, but in 
the discussion I speculate over their possible origin (sections 6.2.2.3 and 
6.5.2.3). 
One of the striking results from these profiling experiments is that in all 
populations, other than Ly6Chi monocytes, there is only a percentage of each 
cell population that takes up CCL2AF647 in a CCR2 dependent fashion. 
Furthermore, in contrast to results I generated with MC-21, several cell 
populations that were thought to be negative for CCR2 or express low levels of 
CCR2, were found to be CCR2+, including NK cells, CD8α+ cDCs, pDCs and CD11b+ 
cDCs. Chemokine receptors are often able to define functionally distinct 
leukocytes subsets, therefore these results provide new insight into CCR2 
expression and potentially undiscovered roles for CCR2 in vivo.  
The absence of CCR2 is known to lead to deficiencies in peripheral Ly6Chi 
monocytes, as they are retained in the BM and clearly require CCR2 for their 
release (Serbina and Pamer, 2006). My results support these observations, as 
there were decreased Ly6Chi monocytes in the spleen and blood of the CCR2 KO, 
with a corresponding increase in the BM. My results also showed that the 
Chapter 3  126 
 
absence of CCR2 led to alterations in the frequency of only a few of the other 
identified CCR2+ populations. T cells in PLNs and blood Population B cells were 
significantly reduced in the CCR2 KO. In contrast, there was an increase in the 
frequency of B cells present in the PLNs of the CCR2 KO.  
The findings in this chapter are discussed in greater detail in the Discussion 
section. Having optimised and detailed the use of the CCL2AF647 assay to 
accurately detect CCR2, in the next chapter I explore the consequence of in vivo 
LPS treatment on the CCR2 and D6 activity of the described CCR2/D6+ 
populations. Furthermore, having established that CCR2 deletion affects the 
frequency of a number of the CCR2+ populations, I explore the effect of systemic 
inflammation on the frequency of splenic CCR2+ populations.
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Figure 3-1: Antibody mediated CCR2 detection. 
BM cells derived from WT (black line) and CCR2 KO (shaded grey area) were stained with 
commercial anti-CCR2 antibodies. Epitomics anti-CCR2 antibody was tested at 718 µg/ml (1:10), 
143.6 µg/ml (1:50), 71.8 µg/ml (1:100), 28.72 µg/ml (1:250) and 14.36 µg/ml (1:500) and incubated 
with BM cells for either 1 hr or 15 mins. Novus biologicals antibody was tested on BM cells at 100 
µg/ml (1:10), 20 µg/ml (1:50), 10 µg/ml (1:100), 4 µg/ml (1:250) and 2 µg/ml (1:500) for either 1 hr 
or 15 mins. (A) Staining following a 1 hr incubation with the highest tested concentration of each 
antibody on cells gated based on FSC and SSC properties. (B-E) CCR2 geometric mean 
fluorescence intensity (ΔMFI) was determined for each dilution of the Epitomics (B&C) and Novus 
(D&E) antibodies for both WT (black bars) and CCR2 KO (white bars) BM cells following staining 
for the two different incubation periods, 15 mins (B&D) and 1 hr (C&E). n=1. 
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Figure 3-2: Testing the MC-21 anti-mouse CCR2 antibody. 
Live cells from the spleen (A), BM (B), or blood (C) isolated from WT and CCR2 KO mice were 
stained with 2.5 µg/ml (1:200), 5 µg/ml (1:100) or 10 µg/ml (1:50) MC-21 anti-CCR2 antibody or WT 
cells were stained with isotype control antibody. Graphical representation of the calculated CCR2 
geometric mean fluorescence intensity (ΔMFI) of WT cells (black bars) or CCR2 KO (white bars) or 
WT cells stained with isotype (grey bars). Data are from three individual mice per genotype (mean 
+ SD), except the isotype result that was generated from a single mouse. Data were analysed by 
unpaired T-test comparing WT to CCR2 KO at each dilution p<0.05 *. 
1:50 1:100 1:200
0.0
250.0
500.0
750.0
1000.0
WT
CCR2 KO
IsotypeWT 
CCR2 KO 
WT Isotype 
1:50 1:100 1:200
0.0
50.0
100.0
150.0
200.0
250.0
300.0
350.0
400.0
450.0
WT
CCR2 KO
Isotype
1:50 1:100 1:200
0.0
200.0
400.0
600.0
800.0
1000.0
1200.0
1400.0
WT
CCR2 KO
Isotype
0.0 
50.0 
100.0 
50.0 
00.0 
50.0 
00.0 
50.0 
00.0 
50.0 
0.0 
00.0 
00.0 
00.0 
00.0 
00.0 
00.0 
400.0 
0.0 
250.0 
500.0 
.0 
1 .0 
1:  1:  1:  1:  1:1  1:2  
1:  00 1:  
Dilution Factor Dilution Factor 
Dilution Factor 
C
C
R
2 
!M
FI
 
C
C
R
2 
!M
FI
 
C
C
R
2 
!M
FI
 
A B 
C 
* 
BM Spleen 
Blood 
* 
* 
Chapter 3  129 
 
 
Figure 3-3: Further testing of the MC-21 anti-mouse CCR2 antibody. 
(A) Live cells from the spleen (top), BM (middle) or blood (bottom) isolated from WT mice were 
stained with 5 µg/ml (1:100) MC-21 anti-CCR2 antibody (left hand panel) and compared to an 
isotype control (central panel) or MC-21 staining of CCR2 KO cells (right hand panel). (B-D) 
Graphical representation of the calculated % of live cells within the gated populations in (A). Data 
are from three individual mice per genotype, except the isotype result which was generated from a 
single mouse (mean + SD). Data were analysed by unpaired T-test comparing WT to CCR2 KO 
p<0.05 * and p<0.01 **. 
0.0
2.5
5.0
WT
CCR2 KO
Isotype
10
20
30
40
50
60
WT 
CCR2 KO 
WT Isotype 
M
C-
21
 
Ly6C 
Spleen 
BM 
Blood 
WT Isotype CCR2 KO 
0.0 
30.0 
60.0 
90.0 
Ly
6C
+ 
M
C-
21
/Is
o-
 
%
 o
f l
iv
e 
ce
lls
 
A 
B 
Ly
6C
+ 
M
C-
21
/Is
ol
o 
Ly
6C
- M
C-
21
/Is
o-
 
Ly
6C
- M
C-
21
/Is
oh
i 
Ly
6C
- M
C-
21
/Is
ol
o 
Ly
6C
hi
 M
C-
21
/Is
oh
i 
 
.0 
40.0 
60.0 
%
 o
f l
iv
e 
ce
lls
 
C 
0.0
30.0
60.0
90.0
WT
CCR2 KO
Isotype
0.0 
30.0 
60.0 
0.0 
%
 o
f l
iv
e 
ce
lls
 
D 
0.0
0.0
0.0
.0
WT
CCR2 KO
I otype
** 
** 
* 
BM Spleen 
Blood 
Ly
6C
+ 
M
C-
21
/Is
o-
 
Ly
6C
+ 
M
C-
21
/Is
ol
o 
Ly
6C
- M
C-
21
/Is
o-
 
Ly
6C
- M
C-
21
/Is
oh
i 
Ly
6C
- M
C-
21
/Is
ol
o 
Ly
6C
hi
 M
C-
21
/Is
oh
i 
Ly
6C
+ 
M
C-
21
/Is
o-
 
Ly
6C
+ 
M
C-
21
/Is
ol
o 
Ly
6C
- M
C-
21
/Is
o-
 
Ly
6C
- M
C-
21
/Is
oh
i 
Ly
6C
- M
C-
21
/Is
ol
o 
Ly
6C
hi
 M
C-
21
/Is
oh
i 
** 
50.0 
30.0 
20.0 
10.0 
2.5 * 
Chapter 3  130 
 
 
Figure 3-4: Detection of CCR2 expression using MC-21 antibody. 
Specific cell populations in the spleen (A&B), BM (C&D) and blood (E&F) were identified by FACS, 
according to specific lineage markers as indicated. The level of CCR2 expression was assessed 
using the MC-21 antibody (black line) and compared to isotype controls (shaded grey area) or 
CCR2 KO stained with MC-21 (grey line) and is shown in representative histograms. The 
proportion of cells positive for staining with MC-21 (MC-21/Iso+) was determined for each 
population by considering anything above the isotype control to be positive. The proportion of MC-
21/Iso+ cells within each population was calculated for WT, CCR2 KO and isotype control samples 
in the spleen (B), BM (D) and blood (F). Data are from three individual mice per genotype, except 
the isotype result, which was generated from a single WT mouse (mean + SD). Data were 
analysed by unpaired T-test comparing WT to CCR2 KO p<0.05 *. 
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Figure 3-5: Using fluorescently labelled CCL2 to detect CCR2. 
CCL2AF647 is incubated with a single cell suspension of cells generated from the tissue of choice for 
1 hr at 37°C. Cells are subsequently stained with fluorescently labelled antibodies against cell 
surface markers and analysed using flow cytometry. Using a combination of samples from WT 
(black line) and CCR2 KO (shaded grey area) animals the receptor responsible for the uptake of 
CCL2AF647 can determined. The histograms illustrate typical results that may be generated with the 
assay when either no CCR2 dependent uptake (left hand panel) or CCR2 dependent uptake 
(middle panel) is observed. Furthermore, in most cases a control competition sample which refers 
to the addition of a 10-fold molar excess of unlabelled murine CCL22 (mCCL22) was included (grey 
line). In addition to CCR2, the atypical chemokine receptor D6 can also bind CCL2AF647. The 
addition of mCCL22 (right hand panel) can confirm that uptake is in fact due to D6, as D6 is the 
only receptor that binds to CCL2 and CCL22. 
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Figure 3-6: mCCL22 competition is specific for D6 mediated uptake. 
(A) Splenocytes isolated from WT (far left hand panel) or CCR2 KO (left hand panel) animals were 
incubated with CCL2AF647 without competition. CCL2AF647 uptake in CCR2 KO splenocytes was also 
competed with 10-fold molar excess of mCCL22 (right hand panel) or mCCL19 (far right hand 
panel). Yellow box indicates the presence of a CD19lo population that possesses CCR2 dependent 
uptake. (B) The proportion of CCL2+ cells within CD19+ and CD19- populations, as gated in (A) 
were calculated for WT, CCR2 KO and competition samples. Data are from three individual mice 
per genotype (mean + SD). Data were analysed by one-way ANOVA with Tukey post-test p<0.01 
** and p<0.001 ***. 
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Figure 3-7: CCL2AF647 uptake assay can detect CCR2 activity in multiple tissues. 
(A) The assay was tested in a range of tissues, the spleen (top row), BM (middle row) and blood 
(bottom row). Representative plots of CCL2AF647 uptake in WT (left hand panels), CCR2 KO without 
(middle panels) and with mCCL22 competition (right hand panels). (B-D) Graphical representation 
of the calculated % of live cells within the gated populations in (A). Data are from three individual 
mice per genotype (mean + SD). Data were analysed by one-way ANOVA with Tukey post-test 
p<0.05 *, p<0.01 ** and p<0.001 ***. 
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Figure 3-8: Competition of the CCR2 and D6 independent uptake in BM. 
Cells isolated from CCR2 KO BM were incubated with an excess of a range of murine CC 
chemokines ligands at 10-fold molar excess. Representative plots of CCL2AF647 uptake in BM of 
CCR2 KO animals with competition. Red boxes indicate the CCR2 and D6 independent uptake and 
the proportion of live cells within each box is indicated. Plots are representative of three biological 
replicates. 
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Figure 3-9: Characterisation of CCL2 receptor activity on murine splenic lymphocytes using 
CCL2AF647. 
Murine NK cells (A), γδ+ T cells (B), CD8α+ and CD4+ T cells (C) and B cells, including MZ-B cells 
and CD21- B cells (D) were gated as depicted in the left hand panels of the figure. Representative 
histograms of WT (black line) and CCR2 KO (shaded grey area) cells incubated with CCL2AF647 
alone, or CCL2AF647 uptake in CCR2 KO competed with 10-fold molar excess mCCL22 (grey line) 
are shown for each gated population. Proportion of CCL2+ cells is illustrated in histograms for each 
cell population, calculated by subtracting % CCL2+ cells in CCR2 KO + mCCL22 samples from WT 
samples. (E) The proportion of CCL2+ cells within each population was calculated by considering 
anything above CCR2 KO + mCCL22 sample to be positive. Data are from 3 or more individual 
mice per genotype (mean + SD). Data were analysed by one-way ANOVA with Tukey post-test 
p<0.01 ** and p<0.001 ***. 
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Figure 3-10: Characterisation of CCL2 receptor activity on murine splenic myeloid cells 
using CCL2AF647. 
Murine neutrophils and monocytes (A) and macrophages (B) were gated as depicted in the left 
hand plots of the figure. Representative histograms of WT (black line) and CCR2 KO (shaded grey 
area) cells incubated with CCL2AF647 alone, or CCL2AF647 uptake in CCR2 KO competed with 10-
fold molar excess mCCL22 (grey line). Proportion of CCL2+ cells is illustrated in histograms for 
each cell population, calculated by subtracting % CCL2+ cells in CCR2 KO + mCCL22 samples 
from WT samples. (C) The proportion of CCL2+ cells within each population was calculated by 
considering anything above CCR2 KO + mCCL22 sample to be positive. Data are from 3 or more 
individual mice per genotype (mean + SD). Data were analysed by one-way ANOVA with Tukey 
post-test p<0.05 * and p<0.001 ***. 
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Figure 3-11: Characterisation of CCL2 receptor activity on murine splenic DCs using 
CCL2AF647. 
CD11b+ cDCs, CD8α+ cDCs, and CD11c+MHCII- cells (A) and pDCs (B) were gated as depicted in 
the left hand panels of the figure. Both cDC populations and the CD11c+MHCII- were gated 
following the exclusion of dead cells, CD19+, NK1.1+ and CD3+ cells. Representative histograms of 
WT (black line) and CCR2 KO (shaded grey area) cells incubated with CCL2AF647 alone, or 
CCL2AF647 uptake in CCR2 KO competed with 10-fold molar excess mCCL22 (grey line). Proportion 
of CCL2+ cells is illustrated in histograms for each cell population, calculated by subtracting % 
CCL2+ cells in CCR2 KO + mCCL22 samples from WT samples. (C) The proportion of CCL2+ cells 
within each population was calculated by considering anything above CCR2 KO + mCCL22 sample 
to be positive. Data are from 3 or more individual mice per genotype (mean + SD). Data were 
analysed by one-way ANOVA with Tukey post-test p<0.05 * and p<0.001 ***. 
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Figure 3-12: CCL2 receptor activity of murine BM cells as characterised by using CCL2AF647 
assay. 
Murine BM neutrophils, monocytes, Gr1hiCD115+ cells, Populations A, B and C (A), B cells, CD11c+ 
cells and pDCs (B) were gated as depicted in the left hand plots of the figure. Representative 
histograms of WT (black line) and CCR2 KO (shaded grey area) cells incubated with CCL2AF647 
alone, or CCL2AF647 uptake in CCR2 KO competed with 10-fold molar excess mCCL22 (grey line). 
Proportion of CCL2+ cells is illustrated in histograms for each cell population, calculated by 
subtracting % CCL2+ cells in CCR2 KO + mCCL22 samples from WT samples. Physical properties 
of monocytes (red), neutrophils (brown), Population A (light blue), Population B (yellow), Population 
C (purple) and the Gr1hiCD115+ population (green) are shown in (A). (C) The proportion of CCL2+ 
cells within each population was calculated by considering anything above CCR2 KO + mCCL22 
sample to be positive. Data are from 3 or more individual mice per genotype (mean + SD). Data 
were analysed by one-way ANOVA with Tukey post-test p<0.05 * and p<0.001 ***. 
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Figure 3-13: CCL2 receptor activity of murine blood cells as characterised by using 
CCL2AF647 assay. 
Murine blood neutrophils, monocytes, Gr1hiCD115+ cells, Populations A, B and C (A), B cells, 
CD11c+ cells and pDCs (B) were gated as depicted in the left hand plots of the figure. 
Representative histograms of WT (black line) and CCR2 KO (shaded grey area) cells incubated 
with CCL2AF647 alone, or CCL2AF647 uptake in CCR2 KO competed with 10-fold molar excess 
mCCL22 (grey line). Proportion of CCL2+ cells is illustrated in histograms for each cell population, 
calculated by subtracting % CCL2+ cells in CCR2 KO + mCCL22 samples from WT samples. 
Physical properties of monocyte (red), neutrophils (brown), Population A (light blue), Population B 
(yellow), Population C (purple) and the Gr1hiCD115+ population (green) are shown in (A). (C) The 
proportion of CCL2+ cells within each population was calculated by considering anything above 
CCR2 KO + mCCL22 sample to be positive. Data are from 3 or more individual mice per genotype 
(mean + SD). Data were analysed by one-way ANOVA with Tukey post-test p<0.001 ***. 
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Figure 3-14: Characterisation of CCL2 receptor activity on murine LN cells using CCL2AF647. 
Murine LN γδ+ T cells and TCR αβ CD3+ T cells (A), B cells (B), and migratory and resident cDCs 
(C) were gated as depicted in the left hand panels of the figure. Representative histograms of WT 
(black line) and CCR2 KO (shaded grey area) cells incubated with CCL2AF647 alone, or CCL2AF647 
uptake in CCR2 KO competed with 10-fold molar excess mCCL22 (grey line). Proportion of CCL2+ 
cells is illustrated in histograms for each cell population, calculated by subtracting % CCL2+ cells in 
CCR2 KO + mCCL22 samples from WT samples. (D) The proportion of CCL2+ cells within each 
population was calculated by considering anything above CCR2 KO + mCCL22 sample to be 
positive. Data are from 3 or more individual mice per genotype (mean + SD). Data were analysed 
by one-way ANOVA with Tukey post-test p<0.001 ***. 
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Figure 3-15: Frequency of cell populations in WT and CCR2 KO. 
Single cell suspensions from WT (black bars) and CCR2 KO (white bars) spleen (A), BM (B), blood 
(C) and PLNs (D) were analysed for the frequency of individual cell populations. Populations were 
gated as dictated as per Figures 3-9 to 3-14. Data are from 3 or more individual mice per genotype 
(mean + SD). Data were analysed by unpaired T-test p<0.05 *, p<0.01 ** and p<0.001 ***. 
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Figure 3-16: CCL2AF647 uptake assay can detect CCL2 receptor activity in other mammalian 
species. 
(A) Rat splenocytes were incubated with media alone (shaded histogram), CCL2AF647 without 
competition (black line) or CCL2AF647 with either rCCL2 or mCCL22 (grey line). CD4+ cDCs and 
pDCs were gated as depicted in the figure following exclusion of dead cells, CD45RA, Igκ, 
CD45RC, TCRαβ and Igλ positive cells. Subsequent to exclusion of dead cells and CD45R, 
CD45RC and TCRαβ positive cells, monocytes and neutrophils were identified by gating as 
described in the figure. (B) Human peripheral blood mononuclear cells were incubated with 
CCL2AF647 without competition (black line), CCL2AF647 with either hCCL2 (shaded grey area) or 
hCCL22 (grey line). Following exclusion of dead cells, monocytes, B cells and NK cells were gated 
as depicted in the figure. pDCs were gated as depicted in the figure following exclusion of dead 
cells, CD3, CD56, CD14, CD15 and CD19 positive cells. n=1. 
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Figure 3-17: Effect of the presence of unlabelled CCR2 ligands on CCR2 activity of 
splenocytes, as measured by CCL2AF647. 
Single cell suspensions of WT and CCR2 KO murine splenocytes were incubated with 25 nM 
CCL2AF647 with or without competition. Competition refers to the addition of 1.5625 – 25 nM of 
murine CCL2, CCL3, CCL7 or CCL12. (A) Representative plots of CCL2AF647 uptake by CCR2 KO 
and WT splenocytes without competition, and WT splenocytes with competition with 25 nM 
mCCL2, mCCL3, mCCL7 or mCCL12. Red boxes highlight CCL2AF647 uptake by Ly6C- cells and 
the proportion of live cells within the gate is shown. Monocytes gated as Ly6Chi, CD11b+ and Gr1lo 
(B) and Ly6C-CD11b+ cells (C) were analysed for CCR2 activity. Representative histograms of 
CCL2AF647 uptake are shown. CCR2 KO without competition (shaded grey area), WT with 
competition with murine chemokines, CCL2 (blue line), CCL3 (red line), CCL7 (green line) and 
CCL12 (orange line). For each condition CCL2 geometric mean fluorescence intensity (ΔMFI) was 
calculated, n=3 except for CCR2 KO alone controls where n=1 (dotted grey line) (mean ±SD). Data 
were analysed by two-way ANOVA with Bonferroni post-test. Statistics were generated by 
comparing individual concentrations of each chemokine to competition with the same concentration 
of CCL2 p<0.01 ** and p<0.001 ***. 
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Figure 3-18: Effect of chemokine exposure on CCR2 activity of splenocytes. 
Single cell suspensions of WT and CCR2 KO murine splenocytes were incubated with CCL2AF647 
subsequent to incubation with an unlabelled chemokine. Pre-incubation refers to the prior exposure 
of splenocytes with 0 – 250 nM of murine CCL2, CCL7 or CCL12 before washing in binding buffer 
and then incubation with 25 nM CCL2AF647. (A) Representative plots of CCL2AF647 uptake by CCR2 
KO without prior exposure to ligand, and WT splenocytes with or without prior exposure to 250 nM 
mCCL2, mCCL3, mCCL7 or mCCL12. Red boxes highlight CCL2AF647 uptake by Ly6C- cells and 
the proportion of live cells within gate is shown. Monocytes gated as Ly6Chi, CD11b+ and Gr1lo (B) 
and Ly6C-CD11b+ cells (C) were analysed for CCR2 activity. Representative histograms of 
CCL2AF647 uptake are shown. CCR2 KO without prior exposure (shaded grey area), WT without 
prior exposure (black line), and WT exposed to unlabelled murine chemokines, CCL2 (blue line), 
CCL3 (red line), CCL7 (green line) and CCL12 (orange line). For each condition CCL2 geometric 
mean fluorescence intensity (ΔMFI) was calculated, n=3 except for CCR2 KO alone controls where 
n=1 (dotted grey line) (mean ±SD). Data were analysed by two-way ANOVA with Bonferroni post-
test. Statistics were generated by comparing individual concentrations of each chemokine to 
competition with the same concentration of CCL2 p<0.05* and p<0.001 ***. 
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Chapter 4 – Impact of systemic inflammation on 
CCL2 receptor activity 
CCR2 exerts key homeostatic functions, but both CCR2 and D6 are receptors for 
chemokines produced at high levels during times of inflammation (Serbina and 
Pamer, 2006; Hansell et al., 2011b). Consequently, these receptors play major 
roles during inflammatory responses (Fra et al., 2003; Bonecchi et al., 2004; 
Serbina et al., 2008; Nakano et al., 2009; Hansell et al., 2011b). In Chapter 3 I 
have presented data offering a comprehensive analysis of CCR2 bearing cells in 
vivo and the impact of CCR2 deletion on these cell populations. In this chapter I 
examine the effect of systemic inflammation on CCL2 receptor activity and on 
the size of these populations in the presence and absence of CCR2. As a simple 
model of systemic inflammation in mice, I used intravenous (i.v.) injection of E. 
coli LPS. 
LPS is a potent proinflammatory agent that upon injection into an experimental 
animal induces systemic inflammation. Furthermore, the early expression of 
CCL2, a ligand for both CCR2 and D6, has been reported to positively predict the 
development of LPS induced systemic inflammation (Juskewitch et al., 2012). 
There is extensive literature on the effects of LPS, both in vivo and in vitro 
derived data. For example, LPS induced inflammation in vivo can affect the 
cellular composition of lymphoid organs. It has been reported to cause a 
reduction in splenic cDC numbers (De Smedt et al., 1996), as a consequence of 
increased cell turnover and a shortened lifespan (Kamath et al., 2000), as 
activated cDCs are subject to apoptotic cell death (Zanoni et al., 2009). In 
contrast, neutrophils and macrophages accumulate in the spleen of LPS treated 
animals (Chandra et al., 2008). These are all cells of the innate immune system, 
which have been described to possess TLR4, the receptor for LPS. However, a 
cell does not necessarily need to express TLR4 in order to respond to LPS, as LPS 
can have indirect effects on cells. For example, the differentiation of naïve T 
cells, which possess little or no TLR4 can be indirectly mediated by LPS induced 
activation of cDCs (Rahman et al., 2009; Jin et al., 2012). However, the 
maturation state of a cell can also change their responsiveness to LPS, as 
effector CD4+ T cells can be directly activated by LPS (González-Navajas et al., 
2010; Jin et al., 2012). Therefore, a broad range of cells including myeloid, 
lymphoid and DCs should be able to respond to LPS either directly or indirectly. 
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LPS treatment has also been shown in vitro and in vivo to affect the expression 
of CCR2. The surface level of CCR2 on human monocytes is known to be affected 
by LPS mediated activation of TLR4 in vitro (Xu et al., 2000; Parker et al., 
2004). Zhou et al. have also shown that CCR2 expression, both transcript and 
surface protein are downregulated by murine monocytes in response to LPS in 
vivo (Zhou et al., 1999). However, these data were derived using an anti-CCR2 
antibody, which, as I have shown in Chapter 3, suffers from poor sensitivity and 
as a consequence, an inability to detect low levels of CCR2. This has meant that, 
in many cases, CCR2 downregulation is only measured at the transcript level. 
Due to their high expression of CCR2, Ly6Chi monocytes are the usual cell of 
choice for studying CCR2 function and regulation. My results in Chapter 3, also 
illustrated that Ly6Chi monocytes had significantly higher CCR2 activity than 
other cell populations. CCR2 may behave differently on other cell populations, 
perhaps only playing roles in their migration under specific inflammatory 
conditions, being subject to different regulation, or even having different 
specificity for chemokines. Indeed, this is what my data in Figures 3-17 and 3-18 
suggest. Therefore, by only using a population of cells that has high levels of 
CCR2 to examine its function and regulation we might form conclusions that are 
inaccurate for other CCR2+ populations.  
Furthermore, in Chapter 3, I demonstrated that several of the populations 
bearing CCL2 receptors, such as pDCs and BM Ly6Chi monocytes, showed 
evidence of possessing both CCR2 and D6 activity. Specific chemokine receptors, 
when co-expressed by individual cells, can modulate the function of the other 
receptor. The co-expression of CXCR4 and CXCR7 leads to the formation of 
heterodimers and leads to enhanced migration of cancer cells (Décaillot et al., 
2011). D6 has also been shown to affect the function of CXCR5 on innate-like B 
cells, leading to a decrease in migration in response to the CXCR5 ligand, CXCL13 
(Hansell et al., 2011b). Perhaps similar to D6 on innate-like B cells, the presence 
of D6 on a CCR2+ population might also be important for CCR2 function on these 
cells. Furthermore, the dynamics of CCR2 and D6 regulation by LPS, in whole 
animals, is not known. 
Therefore in order to establish the effects of LPS on both the activity of CCL2 
receptors and the size of the CCL2+ populations, I performed a time-course of 
LPS induced inflammation in WT and CCR2 KO animals. This time-course was 
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performed in collaboration with Chris Hansell, who was examining the effects of 
LPS on splenic B cell populations. A low dose of LPS (15 µg per mouse) was 
chosen, as it was reported to affect some of the CCR2 expressing populations, 
such as cDCs (De Smedt et al., 1998; Zanoni et al., 2009). WT and CCR2 KO 
animals were either treated i.v. with 100 µl of sterile PBS or 15 µg of LPS 
dissolved in 100 µl of sterile PBS. Spleens and BM were harvested 24 or 48 hrs 
after PBS treatment, or 24, 48 or 72 hrs after LPS administration. These time-
points were chosen because LPS induces a rapid and transient inflammation and 
we believed that these time-points would facilitate the examination of the 
induction and resolution phases of inflammation. CCL2 has been reported to be a 
predictive marker of the development of systemic inflammation by LPS 
(Juskewitch et al., 2012), therefore high levels of CCL2 might correlate with the 
early time-points of the time-course, and thus CCR2 might be desensitised and 
unable to bind and internalise CCL2AF647. In contrast, I expected that expression 
of the atypical chemokine receptor, D6, by cell populations, such as MZ-B cells 
and pDCs to be relatively unaffected by LPS treatment and D6 would facilitate 
the scavenging of inflammatory chemokines, including CCL2, which might aid in 
the resolution of LPS induced inflammation. 
Furthermore, based on published data (Ulich et al., 1991), I expected that LPS 
would cause a rapid recruitment of neutrophils into the spleen. My data in 
Chapter 3, suggests that their recruitment would be CCR2 independent, as these 
cells were not found to possess CCR2 activity (Figure 3-10). In contrast, I 
hypothesised that recruitment of Ly6Chi monocytes (and/or other CCR2+ 
populations) will be reduced in CCR2 KOs. However, I expected the frequency of 
Ly6Chi monocytes in the spleen of WT animals to be increased following LPS 
induced inflammation, as Chandra et al. reported increased number of splenic 
macrophages 24 hrs after LPS treatment (Chandra et al., 2008). I also expected 
there to be decreased numbers of splenic cDCs at the later time-points in LPS 
time-course, due to their increased turnover rate (Kamath et al., 2000). 
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4.1 Exploration of the dynamic changes in splenic 
leukocyte populations in response to systemic LPS 
administration and the affect of CCR2 deficiency 
I monitored CCL2 receptor activity and the abundance of the several CCL2+ 
populations over the duration of a LPS time-course, in both the spleen (Figure 4-
1 to 4-10) and the BM (Figure 4-11), in parallel with Chris Hansell who assessed 
CCL2 receptor activity in B cells. His data are included here with permission, for 
comparative purposes (Figure 4-5). Splenic cDC maturation was also examined 
(Figure 4-9). Uptake of CCL2AF647 was measured in WT and CCR2 KO samples with 
or without competition with mCCL22. In previous experiments I only examined 
D6 activity in CCR2 KO animals by competing CCL2AF647 uptake by CCR2 KO cells 
with mCCL22. This provides information about D6 activity only in the absence of 
CCR2. The absence of CCR2 might conceivably affect expression or the activity 
of D6: perhaps D6 is only expressed or detectable when CCR2 is absent. By 
including WT samples with mCCL22 competition I hoped to establish whether D6 
activity was detectable in the presence of CCR2. The frequency of CCL2+ 
populations was determined at each time-point in the LPS time-course and all 
data are presented as a proportion of live cells rather than as an absolute 
number of cells. Therefore, I can not describe alterations in the number of 
particular cell types, but these data do provide information about any increase 
or decrease in the proportion of live splenocytes that are a particular cell type. 
There were, however, no dramatic differences in the total number of cells 
retrieved from WT and CCR2 KO tissues. 
I will describe the data generated for each CCL2+ cell population individually, 
but as all cell types were analysed simultaneously, and as a consequence all cell 
data are linked, I will first describe some broad observations that were true for 
the majority of cell types. All cell populations found to possess CCR2 activity in 
PBS control mice had a reduction in CCR2 dependent CCL2AF647 uptake 24 hrs 
after LPS administration. In contrast, LPS did not cause a reduction in D6 
dependent CCL2AF647 uptake by the few cell populations that were found to 
possess D6 activity in resting CCR2 KO animals, such as MZ-B cells, pDCs and BM 
Ly6Chi monocytes. CCR2 activity was restored or upregulated at later time-points 
in the LPS time-course in all CCL2+ cell populations other than pDCs. 72 hrs after 
LPS treatment pDCs exhibited a switch in the receptor responsible for CCL2AF647 
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uptake, as all CCL2AF647 uptake at this time-point was not mediated by CCR2, but 
by D6. Furthermore, in every cell population, including CCR2- neutrophils, D6 
activity was upregulated in CCR2 KO cells 48 hrs after LPS. However, this activity 
was not detectable in the majority of WT cell populations at 48 hrs. There now 
follows a more detailed description of the data for each individual cell type 
analysed. 
4.1.1 Splenic Ly6Chi monocytes 
Ly6Chi monocytes had high levels of CCR2 dependent uptake of CCL2AF647 in PBS 
treated mice, which was reduced substantially 24 hrs after LPS treatment, but 
not completely lost (Figure 4-1). Quantification of the number of CCL2+ Ly6Chi 
monocytes revealed a significant reduction in the number of CCL2+ cells in CCR2 
KO compared to WT at all time-points as expected (Figure 4-1C). Furthermore, 
there was a significant reduction in the number of CCL2+ cells in WT samples at 
24 hrs. However, there were still significant levels of CCR2 dependent uptake 
remaining. By 48 and 72 hrs after LPS treatment, CCL2 ΔMFI (Figure 4-1B) and 
the percentage of CCL2+ cells were restored to levels comparable to PBS controls 
(Figure 4-1C), indicating restoration of CCR2 dependent uptake. In contrast to 
histogram overlays that suggested evidence of D6 activity in both WT and CCR2 
KO samples (Figure 4-1A), there were no statistically significant levels of D6 
activity detected at any time-point, except in KO Ly6Chi monocytes 48 hrs after 
LPS treatment (Figure 4-1C).  
The decrease in CCR2 activity at 24 hrs might be explained by partial 
desensitisation or downregulation of CCR2, or by changes in the frequency of 
Ly6Chi monocytes present in the spleen. However, the decrease in CCL2+ Ly6Chi 
monocytes detected at 24 hrs could not be correlated with a decrease in the 
proportion of live WT splenocytes that were Ly6Chi monocytes (Figure 4-2A). At 
later time-points in the LPS time-course there is a significant increase in Ly6Chi 
monocytes as a percentage of total cells in the spleen of WT animals compared 
to PBS treated mice (p<0.01). Furthermore, as expected CCR2 KO animals had a 
deficit in peripheral Ly6Chi monocytes in PBS-treated mice, however 24 hrs after 
LPS treatment this deficit was rescued, as a comparable proportion of spleen 
cells were Ly6Chi monocytes in WT and CCR2 KO spleens. The increase in the 
frequency of Ly6Chi monocytes as a proportion of live splenocytes in CCR2 KO 
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animals is highlighted in Figure 4-2B and C. However, the splenic CCR2 KO Ly6Chi 
monocyte deficit was restored by 48 hrs after LPS administration, and a greater 
proportion of splenocytes were Ly6Chi monocytes in WT compared to CCR2 KOs 
at 48 and 72 hrs (Figure 4-2A).  
Thus, LPS transiently downregulates, but does not completely remove CCR2 
activity on Ly6Chi monocytes, and rescues the Ly6Chi monocyte deficit in CCR2 
deficient mice, but both parameters are rapidly restored. It is also notable that 
even at 24 hrs after LPS administration, there is more CCR2 activity on Ly6Chi 
monocytes than on most other CCR2 expressing cells in resting mice (see Chapter 
3 and following results). 
4.1.2 Splenic NK cells 
Similar to Ly6Chi monocytes, the large majority of CCL2AF647 uptake by splenic NK 
cells was CCR2 dependent in PBS and LPS treated WT mice. Furthermore, like 
Ly6Chi monocytes, CCL2 ΔMFI data suggested decreased CCL2AF647 uptake 24 hrs 
after LPS treatment (Figure 4-3B). There was, however, no significant reduction 
in the number of CCL2+ NK cells at this time-point, and significant levels of CCR2 
activity were still detectable (Figure 4-3C). At 48 and 72 hrs there was a 
dramatic increase in CCL2AF647 uptake by WT cells, which was also CCR2 
dependent. Furthermore, histogram overlays suggested evidence of D6 activity 
in CCR2 KO NK cells at 48 and 72 hrs, and low levels of D6 activity in WT NK cells 
at 48 hrs (Figure 4-3A). In contrast, CCL2 ΔMFI data demonstrated significant 
levels of D6 activity only in WT NK cells at 48 and 72 hrs (Figure 4-3B). However, 
quantification of the number of CCL2+ NK cells indicated that a proportion of 
CCR2 KO NK cells possessed D6 activity and it was limited to the 48 hr time-point 
(Figure 4-3C). These results suggest that WT and CCR2 KO NK cells possess low, 
but significant levels of D6 activity 48 hrs after LPS administration. 
LPS also appeared to affect the frequency of splenic NK cells, as there was a 
significant reduction in the frequency of total NK cells in the spleen of WT 
(p<0.05) and CCR2 KO (p<0.01) animals, 24 hrs after LPS treatment compared to 
PBS controls (Figure 4-3D). However, there was no change in the proportion of 
NK cells that were CCL2+, which suggests that both CCL2+ and CCL2- NK cells 
must be reduced (Figure 4-3C). The decrease in splenic NK cell frequency might 
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be explained by NK cells leaving the spleen and entering the blood, or by cell 
death. If the decrease in frequency is due to their exit from the spleen, this 
mobilisation does not appear to be CCR2 dependent as the decrease was also 
present in CCR2 KO animals. Furthermore, the proportions of splenic NK cell 
were restored at later time-points to levels comparable to PBS controls, but it 
was not due to CCR2 dependent processes, as it was also found in the CCR2 KO. 
Therefore, CCR2 does not appear to be involved in regulating NK cell abundance 
in the spleen before or after LPS treatment. Thus, LPS induces downregulation 
of CCR2 activity on NK cells, and reduces their abundance as a proportion of live 
splenocytes, but by 48 hrs these cells reappear and show enhanced CCR2 
activity. 
4.1.3 Splenic neutrophils 
Interestingly, neutrophils possessed no CCR2 or D6 dependent uptake in 
homeostasis, but were found to uptake CCL2AF647 48 and 72 hrs after LPS 
treatment (Figure 4-4). This uptake was CCR2 independent, as it was still 
present in the CCR2 KO samples. Competition of uptake in both WT and CCR2 KO 
samples with the D6 ligand, mCCL22 demonstrated that uptake was in fact due 
to D6. The increase in D6 activity might be explained by the upregulation of D6 
activity on the original splenic neutrophil population or infiltration of “new” 
neutrophils possessing D6 activity. There was a significant increase in the 
frequency of splenic neutrophils 48 hrs after LPS (p<0.001), before returning to 
levels comparable to PBS control at 72 hrs (Figure 4-4D). The frequency of CCR2 
KO splenic neutrophils followed similar trends, although there was a significant 
increase in the proportion of live splenocytes that were neutrophils in CCR2 KO 
animals compared to WT 24 hrs after LPS treatment (p<0.001). Therefore, 
neutrophils did not display any dependence on CCR2 for infiltration into the 
spleen, but rather their abundance in spleen early after LPS treatment was 
somewhat suppressed by CCR2. 
4.1.4 Splenic MZ-B cells 
MZ-B cells in a resting animal do not possess CCR2 activity and all CCL2AF647 
uptake is D6 dependent, as shown in Chapter 3. Unlike the observed loss of CCR2 
activity by Ly6Chi monocytes and NK cells 24 hrs after LPS treatment, D6 activity 
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on MZ-B cells was maintained (Figure 4-5). 48 and 72 hrs after LPS administration 
D6 mediated uptake of CCL2AF647 was dramatically increased over the PBS 
control, as indicated by an increase in the CCL2 ΔMFI of MZ-B cells (Figure 4-5B). 
There was also a corresponding significant increase in the frequency of CCL2+ 
MZ-B cells at 48 hrs, but there was no parallel increase at 72 hrs (Figure 4-5C). 
The increase in CCL2+ MZ-B cells might be explained by an overall increase in the 
splenic MZ-B cell frequency, however statistical analysis showed no significant 
increase in MZ-B cell frequency at any time-point when compared to PBS control 
(Figure 4-5D). Furthermore, there was no statistically significant effect of CCR2 
deletion on the frequency of splenic MZ-B cells (Figure 4-5D). 
4.1.5 Splenic pDCs 
Like Ly6Chi monocytes and NK cells, pDCs also had a significant reduction in 
CCR2 activity at 24 hrs, but like MZ-B cells appeared to maintain D6 mediated 
CCL2AF647 uptake, albeit at much lower levels than MZ-B cells (Figure 4-6). By 48 
hrs pDCs had restored some CCR2 dependent uptake of CCL2AF647, and CCR2 KO 
samples also possessed significant levels of D6 activity (Figure 4-6C). CCL2AF647 
uptake was restored 72 hrs after LPS treatment to levels comparable to the PBS 
control, as demonstrated by both CCL2 ΔMFI data (Figure 4-6B) and percentage 
of CCL2+ cells (Figure 4-6C). Surprisingly however, this uptake was also present 
in CCR2 KO pDCs. Competition of CCL2AF647 uptake with mCCL22 in both WT and 
CCR2 KO samples indicated that uptake was predominantly D6 dependent, as 
there was a significant reduction in CCL2AF647 uptake in the presence of mCCL22, 
although substantially more non-specific uptake of CCL2AF647 was also observed. 
Furthermore, unlike resting mice, it was no longer possible to distinguish CCL2hi 
and CCL2lo populations of pDCs. 
The frequency of splenic pDCs was relatively unaffected by LPS treatment, or by 
CCR2 deletion (Figure 4-6D). Therefore, CCR2 did not appear to play a role in 
controlling pDC abundance in the spleen during homeostasis or inflammation. 
Furthermore, consistent with Ly6Chi monocytes and NK cells, LPS induces 
downregulation of CCR2 activity on pDCs, and similar to MZ-B cells there was no 
effect of LPS on D6 activity 24 hrs after LPS. In contrast to all other populations 
possessing CCR2 activity, pDCs did not restore CCR2 activity by 72 hrs, but both 
WT and CCR2 KO pDCs significantly upregulated D6 activity. 
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4.1.6 Splenic cDCs 
Uptake of CCL2AF647 by CD11b+ cDCs in PBS control WT animals (Figure 4-7) was 
CCR2 dependent and had nearly completely disappeared by 24 hrs after LPS 
treatment. At 48 and 72 hrs CCL2AF647 uptake was significantly increased in 
CD11b+ cDCs over that of PBS controls, and this uptake was dependent on CCR2, 
and due primarily to an increase in the proportion of cells that were CCL2+. 
There was no evidence of D6 activity in WT CD11b+ cDCs at any time-point. In 
contrast, CD11b+ cDCs from CCR2 KO animals possessed very weak D6 activity 48 
hrs after LPS treatment, which was lost by 72 hrs. 
CD8α+ cDCs in PBS control WT animals possessed both CCR2 and very low levels 
of D6 activity (Figure 4-8). D6 activity was not present in CCR2 KO animals in PBS 
controls. Like CD11b+ cDCs, 24 hrs after LPS treatment there was a near 
complete loss of CCL2AF647 uptake, which was restored to levels comparable to 
PBS control by 48 hrs. Furthermore, WT and CCR2 KO CD8α+ cDCs possessed low, 
but significant levels of D6 activity 48 hrs after LPS treatment. D6 activity in 
both WT and CCR2 KO CD8α+ cDCs was lost by 72 hrs and all CCL2AF647 uptake by 
WT CD8α+ cDCs at this time-point was CCR2 dependent. 
As mentioned earlier, LPS is known to mediate CCR2 downregulation via TLR4 
activation (Zhou et al., 1999; Xu et al., 2000; Parker et al., 2004). However, an 
alternative theory to explain the downregulation of CCR2 activity 24 hrs after 
LPS treatment is that LPS activates cells, such as cDCs resulting in their 
maturation. Maturation of DCs can effect expression of chemokine receptors 
(Sallusto et al., 1998; Vecchi et al., 1999), thus I monitored expression of CD86, 
an activation marker on both cDC subsets (Figure 4-9). The downregulation of 
CCR2 activity by cDCs 24 hrs after LPS treatment was inversely correlated with 
their acquisition of the activation marker CD86. cDCs in resting animals had 
minimal levels of CD86 expression, which was significantly increased in WT and 
CCR2 KO samples at the 24 hrs time-point. CD86 expression was returned to PBS 
control levels by 48 and 72 hrs. 
Alternatively, the reduction in CCR2 activity might be explained by migration of 
cDCs from the spleen or apoptosis of the cells. Zanoni et al. reported that 24 
and 48 hrs after LPS treatment there was a marked reduction in the number of 
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cDCs within the spleen (Zanoni et al., 2009). Furthermore, they demonstrated 
that LPS induced activation of cDCs was associated with their death by 
apoptosis. My data support this observation as 48 hrs after LPS administration 
there was a dramatic decrease in the frequency of cDCs in the spleen of WT and 
CCR2 KO animals and these cells were even less abundant at 72 hrs (Figure 4-
10). However, at 24 hrs the frequencies of both cDC subsets were unaffected by 
LPS treatment in WT animals, but there was a significant decrease in the 
frequency of both CD11b+ and CD8α+ cDCs in CCR2 KOs compared to WT animals 
(highlighted in Figure 4-10C). Interestingly, decreased cDC numbers at 48 and 72 
hrs was associated with the restoration of CCR2 activity by CD8α+ cDCs (Figure 4-
8) or upregulation of CCR2 dependent CCL2AF647 uptake in the case of CD11b+ 
cDCs (Figure 4-7). These results suggest that a significantly lower number of 
cDCs when compared to PBS control were responsible for the high levels of CCR2 
activity observed at the later time-points. 
Collectively these results clearly indicate that the dynamics of the CCL2 
receptor activity post LPS treatment are influenced by cell type and the 
receptor mediating the activity. CCR2 activity was typically downregulated 24 
hrs after LPS administration. In contrast, there was no reduction in D6 
dependent CCL2AF647 uptake by MZ-B cells and pDCs at this time-point. CCR2 
activity was restored or upregulated 48 and 72 hrs after LPS administration, in 
all CCL2+ cell populations, other than pDCs. Strikingly, all CCL2AF647 uptake by 
WT and CCR2 KO pDCs 72 hrs after LPS treatment was D6 dependent. 
Furthermore, neutrophils, which do not possess any CCR2 or D6 dependent 
CCL2AF647 in PBS controls or 24 hrs after LPS, were found to significantly 
upregulate D6 activity on a small number of cells at 48 hrs and most notably at 
72 hrs. Interestingly, regardless of their expression of CCR2 or D6 in resting 
animals, all cell populations in CCR2 KO animals were found to internalise 
CCL2AF647 in a D6 dependent manner 48 hrs after LPS. 
During homeostasis the frequency of the majority of splenic CCL2+ cell 
populations, except Ly6Chi monocytes, were unaffected by the absence of CCR2. 
However, the frequency of Ly6Chi monocytes and cDCs were drastically and 
reciprocally affected by the absence of CCR2 during inflammation with the 
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Ly6Chi monocyte defect seen in resting CCR2 KO mice being transiently rescued 
and a cDC deficit emerging. 
4.2 Examination of the role of CCR2 in monocyte 
mobilisation during systemic inflammation 
I have already discussed the fundamental role CCR2 plays in the mobilisation of 
monocytes from the BM. Several groups and my own results have demonstrated 
the scarcity of peripheral Ly6Chi inflammatory monocytes in CCR2 KO mice and 
their coincident increase in the BM of these animals (Figure 3-15), illustrating 
the requirement of CCR2 for monocyte mobilisation during homeostasis 
(Geissmann et al., 2003; Serbina and Pamer, 2006). Furthermore, CCR2 is 
necessary for monocyte emigration from the BM during infections, such as with 
Listeria monocytogenes (Serbina and Pamer, 2006) or Leishmania amazonesis 
(Strauss-Ayali et al., 2007) and inflammation (Geissmann et al., 2003). However, 
my data suggest that LPS injection rescues the CCR2 KO Ly6Chi monocyte 
mobilisation defect (Figure 4-2). Therefore, I next sought to establish if systemic 
inflammation induced by LPS also affected the CCR2 activity and frequency of 
Ly6Chi monocytes within the BM (Figure 4-11). Similar to splenic Ly6Chi 
monocytes, BM Ly6Chi monocytes had high levels of CCR2 activity, which were 
substantially reduced 24 hrs after LPS treatment (Figure 4-11B). However, there 
was no significant reduction in the proportion of CCL2+ BM Ly6Chi monocytes that 
were present at 24 hrs. There were still significant levels of CCR2 mediated 
uptake of CCL2AF647 present at this time-point (Figure 4-11C). CCR2 dependent 
uptake of CCL2AF647 uptake was restored by 48 and 72 hrs after LPS treatment. 
In contrast to splenic Ly6Chi monocytes (Figure 4-1), there was evidence of D6 
activity in PBS treated CCR2 KO control animals. Furthermore, there was no 
reduction in D6 dependent CCL2AF647 uptake by CCR2 KO BM Ly6Chi monocytes at 
24 hrs, and D6 activity was also maintained at 48 hrs. However by 72 hrs there 
was no evidence of D6 activity and all uptake was CCR2 dependent (Figure 4-
11C). mCCL22 was also able to significantly reduce CCL2AF647 uptake by WT BM 
Ly6Chi monocytes in PBS treated mice, and 48 and 72 hrs after LPS treatment, 
indicative of D6 activity (Figure 4-11A and B). 
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The retention of Ly6Chi monocytes in the BM of resting CCR2 KO animals is well 
established (Serbina and Pamer, 2006). Accordingly, I have found that resting 
CCR2 KO animals have a greater proportion of live BM cells that are Ly6Chi 
monocytes compared to WT animals (Figures 3-15 and 4-11D). However, there 
was a significant reduction (p<0.001) in the frequency of Ly6Chi monocytes in 
CCR2 KO BM 24 hrs after LPS administration. CCR2 KO animals had similar 
proportions of Ly6Chi monocytes in the BM as WT animals (Figure 4-11D). This 
decrease in Ly6Chi monocyte frequency could be correlated with the earlier 
described restoration of peripheral Ly6Chi monocytes in CCR2 KOs 24 hrs after 
LPS treatment (Figure 4-2). At later time-points the proportion of Ly6Chi 
monocytes in CCR2 KO BM was restored to levels comparable to PBS treated 
CCR2 KO controls. In contrast to resting animals there was no difference in the 
proportion of Ly6Chi monocytes present in BM of WT and CCR2 KOs, as there was 
a significant increase (p<0.001) in the proportion of Ly6Chi monocytes in WT BM 
48 hrs after LPS administration. 
4.2.1 Evaluation of the role of CXCR2 on monocytes in the 
absence of CCR2 
Due to other research conducted in the lab, which demonstrated that BM Ly6Chi 
monocytes express another inflammatory chemokine receptor CXCR2, I proposed 
that, in the absence of CCR2, CXCR2 might play a role in the release of Ly6Chi 
monocytes from the BM during LPS induced inflammation. CCR2 KO animals were 
treated with a CXCR2 antagonist, SB225002 (Bento et al., 2008) followed by LPS 
3 hrs later (Figure 4-12). The absolute number of Ly6Chi monocytes and 
neutrophils were determined in both the spleen and the BM 24 hrs after 
SB225002 treatment. Neutrophils are a rich source of CXCR2 and are highly 
dependent on CXCR2 for their mobilisation from the BM into the periphery (Eash 
et al., 2010), thus a decrease in BM neutrophil numbers was used as a positive 
control to determine if the CXCR2 antagonist worked. As Figure 4-12B shows, LPS 
treatment results in a significant reduction of BM neutrophils, with a parallel 
increase in splenic neutrophils. Prior treatment with SB225002 appeared to 
result in a lower proportion of neutrophils emigrating from the BM and thus a 
smaller increase in splenic neutrophil numbers, although neither result was 
statistically significant. The results do, however suggest that the CXCR2 
antagonist did function in diminishing CXCR2 activity. The same was true with 
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Ly6Chi monocytes: LPS caused significant mobilisation of BM monocytes into the 
periphery, but SB225002 had no significant effects on this LPS induced 
mobilisation (Figure 4-12C). 
These results have demonstrated that LPS can induce CCR2 independent 
mobilisation of Ly6Chi monocytes from the BM into the periphery. Furthermore, 
this mobilisation appears not to be CXCR2 dependent. 
4.3 Summary 
In this chapter, I have established that induction of systemic inflammation using 
a low dose of LPS alters the frequency of several of the CCL2+ populations, 
including monocytes and cDCs. Furthermore, one of the significant findings that 
arose by studying the effects of LPS on Ly6Chi monocytes was that 24 hrs after 
LPS administration the peripheral deficit in Ly6Chi monocytes in CCR2 KO animals 
was rescued, as LPS induced CCR2 independent mobilisation of BM monocytes. 
However, in a few preliminary experiments I was unable to confirm the 
mechanism for this emigration. 
LPS induced inflammation resulted in a significant downregulation of CCR2 
activity on all analysed CCL2+ populations by 24 hrs after treatment, but did not 
affect D6 activity. However, in CCR2hi populations, such as Ly6Chi monocytes and 
NK cells, although LPS did cause a reduction in CCR2 dependent CCL2AF647 uptake 
there were still significant levels of CCR2 activity detectable, according to the 
calculated percentage of CCL2+ cells present. At later time-points CCR2 activity 
had been restored to the baseline level in PBS controls or was significantly 
increased above baseline, in all CCL2+ populations except pDCs. By 72 hrs of 
treatment pDCs did not re-establish CCR2 activity, but demonstrated high levels 
of the atypical chemokine receptor, D6. Several of the CCL2+ populations in 
CCR2 KO animals acquired D6 activity, but in many cases it was limited to 48 hrs 
after LPS administration. Furthermore, MZ-B cells and neutrophils, both of which 
do not exhibit any CCR2 dependent CCL2AF647 uptake, significantly upregulated 
D6 activity at 48 hrs in both WT and CCR2 KO animals. 
This comprehensive profiling of CCR2 activity led to the establishment of CCR2 
activity on splenic pDCs. I have demonstrated approximately half of pDCs are 
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CCL2hi, and although LPS had no effect on splenic pDC frequency, it did affect 
their CCR2 activity, as well as their D6 activity. As briefly discussed earlier, a 
role for CCR2 or D6 on pDCs has yet to be described. Thus, in the next chapter I 
perform an in depth analysis of CCR2 on pDCs and examine potential functional 
and transcriptional differences between CCL2hi and CCL2lo pDCs. In short, I 
examine whether the presence or absence of CCR2 activity defines functionally 
distinct subsets of pDCs. 
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Figure 4-1: Effect of LPS on CCL2 receptor activity of splenic Ly6Chi monocytes. 
WT and CCR2 KO animals were treated i.v. with PBS for 24 or 48 hrs, or LPS for 24, 48 and 72 
hrs. Splenocytes from WT and CCR2 KO animals were incubated with CCL2AF647 with or without 
mCCL22 competition. (A) Representative histogram of CCL2AF647 uptake by Ly6Chi monocytes, 
gated as described in Figure 3-10 (Ly6ChiCD11b+Gr1lo), from WT (black line) and CCR2 KO cells 
(shaded purple area) without competition, and WT (blue line) and CCR2 KO (green line) samples 
with mCCL22 competition. (B) CCL2 geometric mean fluorescence intensity (ΔMFI) of WT (black 
line) and CCR2 KO (purple line) incubated with CCL2AF647 without competition. CCL2AF647 uptake in 
WT (blue line) and CCR2 KO (green line) splenic Ly6Chi monocytes competed with a 10-fold molar 
excess of mCCL22. (C) Proportion of Ly6Chi monocytes that were CCL2+. Data were generated 
from three or more individual mice per genotype (mean ± SD). Data were analysed by either one-
way ANOVA with Tukey post-test or two-way ANOVA with Bonferroni post-test p<0.05 * and 
p<0.001 ***. Statistical significant in (B) is shown between WT to CCR2 KO by * symbols.
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Figure 4-2: Effect of LPS on the frequency of splenic Ly6Chi monocytes. 
WT (black line) and CCR2 KO (grey line) animals were treated i.v. with PBS for 24 or 48 hrs, or 
LPS for 24, 48 and 72 hrs. (A) Frequencies of Ly6Chi monocytes, gated as depicted in Figure 3-10 
(Ly6ChiCD11b+Gr1lo) over the LPS time-course. (B&C) WT and CCR2 KO animals were treated i.v. 
with PBS or LPS for 24 hrs. (B) Illustration of the reduction of peripheral Ly6Chi monocytes in the 
spleen of CCR2 KO and their restoration in CCR2 KO following LPS treatment. (C) Frequency of 
monocytes as determined by gating as depicted in Figure 3-10 in PBS control animals (black bars) 
or following 24 hrs of LPS (white bars). Data were generated from three or more individual mice per 
genotype (mean ± SD). Data were analysed by two-way ANOVA with Bonferroni post-test p<0.05 *, 
p<0.01 ** and p<0.001 ***. 
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Figure 4-3: Effect of LPS on CCL2 receptor activity and frequency of splenic NK cells. 
WT and CCR2 KO animals were treated i.v. with PBS for 24 or 48 hrs, or LPS for 24, 48 and 72 
hrs. Splenocytes from WT and CCR2 KO animals were incubated with CCL2AF647 with or without 
mCCL22 competition. (A) Representative histogram of CCL2AF647 uptake by NK cells, gated as 
described in Figure 3-9 (DX5+), from WT (black line) and CCR2 KO cells (shaded purple area) 
without competition, and WT (blue line) and CCR2 KO (green line) samples with mCCL22 
competition. (B) CCL2 geometric mean fluorescence intensity (ΔMFI) of WT (black line) and CCR2 
KO (purple line) incubated with CCL2AF647 without competition. CCL2AF647 uptake in WT (blue line) 
and CCR2 KO (green line) splenic NK cells competed with a 10-fold molar excess of mCCL22. (C) 
Proportion of NK cells that were CCL2+. (D) Frequencies of NK cells over the LPS time-course. 
Data were generated from three or more individual mice per genotype (mean ± SD). Data were 
analysed by either one-way ANOVA with Tukey post-test or two-way ANOVA with Bonferroni post-
test p<0.05 * and p<0.001 ***. Statistical significant in (B) is shown between WT to CCR2 KO by * 
symbols and WT to WT with mCCL22 by + symbols. 
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Figure 4-4: Effect of LPS on CCL2 receptor activity and frequency of splenic neutrophils. 
WT and CCR2 KO animals were treated i.v. with PBS for 24 or 48 hrs, or LPS for 24, 48 and 72 
hrs. Splenocytes from WT and CCR2 KO animals were incubated with CCL2AF647 with or without 
mCCL22 competition. (A) Representative histogram of CCL2AF647 uptake by neutrophils, gated as 
described in Figure 3-10 (Ly6CinterCD11b+Gr1hi), from WT (black line) and CCR2 KO cells (shaded 
purple area) without competition, and WT (blue line) and CCR2 KO (green line) samples with 
mCCL22 competition. (B) CCL2 geometric mean fluorescence intensity (ΔMFI) of WT (black line) 
and CCR2 KO (purple line) incubated with CCL2AF647 without competition. CCL2AF647 uptake in WT 
(blue line) and CCR2 KO (green line) splenic neutrophils competed with a 10-fold molar excess of 
mCCL22. (C) Proportion of neutrophils that were CCL2+. (D) Frequencies of neutrophils over the 
LPS time-course. Data were generated from three or more individual mice per genotype (mean ± 
SD). Data were analysed by either one-way ANOVA with Tukey post-test or two-way ANOVA with 
Bonferroni post-test p<0.01 ** and p<0.001 ***. Statistical significant in (B) is shown between WT to 
WT with mCCL22 by + symbols and CCR2 KO to CCR2 KO with mCCL22 by ° symbols. 
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Figure 4-5: Effect of LPS on CCL2 receptor activity and frequency of splenic MZ-B cells. 
WT and CCR2 KO animals were treated i.v. with PBS for 24 or 48 hrs, or LPS for 24, 48 and 72 
hrs. Splenocytes from WT and CCR2 KO animals were incubated with CCL2AF647 with or without 
mCCL22 competition. (A) Representative histogram of CCL2AF647 uptake by MZ-B cells, gated as 
CD19+IgMhiIgDloCD21+, from WT (black line) and CCR2 KO cells (shaded purple area) without 
competition, and WT (blue line) and CCR2 KO (green line) samples with mCCL22 competition. (B) 
CCL2 geometric mean fluorescence intensity (ΔMFI) of WT (black line) and CCR2 KO (purple line) 
incubated with CCL2AF647 without competition. CCL2AF647 uptake in WT (blue line) and CCR2 KO 
(green line) splenic MZ-B cells competed with a 10-fold molar excess of mCCL22. (C) Proportion of 
MZ-B cells that were CCL2+. (D) Frequencies of MZ-B cells as a proportion of live B cells over the 
LPS time-course. Data were generated from three or more individual mice per genotype (mean ± 
SD). Data were analysed by either one-way ANOVA with Tukey post-test or two-way ANOVA with 
Bonferroni post-test p<0.05 *, p<0.01 ** and p<0.001 ***. Statistical significant in (B) is shown 
between WT to CCR2 KO by * symbols, WT to WT with mCCL22 by + symbols and CCR2 KO to 
CCR2 KO with mCCL22 by ° symbols. These data were provided by Chris Hansell. 
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Figure 4-6: Effect of LPS on CCL2 receptor activity and frequency of splenic pDCs. 
WT and CCR2 KO animals were treated i.v. with PBS for 24 or 48 hrs, or LPS for 24, 48 and 72 
hrs. Splenocytes from WT and CCR2 KO animals were incubated with CCL2AF647 with or without 
mCCL22 competition. (A) Representative histogram of CCL2AF647 uptake by pDCs, gated as 
described in Figure 3-11 (B220+CD11c+Ly6C+CD11b-), from WT (black line) and CCR2 KO cells 
(shaded purple area) without competition, and WT (blue line) and CCR2 KO (green line) samples 
with mCCL22 competition. (B) CCL2 geometric mean fluorescence intensity (ΔMFI) of WT (black 
line) and CCR2 KO (purple line) incubated with CCL2AF647 without competition. CCL2AF647 uptake in 
WT (blue line) and CCR2 KO (green line) splenic pDCs competed with a 10-fold molar excess of 
mCCL22. (C) Proportion of pDCs that were CCL2+. (D) Frequencies of pDCs over the LPS time-
course. Data were generated from three or more individual mice per genotype (mean ± SD). Data 
were analysed by either one-way ANOVA with Tukey post-test or two-way ANOVA with Bonferroni 
post-test p<0.05 *, p<0.01 ** and p<0.001 ***. Statistical significant in (B) is shown between WT to 
CCR2 KO by * symbols, WT to WT with mCCL22 by + symbols and CCR2 KO to CCR2 KO with 
mCCL22 by ° symbols. 
Fig 4-5 CCL2+
0 24 48 72
0
25
50
75
WT
WT CCL22
CCR2 KO
CCR2 KO + CCL22
0 24 48 72
0
250
500
750
1000
Time p.i. (hrs)
PBS  8  
Time (hrs) 
C
C
L2
 !
M
FI
 
0 
0 
0 
0 
*** 
°°° B 
PBS 24 48 72 
Time (hrs) 
0.0 
25.0 
50.0 
75.0 
%
 C
C
L2
+ 
C 
** 
*** 
*** 
*** 
Frequency
0 24 48 72
0.0
0.1
0.2
0.3
0.4
0.5
WT
CCR2 KO
Time (hrs)
PBS  8  
Time (hrs) 
%
 o
f l
iv
e 
ce
lls
 
.  
.0 
0.1 
 
.  
.  
D WT 
CCR2 KO 
50 
WT 
WT + mCCL22 
CCR2 KO 
CCR2 KO + mCCL22 
* 
*** 
*** 
** 
++ 
+++ 
* 
*** 
*** 
A 
CCL2AF647 
%
 o
f m
ax
. 
0 
20 
40 
60 
80 
100 
24 hrs LPS 48 hrs LPS 72 hrs LPS PBS 
Chapter 4  165 
 
 
Figure 4-7: Effect of LPS on CCL2 receptor activity of splenic CD11b+ cDCs. 
WT and CCR2 KO animals were treated i.v. with PBS for 24 or 48 hrs, or LPS for 24, 48 and 72 
hrs. Splenocytes from WT and CCR2 KO animals were incubated with CCL2AF647 with or without 
mCCL22 competition. (A) Representative histogram of CCL2AF647 uptake by CD11b+ cDCs, gated 
as described in Figure 3-11 (MHCIIhiCD11chiCD11b+CD8α-), from WT (black line) and CCR2 KO 
cells (shaded purple area) without competition, and WT (blue line) and CCR2 KO (green line) 
samples with mCCL22 competition. (B) CCL2 geometric mean fluorescence intensity (ΔMFI) of WT 
(black line) and CCR2 KO (purple line) incubated with CCL2AF647 without competition. CCL2AF647 
uptake in WT (blue line) and CCR2 KO (green line) splenic CD11b+ cDCs competed with a 10-fold 
molar excess of mCCL22. (C) Proportion of CD11b+ cDCs that were CCL2+. Data were generated 
from three or more individual mice per genotype (mean ± SD). Data were analysed by either one-
way ANOVA with Tukey post-test or two-way ANOVA with Bonferroni post-test p<0.05 * and 
p<0.001 ***. Statistical significant in (B) is shown between WT to CCR2 KO by * symbols. 
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Figure 4-8: Effect of LPS on CCR2 activity of splenic CD8α+ cDCs. 
WT and CCR2 KO animals were treated i.v. with PBS for 24 or 48 hrs, or LPS for 24, 48 and 72 
hrs. Splenocytes from WT and CCR2 KO animals were incubated with CCL2AF647 with or without 
mCCL22 competition. (A) Representative histogram of CCL2AF647 uptake by CD8α+ cDCs, gated as 
described in Figure 3-11 (MHCIIhiCD11chiCD11b-CD8α+), from WT (black line) and CCR2 KO cells 
(shaded purple area) without competition, and WT (blue line) and CCR2 KO (green line) samples 
with mCCL22 competition. (B) CCL2 geometric mean fluorescence intensity (ΔMFI) of WT (black 
line) and CCR2 KO (purple line) incubated with CCL2AF647 without competition. CCL2AF647 uptake in 
WT (blue line) and CCR2 KO (green line) splenic CD8α+ cDCs competed with a 10-fold molar 
excess of mCCL22. (C) Proportion of CD8α+ cDCs that were CCL2+. Data were generated from 
three or more individual mice per genotype (mean ± SD). Data were analysed by either one-way 
ANOVA with Tukey post-test or two-way ANOVA with Bonferroni post-test p<0.05 * and p<0.001 
***. Statistical significant in (B) is shown between WT to CCR2 KO by * symbols, WT to WT with 
mCCL22 by + symbols and CCR2 KO to CCR2 KO with mCCL22 by ° symbols. 
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Figure 4-9: Maturation of cDCs in response to LPS. 
WT (black line) and CCR2 KO (grey line) animals were treated i.v. with PBS for 24 or 48 hrs, or 
LPS for 24, 48 and 72 hrs and the expression of the activation marker CD86 by CD11b+ cDCs 
(A&B) and CD8α+ cDCs (C&D) was examined, gated as described in Figure 3-11. Representative 
plots of CD86 expression by WT CD11b+ cDCs (A) and CD8α+ cDCs (B). CD86 geometric mean 
fluorescence intensity (ΔMFI) of CD11b+ cDCs (C) and CD8α+ cDCs (D) was monitored over the 
time-course. Gating of the two populations has been described in Figure 3-11. Data were 
generated from five or more individual mice per genotype (mean ± SD). Data were analysed by 
two-way ANOVA with Bonferroni post-test comparing each time point in the individual murine 
strains p<0.001 ***. 
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Figure 4-10: Effect of LPS on splenic cDC frequencies. 
WT (black line) and CCR2 KO (grey line) animals were treated i.v. with PBS for 24 or 48 hrs, or 
LPS for 24, 48 and 72 hrs. Frequencies of (A) CD11b+ cDC and (B) CD8α+ cDC, gated as depicted 
in Figure 3-11. Data were generated from five or more individual mice per genotype (mean ± SD). 
Data were analysed by two-way ANOVA with Bonferroni post-test p<0.001 ***. (C) Illustration of the 
decrease in CD11b+ cDCs and CD8α+ cDCs numbers following a pre-gate for CD11chiMHCIIhi cells 
in the spleen of CCR2 KO mice 24 hrs after LPS administration. Numbers in each gate represent 
proportion of live cells within the gate. 
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Figure 4-11: Effect of LPS on CCR2 activity and frequency of BM Ly6Chi monocytes. 
WT and CCR2 KO animals were treated i.v. with PBS for 24 or 48 hrs, or LPS for 24, 48 and 72 
hrs. BM cells from WT and CCR2 KO animals were incubated with CCL2AF647 with or without 
mCCL22 competition. (A) Representative histogram of CCL2AF647 uptake by BM Ly6Chi monocytes, 
gated as described in Figure 3-12 (CD115+CD11b+Ly6C+Gr1lo), from WT (black line) and CCR2 KO 
cells (shaded purple area) without competition, and WT (blue line) and CCR2 KO (green line) 
samples with mCCL22 competition. (B) CCL2 geometric mean fluorescence intensity (ΔMFI) of WT 
(black line) and CCR2 KO (purple line) incubated with CCL2AF647 without competition. CCL2AF647 
uptake in WT (blue line) and CCR2 KO (green line) BM Ly6Chi monocytes competed with a 10-fold 
molar excess of mCCL22. (C) Proportion of BM Ly6Chi monocytes that were CCL2+. (D) 
Frequencies of Ly6Chi monocytes over the LPS time-course. Data were generated from three or 
more individual mice per genotype (mean ± SD). Data were analysed by either one-way ANOVA 
with Tukey post-test or two-way ANOVA with Bonferroni post-test p<0.05 *, p<0.01 ** and p<0.001 
***. Statistical significant in (B) is shown between WT to CCR2 KO by * symbols and WT to WT 
with mCCL22 by + symbols. 
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Figure 4-12: Assessment of the CXCR2 dependence of LPS induced monocyte mobilisation. 
(A) CCR2 KO animals were treated i.p. with 0.3 mg/kg CXCR2 antagonist SB225002 or PBS for 3 
hrs. Mice were then treated i.v. with PBS or LPS for 21 hrs. (B) Absolute number of neutrophils in 
BM and spleen, as determined by gating as depicted in Figure 3-10 (CD115-CD11b+Ly6C+Gr1hi) 
and 3-9 (Ly6CinterCD11b+Gr1lo), respectively. (C) Absolute number of monocytes in BM and spleen, 
as determined by gating as depicted in Figure 3-10 (CD115+CD11b+Ly6C+Gr1lo) and 3-9 
(Ly6ChiCD11b+Gr1lo), respectively. Animals were treated with PBS i.p. and then i.v. (white bars), 
PBS i.p. and then LPS i.v. (black bars), SB225002 i.p. then PBS i.v. (red bars)  and SB225002 i.p. 
and LPS i.v. (blue bars). For each condition, n= 3 (mean + SD). Data were analysed by one-way 
ANOVA with Tukey post-test p<0.05 *, p<0.01 ** and p<0.001 ***. 
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Chapter 5 – CCL2 receptors and pDCs 
In recent years research on pDCs has intensified. As discussed in the Introduction 
they have now been accredited with a variety of roles, including anti-viral (Naik 
et al., 2005a; Reizis et al., 2011a) and tumour responses (Wei et al., 2005; Matta 
et al., 2010), and, although less efficient than cDCs, mature pDCs possess the 
ability to prime and cross-prime naïve T cells (Asselin-Paturel et al., 2001; 
Colonna et al., 2004; Villadangos and Young, 2008). Many of these roles have 
been assigned to particular subsets of pDCs, which are delineated by surface 
markers. For example, the expression of CCR9 by pDCs is reported to be 
associated with tolerogenic properties of these cells (Hadeiba et al., 2008; 
Björck et al., 2011; Schlitzer et al., 2011), and several other potential subsets of 
pDCs have been described based on expression of markers, such as CD9 (Björck 
et al., 2011) and CD8α (Lombardi et al., 2012). These studies demonstrate the 
existent of functionally distinct subsets of pDCs that are identifiable by 
differences in expression of a single marker. Moreover, the homing capabilities 
of pDCs, and indeed all other immune cells, are critical for them to exert their 
functions in specific tissues or tissue compartments, or at specific times (e.g. 
homeostasis or inflammation). Therefore, it is interesting that a proportion of 
pDCs have been found to possess CCR2 and D6 activity. The increased sensitivity 
of the CCL2AF647 assay, in addition to its ability to examine the activity of both 
CCR2 and D6, means that this is one of the first times that pDCs have been 
reliably described to possess CCR2, and certainly the first time that they have 
been shown to have D6 activity. To my knowledge, CCR2 and D6 have not been 
assigned a role on pDCs. Thus, in this results chapter I aim to characterise the 
two pDC subsets, CCL2hi and CCL2lo, both functionally and genetically. 
5.1 Detection of two subsets of pDCs based on CCR2 
activity 
First, in Figure 5-1, using splenocytes as an example, I describe the gating 
strategy, by which two subsets of pDC based on CCL2AF647 uptake, have been 
identified so far. pDCs were identified as B220+CD11c+Ly6C+CD11b-, and although 
other cell populations may express one or more of these markers, pDCs are the 
only population that have this pattern of expression (Asselin-Paturel et al., 
2003). Many groups have identified pDCs, as B220+CD11c+ cells, including no 
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further markers. However, examination of Ly6C and CD11b illustrates that gating 
as simply B220+CD11c+ would include numerous cell populations (Blasius et al., 
2007). B220+CD11c+ cells excluding pDCs, (i.e. B220+CD11c+Ly6C+/-CD11b+/- cells) 
were gated and called Population D. Similar to pDCs, this population possessed 
high levels of CCR2 activity and also weak D6 activity (Figure 5-1). This gating 
strategy did not include a marker that is considered to be pDC specific, such as 
PDCA-1 or SiglecH (Asselin-Paturel et al., 2003; Zhang et al., 2006; Blasius et al., 
2006a; 2006b). Thus, further characterisation was required. Following the gating 
as described in Figure 5-1, the expression of PDCA1 and SiglecH was determined 
on CCL2hi, CCL2lo pDCs, and Population D (Figure 5-2A). Both CCL2hi and CCL2lo 
subsets expressed high levels of both PDCA1 and SiglecH, illustrating that they 
are truly pDCs. In contrast, Population D did not express either PDCA1 or 
SiglecH. This indicates that only B220+CD11c+ cells that are Ly6C+ and CD11b- are 
in fact pDCs. The identity of Population D is uncertain, but it is likely to include 
a subset of NK cells that have been identified as B220+CD11c+NK1.1+CD11b+ 
(Blasius et al., 2007). As further confirmation of the lineage of the two CCL2 
subsets of pDCs, pDCs were identified by a more simple gating strategy that is 
frequently published, PDCA1+CD11c+ (Figure 5-2B). Within the PDCA1+CD11c+ 
population the two subsets based on CCL2 uptake were present. Thus, these 
data confirm the existence of two subsets of pDCs based on CCL2AF647 uptake in 
spleen. Furthermore, in Chapter 3 and Figure 4-6, I proved that CCL2AF647 uptake 
was primarily, but not exclusively CCR2 dependent, as there was evidence of D6 
on splenic, BM and blood pDCs. 
I next determined whether pDCs elsewhere in the lymphoid system could be 
delineated into two subsets based on CCL2AF647 (Figure 5-3). By using the 
CCL2AF647 assay I was able to establish that pDCs in all tissues tested could be 
segregated into CCL2hi and CCL2lo populations, with the relative proportion of 
CCL2hi pDCs in each tissue indicated in the histograms. In the spleen, PLNs, MLNs 
and blood, CCL2hi contributed approximately 50% of the pDC population, 
whereas the proportions of CCL2hi to CCL2lo pDCs appeared to be altered in BM, 
with a lower number of CCL2hi pDCs detected. In each tissue the majority of 
uptake was CCR2 dependent, but there was also evidence of D6 expression in 
CCR2 KO pDCs. Furthermore, examination of WT pDCs for D6 activity indicated 
that in the spleen and BM, both CCL2hi and CCL2lo pDCs possessed D6 activity, 
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whereas in the blood, MLNs and PLNs only CCL2lo pDCs possessed D6 activity. 
Notably, pDCs in the BM and blood had greater overall CCL2 receptor activity in 
both WT and CCR2 KO mice than pDCs in spleen and LNs. 
Thus, two subsets of pDCs can be identified on CCR2 activity in the spleen, 
blood, MLNs, PLNs and BM. The key objective in the remainder of my thesis was 
therefore to assess if CCR2 expression defines two functionally distinct pDC 
subsets and explore the indispensable roles played by CCR2 on these cells. 
5.2 Flt3L mediated in vivo expansion and in vitro 
generation of pDCs and their CCR2 activity 
pDCs represent only a low number of splenic cells, comprising only ~0.3% of the 
splenic populations. They are also rare cells in blood, BM and LNs (Reizis et al., 
2011a). As both the CCL2hi and CCL2lo subsets of pDCs comprise approximately 
50% of pDCs this would equate to less than 0.15% of splenic cells. Most functional 
studies require large numbers of purified cells, thus the low cell numbers 
present a challenge when working with these cells. Therefore, in order to 
further characterise the two pDC subsets identified, in addition to conducting 
functional studies using these cells, larger numbers of cells were required than 
could be purified from resting mice. The vast majority of pDC research is 
conducted using human peripheral blood pDCs. Alternatively, in the murine 
system, pDC numbers can be expanded in vivo and in vitro by using Flt3L. As 
described in the Introduction, Flt3L plays a pivotal role in the generation of pDCs 
in the BM, driving differentiation of a DC progenitor to the pDC lineage (Naik et 
al., 2005a; Reizis et al., 2011a). Many groups have described the generation of 
large numbers of pDCs in vitro by using Flt3L to drive differentiation of BM cells 
into pDCs (Brawand et al., 2002; Gilliet et al., 2002; Naik et al., 2005b; 2010). 
Another method used to expand murine pDCs in vivo is the treatment of animals 
with Flt3L or inoculation (s.c.) with Flt3L secreting tumours (Maraskovsky et al., 
1996; Mach et al., 2000). Thus, I next performed some pilot experiments to 
explore the effect of in vitro and in vivo Flt3L to identify the optimal method to 
expand pDCs, while retaining their segregation into CCL2hi and CCL2lo subsets. 
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5.2.1 In vitro generation of pDCs 
The generation of BM-derived pDCs (BM-pDCs) using Flt3L has been extensively 
described (Gilliet et al., 2002; Naik et al., 2005b). In the majority of these 
papers, the Flt3L used was either recombinant human (rh) Flt3L, or present in 
conditioned media (CM) from cell lines that have been engineered to stably 
produce murine Flt3L. CHO-Flt3L and B16FL, two cell lines containing Flt3L 
expression constructs, were obtained from the Simon Milling Laboratory 
(University of Glasgow, U.K.) and Oliver Pabst (Medizinischen Hochschule 
Hannover, Germany), respectively, and the amount of Flt3L generated from 
these cell lines was measured by ELISA (Figure 5-4). Both cell lines produced 
substantial quantities of Flt3L. 
Next, these Flt3L-containing CM, along with rhFlt3L, were tested for their ability 
to generate BM-pDC over a range of concentrations and incubation times (Figure 
5-5). In this first experiment, the frequency of generated pDCs was not 
determined, only the frequency of live cells. In accordance with published 
observations (Seth et al., 2011), rhFlt3L was a poor differentiator of BM-DCs, as 
the proportion of total live cells was never higher than 8% at all concentrations 
and time-points tested (Figure 5-5A). Treatment of BM cells with CM from CHO-
Flt3L and B16FL resulted in an increase in number of live cells compared to 
rhFlt3L (Figure 5-5B&C). Furthermore, this appeared to have a concentration 
dependent effect, with the two highest concentrations, 50 ng/ml and 100 ng/ml 
Flt3L generating the greatest frequency of live cells. Therefore, in the next 
experiment I incubated BM cells with the two most effective concentrations of 
CHO-Flt3L or B16FL CM (50 or 100 ng/ml) and determined the absolute number 
of pDCs produced 7-10 days after setting up the cultures (Figure 5-5D&E). The 
number of BM-pDC produced using B16FL Flt3L gradually decreased over the 
time-course, with the highest number of BM-pDC being produced at day 7 with 
100 ng/ml. In contrast, Flt3L from CHO-Flt3L produced higher numbers of BM-
pDC at day 8. In fact, 100 ng/ml Flt3L from CHO-Flt3L appeared to produce 
higher numbers of BM-pDC than Flt3L from B16FL, at all times tested. The same 
was true with 50 ng/ml Flt3L from CHO-Flt3L except at day 7, where 100 ng/ml 
of Flt3L from B16FL produced a higher number of BM-pDC. In terms of absolute 
numbers, the optimum condition for BM-pDC production was 100 ng/ml Flt3L 
from CHO-Flt3L. It produced ~6x106 live BM-pDC from 1x107 BM cells. These 
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experiments were only pilot studies, so only one data point was generated for 
each condition and no statistical analyses were conducted. However, they 
showed that BM-pDCs could be successfully generated in high numbers in vitro. 
5.2.2 CCL2 receptor activity of in vitro BM-pDCs 
I analysed CCL2 receptor activity of BM-pDCs at day 8, 9 or 10 of culture with 
either Flt3L containing CM from CHO-Flt3L (Figure 5-6A) or B16FL (Figure 5-6B). 
At all conditions tested, BM-pDCs internalised CCL2AF647 in a predominantly CCR2 
dependent manner, as illustrated by competition with mCCL2, that was far less 
apparent when using mCCL22. mCCL22 competition did cause some reduction in 
CCL2AF647 uptake, mainly with CHO-Flt3L treated cells, but also at day 8 and 9 of 
culture with B16FL treatment, indicative of D6 activity in these cells. There also 
appeared to be an effect on the relative proportions of CCL2hi and CCL2lo pDCs 
observed in vivo, with a higher proportion of CCL2hi pDCs being found at day 8. 
Furthermore, at later points of culture there were alterations in the profiles of 
uptake, with diminished CCL2AF647 uptake observed. There was also a lot of 
variation between pDCs derived with different Flt3L sources, particularly in the 
ability of mCCL2 to compete CCL2AF647 uptake. Thus, although encouraging, these 
results led to some concerns about the potential reproducibility of generating 
CCR2-expressing pDCs in vitro. Moreover, it was felt that in vivo expanded pDCs 
might represent a more physiological source of pDCs. Thus, this method was next 
explored. 
5.2.3 In vivo expansion of pDCs 
I tested two commonly used methods to expand the number of pDCs in vivo 
(Figure 5-7). Due to the expense and limited availability of rhFlt3L, experiments 
using this reagent were conducted in collaboration with Calum Bain and Vuk 
Cerovic (University of Glasgow) who required the treatment to be done in 
CX3CR1GFP/+ mice. As discussed in the Introduction, CX3CR1GFP/+ mice are reporter 
mice with a targeted replacement of CX3CR1 by a GFP reporter. They are 
frequently used to explore the role of Ly6Clo monocytes and macrophages (Jung 
et al., 2000; Auffray et al., 2007; 2009a). Calum Bain and Vuk Cerovic were 
interested in the macrophage and DC populations in the gut and MLNs of the 
CX3CR1GFP/+ mice, and I was able to analyse pDCs in spleen, blood and PLNs. 
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Thus, CX3CR1GFP/+ mice were treated i.p. for 10 days with rhFlt3L and the 
absolute number of pDCs in secondary lymphoid organs and blood was 
determined. Alternatively, WT mice were injected s.c. with ~2x106 B16FL 
tumour cells. As described in the original paper that details the generation and 
use of B16FL cells, they have the ability to form a pigmented melanoma that 
spontaneously secretes murine Flt3L resulting in an increase in the number of 
peripheral DCs (Mach et al., 2000). 13 days after injection of cells, the absolute 
number of pDCs and B220-CD11c+ cells were determined in the spleen, blood and 
PLN. The treatment of WT or CX3CR1GFP/+ animals with B16FL or rhFlt3L, 
respectively, resulted in a marked increase in the frequency of pDCs in the 
spleen (Figure 5-7A), blood (Figure 5-7B) and PLNs (Figure 5-7C), as illustrated 
by representative plots. Furthermore, as Flt3L treatment does not result in a 
specific expansion of pDCs (it also expands cDCs populations), these plots show a 
dramatic increase in B220-CD11c+ cells, a population which includes cDCs. 
Although images are not shown, treatment with either form of Flt3L resulted in 
splenomegaly, and thus upon calculation of absolute cell numbers there was a 
dramatic increase in the number of pDCs and B220-CD11c+ cells in the spleen 
(Figure 5-7A), blood (Figure 5-7B) and PLNs (Figure 5-7C). 
5.2.4 CCL2 receptor activity of in vivo expanded pDCs 
I also analysed the CCL2 receptor activity of splenic (Figure 5-8A) and PLN pDCs 
(Figure 5-8B) from B16FL or rhFlt3L treated WT mice. In both tissues, regardless 
of method of pDC expansion, there was uptake of CCL2AF647. The proportion of 
CCL2hi and CCL2lo pDCs was determined in spleen (Figure 5-8C) and PLNs (Figure 
5-8D) in untreated and Flt3L treated animals. In the spleen there appeared to be 
no effect of Flt3L treatment on the ratio of CCL2hi to CCL2lo pDCs, with both 
populations contributing ~50% of pDCs. The same was true for PLN pDCs, 
however trends suggested that treatment with rhFt3L resulted in an increase in 
CCL2lo pDCs to ~60% and a concomitant decrease in CCL2hi pDCs. No statistics are 
available for this observation, due to the low number of biological replicates in 
this experiment. Nonetheless, it is clear that Flt3L treatment leads to an 
expansion of pDCs in vivo and that these cells broadly retain the CCL2AF647 
uptake profiles of untreated mice. 
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To conclude, I found that Flt3L treatment in vitro generated large numbers of 
BM-pDCs and in vivo resulted in a dramatic increase in the number of pDCs. 
Furthermore, in vivo treatment with Flt3L had minor, if any, effects on the CCR2 
activity of pDCs, as there was no obvious perturbation to the ratio of CCL2hi and 
CCL2lo pDCs. In contrast, although in vitro generated BM-pDCs possessed CCR2 
activity, the activity appeared diminished at later points in culture and results 
between cultures were highly variable. While BM-pDCs represent a useful model 
for the generation of a large number of cells, the results can be difficult to 
correlate to a biological system. Analysis of in vivo expanded pDC populations 
allows the assessment of pDC development and function in situ under more 
physiologically relevant conditions. Taking all this into account, when large 
numbers of pDCs were required in the following work they were expanded by in 
vivo treatment with Flt3L. Furthermore, due to the limited availability and 
substantial cost of rhFlt3L, pDC numbers were routinely expanded by treating 
animals with B16FL cells. Throughout, I routinely generated large numbers of 
pDCs that consistently showed CCL2AF647 uptake profiles that were very similar to 
untreated control animals. 
5.3 Isolating CCL2hi and CCL2lo pDCs 
To perform transcriptional and functional comparisons between the CCL2hi and 
CCL2lo pDCs, I devised a sorting strategy that would facilitate the isolation of 
either total pDCs, which were not subject to exposure of CCL2AF647, or CCL2hi and 
CCL2lo pDCs using a BD FACS Aria (Figure 5-9A). Total splenic pDCs from a B16FL 
treated animal were identified using several parameters, including the pDC 
specific marker SiglecH. Alternatively, after incubation with CCL2AF647 for 1 hr, 
CCL2hi and CCL2lo pDCs were gated and sorted. Purity checks were habitually run 
following sorting of cells and, as Figure 5-9B illustrates, purity was routinely 
between 90-95%. 
5.4 Migration of pDCs in response to CCL2 
The CCL2/CCR2 pathway has been shown to mediate migration of a range of cell 
types, such as monocytes (Geissmann et al., 2003; Serbina and Pamer, 2006), 
mast cells (Collington et al., 2010) and dendritic cells (Osterholzer et al., 2008; 
Jimenez et al., 2010). To my knowledge, the studies demonstrating CCR2 
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dependent migration of pDCs all have used human pDCs from peripheral blood 
(Penna et al., 2001; Kohrgruber et al., 2004). Thus, I examined whether murine 
pDCs also respond chemotactically to mCCL2. Sorted total pDCs from the spleen 
of B16FL tumour bearing mice clearly had a chemotactic response to mCCL2 in in 
vitro transwell migration assays (Figure 5-10). Total pDCs were used, as 
exposure to CCL2AF647 would be expected to desensitise CCR2 to further exposure 
of mCCL2 in the migration assay. As the concentration of mCCL2 increased there 
was a parallel increase in the absolute number of migrated pDCs. There were, 
however some cells that migrated in the absence of mCCL2, but there were 
significantly more migrated pDCs in the presence of mCCL2 at all concentrations 
tested. Thus, mouse pDCs respond chemotactically to CCL2 gradients in vitro. 
5.5 Expression of known pDC markers by CCL2hi and 
CCL2lo pDCs 
Next, I tried to establish whether expression of markers known to be capable of 
subdividing pDCs correlated with the two pDC subsets I had defined by CCL2AF647 
uptake. Current pDC literature allowed me to identify a list of surface markers 
that pDCs are known to express, and which, in many cases, have been used to 
characterise subsets of pDCs. Thus, using flow cytometry I determined their 
expression on the two CCL2 pDC subsets in untreated controls (i.e. mice not 
carrying B16FL tumours) (Figures 5-11 to 5-13). 
First, I examined the expression of other chemokine receptors by the two 
subsets (Figure 5-11). CCR9 is a homing receptor for pDCs to the small intestine 
(Wendland et al., 2007), and both CCR2 subsets expressed CCR9. However, there 
was a small population of CCL2hi pDCs that did not express CCR9, thus there 
were significantly more CCL2lo pDCs present that expressed CCR9. This is 
potentially interesting as pDC progenitors and non-tolerogenic pDCs are 
reportedly CCR9- (Hadeiba et al., 2008; Björck et al., 2011; Schlitzer et al., 
2011; 2012). Furthermore, by using a reporter CX3CR1GFP/+ mouse, I was able to 
determine that both subsets expressed the GFP reporter and so probably express 
CX3CR1. This chemokine receptor has been reported by others to be expressed 
by pDCs, also using GFP reporter mice (Schlitzer et al., 2011). Notably CCL2hi 
pDCs had significantly higher expression of GFP than CCL2lo pDCs, albeit only 
being marginally higher in CCL2hi cells. Surprisingly, both subsets were negative 
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for the chemokine receptor CCR7, which has been reported to be expressed by 
pDCs at low levels and induced by their activation. It has also been shown to be 
vital for their migration to PLNs (Seth et al., 2011). As a control for staining with 
the anti-CCR7 antibody I examined all live splenic cells for CCR7 
immunoreactivity, the majority of which will be T and B lymphocytes that are 
known to express CCR7. I found that all were negative for anti-CCR7 
immunoreactivity (Figure 5-5E). This indicates that the CCR7 antibody failed to 
detect CCR7, highlighting the problem, discussed earlier in Chapter 3, with 
antibodies targeted against mouse chemokine receptors being unreliable 
detection reagents. 
Other groups have reported that CCR5 is involved in pDC transmigration across 
HEVs into LNs (Diacovo et al., 2005) and also in pDC migration to inflammatory 
sites (Penna et al., 2001). Commercially available anti-mouse CCR5 antibodies 
had been rigorously tested in our lab by others, but failed to provide consistent 
detection of CCR5 (Ross Kinstrie and Rob Nibbs personal communication). Thus, I 
attempted to examine CCR5 activity on splenic pDCs using a CCL5AF647 uptake 
assay (Figure 5-11C&D). CCL5 can be bound by several receptors, including 
CCR1, CCR3, CCR5 and D6, therefore in order to determine CCR5 specific uptake 
several controls needed to be included. Competition of CCL5AF647 uptake with an 
excess of CCL5 demonstrates that uptake is mediated by one or more of the 
CCL5 binding receptors, whereas competition with excess CCL4 demonstrates 
CCR5 or D6 involvement, due to their exclusive ability to bind to both CCL5 and 
CCL4. Histogram overlays (Figure 5-11A) and the CCL5 ΔMFI data (Figure 5-11D) 
suggested that competition with mCCL4 caused a significant reduction in 
CCL5AF647 uptake, indicating either CCR5 or D6 activity. I have already shown 
evidence of D6 activity on these cells, thus D6 might be the receptor exclusively 
responsible for this uptake. In contrast, all CCL5AF647 uptake was competed with 
mCCL5. Thus, the uptake not competed by mCCL4 was probably mediated by 
CCR3 or CCR1, which bind mCCL5 but not CCL4. Notably, pDCs were 
homogeneous in these assays, and distinct subsets were not observed. So high 
CCR2 expression is unlikely to correlate with absence or presence of CCL5 
receptors. 
In addition to examining expression of chemokine receptors, I examined 
expression of integrins that aid the migration of cells in vivo (Figure 5-12). 
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CD62L is reportedly crucial for the transmigration of pDCs into PLNs (Nakano et 
al., 2001; Diacovo et al., 2005), but my data suggest very low, if any, expression 
in both subsets. However, there was a statistically significant decrease in CD62L 
expression by CCL2lo pDCs compared to CCL2hi, which might indicate a lower 
capacity to transmigrate into PLNs. However, previous data suggest that CCL2hi 
and CCL2lo pDCs are as abundant in PLNs as they are in spleen and blood (Figure 
5-3). The subsets were also found to have very low levels of expression of the 
integrin α4β7, which is involved in pDC migration to the small intestine and MLNs 
(Hadeiba et al., 2008). 
pDCs have been described as possessing tolerogenic properties. However, only a 
subset of pDCs are reported to be tolerogenic (Matta et al., 2010). Several 
groups have identified a tolerogenic pDC subset by differences in expression of 
CD8α (Lombardi et al., 2012), and CCR9 (Hadeiba et al., 2008). Tolerogenic pDCs 
are reported to express CD8α and also CCR9 (Hadeiba et al., 2008; Lombardi et 
al., 2012). Nearly all pDCs in both CCL2 subsets have already been found to 
express CCR9 (Figure 5-11), although the CCL2hi subset appears to be a mixed 
population as it contains CCR9+ and CCR9- pDCs. Interestingly, it also contained a 
very small population of CD8α- cells, however there were no statistically 
significant differences in the proportion of CCL2hi and CCL2lo pDCs expressing 
CD8α and a large fraction of pDCs could be classified as CD8α+ (Figure 5-12). 
As discussed in the Introduction, several markers, such as CD4 (O'Keeffe et al., 
2002), Ly49Q (Kamogawa-Schifter et al., 2005) and CD9 (Björck et al., 2011) can 
be used to delineate immature and mature pDCs. I next sought to determine 
whether the CCL2hi and CCL2lo subsets differed in their maturation status (Figure 
5-12). Immature BM pDCs are thought to acquire Ly49Q before migrating into the 
periphery (Omatsu et al., 2005; Toma-Hirano et al., 2007), therefore it should 
be expected that all splenic pDCs should be Ly49Q+. However, the two subsets of 
pDCs defined by CCR2 activity were negative for Ly49Q. Likewise, newly formed 
BM pDCs are CD9+ and lose CD9 expression upon migration into the periphery and 
become mature CD9- pDCs (Björck et al., 2011). This suggests that all splenic 
pDCs should be CD9-, however the two subsets were found to express low levels 
of CD9. These data conflict as the lack of Ly49Q expression indicates that the 
splenic pDC subsets are immature pDCs, whereas the low levels of CD9 suggest 
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that only a fraction of the splenic pDCs are immature, with the majority of cells 
being mature CD9- pDCs. CD4 is also defined as a maturation marker, with CD4- 
pDCs being precursors to the mature CD4+ pDCs (O'Keeffe et al., 2002). 
Therefore, the CD4 expression data offers support to the CD9 data, as both 
subsets differentially expressed CD4, indicating the presence of both immature 
and mature pDCs. 
To confirm that the low or lack of expression of markers was accurate and not 
due to a failure of the antibodies to detect their targets, I examined expression 
of CD62L, α4β7 and Ly49Q in all live splenocytes (Figure 5-12C). This should 
serve as a positive control, as some cells within the spleen should be positive for 
the tested markers. For example, splenic Gr1+ cells, such as neutrophils and 
monocytes have been reported to express Ly49Q (Toyama-Sorimachi et al., 
2004). Antibodies against CD62L and α4β7 bound to a subset of cells to a greater 
extent than isotype control antibodies, suggesting they have the capacity to 
recognise their Ag on cells. This was not the case with the anti-Ly49Q antibody. 
This might indicate that it can not reliably detect Ly49Q protein. 
In Chapter 4, I described the correlation of CCR2 downregulation with expression 
of the activation marker CD86 on cDCs. Therefore the differences in CCR2 
activity by the two subsets could be due to differences in their activation status. 
However, the two subsets were essentially negative for the activation markers 
OX40L, CD69, and CD86, showing that the difference in CCR2 activity was not a 
consequence of differences in activation (Figure 5-13). The failure to detect the 
expression of either activation marker on pDCs might be explained by the 
antibodies failing to reliably detect the surface marker, similar to the CCR7 
antibodies (Figures 5-11E and 5-12C). However, this is unlikely because in a 
naïve animal i.e. an animal not undergoing an inflammatory response, there 
would be very few activated cells. Anti-CD86 showed some specific staining 
when ‘all live cells’ were examined (Figure 5-32C). Although I did not have a 
positive control of activated cells within this experiment, I, and other members 
of the lab, have successfully used the anti-CD86 and anti-CD69 antibodies in 
experiments involving other cell types, so they are able to detect their 
respective targets. Thus, the weak staining on pDCs, in this case is probably an 
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accurate representation of the very low expression of the activation markers by 
resting pDCs. 
In summary, the expression of no known pDC subset marker fully segregated the 
two subsets delineated by CCR2 activity in WT animals, and the data indicates 
that there are no major differences in the maturation or activation of these two 
subsets. CD8α and CD4 split the two CCL2 subsets into CD8α+/- and CD4+/-. CCR9 
was also able to segregate the CCL2hi population into two subsets (CCR9+ and 
CCR9-), albeit it to a lesser extent than CD8α and CD4, because CCR9- pDCs were 
very rare in the spleen. 
5.6 Morphology of CCL2hi and CCL2lo pDCs 
Next, I wished to explore functional and transcriptional differences between 
CCL2hi and CCL2lo pDCs. First, following the isolation of CCL2hi and CCL2lo pDCs 
from the spleens of B16FL tumour bearing mice, the gross morphology of resting 
or activated cells was determined by light microscopy (Figure 5-14). As Figure 5-
14 illustrates there were no major differences in the morphology of the cells. 
Both CCL2hi and CCL2lo pDCs appeared lymphocytic in morphology, round cells 
with large nuclei to cytoplasm ratio and unruffled plasma membranes. 
Approximately 50% of CCL2lo pDCs did however appeared to have several 
vacuoles present in their nuclei. The morphology of the two pDC subsets was 
also determined following stimulation with CpG-C. CpG-C is a type C 
oligonucleotide that is recognised by TLR9 and is capable of stimulating both 
maturation and IFNα/β production by pDCs (Berghöfer et al., 2007). After 
stimulation for 18 hrs with CpG-C, both subsets appear to be slightly larger in 
size, with a more irregular shape and ruffled membranes. 
Thus, I have been unable to find any major morphological differences between 
the two subsets before or after activation. However, in resting cells some CCL2lo 
pDCs appeared to have vacuoles present in their nuclei, which might be 
explained by dying cells or nuclear blebbing. However, this observation was not 
pursued and instead I examined the functional properties of CCL2lo and CCL2hi 
pDCs. 
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5.7 In vitro function of the two subsets 
Functionally distinct subsets of pDCs have been delineated by the expression of a 
single marker. For example, CCR9 expression is reportedly associated with a 
tolerogenic subpopulation of pDCs (Hadeiba et al., 2008; Björck et al., 2011; 
Schlitzer et al., 2011), although it is notable that in my hands nearly all pDCs are 
CCR9+. Therefore, my next aim was to see if CCR2 expression correlated with 
specific functional attributes of pDCs. To accomplish this, I performed a series of 
ex vivo experiments to illuminate any functional differences between the two 
pDC subsets that I had identified based on differential CCR2 activity. 
5.7.1 T cell stimulatory capacity of CCL2hi and CCL2lo pDCs 
As pDCs, like all APCs, possess both MHC class I and II and therefore the ability 
to present Ag to T cells (Reizis et al., 2011a), I aimed to establish the ability of 
the two pDC subsets to process and present Ag to naïve T cells. First, I 
determined the optimal conditions to drive proliferation of naïve OVA specific 
CD4+ and CD8α+ T cells (Figure 5-15 and 5-17). To do this, total pDCs or B220-
CD11c+ cells were sorted from the spleens of mice carrying B16FL tumours. B220-
CD11c+ splenocytes will be highly enriched for cDCs, and are referred to as cDCs 
here after, but they will contain other cell types (see Figure 3-11). The 
associated purities are shown in Figure 5-15A. In all these experiments cDCs 
were used as a positive control to confirm that the T cells were capable of 
proliferation in response to Ag-specific activation. To establish optimum 
conditions for pDC driven naïve T cell proliferation, different ratios of total pDCs 
were incubated with increasing concentrations of OVA, washed extensively and 
incubated with 1x105 naïve TCR transgenic OVA-specific CD4+ T cells (OTII) 
(Figure 5-15B) or CD8α+ T cells (OTI) (Figure 5-17). These T cells were labelled 
with CFSE, and the number of T cells undergoing more than 3 divisions was 
calculated by examining CFSE dilution. In the absence of OVA, there were a 
minimal number of T cells that had divided. Incubation of DCs with OVA, 
stimulated T cell division, but as the concentration of OVA was increased from 1 
to 5 mg/ml there were nominal increases on the number of naïve CD4+ T cells 
that had divided in the presence of pDCs (Figure 5-15B). In contrast, as the 
concentration of OVA was increased there was a parallel increase in the number 
of naïve CD8α+ T cells that had divided in the presence of pDCs (Figure 5-17). 
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Furthermore, proliferation rates of both CD4+ and CD8α+ reduced as the ratio of 
pDCs to T cells decreased. Therefore, in subsequent experiments with CD4+ or 
CD8α+ T cells, the optimal conditions of 3 mg/ml OVA with a 1:1 ratio of pDCs to 
T cells were used. 
Notably, under these optimal conditions, cDCs were far more effective at 
priming T cells with over 80% of CD4+ and CD8α+ T cells divided, compared to 
30% of CD4+ T cells and 75% of CD8α+ T cells with pDCs at a 1:1 ratio. Strikingly 
cDCs were far more effective than pDCs when present at low numbers in 
cultures. Even at a 1:128 DC:T cell ratio, cDCs were able to induce T cell 
proliferation comparable to pDCs at highest dilutions tested (Figures 5-15 and 5-
17). Thus, pDCs are clearly much less effective inducers of naïve CD4+ T cell 
proliferation than cDCs, but when present in high numbers pDCs do seem to 
possess the ability to cross-present Ag to naïve CD8α+ T cells. 
Next, I examined the ability of CCL2hi and CCL2lo pDC subsets to process and 
present Ag to naïve OVA-specific CD4+ T cells (Figure 5-16) and stimulate naïve 
CD4+ T cell proliferation. Figure 5-16B shows representative histograms of CFSE 
dilution, which show that cDCs caused high levels of T cell proliferation, 
whereas both CCL2hi and CCL2lo pDCs produced low amounts. When the number 
of T cells that had undergone more than 3 divisions was quantified (Figure 5-
16C) this result becomes even more apparent, over 40% of the CD4+ T cells in the 
presence of cDCs had undergone more than 3 divisions, while less than 5% of 
CD4+ T cells had undergone more than 3 divisions when cultured with either 
CCL2hi or CCL2lo pDCs. In spite of these low numbers of divided T cells, there was 
a significant decrease in the number of divided T cells when naïve CD4+ T cells 
were incubated with CCL2lo pDCs than CCL2hi pDCs. However, when the 
frequency of T cells in each division was quantified, there was no significant 
difference between the two subsets, and the majority of T cells remained 
undivided (Figure 5-16D). 
As the purity checks in Figure 5-16A show there were small numbers of B220-
CD11c+ cells, which may be cDCs present in each CCL2hi and CCL2lo subset 
sample. Although only a very low number of these cells were present in pDC 
cultures they might be responsible for the low amounts of T cell proliferation 
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observed. If cDCs contributed only 1% of cells contaminating pDC cultures they 
would still represent ~1000 cells in the culture. Notably, a 1:128 ratio of cDCs to 
T cells (i.e. less than 1000 cDCs in the culture) produced similar proliferation 
observed as at 1:1 ratio of pDCs to T cells (Figure 5-15). It is therefore possible 
that pDCs, at least in my hands, do not process and present OVA at all to CD4+ T 
cells, and the proliferation observed was a consequence of cDC contamination. 
The ability of pDCs to present Ag and prime naïve CD4+ T cells is a source of 
controversy (Sapoznikov et al., 2007; Kool et al., 2011), but, regardless of this, 
it is clear from my data that purified CCL2hi and CCL2lo pDCs did not differ 
substantially in their ability to prime CD4+ T cells. 
Next, I analysed the ability of the two subsets of pDCs to cross-present OVA to 
naïve TCR transgenic Ag-specific CD8α+ T cells (Figure 5-18). In contrast to CD4+ 
T cell priming, both pDC subsets were capable of inducing high levels of CD8α+ T 
cell proliferation as shown by CFSE dilution (Figure 5-18A). However, 
approximately 20% of T cells remained undivided in cultures with either pDC 
subset. In contrast, in cultures of CD8α+ T cells with cDCs there were much 
lower numbers of undivided T cells. Accordingly, the frequency of T cells that 
had undergone more than three divisions was higher in cDCs (Figure 5-18B). 
There were no differences in the number of T cells that had undergone more 
than 3 divisions when cultured with CCL2hi or CCL2lo pDCs (Figure 5-18B). 
Likewise, when the frequency of T cells in each division was quantified there 
was also no difference between the two pDC subsets (Figure 5-18C). 
Figure 5-18D shows the proportion of DCs and T cells in the culture after day 3. 
These plots show, as expected, that all B220-CD11c- cells were the added 
transgenic CD8α+ T cells. More importantly these plots show that there were 
very few contaminating B220-CD11c+ cDCs in all pDC cultures, which could not 
account for the high level of CD8α+ T cells proliferation (Figure 5-17). Thus, the 
majority of the observed proliferation in the pDC cultures was likely due to pDCs 
rather than contaminating cDCs, although contributions by non-pDCs cannot be 
completely excluded. 
There is a discrepancy in the percentage of T cells, both CD4+ and CD8α+ that 
divided when incubated with total pDCs or the two subsets of pDCs. I found that 
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a much high proportion of CD4+ T cells (~30%) and CD8α+ T cells (~75%) divided 
when cultured with total pDCs than sorted CCL2hi and CCL2lo pDCs. CCL2hi and 
CCL2lo pDCs only caused ~5% of CD4+ T cells (Figure 5-16C) and ~50% of CD8α+ T 
cells to proliferate (Figure 5-18B). Thus, incubation at 37°C with CCL2AF647 may 
affect pDCs ability to present OVA to T cells. Importantly, the decrease in T cell 
priming efficiency was also observed with cDCs in the same experiments, even 
though they were not exposed to CCL2AF647. One possible explanation could be 
that in order to retrieve adequate numbers of CCL2hi and CCL2lo pDCs there was 
a considerable lengthening of the sort time (the sort took over 12 hrs, twice as 
long as a sort for total pDCs), which could negatively impact the viability of 
sorted cells. 
5.7.1.1 Effect of pDC activation by TLR7 ligand on CD8α+ T cell stimulation 
I next examined whether activation of the two pDC subsets affected their ability 
to present Ag and stimulate T cell proliferation (Figure 5-19). I concentrated on 
naïve CD8α+ T cells because pDCs stimulated a higher proliferative response in 
these cells compared to naïve CD4+ T cells. As Figures 5-19A and 5-19B illustrate, 
in the presence of the TLR7 agonist R848, there was a significant increase in the 
frequency of divided T cells. Importantly, there were no differences in the T cell 
stimulatory capacity between the two pDC subsets in the presence or absence of 
R848 stimulation (Figure 5-19B). I then calculated the frequency of T cells in 
each division when stimulated with CCL2hi (Figure 5-19C) or CCL2lo pDCs (Figure 
5-19D) with or without R848 activation. Both subsets presented similar trends in 
that there was a significant reduction in the number of cells in division 0 and 1 
in the presence of R848 and an increase in the number of cells in the later 
divisions, particularly divisions 4, 5 and 6. A relatively minor difference between 
the subsets was that R848 stimulated CCL2lo pDC samples had significantly more 
T cells that had undergone 5 or 6 divisions than in the absence of R848, whereas 
the increase present in CCL2hi samples was not significant. However, there were 
no other obvious differences between the two subsets and the data firmly 
indicate that R848 stimulated CCL2hi or CCL2lo pDCs do not differ substantially in 
their ability to stimulate naïve CD8α+ T cell proliferation. 
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5.7.1.2 Establishing the impact of mCCL2 on pDC induced CD8α+ T cell 
proliferation  
In light of the observed differences in CCR2 activity between the two subsets, I 
monitored the effect of continuous exogenous mCCL2 exposure on the ability of 
the two pDC subsets to induce CD8α+ T cell proliferation (Figure 5-20). Either 0, 
12.5 or 25 nM of exogenous mCCL2 was added to the co-culture of pDCs with 
CD8α+ T cells. Representative histograms of CFSE dilution illustrate that there 
were no major differences in the induction of T cell proliferation between the 
two subsets and mCCL2 had no effect. Also, when the number of CD8α+ T cells 
that had undergone more than 3 divisions was calculated there were no 
differences between the two subsets, and mCCL2 had no effect on the CD8α+ T 
cell stimulatory capacity of the two subsets. 
To summarise, these results indicate that FACS-purified pDCs from the spleens of 
B16FL tumour bearing mice are unable to, or have limited ability to, process and 
present OVA to naïve CD4+ T cells. They are, however, able to stimulate 
proliferation of OVA specific naïve CD8α+ T cells. CCR2 activity did not segregate 
with any differences in the CD8α+ T cell stimulatory capacity of pDCs, either in 
steady-state or after activation by the TLR7 agonist R848. Furthermore, the 
addition of exogenous mCCL2 did not affect the ability of either pDC subset to 
stimulate CD8α+ T cell proliferation. While these results do not exclude the 
possibility that CCR2 expression may affect other pDC functions, they 
conclusively demonstrate that CCR2 expression/activity has no impact on the 
ability of pDCs to present Ag, at least in vitro. 
5.7.2 Analysing IFNα  production by the two subsets 
One key role of pDCs is in defence against viral infections, executed following 
their activation by TLR7/9 and subsequent mass IFNα/β production (Gibson et 
al., 2002; Björck et al., 2011). Thus, I next assessed the ability of the two 
subsets (purified from the spleens of B16FL treated mice) to produce IFNα in 
response to the TLR7 agonist, R848 and a TLR9 agonist, CpG type A (CpG-A) 
(Figure 5-21). CpG-As are known for their propensity to induce pDCs to produce 
large amounts of IFNα. In accordance with this, both CCL2hi and CCL2lo pDCs 
produced copious amounts of IFNα when stimulated with CpG-A. Stimulation 
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with R848 also caused IFNα production, but it was significantly lower than with 
CpG-A. There were no significant differences between the subsets in their ability 
to produce IFNα in response to TLR7/9 activation in this experimental setup. 
Collectively, considering marker expression, morphology, T cell activation and 
IFNα production, I have shown that there are no substantial functional 
differences between CCL2hi and CCL2lo pDCs. 
5.8 Determining transcriptional differences between 
CCL2hi and CCL2lo pDCs using transcriptomics 
Other than possibly CCR2, and subtle changes in expression of CCR9 and CX3CR1, 
my analysis to this point had failed to establish any major differences in surface 
protein expression between CCL2hi and CCL2lo pDC subsets. Nevertheless, only a 
minor number of markers were tested, so I decided to more broadly examine 
transcriptional differences between the two subsets. Thus, a comparison 
between CCL2hi and CCL2lo pDCs was performed by using microarray technology. 
5.8.1 Experimental design 
The primary objective of this study was to compare the transcriptional profiles 
of CCL2hi and CCL2lo pDCs. However, to isolate these subsets it would be 
necessary to incubate splenocytes with CCL2AF647 for 1 hr at 37°C prior to sorting 
the cells. It was theorised that this incubation could result in alterations in the 
gene expression profile of the cells as a result of, for example, CCR2 signalling, 
differentiation, or cell death. Thus, it was felt at the outset of the experiment 
that it was important to try to control for this. To do this, I chose to use total 
pDCs purified from B16FL treated mice, without incubating them ex vivo at 37°C 
or exposing them to CCL2AF647. In brief, following the preparation of a single cell 
suspension, cells were stained, total pDCs purified and RNA for the microarray 
was isolated from the cells. It was hypothesised that if genes were identified as 
differentially expressed between CCL2hi and CCL2lo pDCs, subsequent 
comparisons of CCL2hi pDCs to total pDCs, and CCL2lo pDCs to total pDCs, would 
give an indication of whether gene expression had been modulated by culture. 
To assist with this analysis, it is important to consider that ~50% of total pDCs 
have high CCR2 activity and ~50% have low CCR2 activity. Thus, if a gene was 
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found to be expressed higher in CCL2hi pDCs than CCL2lo pDCs, then, if its 
expression was unaffected by culture, we would expect that transcripts for this 
gene would be higher in CCL2hi pDCs than total pDCs, and lower in CCL2lo pDCs 
than total pDCs. A graphical representation of this is displayed in Figure 5-22A. 
Similarly, if a gene was found to be expressed at lower levels in CCL2hi than 
CCL2lo pDCs, then, if its expression was unaffected by culture, we would expect 
that this gene would be lower in CCL2hi pDCs than total pDCs, and higher in 
CCL2lo pDCs than total pDCs (Figure 5-22B). However, if a gene was differentially 
expressed between CCL2hi and CCL2lo pDCs, but its expression had been affected 
by culture, then a different profile would be expected when CCL2hi or CCL2lo 
pDC expression was compared to total pDCs (Figure 5-22C&D). For example, if a 
gene was found to be expressed higher in CCL2hi pDCs than CCL2lo pDCs, but had 
been upregulated by culture in both subsets, then we would expect transcripts 
for this gene to be higher in CCL2hi pDCs and CCL2lo pDCs when compared to 
total pDCs (Figure 5-22C). Similarly, if a gene was found to be expressed at 
lower levels in CCL2hi pDCs than CCL2lo pDCs, but had been downregulated by 
culture in both subsets, then we would expect transcripts for this gene to be 
lower in CCL2hi and CCL2lo pDCs than total pDCs (Figure 5-22D). Thus, by 
comparing CCL2hi and CCL2lo pDCs to total pDCs, we hoped that we would be 
able to get an indication of the impact of culture on the expression of each 
individual gene. 
5.8.2 Performing the microarray 
Total pDCs, CCL2hi and CCL2lo pDCs were sorted from the spleens of B16FL 
tumour bearing mice, RNA was extracted and it was sent to the Glasgow 
University Polyomics Facility for analysis. Each sample was tested for RNA 
concentration and integrity (Figure 5-23). RNA integrity number (RIN) is a 
software algorithm, which assigns a value to each RNA sample based on the 
presence or absence of degradation products. The optimal value for RIN is 10, 
which indicates that RNA is intact and has not been digested by RNase enzymes 
resulting in smaller fragments of RNA that can effect downstream applications, 
in this case microarray (Schroeder et al., 2006). As the table in Figure 5-23 
illustrates, all samples had good RNA integrity, although unfortunately due to a 
malfunction of one of the RNA 6000 Nano kits, no values were retrieved for the 
CCL2hi 3 and CCL2lo 3 samples. Furthermore, the ratio of 260/280 gives 
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information in regards to RNA purity with the optimal value being 2.1. A high 
level of protein contamination of the RNA sample will result in a lower 260/280 
value being calculated. Thus, as values in Figure 5-23 illustrate all samples were 
relatively pure. 
Based on this analysis, it was decided to proceed with the microarray. The 
Mouse Gene 1.0 ST Array from Affymetrix was chosen, as it comprises probes 
that target exons of over 28,000 known genes and requires low amounts of RNA, 
working with as low as 100 ng of RNA. Each gene on the chip is represented by 
27 probes that are distributed across the full length of the gene. These probes 
are in set pairs, each pair consisting of a perfect match and a mismatch 
oligonucleotide. As the name implies, the perfect match probe matches exactly 
the sequence of the gene, whereas the mismatch probe differs by a single 
central base substitution. Mismatch probes facilitate the identification of 
background noise caused by non-specific hybridisation compared to specific 
hybridisation. Non-specific binding is only one of the many variations that 
microarrays are subject to, with variation deriving from differences in samples, 
differences in chips, and the hybridisation between chips (Jiang et al., 2008). 
Therefore, normalisation of data is required to correct for these sources of 
standard variation. First, the data were subject to GC-RMA normalisation, which 
facilitates background correction. GC-RMA is an improved version of the robust 
multi-array average (RMA) method. RMA is an algorithm that corrects for non-
specific binding by using only the intensity values generated by the perfect 
match probes. The data is then subject to normalisation, resulting in 
approximately the same distribution of perfect match probe values across all 
chips. The intensity values from all the perfect match probes for an individual 
gene are then summarised to give a single intensity value for the gene, which 
correlates with the amount of mRNA present for the corresponding gene (Irizarry 
et al., 2003). GC-RMA builds on the RMA method, as it also accounts for non-
specific hybridisation by normalising probes for their GC content. Each perfect 
match probe will have different levels of GC content. GC is stickier and can lead 
to non-specific binding and a higher level of background than a probe that is AT 
rich. Therefore, the perfect match probe intensities are corrected for their GC 
content by adjusting the value according to a mismatch probe with the same GC 
content. This generates a normalised signal intensity for each gene. Pawel 
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Herzyk, Glasgow University Polyomics Facility, helped in the selection of the 
appropriate array, in addition to processing and normalising the data. 
Furthermore, Dr. Herzyk also calculated the fold change (FC) between the 
CCL2hi, CCL2lo and total pDC samples using the normalised values for each gene. 
He also performed a large scale one-way ANOVA to calculate the differences 
between the samples with Storey multiple-testing correction. 
5.8.3 Examination of genes differentially expressed in CCL2hi or 
CCL2lo pDCs 
Before the microarray data was interpreted to establish differences in gene 
expression between the two subsets, some restrictions were applied that would 
minimise the chance of false positives. I applied a cut off of a FC of 1.5 between 
the CCL2hi and CCL2lo pDCs. Therefore, the CCL2hi or CCL2lo pDCs must express a 
gene 1.5x more than the other subset in order for it to be included. A further 
restraint was applied to the data, in that the calculated p-value for the FC had 
to be p<0.005, which upon correction for multiple-testing correlates to a q-value 
of 0.344 generating a false discovery rate of 34.4%. Using these limits, a list of 
genes that were potentially differentially expressed between CCL2hi and CCL2lo 
pDCs was generated and is represented as a heat-map in Figure 5-24. This initial 
characterisation revealed a number of things. First, it was noticeable that CCL2lo 
pDCs expressed less CCR2 than CCL2hi pDCs. Furthermore, several of the genes 
expressed at higher levels in CCL2lo pDCs have been suggested to have roles in 
tumour growth suppression, such as rhobtb2 (Mao et al., 2009), phf17 (Zhou et 
al., 2005) and ephb2 (Kandouz et al., 2010). Also, in the CCL2hi pDCs, interferon 
induced transmembrane proteins (ifitm) 1 and 3 were upregulated compared to 
CCL2lo pDCs. These proteins are thought to contribute to viral defence (Huang et 
al., 2011). The list also showed that pDC enriched genes, such as E2-2 and 
pacsin1 (Ghosh et al., 2010; Reizis et al., 2011a) were not differentially 
expressed between the two subsets and that markers that were earlier assessed 
by flow cytometry, and D6 and other chemokine receptors were not 
differentially expressed at the level of mRNA transcripts. 
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5.8.4 Impact of culture on expression of genes identified as 
differentially expressed by CCL2hi and CCL2lo pDCs 
I next determined whether incubation with CCL2AF647 at 37°C had any discernible 
effects on the expression of the genes shown in Figure 5-24. As discussed above, 
by comparing the calculated FCs in expression of a gene between the three 
groups of pDCs i.e. CCL2hi pDCs vs. CCL2lo pDCs, CCL2hi pDCs vs. total pDCs and 
CCL2lo pDCs vs. total pDCs, it was possible to establish whether incubation had 
substantially affected the expression of the gene of interest (Figure 5-25).  
If we assume that cells with low and high CCR2 activity are present at roughly 
equal proportions in the total pDC preparation (not an unreasonable assumption 
based on work presented earlier in this thesis), then, based on the observed FC 
between CCL2hi and CCL2lo pDCs, it is possible to estimate the expected FC when 
CCL2hi pDCs vs. total pDCs and CCL2lo pDCs vs. total pDC comparisons are made, 
if there had been no effect of culture on gene expression. This is summarised in 
Table 5-1. 
Table 5-1: Expected FCs when a gene is expressed at higher levels in CCL2hi pDCs than 
CCL2lo pDCs, and its expression is not affected by culture. 
When this is considered, some genes in Figure 5-25, such as ifitm1, card10, 
map3k14 and particularly jup, clearly showed higher FC in CCL2hi pDCs vs. total 
pDCs and CCL2lo pDCs vs. total pDCs than anticipated. This indicates that these 
genes are upregulated to the same extent in both CCL2hi and CCL2lo pDCs during 
culture. In contrast, two genes showed a somewhat lower FC in CCL2hi pDCs vs. 
total pDCs than predicted. These genes were cd200r1 and, most notably, ccr2. 
With a FC in CCR2 expression between CCL2hi and CCL2lo pDCs of 3.26, if there 
had been no impact of culture and assuming that cells with low and high CCR2 
CCL2hi pDCs vs. total 
pDCs 
Expected FC, if no affect 
of culture 
CCL2lo pDCs vs. total 
pDCs 
Expected FC, if no affect 
of culture 
CCL2hi pDCs vs. CCL2lo 
pDCs 
Observed FC 
1.20x – 1.33x 0.67x – 0.80x 1.50x – 2.00x 
1.33x – 1.42x 0.57x - 0.67x 2.00x – 2.50x 
1.42x – 1.50x 0.50x – 0.57x 2.50x – 3.00x 
1.50x – 1.56x 0.44x – 0.50x 3.00x – 3.50x 
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activity are present at roughly equal proportions in the total pDC preparation, 
then a FC of 1.53 would be expected for the CCL2hi pDCs vs. total pDC 
comparison and of 0.47 for CCL2lo pDCs vs. total pDCs. The actual values were 
0.82 and 0.25, respectively. One interpretation of these observations is that 
culture in CCL2AF647 leads to a reduction in CCR2 transcripts in both CCL2hi and 
CCL2lo pDCs. 
A similar analysis can be undertaken for the genes that are lower in CCL2hi pDCs 
than CCL2lo pDCs (Figure 5-25B). With the assumptions outlined above, the 
predicted FC in CCL2hi pDCs vs. total pDCs and CCL2lo pDCs vs. total pDCs, based 
on the observed FC in CCL2hi pDCs vs. CCL2lo pDCs are shown in Table 5-2. 
Table 5-2: Expected FCs when a gene is expressed at lower levels in CCL2hi pDCs than 
CCL2lo pDCs, and its expression is not affected by culture. 
Many genes expressed at lower levels in CCL2hi pDCs than CCL2lo pDCs behave 
roughly as expected and give similar profiles in the graph in Figure 5-25B. 
However, some genes, most notably ppargc1a, give greater FC in CCL2hi pDCs vs. 
total pDCs and CCL2lo pDCs vs. total pDCs than expected, suggesting that they 
are upregulated in both subsets by culture. Others, such as ppm1e and rhobtb2, 
had somewhat lower FC in CCL2hi pDCs vs. total pDCs and CCL2lo pDCs vs. total 
pDCs, so may be downregulated in both subsets as a result of culture. 
5.8.5 Alterations in gene expression in pDCs as a result of culture 
with CCL2AF647 
Next, I specifically examined whether there were expression differences 
apparent in the microarray data of genes other than those analysed in Figures 5-
24 and 5-25 that could be attributable to incubation of the pDCs in CCL2AF647 at 
37°C. This was done by comparing expression of all genes between CCL2hi pDCs 
and total pDCs (the former had been incubated at 37°C and exposed to 
CCL2AF647, while the latter had been purified straight from a single cell 
CCL2hi pDCs vs. total 
pDCs 
Expected FC, if no affect 
of culture 
CCL2lo pDCs vs. total 
pDCs 
Expected FC, if no affect 
of culture 
CCL2hi pDCs vs. CCL2lo 
pDCs 
Observed FC 
0.62x – 0.80x 1.20x – 1.38x 0.67x –0.45x 
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suspension of splenocytes from mice carrying B16FL tumours). When setting the 
p-value as <0.005, large numbers of genes showed a >2-fold increase or decrease 
in expression in CCL2hi pDCs compared to total pDCs (~250 and ~150 genes, 
respectively). With almost all these genes, similar FCs were seen when CCL2lo 
pDCs were compared with total pDCs (data not shown). Thus, incubation caused 
substantial changes in gene expression in pDCs, but it appeared to have similar 
effects on both subsets. For purposes of simplification, only genes that showed a 
>3-fold increase or decrease in expression in CCL2hi pDCs compared to total pDCs 
are shown in Figure 5-26. All these genes with their respective FCs are shown in 
Appendix 1. Of these, many genes were more highly expressed in CCL2hi pDCs 
than total pDCs, but a few were expressed at lower levels in CCL2hi compared to 
total pDCs. One transcript, hspb1, was 20-30-fold more abundant in cultured 
pDCs than freshly-isolated cells, while others, such as il1r2, vdr, bag2 and 
tnfsf9, were >5-fold higher in cultured pDCs. Some genes showed differential 
expression between CCL2hi and CCL2lo pDCs of >1.5 FC, but these had been 
excluded from preceding analyses because they had p-values that were too high. 
To get some indication of what might be happening to the pDCs during culture, I 
examined data publicly available through the Immunological Genome Project 
(Immgen) (http://www.immgen.org). The Immgen database contains expression 
data for all genes by a large number (>250) of purified primary immune cell 
types (Bezman et al., 2011; Benoist et al., 2012; Malhotra et al., 2012; Miller et 
al., 2012). I specifically looked at expression of the genes I had identified by 
first using the ‘Dendritic Cells’ section of this database with a view to assessing 
their expression by pDCs. This section contains data for pDCs from spleen and 
LNs, along with data from a large array of other DC subtypes, such as splenic and 
LN cDCs, lung and intestinal DC subsets, and skin-derived Langerhans cells (LCs). 
Remarkably, most of the genes that were >3-fold higher in cultured pDCs than 
fresh total pDCs were barely expressed by pDCs, but they were abundant in 
other DC subsets. Moreover, when I looked at other non-DC cell types on the 
Immgen database, it was apparent that many of these genes were in fact 
restricted to DCs. This is depicted in Figure 5-26 where the genes are colour 
coded according to the cell type they were found to have highest expression of 
the gene: blue represents genes reported to be expressed at high levels by LCs, 
red by the several cDC subsets and black by cell types other than cDCs, LCs and 
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pDCs. Furthermore, genes expressed at higher levels in pDCs than LCs are shown 
in pink and genes with similar expression levels between pDCs and LCs are shown 
in green. These results suggest that the majority of genes affected by culture 
were those reported to be expressed specifically at high levels by LCs and cDCs, 
and most were weakly, or not expressed at all, by pDCs. Since I had purified 
pDCs to near homogeneity for the microarray study, it is possible that this 
reflects some form of differentiation of these cells to LC/cDC-like cells in 
culture. This will be discussed further in the Discussion in Chapter 6. 
Thus, incubation at 37°C with CCL2AF647 appears to affect expression of many 
genes in pDCs, and this needs to be considered when interpreting transcriptional 
differences between CCL2hi and CCL2lo pDCs. However, it appears that both 
subsets were similarly affected by incubation. Moreover, with a few notable 
exceptions, the transcript level of most of the genes differentially expressed 
between CCL2hi and CCL2lo pDCs does not appear to be substantially altered by 
culture. 
5.8.6 Further analysis of gene differences between the two 
subsets 
Due to time constraints, not all the genes in the initial list (Figure 5-24) could be 
subject to further analysis. Therefore, additional restrictions needed to be 
applied. The Immgen database was again used to determine the reported 
expression levels of each gene in pDCs. Any gene that was not expressed at an 
appreciable level in pDCs, according to Immgen, was removed from the list. This 
generated a much shorter list of pDC-expressed genes (Figure 5-27A). Similar to 
the earlier list it consisted of a range of genes that encode for transcription 
factors, signalling molecules and cell surface receptors, including CCR2.  
Next, the microarray results needed to be subjected to quality control. I 
selected a number of genes from the list in Figure 5-27 that had a broad range of 
expression in pDCs i.e. low and highly expressed genes according to Immgen. 
Each of these genes was specifically chosen for their low p-values and/or high 
FC. Furthermore, a relatively even distribution of genes upregulated in either 
the CCL2hi or the CCL2lo pDCs was maintained, as 6 genes were selected that 
were upregulated in either the CCL2hi or CCL2lo subset. Several of the selected 
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genes were also chosen for their described roles. For example, gbp4 was 
selected for the reported effects it possesses in regulating type 1 IFN production 
by targeting irf7 (Hu et al., 2011). cox6a2 was included due to its high 
expression in pDCs, being one of the most pDC specific genes that was 
differentially expressed between the two subsets. rarg was chosen as it has been 
demonstrated that an absence of rarg can lead to a decrease in pDC numbers in 
the spleen (personal communication by Stephanie Houston, University of 
Glasgow). phf17 has been described as possessing tumour suppression properties 
(Zhou et al., 2005), which is in contrast to the described role of pDCs that can 
suppress the immune response to tumours by rendering the immune system 
tolerogenic (Kim et al., 2007). Furthermore, several of the genes, such as il17rb, 
il13ra1 and cd200r1 were all chosen because they are surface receptors with 
potential immunoregulatory roles. As one of the receptors for IL-25 (IL-17E), IL-
17RB has been associated with the development of IL-25 induced pulmonary 
inflammation (Rickel et al., 2008). IL-13 has been reported to reduce human pDC 
responsiveness to CpG, as in its presence CpG activated pDCs had lower 
expression of the activation markers CD83 and CD86 (Tel et al., 2010). CD200 
the ligand of CD200R1 can influence an immune response by controlling 
polarisation of cytokine production, and its aberrant expression is associated 
with autoimmune diseases, such as SLE (Li et al., 2012). Furthermore, pDCs can 
be induced to release IFNα as a consequence of CD200R1 engagement by CD200-
expressing cells (Manlapat et al., 2007). 
Quality control checks were run on the list of genes in Figure 5-27B by 
quantifying their expression in CCL2hi and CCL2lo pDCs using QPCR. The QPCR was 
conducted using cDNA produced from the same RNA that was sent for 
microarray. However, there was a malfunction in the QPCR and all results 
produced were ‘flagged’ and an accurate reading for expression could not be 
determined (results not shown). There was insufficient time to generate further 
pDC samples, so as an alternate means to validate the microarray data, I 
examined the expression of a select few genes that encode surface receptor 
proteins by FACS, such as IL-13Ra1 and CD200R1 (Figure 5-28). Following gating 
of total pDCs in B16FL treated animals, the expression of CD200R1 and IL-13Ra1 
on CCL2hi and CCL2lo pDCs was determined. Comparison of CD200R1 and IL-13Ra1 
staining of WT cells to the appropriate isotype stain (Figure 5-28A) illustrates 
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that there is staining of both CCL2hi and CCL2lo pDCs with each antibody. When 
these results were quantified there was no difference in the calculated CD200R1 
ΔMFI of CCL2hi and CCL2lo pDCs. There was however a significant increase in the 
IL-13Ra1 ΔMFI of CCL2hi pDCs compared to CCL2lo pDCs, which was consistent 
with the microarray data in Figure 5-27. Next it was theorised that treatment 
with Flt3L may have affected the expression of CD200R1 or IL-13Ra1 from levels 
that would be detected in an untreated WT animal. Therefore, I determined the 
frequency of CCL2hi and CCL2lo pDCs that expressed CD200R1 in WT B16FL 
treated and untreated animals, in addition to untreated CD200R1 KO animals 
(Figure 5-28C). The CD200R1 KO was included as an additional control to confirm 
true antibody staining in the WT animals. The number of CCL2lo pDCs with 
CD200R1 immunoreactivity was significantly higher in untreated WT than B16FL 
treated, but CD200R1 staining was also detected on both subsets of pDCs in the 
CD200R1 KO. This once again highlights the problems with antibodies targeted 
against surface receptors. I also established the frequency of CCL2hi and CCL2lo 
pDCs in a B16FL treated or untreated WT that express IL-13Ra1 (Figure 5-28D). 
Consistent with the earlier observation, IL-13Ra1 expression was lower in CCL2lo 
pDCs in both treated and untreated animals, however there was only a small 
proportion of both CCL2 subsets that were IL-13Ra1+. Flt3L treatment does 
however appear to cause a significant reduction in IL-13Ra1 expression by CCL2hi 
and CCL2lo pDCs. 
In an initial experiment I also tried to examine IL-17RB expression by the two 
subsets with no success. IL-17RB antibodies are unavailable commercially but 
were obtained from Andrew McKenzie’s lab (University of Cambridge, UK) 
(Ballantyne et al., 2007). The conjugation of the antibody to a fluorophore failed 
and due to time constraints further attempts were not conducted. 
5.8.7 Effect of IL-13 on the activation of CCL2hi and CCL2lo pDC 
Taking into account the results illustrating that IL-13Ra1 is differentially 
expressed between the two pDC subsets, I next tested the effect exogenous IL-
13 had on CpG-C induced pDC activation (Figure 5-29). Previous results have 
shown that IL-13 modulated TLR9 induced activation of human pDCs as measured 
by the expression of activation markers (Tel et al., 2010). It was found that 
incubation of both CCL2hi and CCL2lo pDCs (isolated from spleens of B16FL 
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tumour bearing mice) with CpG-C resulted in the division of both subsets into a 
further two populations based on SiglecH expression, one being high and one low 
for SiglecH (Figure 5-29A). The SiglecHhi and SiglecHlo populations were then 
examined for expression of the activation markers CD86 and ICOS-L (Figure 5-
29B&C). The expression of both activation markers was found to be restricted to 
the SiglecHhi populations of both CCL2hi and CCL2lo pDCs, with the SiglecHlo 
population having similar expression of the activation markers as unstimulated 
total pDCs. The addition of IL-13 had no effect on the activation of the SiglecHhi 
populations of both CCL2hi and CCL2lo subsets, as determined by the expression 
of CD86 (Figure 5-29D) and ICOS-L (Figure 5-29E). There was no difference in the 
relative proportions of SiglecHhi and SiglecHlo pDCs in the two CCL2 subsets. 
Furthermore, IL-13 had no effect on the frequency of SiglecHhi and SiglecHlo 
pDCs (Figure 5-29F). There was also no difference in the survival of cells, as 
there were similar frequencies of live CCL2hi and CCL2lo pDCs, which were also 
unaffected by IL-13 (Figure 5-29G). 
5.8.8 Summary of microarray analysis 
In brief summary, this section of my thesis has shown that some transcriptional 
differences exist between CCL2hi and CCL2lo pDCs, but it is clear that these two 
subsets do not differ dramatically at the level of gene expression. Importantly, 
they confirmed that CCL2hi pDCs have higher levels of CCR2 transcripts than the 
CCL2lo pDCs. Furthermore, higher IL-13Ra1 transcript levels were detected in the 
CCL2hi pDC subsets. Antibody staining of IL-13Ra1 surface protein also helped to 
confirm the existence of a small difference in IL-13Ra1 expression by the two 
CCL2 subsets, as although there was only a low proportion of pDCs that were IL-
13Ra1+, CCL2hi pDCs had significantly more IL-13Ra1 on their surface. However, 
addition of IL-13 to cultures had no affect on CpG-induced activation. 
Furthermore, these data suggest that the two pDC subsets do not differ in 
viability or in their ability to mature in response to CpG. The microarray data 
will be discussed in more detail in Chapter 6. 
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5.9 Strain dependent differences in the phenotype of 
pDCs 
The in vitro analyses demonstrated that CCL2hi and CCL2lo pDCs were very 
similar phenotypically in many assays. However, the development, phenotype 
and function of pDCs in vivo might be influenced by CCR2 deficiency. Thus, I 
next compared pDCs from WT and CCR2 KO mice. D6 KO mice were also included 
in the analysis. These animals were available, and my results have provided 
evidence for D6 expression by pDCs. First, I examined CCL2AF647 uptake by WT, 
D6 KO and CCR2 KO pDCs in a range of tissues (Figure 5-30). Previously, I have 
shown that the majority of CCL2AF647 uptake by pDCs is CCR2 dependent. 
Furthermore, I also demonstrated that both WT and CCR2 KO pDCs possessed D6 
activity (Figure 5-3). Therefore, it was expected that in the absence of CCR2, 
pDCs would only internalise a little CCL2AF647 due to the presence of D6. D6 KO 
pDCs were expected to have profiles similar to WT pDCs i.e. large amount of 
CCR2 dependent CCL2AF647 uptake, but it would be reduced in comparison to WT 
pDCs due to the absence of D6 dependent CCL2AF647 uptake. As expected in all 
tested tissues, CCR2 KO pDCs internalised little CCL2AF647, due to the deficiency 
in CCR2 mediated CCL2AF647 uptake (Figure 5-30). Unexpectedly, in the first 
experiment, all D6 KO pDCs in every tested tissue appeared to be CCL2hi (Figure 
5-30 left hand FACS panel). However, on repeating the experiments, I found that 
this phenotype was not always present, and approximately 50% of the time D6 
KO pDCs had profiles similar to WT animals (Figure 5-30 right hand FACS panel). 
In the case of D6 KO splenic pDCs these profiles have been observed in 4 
independent experiments, normal uptake profiles (i.e. similar to WT pDC) were 
found in 5 animals, whereas the abnormal profile (i.e. all pDCs are CCL2hi) was 
found in 7 animals. The reason for this striking difference between D6 KO mice is 
unclear. It does, however, mean that data produced using D6 KO pDCs need to 
be interpreted with caution. 
I next sought to determine whether there were any strain differences in the 
expression of the majority of the markers discussed in section 1.5 (Figure 5-31 
and Figure 5-32). The percentage of pDCs that were positive for expression of 
each marker in WT, CCR2 KO and D6 KO was determined in the spleen (Figure 5-
31A) and BM (Figure 5-32A). In the spleen the only tested markers that showed 
any strain dependent differences in expression were CD8α, CD62L, CCR7 and 
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CD69. The most striking difference was with CD8α. CD8α was expressed by 
significantly fewer pDCs in D6 KO compared to WT, whereas CCR7 was expressed 
by significantly more pDCs in the D6 KO. CD62L and CD69 were both expressed at 
very low levels, but differences between the mouse strains were still present. 
CD62L was expressed by significantly more pDCs in the D6 KO and CD69 was 
expressed by significantly fewer pDCs in D6 KO and CCR2 KO, compared to WT. 
These differences were highlighted in histogram overlays in Figure 5-31B, 
illustrating the higher expression of CD62L and lower expression of CD8α by 
splenic D6 KO pDCs compared to WT and CCR2 KO. Also, illustrated is the 
increase in CD69 expression by WT pDCs compared to D6 KO and CCR2 KOs. 
Quantification of the ΔMFI of each of these markers supported the observed 
strain differences, and showed the dramatic decrease in CD8α expression by D6 
KO pDCs (Figure 5-31C). Earlier in Figure 5-11, I demonstrated that the anti-
CCR7 antibody failed to detect CCR7 on WT splenic pDCs or on total live 
splenocytes. The spleen is a rich source of T and B lymphocytes, which are 
known to express CCR7, therefore I reported that the antibody was unreliable. 
However, the antibody mediated detection of CCR7 on splenic D6 KO pDCs and 
representative histogram overlays showed the presence of a CCR7hi population 
within the D6 KO that was absent in the other strains. In contrast, when CCR7 
expression was examined on total live splenocytes it again failed to detect CCR7 
by T or B lymphocytes (Figure 5-31B). Therefore the anti-CCR7 antibody is an 
unreliable method to detect CCR7 and the significant increase in ‘CCR7 
expression’ by D6 KO splenic pDCs is unclear. 
When the expression of these markers was analysed on BM pDCs there were some 
notable differences between the strains (Figure 5-32), and within strains when 
compared to the profile generated by splenic pDCs (Figure 5-31A). Similar to 
splenic pDCs, few WT and CCR2 KO BM pDCs expressed CD9, but dramatically a 
significant and much higher proportion of D6 KO BM pDCs were found to express 
CD9. As with splenic pDC data, CD62L was expressed at low levels, but 
significantly more pDCs in the D6 KO expressed CD62L, compared to WT and 
CCR2 KO. The same was true for CCR7, but for the aforementioned reasons this 
result is questionable. However, in contrast to the spleen data, there were no 
detectable differences in CD8α expression. Furthermore, a higher proportion of 
WT pDCs expressed the activation markers, CD69 and CD86, but expression of 
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both of these markers, as shown in histogram overlays and ΔMFI was very low in 
all three strains. A significantly greater proportion of WT pDCs expressed the gut 
homing integrin α4β7, but there a significant reduction in the proportion of pDCs 
expressing the gut homing chemokine receptor, CCR9 in WT animals, compared 
to D6 KO and CCR2 KOs. CCR9 ΔMFI data suggested that the increase in the 
proportion of pDCs in D6 KO BM expressing CCR9 was due to an increase in CCR9 
expression by CCR9+ cells. In contrast, the increase in CCR9+ CCR2 KO pDCs 
appeared to be because of the absence of CCR9- pDCs, as nearly 100% of CCR2 
KO pDCs were CCR9+. There were also some strain dependent differences 
observed in CCR2 KO BM pDCs in regards to CD4 expression. There was a 
significant increase in the number of CCR2 KO BM pDCs that expressed CD4 
compared to both WT and D6 KO. These differences are highlighted in Figure 5-
32B, where representative histograms show the strain differences in expression 
of the discussed markers. Furthermore, calculation of the ΔMFI of each of the 
markers further emphasised some of the striking differences in expression by BM 
pDCs from the different mice strains, in particular CD9 expression by D6 KO pDCs 
(Figure 5-32C). 
Finally, examination of absolute number of splenic and BM pDCs in WT, CCR2 KO 
and D6 KO animals (Figure 5-33) illustrated that the deletion of either CCR2 or 
D6 had no apparent effects on pDC numbers. 
These results have illustrated that in mice lacking CCR2 or D6 there are some 
unexpected differences in the expression of certain surface markers, most 
strikingly CD9 in the D6 KO BM pDCs. However, interpretation of the D6 KO data 
requires caution because of the marked variability in results of CCL2AF647 uptake 
assays. The results described above were generated from three D6 KO mice, one 
of which had the abnormal CCL2AF647 uptake profile. Further experiments are 
required to assess the reproducibility of the findings, dissect the mechanisms 
responsible, and define their impact on pDC function.  
5.10 Investigating a role for CCR2 on pDCs during 
inflammation in vivo 
In Chapter 3, I showed that there was no difference in the frequency of pDCs 
between WT and CCR2 KO animals in the spleen, BM and blood (Figure 3-15). 
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Furthermore, in Figure 5-33 I determined the absolute number of BM and splenic 
pDCs in WT and CCR2 KO animals and found no significant differences. These 
results indicate that CCR2 is not required for steady-state pDC migration to 
spleen or for their emigration from the BM. 
5.10.1 Effect of CCR2 deficiency on pDCs during cutaneous 
inflammation 
As CCR2 only appeared to have a minor role in pDC migration during homeostatic 
conditions, I next tested whether CCR2 plays a role in pDC migration during 
inflammation. It is known that imiquimod treatment leads to skin inflammation 
and the recruitment of pDCs to the site of inflammation reportedly in a CCL2 
dependent manner (Palamara et al., 2004; Drobits et al., 2012). Imiquimod is a 
TLR7 agonist that has potent anti-viral and anti-tumour effects (Gibson et al., 
2002). Thus, I determined the absolute number of pDCs in the skin of WT and 
CCR2 KO animals subsequent to their daily treatment for 7 days with cutaneous 
application of imiquimod (Figure 5-34). Unexpectedly, there was a significant 
increase in the number of pDCs that migrated to the skin of CCR2 KO animals 
than that of WT animals, indicating that CCR2 is not required for pDC migration 
to the skin. However, this increase in pDC numbers in the skin could be 
explained by a dependence on CCR2 for pDC escape from the skin into draining 
LNs. Therefore, I next determined the absolute number of pDCs in the draining 
inguinal LNs in WT and CCR2 KO, but found no difference in pDCs numbers 
between these two strains (Figure 5-35). I also examined the effect of imiquimod 
treatment on pDC numbers in other immune compartments. There was no 
difference in the absolute number of splenic pDCs between the two strains, but 
imiquimod treatment appeared to cause a decrease in the number of splenic 
pDCs (Figure 5-36). Trends in data suggest that imiquimod treatment might 
cause a decrease in BM pDC numbers, with a corresponding increase in the blood 
of CCR2 KOs (Figures 5-37 and 5-38). However, the results were not significant 
according to statistical analysis and further repeat experiments will be required. 
5.10.2 Effect of imiquimod on CCR2 activity of pDCs 
In addition to determining the absolute number of pDCs within the tissues, I also 
examined the effect of imiquimod treatment on the CCR2 activity of pDCs. In 
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the inguinal LN (Figure 5-35), spleen (Figure 5-36) and BM (Figure 5-37) the 
proportion of CCL2hi and CCL2lo pDCs was perturbed, as they no longer 
constituted ~50% of the total pDC population. There was only ~25% CCL2+ pDCs in 
WT samples, which was still significantly higher then in CCR2 KO, indicating 
some residual CCR2 dependent uptake by WT pDCs. The WT and CCR2 KO pDCs 
also possessed D6 activity, demonstrated by competition with mCCL22. There 
was an increase in the proportion of CCL2lo pDCs in WT samples, but there were 
still significantly more CCL2lo pDCs in the CCR2 KO. Blood samples followed 
similar trends to the other tissues in that pDCs possessed CCR2 and D6 
dependent uptake, but the ratio of CCL2hi and CCL2lo pDCs was relatively 
unaltered, with CCL2hi pDC contributing ~45% of total pDCs (Figure 5-38). 
In summary, although pDCs migrate to CCL2 in vitro, I have been unable to find 
an indispensable in vivo role for CCR2 on pDCs in the models used. 
5.11 Summary 
The data in this chapter have demonstrated that two subsets of pDCs based on 
CCL2 uptake are identifiable. These were present in all tested lymphoid tissues 
and possessed both CCR2 and D6 activity. I found that although Flt3L could 
induce the formation of BM-derived pDCs in vitro there were variations in the 
CCR2 activity of the cells at the different time-points and with the different 
sources of Flt3L. Therefore, following initial pilot experiments I successfully 
used B16FL cells to increase pDC numbers by approximately 10-fold in vivo, with 
no affects on CCR2 activity, as both CCL2hi and CCL2lo pDC subsets were still 
present. The resultant increase in pDC numbers as a consequence of Flt3L 
treatment facilitated sorting of reasonable numbers of CCL2hi and CCL2lo pDCs, 
which could be examined for transcriptomic and functional differences. 
Comparisons of the two subsets at the transcript level illustrated that CCR2 was 
differentially expressed, but there was no difference in D6 transcript levels 
between the two subsets. Several other genes were also differentially expressed 
by the two CCL2 subsets, such as il13ra1. However, IL-13 did not affect the 
activation of either pDC subset. Furthermore, these results showed that 
although incubation at 37°C with CCL2AF647 did affect expression of many genes, 
only a few genes that were differentially expressed by the two CCL2 subsets 
were affected. 
Chapter 5  204 
 
There were no significant functional differences between the two subsets, both 
subsets possessed similar capacities to produce IFNα in response to TLR7/9 
agonists. Furthermore, both subsets were able to process and present Ag to 
naïve CD8α+ T cells, and to a limited extent CD4+ T cells. In addition, activation 
of pDC by R848 treatment resulted in an increase in the ability of both subsets to 
stimulate CD8α+ T cell proliferation. However, exogenous CCL2 had minimal 
affects on the ability of the CCL2hi and CCL2lo subsets to stimulate CD8α+ T cell 
proliferation. 
My results suggest that CCR2 may have a role in pDC migration, as I have shown 
that the CCL2/CCR2 pathway can mediate migration of total pDCs in vitro. 
However, pDCs showed no dependence on CCR2 for their emigration from the BM 
or into peripheral tissues in a resting animal. Furthermore, imiquimod induced 
inflammation resulted in an increase in pDC migration to the skin, which was 
CCR2 independent. Interestingly, although imiquimod treatment resulted in 
downregulation of CCR2 activity on pDCs there appeared to be no affect on D6 
activity, as it was still present in pDCs in all tested tissues. Furthermore, 
examination of the surface phenotype of pDCs in WT, D6 KO and CCR2 KO 
animals illustrated strain dependent differences in expression of several 
markers, in particular D6 deletion led to a substantial increase in CD9 expression 
by BM pDCs. These apparent chemokine receptor dependent changes in surface 
immunophenotype clearly merit further investigation. 
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Figure 5-1: Detection of two subsets of splenic pDCs based on CCL2AF647 uptake. 
Following exclusion of doublets, live splenocytes were gated as B220+CD11c+. Subsequently, a 
more stringent B220+CD11c+ gate was applied. B220+CD11c+ cells were then gated as Ly6C+ and 
CD11b- (pDCs). The remaining B220+CD11c+ cells, excluding pDCs were also gated (Population 
D). CCL2AF647 uptake was then examined within these populations. Representative histograms of 
WT (black line) and CCR2 KO (shaded grey area) cells incubated with CCL2AF647 alone, or 
CCL2AF647 uptake in CCR2 KO competed with 10-fold molar excess mCCL22 (grey line). The 
CCL2AF647 histogram overlays of pDCs are the same as ones shown in Figure 3-11. Plots are 
representative of a minimum of three biological replicates. 
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Figure 5-2: Confirmation that the two subsets are truly pDCs. 
(A) Splenic pDCs and Population D were gated as described in Figure 5-1, and the two pDC 
subsets based on CCL2AF647 and Population D were examined for the expression of two pDC 
specific markers, PDCA1 and SiglecH. (B) Following exclusion of doublets, live splenocytes were 
gated as PDCA1+CD11c+. CCL2AF647 uptake was then examined within this population. Plots are 
representative of a minimum of three biological replicates. 
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Figure 5-3: Two subsets of pDCs can be defined by CCL2AF647 uptake in other lymphoid 
tissues. 
pDCs from the spleen, BM, blood, MLNs and PLNs of WT and CCR2 KO were gated as described 
in Figure 5-1, and analysed for uptake of CCL2AF647. WT (black) and CCR2 KO (grey) cells 
incubated with CCL2AF647 alone, or CCL2AF647 uptake was competed with 10-fold molar excess 
mCCL22 in WT (red) or CCR2 KO (blue). Representative contour plots from each mouse strain and 
histogram overlays show CCL2AF647 uptake by pDCs. The proportion of CCL2hi cells is shown in 
each histogram. Plots are representative of a minimum of three biological replicates. 
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Figure 5-4: Production of Flt3L by CHO-Flt3L and B16FL cells. 
(A) Conditioned media retrieved from cultures of B16FL (black line) and CHO-Flt3L (grey line) cells 
were assessed for Flt3L content by ELISA after dilution. (B) Concentration of Flt3L in conditioned 
media as determined by ELISA in A by comparison to a standard curve. 
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Figure 5-5: In vitro Flt3L expansion of pDCs. 
(A-C) 2x106 BM cells per condition were incubated for 7-10 days in the presence of varying 
concentrations of rhFlt3L (A), CHO-Flt3L (B) or B16FL (C). The frequency of total live cells (i.e. 
ViaProbe negative cells) was determined for each condition, 1 ng/ml (black line), 5 ng/ml (red line), 
10 ng/ml (green line), 50 ng/ml (purple line) and 100 ng/ml (blue line). (D&E) 1x107 BM cells per 
condition were incubated for 7-10 days in the presence of either 50 ng/ml CHO-Flt3L (black line), 
100 ng/ml CHO-Flt3L (grey line), 50 ng/ml B16FL (dark blue line) or 100 ng/ml B16FL (light blue 
line). The absolute number of live BM-pDCs, gated as indicated in (D) was determined for each 
condition. 
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Figure 5-6: Effect of in vitro Flt3L treatment on CCR2 activity of pDCs. 
CHO-Flt3L (A) or B16FL (B) WT BM-pDCs at day 8, day 9 or day 10 of culture with 100 ng/ml Flt3L 
(gated as described in Figure 5-5), were analysed for uptake of CCL2AF647. Histogram overlays 
show CCL2AF647 uptake by pDCs with no competition (blue line), or CCL2AF647 uptake competed 
with 10-fold molar excess of either mCCL22 (red line) or mCCL2 (shaded grey area). The 
percentage of CCL2hi cells in each culture is indicated in each histogram. 
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Figure 5-7: In vivo Flt3L expansion of pDCs. 
WT animals were left untreated (B16FL control) or injected s.c. with 2x106 B16FL tumour cells 
(B16FL treated) and were sacrificed 13 days later. CX3CR1GFP/+ mice were injected i.p with 10 µg 
rhFlt3L (rhFlt3L treated) or PBS (rhFlt3L control) for 10 consecutive days. Representative plots 
illustrate the increase in pDC proportions (black gate) and B220-CD11c+ cells (red gate) in the 
spleen (A), blood (B) and PLNs (C), with the calculated absolute cell numbers shown. pDCs in 
rhFlt3L control or treated animals were gated as depicted in Figure 5-1. pDCs in B16FL control or 
treated animals were also gated as described in Figure 5-1, however they were also gated as 
SiglecH+. For each control, only one mouse was used and for each treated condition n= 2 (mean + 
SD). 
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Figure 5-8: Effect of in vivo Flt3L treatment on the two subsets of pDCs as defined by 
CCL2AF647 uptake. 
WT animals were left untreated (B16FL control) or injected s.c. with 2x106 B16FL tumour cells 
(B16FL treated) and harvested 13 days later. CX3CR1GFP/+ mice were injected i.p with 10 µg rhFlt3L 
(rhFlt3L treated) or PBS (rhFlt3L control) for 10 consecutive days. Splenic (A) and PLN (B) pDCs 
(gated as described in Figure 5-7) were analysed for uptake of CCL2AF647. Histogram overlays 
show CCL2AF647 uptake by pDCs in control animals (black line) or Flt3L treated, B16FL or rhFlt3L 
(grey lines). (C&D) The frequency of CCL2hi and CCL2lo pDCs was determined in control and 
treated animals, and plotted as a frequency of live pDCs. B16FL Control (white bars), B16FL 
Treated (blue bars), rhFlt3L Control (black bars) and rhFlt3L Treated (red bars). For each control, 
only one mouse used and for each treated condition, n= 2 (+ SD). 
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Figure 5-9: Gating strategy for isolating splenic pDCs and the two subsets of pDCs. 
(A) Following exclusion of doublets, live cells were gated as B220+CD11c+. Subsequently, a more 
stringent B220+CD11c+ gate was applied. B220+CD11c+ cells were then gated as Ly6C+ and 
CD11b-. They were then examined for SiglecH expression and gated as SiglecH+ (named total 
pDCs). CCL2AF647 uptake was then examined within this population, with the subsequent 
populations being named CCL2hi pDCs or CCL2lo pDCs. (B) An example of the typical purities 
gained following a sort for the two subsets of pDCs. 
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Figure 5-10: Migration of pDCs in response to CCL2 in vitro. 
Total pDCs from WT animals carrying B16FL tumours were sorted according to the gating strategy 
depicted in Figure 5-9. 1x105 pDCs were incubated on the top of a chemotactic chamber above 
varying concentrations of unlabelled mCCL2 (0, 1, 12.5 and 50 nM) for 3 hrs. The number of 
migrated cells at each concentration was recorded by FACS. (A) Representative plots of flow 
cytometry of migrating cells in response to 0 nM and 50 nM mCCL2. (B) Graphical representation 
of absolute number of pDCs that migrated in response to increasing levels of mCCL2. Results were 
generated from two independent experiments with 3 or 5 technical replicates per experiment (mean 
± SD). Data were analysed by one-way ANOVA with Tukey post-test comparing migration at all 
concentrations to that observed at 0 nM CCL2 i.e. media alone p<0.05 * and p<0.001 ***. 
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Figure 5-11: Expression of other chemokine receptors by splenic pDCs. 
pDCs from the spleen of WT animals (gated as described in Figure 5-1) were analysed for uptake 
of either CCL2AF647 or CCL5AF647 and expression of other chemokine receptors known to be 
expressed by pDCs. (A) Representative contour plots from WT spleen stained with antibody (blue) 
or appropriate isotype (red). For CX3CR1 detection, a CX3CR1GFP/+ mouse was used. 
Representative histogram overlays show CCL5AF647 uptake by pDCs with no competition (black 
line) or CCL5AF647 uptake competed with 10-fold molar excess of either murine CCL4 (blue line) or 
murine CCL5 (red line). A further control of cells incubated with only binding buffer is shown 
(shaded grey area). (B) The frequency of CCL2hi (black bars) and CCL2lo pDCs (white bars) 
expressing each marker. (C) The proportion of cells taking up CCL5AF647 with no competition (black 
bar) or competed with 10-fold molar excess of either mCCL4 (white bar) or mCCL5 (grey bar). (D) 
CCL5 geometric mean fluorescence intensity (ΔMFI) of WT splenic pDCs. CCL5AF647 with no 
competition (black bar) or competed with 10-fold molar excess of either mCCL4 (white bar) or 
mCCL5 (grey bar). Data were analysed by unpaired T-test (B) or one-way ANOVA with Tukey post-
test (C&D) p<0.05 * and p<0.01 ** n=3 (mean + SD). (E) Illustration of CCR7 staining in all live 
cells. Plots are representative of a minimum of three biological replicates. 
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Figure 5-12: Expression of subset markers by splenic pDC CCL2 subsets. 
pDCs from the spleen of WT animals (gated as described in Figure 5-1), were analysed for uptake 
of CCL2AF647 and expression of markers known to delineate two subsets of pDCs. (A) 
Representative contour plots from WT spleen stained with antibody (blue) or appropriate isotype 
(red). (B) The frequency of CCL2hi (black bars) and CCL2lo pDCs (white bars) expressing each 
marker was determined. n=3 (mean + SD). Data were analysed by unpaired T-test p<0.05 *. (C) 
Illustration of CD62L, α4β7 and Ly49Q staining in all live cells. Plots are representative of a 
minimum of three biological replicates. 
CD8 CD4 CD9 CD62La4b7 Ly49QCD5
0.0
10.0
CCL2+
CCL2-
50
75
100
C
D
9 
C
D
4 
CCL2AF647 
A 
WT 
Isotype 
C
D
8!
 
C
D
9 
0.0 
0.0 
50.0 
75.0 
%
 o
f p
D
C
s p
os
iti
ve
 fo
r m
ar
ke
r 100.0
 
CCL2hi 
CCL2lo 
B 
CD62L 
0 
20 
40 
60 
80 
100 
%
 o
f m
ax
. 
C 
WT 
Isotype 
!4"7 Ly49Q 
C
D
8!
 
C
D
62
L 
!4
"7
 
Ly
49
Q
 
C
D
4 
C
D
62
L 
!4
"7
 
Ly
49
Q
 
* 
Chapter 5  217 
 
 
Figure 5-13: Expression of activation markers by splenic pDC CCL2 subsets. 
pDCs from the spleen of WT animals (gated as described in Figure 5-1), were analysed for uptake 
of CCL2AF647 and expression of activation markers. (A) Representative contour plots from WT 
spleen stained with antibody (blue) or appropriate isotype (red). (B) The frequency of CCL2hi (black 
bars) and CCL2lo pDCs (white bars) expressing each marker. n=3 (mean + SD). Data were 
analysed by unpaired T-test. (C) Illustration of OX40L, CD86 and CD69 staining in all live cells. 
Plots are representative of a minimum of three biological replicates. 
OX40L CD86 CD69
0.0
3.0
6.0
9.0
12.0
CCL2+
CCL2-
CCL2AF647 
C
D
69
 
C
D
86
 
A 
WT 
Isotype 
 6  
0.0 
.0 
.0 
.0 
%
 o
f p
D
C
s p
os
iti
ve
 fo
r m
ar
ke
r .0
 CCL2hi 
CCL2lo 
B 
OX40L 
0 
20 
40 
60 
80 
100 
%
 o
f m
ax
. 
C 
WT 
Isotype 
O
X
40
L 
CD86 CD69 
Chapter 5  218 
 
 
Figure 5-14: Morphology of the two subsets of pDCs. 
~5x104 CCL2hi or CCL2lo pDCs were sorted from the spleen of B16FL tumour bearing WT mice, as 
described in Figure 5-9. Cells were left untreated or activated in the presence of 5 µg/ml CpG-C for 
18 hrs. Cytospins were prepared, fixed and stained using the Rapid Romanowsky staining kit. 
Images were taken with a 40X objective using Olympus BX41 microscope and CellB software. 
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Figure 5-15: Ability of pDCs to stimulate CD4+ T cell proliferation. 
Splenic pDCs were sorted from B16FL treated animals as indicated in Figure 5-9. Likewise, cDCs 
were also sorted from B16FL treated animals as B220-CD11c+ cells. Naïve CD4+CD62L+ OVA 
specific T cells were sorted from the spleen and LNs of OTII animals. DCs were cultured with total 
OVA protein for 3 hrs prior to the addition of 1x105 CFSE labelled T cells to each well. (A) 
Representative plots showing purities of sorted populations. (B) cDCs were cultured with 3 mg/ml, 
whereas total pDCs were cultured with varying amounts of OVA protein, 0 mg/ml (green line), 1 
mg/ml (purple line), 3 mg/ml (blue line) and 5 mg/ml (red line). The ratio of DCs to T cells was 
decreased with the number of CFSE labelled T cells always remaining as 1x105. The frequency of 
T cells divided is the number of T cells that have divided more than three divisions, according to 
CFSE dilution n=1. 
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Figure 5-16: Ability of pDC subsets to stimulate CD4+ T cell proliferation. 
CCL2hi and CCL2lo pDCs were sorted from B16FL treated animals as indicated in Figure 5-9. 
Likewise, cDCs were also sorted from B16FL treated animals as B220-CD11c+ cells. Naïve 
CD4+CD62L+ OVA specific T cells were sorted from the spleen and LNs of OTII animals.1x105 DCs 
were cultured with 3 mg/ml total OVA protein for 3 hrs prior to the addition of 1x105 CFSE labelled 
T cells to each well. (A) Representative plots showing purities of sorted populations. (B) 
Representative CFSE dilution plots generated with cDCs (right hand panel), CCL2hi pDCs (middle 
panel) or CCL2lo pDCs (right hand panel) cultured with 3 mg/ml OVA. Gating is shown for each 
generation of divisions, plus the gating for more than three divisions. (C) Frequency of T cells 
divided more than three divisions when co-cultured with CCL2hi pDCs (black bars), CCL2lo pDCs 
(white bars), cDCs (grey bars) or T cells alone (red bars) at a ratio of 1:1 cultured with 3 mg/ml 
OVA. (D) The frequency of T cells in each generation of divisions when cultured with CCL2hi pDCs 
(black bars) and CCL2lo pDCs (white bars). Data were analysed by unpaired T-test (C) or two-way 
ANOVA with Bonferroni post-test (D) p<0.05 ** n=3 (mean + SD). 
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Figure 5-17: Ability of pDCs to stimulate CD8α+ T cell proliferation. 
Splenic pDCs were sorted from B16FL treated animals as indicated in Figure 5-9. Likewise, cDCs 
were also sorted from B16FL treated animals as B220-CD11c+ cells. Naïve CD8α+CD62L+ OVA 
specific T cells were sorted from the spleen and LNs of OTI animals. DCs were cultured with total 
OVA protein for 3 hrs prior to the addition of 1x105 CFSE labelled T cells to each well. cDCs were 
cultured with 3 mg/ml, whereas total pDCs were cultured with varying amounts of OVA protein, 0 
mg/ml (green line), 1 mg/ml (purple line), 3 mg/ml (blue line) and 5 mg/ml (red line). The ratio of 
DCs to T cells was decreased with the number of CFSE labelled T cells always remaining as 
1x105. The frequency of T cells divided is the number of T cells that have divided more than three 
divisions, according to CFSE dilution n=1. 
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Figure 5-18: Ability of pDC subsets to stimulate CD8α+ T cell proliferation. 
CCL2hi and CCL2lo pDCs were sorted from B16FL treated animals as indicated in Figure 5-9. 
Likewise, cDCs were also sorted from B16FL treated animals as B220-CD11c+ cells. Naïve 
CD8α+CD62L+ OVA specific T cells were sorted from the spleen and LNs of OTI animals.1x105 
DCs were cultured with 3 mg/ml total OVA protein for 3 hrs prior to the addition of 1x105 CFSE 
labelled T cells to each well. (A) Representative CFSE dilution plots generated with cDCs (right 
hand panel), CCL2hi pDCs (middle panel) or CCL2lo pDCs (right hand panel) cultured with 3 mg/ml 
OVA. Gating is shown for each generation of divisions, plus the gating for more than three 
divisions. (B) Frequency of T cells divided more than three divisions when co-cultured with CCL2hi 
pDCs (black bars), CCL2lo pDCs (white bars), cDCs (grey bars) or T cells alone (red bars) at a ratio 
of 1:1 cultured with 3 mg/ml OVA. (C) The frequency of T cells in each generation of divisions when 
cultured with CCL2hi pDCs (black bars) and CCL2lo pDCs (white bars). (D) Representative plots 
showing all cells present at the end of the 3 day culture of T cells with cDCs, CCL2hi pDCs or 
CCL2lo pDCs, illustrating that all B220-CD11c- cells are CD8α+. Data were analysed by unpaired T-
test (B) or two-way ANOVA with Bonferroni post-test (C) n=3 (mean + SD). 
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Figure 5-19: R848 enhances the ability of pDCs to stimulate CD8α+ T cell proliferation. 
CCL2hi and CCL2lo pDCs were sorted from B16FL treated animals as indicated in Figure 5-9. Naïve 
CD8α+CD62L+ OVA specific T cells were sorted from the spleen and LNs of OTI animals. pDCs 
were cultured with 3 mg/ml OVA protein for 3 hrs with or without 1 µg/ml R848 prior to the addition 
of 1x105 CFSE labelled T cells to each well. (A) Representative plots of CFSE dilution generated 
with CCL2hi and CCL2lo pDCs with or without 1 µg/ml R848. (B) Frequency of T cells divided more 
than three divisions when co-cultured with CCL2hi pDCs or CCL2lo pDCs cultured with 3 mg/ml 
OVA with R848 (white bars) or without R848 (black bars) at a ratio of 1:1 (pDC:T cells). (C&D) The 
frequency of T cells in each generation of divisions when cultured with CCL2hi pDCs (C) and 
CCL2lo pDCs (D) with R848 (white bars) or without R848 (black bars). n=3 (mean + SD). Data were 
analysed by unpaired T-test (B) or two-way ANOVA with Bonferroni post-test (C&D) p<0.05 * and 
p<0.001 ***. 
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Figure 5-20: mCCL2 has no effect on the ability of pDCs to stimulate CD8α+ T cell 
proliferation. 
CCL2hi and CCL2lo pDCs were sorted from B16FL treated animals as indicated in Figure 5-9. Naïve 
CD8α+CD62L+ OVA specific T cells were sorted from the spleen and LNs of OTI animals. pDCs 
were cultured with 3 mg/ml OVA protein for 3 hrs prior to the addition of 1x105 CFSE labelled T 
cells to each well. 0-25 nM unlabelled murine CCL2 was then added to the culture for 72 hrs. (A) 
Representative plots of CFSE dilution generated with CCL2hi (top row) and CCL2lo pDCs (bottom 
row) with 0 nM, 12.5 nM or 25 nM mCCL2 added to the culture media. (B) Frequency of T cells 
divided more than three divisions when co-cultured with a ratio of 1:1 CCL2hi pDCs (black bars) or 
CCL2lo pDCs (white bars) to T cells with 0, 12.5 or 25 nM unlabelled mCCL2 n=3 (mean + SD). 
Data were analysed by two-way ANOVA with Bonferroni post-test. 
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Figure 5-21: IFNα production by CCL2hi and CCL2lo pDCs. 
CCL2hi and CCL2lo pDCs were sorted from B16FL treated animals as indicated in Figure 5-9. 1x105 
pDCs were incubated with media alone, 10 µg/ml CpG-A or 10 µg/ml R848 for 8 hrs at 37oC. 
Cytokine production was assessed by ELISA and results show the mean IFNα production in pg/ml 
(n=3-9 from three independent experiments, mean + SD). Data were analysed by two-way ANOVA 
with Bonferroni post-test p<0.05 *. 
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Figure 5-22: Schematic representation of the potential effects of culture on gene expression. 
The potential profiles generated by plotting FC differences between CCL2hi pDCs vs. total pDCs, 
CCL2lo pDCs vs. total pDCs and CCL2hi pDCs vs. CCL2lo pDCs for each individual gene might be 
similar to one of the four graphical representations shown. (A&B) illustrate profiles that might be 
produced if the expression level of a gene was not affected by the incubation step, but was 
expressed at higher levels in CCL2hi (A) and CCL2lo pDCs (B). Profiles similar to those represented 
in (C) and (D) might be produced if expression of a gene found to be differentially expressed 
between CCL2hi and CCL2lo pDCs, but which had been affected by culture. 
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Figure 5-23: RNA quantity and quality from sorted pDCs. 
~2x106 pDCs were sorted from the spleens of B16FL tumour bearing mice, as designated in Figure 
5-9, as either total pDCs (named pDCs 1-4), CCL2hi pDCs (CCL2hi 1-3) or CCL2lo pDCs (CCL2lo 1-
3). RNA was extracted from the sorted cells and sent to the Glasgow University Polyomics Facility 
for analysis. (A) An example of a plot retrieved upon test of RNA integrity using the RNA 6000 
Nano kit with 1 µl of RNA. (B) Table illustrating the concentration of each RNA sample, plus the 
260/280 ratio and RIN. Crosses are present in the CCL2hi 3 and CCL2lo 3 samples because there 
was a malfunction of the chip, and no values could be retrieved. 
 Concentration (ng/ µl) 260/280 
RNA Integrity 
Number (RIN) 
pDC 1 44.48 2.07 9.8 
pDC 2 46.23 2.15 10 
pDC 3 42.28 2.21 10 
pDC 4 29.78 2.21 10 
CCL2hi 1 34.52 2.21 10 
CCL2hi 2 17.34 2.36 9.9 
CCL2hi 3 13.70 2.12 X 
CCL2lo 1 46.29 2.12 10 
CCL2lo 2 16.85 2.50 9.5 
CCL2lo 3 33.60 2.19 X 
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Figure 5-24: Gene differences between the two subsets of pDCs. 
The RNA samples from Figure 5-23 were subject to GC-RMA normalisation. The normalised 
values for each gene were used to calculate the FC in expression between the CCL2hi and CCL2lo 
samples. The samples were compared by one-way ANOVA with Storey’s multiple test correction. 
The data had restrictions applied to the resulting values, a standard cut-off of FC <-1.5 or >1.5 
between CCL2hi and CCL2lo pDCs samples. A further cut-off was added to the p-value p<0.005, 
which correlates to a q-value of 0.344. The heat-map shows normalised signal intensity of the 
gene. The expression value of each gene is mapped to a colour-intensity value, low relative 
expression shown in green and high relative expression in red. 
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Figure 5-25: Effect of incubation on the expression of genes by pDCs. 
The RNA samples from Figure 5-23 were subject to GC-RMA normalisation. The normalised 
intensity values for each gene were used to calculate the FC in expression between the total pDC, 
CCL2hi and CCL2lo samples. The samples were compared by one-way ANOVA with Storey’s 
multiple test correction. The FC differences between CCL2hi pDC vs. total pDCs, CCL2lo pDCs vs. 
total pDCs and CCL2hi vs. CCL2lo pDCs were plotted for each gene in Figure 5-24. A negative FC 
was plotted as a fraction, e.g. 1/-FC. (A) illustrates genes that had higher expression in CCL2hi 
pDCs compared to CCL2lo pDCs. (B) illustrates genes that had higher expression in CCL2lo pDCs 
than CCL2hi pDCs. Those genes specifically mentioned in the text of the Results section are 
indicated for clarity. 
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Figure 5-26: Alteration in gene expression by pDCs, as a consequence of culture. 
The FC differences between CCL2hi pDC vs. total pDCs, CCL2lo pDCs vs. total pDCs and CCL2hi 
vs. CCL2lo pDCs were plotted for all genes with a FC of <-3.0 or >3.0 between the CCL2hi pDCs 
and total pDCs. A further cut-off was added to the p-value p<0.005. A negative FC was plotted as a 
fraction, e.g. 1/- FC. Each gene was examined for its relative expression in cell types using 
Immgen. Genes with high expression in Langerhans cells (LCs) are shown in blue, high expression 
in cDCs (red) and high expression in cells other than LCs, pDCs and cDCs (black). Furthermore, 
genes that were expressed at a higher level in pDCs than LCs are shown in pink and genes with 
similar expression in pDCs and LCs are shown in green. The list of genes is shown in Appendix 1.
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 B 
Gene Symbol Protein encoded p-value FC Immgen 
Map3k14 Mitogen-activated protein kinase 14 0.0002851 1.95226 200 
Gpr174 G protein coupled receptor 174 0.000111972 -2.10444 120 
IL17rb Interleukin 17 receptor B 0.00010161 -1.60046 300 
Rarg Retinoic acid receptor gamma 0.000756156 1.67504 100 
CD200r1 CD200 receptor 1 0.00464454 2.1485 150 
Phf17 PHD finger 17 0.0000815 -1.73842 800 
Ephb2 EPH receptor B2 0.00103052 -1.91057 240 
Gbp4 Guanylate binding protein 4 0.00346687 -1.65053 400 
Cox6a2 Cytochrome c oxidase, subunit VI a, polypeptide 2 0.00146647 -1.50766 1500 
Ccr2 CCR2 0.00363969 3.26149 600 
Il13ra1 Interleukin 13 receptor alpha 1 0.000741429 2.94471 160 
Cysltr1 Cysteinyl leukotriene receptor 1 0.00376865 3.37213 30 
 
Figure 5-27: Final list of genes differences between the two pDC subsets. 
Subsequent to the analysis and restrictions applied to the samples as described in Figure 5-24, the 
apparent expression level of each gene in pDCs was determined according to Immgen. Genes that 
were not found to be expressed in pDCs, according to Immgen, were removed from the list in 
Figure 5-24, generating what shall be referred to as the final list of genes. (A) The heat-map shows 
normalised signal intensity of the gene. The expression value of each gene is mapped to a colour-
intensity value, low relative expression shown in green and high relative expression in red. (B) 
Table illustrating the final list of genes selected as quality controls for the microarray results. One-
way ANOVA was used to compare differences between CCL2hi and CCL2lo pDCs and the 
generated p-values and FC are indicated for each gene. In addition, the final column of the table 
illustrates an approximate value for the expression of each gene in pDCs according to Immgen. 
The values according to Immgen are post-normalisation expression values that have been subject 
to stringent quality control checks. Furthermore, microarray technology can produce background 
signals, thus Immgen performed statistical analysis to generate probabilistic thresholds of 
expression. According to Immgen values >120 have a ≥95% probability of being accurate, 50-120 
is equal to ~50% probability of being accurate and <47 is equivalent to ≥95% probability of the 
gene being silent (http://www.immgen.org/Protocols/ImmGen%20QC%20Documentation_ALL-
DataGeneration_0612.pdf). 
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Figure 5-28: Confirming differences in surface protein expression between the two pDC 
subsets, as detected by the microarray. 
pDCs from the spleen of B16FL treated WT animals (gated as described in Figure 5-1) were 
analysed for uptake of CCL2AF647 and expression of CD200R1 and IL-13Ra1. (A) Representative 
histograms showing staining of CD200R1 and IL-13Ra1 in CCL2hi (black line) and CCL2lo (purple 
line) pDC subsets, with appropriate isotype staining of CCL2hi (grey line) and CCL2lo (green line) 
pDC subsets. (B) Graphical representation of the calculated geometric mean fluorescence intensity 
(ΔMFI) of CD200R1 and IL-13Ra1 expression by B16FL treated WT animals. (C) Frequency of 
CCL2hi and CCL2lo pDCs in B16FL WT, untreated WT and untreated CD200R1 KO animals 
expressing CD200R1, as determined by flow cytometry. (D) Frequency of CCL2hi and CCL2lo pDCs 
in B16FL WT and untreated WT animals expressing IL-13Ra1, as determined by flow cytometry. 
Data are representative of a minimum of three biological replicates (mean + SD). Data were 
analysed by either unpaired T-test (B) or two-way ANOVA with Bonferroni post-test (C&D) p<0.05 
*, p<0.01 ** and p<0.001 ***. 
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Figure 5-29: Effect of IL-13 on CpG-C induced CCL2hi and CCL2lo pDC activation. 
Sorted CCL2hi and CCL2lo pDCs were incubated for 18 hrs with CpG-C and 0, 0.1 or 1.0 µg/ml of 
recombinant IL-13. (A) illustrates the differentiation of pDCs into SiglecHhi and SiglecHlo cells. The 
frequency of CD86+ (B) or ICOS-L+ (C) was determined for both SiglecHhi and SiglecHlo cells, in 
addition to unsorted pDCs gated as depicted in Figure 5-9, which were a homogeneous population 
for SiglecH expression. The effect of IL-13 on the activation status of CCL2hi and CCL2lo was 
determined, by calculating the frequency of each subset expressing CD86 (D) and ICOS-L (E). (F) 
The relative proportions of SiglecHhi and SiglecHlo cells was determined within the CCL2hi and 
CCL2lo subsets, and the effect of IL-13 on the relative proportions was determined. (G) The 
percentage of live cells was determined and the effect of IL-13 on the frequency of live cells was 
determined. Data are representative of 3-5 biological replicates from two independent experiments 
(mean + SD). Data were analysed by two-way ANOVA with Bonferroni post-test p<0.05 *, p<0.01 
** and p<0.001 ***. 
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Figure 5-30: Strain differences in the two subsets of pDCs based on CCL2AF647. 
pDCs from the spleen (A), BM (B), blood (C), MLNs (D) and PLNs (E) of WT (black), D6 KO (blue) 
and CCR2 KO (red) were gated as described in Figure 5-1, and analysed for uptake of CCL2AF647. 
In some tissues there are two histogram overlays shown illustrating the two different phenotypes in 
CCL2AF647 uptake in D6 KO. Plots are representative of a minimum of three biological replicates. 
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Figure 5-31: Strain differences in the expression of surface markers by total splenic pDCs in 
WT, D6 KO and CCR2 KO. 
pDCs from spleen were gated as described in Figure 5-1. (A) The frequency of live pDCs 
expressing markers was determined by using FMOs to set the negative gate. FMOs consisted of 
the pDC stain described in Figure 5-1, plus the isotype for the marker of interest. Any signal 
detected above the FMO samples was considered positive. (B) Representative histogram overlays 
of the surface markers that were found to be differentially expressed by splenic pDCs from WT 
(black), D6 KO (blue) and CCR2 KO (red). Also included is CCR7 expression by all live 
splenocytes. (C) Geometric mean fluorescence intensity (Δ MFI) of markers with significant 
differences in expression between the mice strains in (A). n=3 (mean + SD). Data were analysed 
by one-way ANOVA with Tukey post-test p<0.05 *, p<0.01 ** and p<0.001 ***. 
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Figure 5-32: Strain differences in the expression of surface markers by total BM pDCs in 
WT, D6 KO and CCR2 KO. 
pDCs from BM were gated as described in Figure 5-1. (A) The frequency of live pDCs expressing 
markers was determined by using FMOs to set the negative gate. FMOs consisted of the pDC stain 
described in Figure 5-1, plus the isotype for the marker of interest. Any signal detected above the 
FMO samples was considered positive. (B) Representative histogram overlays of the surface 
markers that were found to be differentially expressed by BM pDCs from WT (black), D6 KO (blue) 
and CCR2 KO (red). Also included is CCR7 expression by all live BM cells. (C) Geometric mean 
fluorescence intensity (Δ MFI) of markers with significant differences in expression between the 
mice strains in (A). n=3 (mean + SD). Data were analysed by one-way ANOVA with Tukey post-
test p<0.05 *, p<0.01 ** and p<0.001 ***. 
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Figure 5-33: No strain differences in the absolute number of splenic and BM pDCs. 
The absolute number of splenic (A) and BM (B) pDCs was determined in untreated WT, D6 KO and 
CCR2 KO animals (n=3-6 mean + SD). pDCs were gated as depicted in Figure 5-9. Data were 
analysed by one-way ANOVA with Tukey post-test. 
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Figure 5-34: Effect of imiquimod treatment on pDC numbers in the skin. 
The dorsal skin of WT and CCR2 KO animals was treated topically with imiquimod for 7 days 
before harvest on the 8th day. (A) Following exclusion of doublets, live cells were gated as CD45+, 
then Ly6C+CD11b- and finally SiglecH+. Representative plots of pDC gating in WT control 
(untreated) animals and imiquimod treated animals. (B) The absolute number of skin pDCs was 
determined in imiquimod treated WT and CCR2 KO animals, and the red line illustrates absolute 
number of pDCs in the skin of a WT control animal (n=5-9 mean + SD). Data were analysed by 
Mann Whitney T test p<0.05 *. 
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Figure 5-35: Effect of imiquimod treatment on inguinal LN pDCs. 
The dorsal skin of WT and CCR2 KO animals was treated topically with imiquimod for 7 days 
before harvest on the 8th day. (A) Following exclusion of doublets, live cells were gated as 
B220+CD11c+, Ly6C+CD11b- and finally SiglecH+. (A) Representative plots of pDC gating in WT 
control (untreated) animals and imiquimod treated animals. (B) The absolute number of inguinal LN 
pDCs was determined in imiquimod treated WT and CCR2 KO animals, and the red line illustrates 
absolute number of pDCs in the inguinal LNs of a WT control animal. (C) Representative 
histograms of CCL2AF647 uptake by pDCs from imiquimod treated WT (black line) and CCR2 KO 
cells (shaded purple area without competition, and WT (blue line) and CCR2 KO (green line) 
samples competed with 10-fold molar excess of mCCL22. (D) The proportion of CCL2hi and CCL2lo 
pDCs was determined (n=9 mean + SD). Data were analysed by Mann Whitney T-test (B) or two-
way ANOVA with Bonferroni post-test (D) p<0.001 ***. 
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Figure 5-36: Effect of imiquimod treatment on splenic pDCs. 
The dorsal skin of WT and CCR2 KO animals was treated topically with imiquimod for 7 days 
before harvest on the 8th day. (A) Following exclusion of doublets, live cells were gated as 
B220+CD11c+, Ly6C+CD11b- and finally SiglecH+. (A) Representative plots of pDC gating in WT 
control (untreated) animals and imiquimod treated animals. (B) The absolute number of splenic 
pDCs was determined in imiquimod treated WT and CCR2 KO animals, and the red line illustrates 
absolute number of splenic pDCs in a WT control animal. (C) Representative histograms of 
CCL2AF647 uptake by pDCs from imiquimod treated WT (black line) and CCR2 KO cells (shaded 
purple area without competition, and WT (blue line) and CCR2 KO (green line) samples competed 
with 10-fold molar excess of mCCL22. (D) The proportion of CCL2hi and CCL2lo pDCs was 
determined (n=9 mean + SD). Data were analysed by Mann Whitney T-test (B) or two-way ANOVA 
with Bonferroni post-test (D) p<0.001 ***. 
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Figure 5-37:	  Effect of imiquimod treatment on BM pDCs. 
The dorsal skin of WT and CCR2 KO animals was treated topically with imiquimod for 7 days 
before harvest on the 8th day. (A) Following exclusion of doublets, live cells were gated as 
B220+CD11c+, Ly6C+CD11b- and finally SiglecH+. (A) Representative plots of pDC gating in CCR2 
KO control (untreated) animals and imiquimod treated animals. (B) The absolute number of BM 
pDCs was determined in imiquimod treated WT and CCR2 KO animals, and the red line illustrates 
absolute number of BM pDCs in a CCR2 KO control animal. (C) Representative histograms of 
CCL2AF647 uptake by pDCs from imiquimod treated WT (black line) and CCR2 KO cells (shaded 
purple area without competition, and WT (blue line) and CCR2 KO (green line) samples competed 
with 10-fold molar excess of mCCL22. (D) The proportion of CCL2hi and CCL2lo pDCs (n=5 mean + 
SD). Data were analysed by unpaired T-test (B) or two-way ANOVA with Bonferroni post-test (D) 
p<0.001 ***. 
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Figure 5-38: Effect of imiquimod treatment on blood pDCs. 
The dorsal skin of WT and CCR2 KO animals was treated topically with imiquimod for 7 days 
before harvest on the 8th day. (A) Following exclusion of doublets, live cells were gated as 
B220+CD11c+, Ly6C+CD11b- and finally SiglecH+. (A) Representative plots of pDC gating in CCR2 
KO control (untreated) animals and imiquimod treated animals. (B) The absolute number of blood 
pDCs was determined in imiquimod treated WT and CCR2 KO animals, and the red line illustrates 
absolute number of blood pDCs in a CCR2 KO control animal. (C) Representative histograms of 
CCL2AF647 uptake by pDCs from imiquimod treated WT (black line) and CCR2 KO cells (shaded 
purple area without competition, and WT (blue line) and CCR2 KO (green line) samples competed 
with 10-fold molar excess of mCCL22. (D) The proportion of CCL2hi and CCL2lo pDCs (n=5 mean + 
SD). Data were analysed by unpaired T-test (B) or two-way ANOVA with Bonferroni post-test (D) 
p<0.001 ***. 
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Chapter 6 – Discussion 
6.1 Introduction 
The immune system is continually responding to challenges by pathogens and 
tissue damage through direct interactions with both self and foreign Ag. The 
location of the immune cells facilitates and coordinates such responses, and 
plays an important role in dictating their outcome. The migration and 
organisation of immune cells is tightly policed by the chemokine system, which 
is broadly divided into two functional groups, homeostatic and inflammatory 
chemokines. Homeostatic chemokines are involved in the development of the 
immune system, and its maintenance. They also facilitate the migration of cells 
around resting tissues. In contrast, inflammatory chemokines mediate the 
migration of immune cells to sites of inflammation. Produced upon inflammatory 
insult, they aid in the initiation of the immune response and its resolution. 
However, some inflammatory chemokine receptors, such as CCR2, also possess 
homeostatic roles e.g. mobilisation of Ly6Chi monocytes from the BM (Serbina 
and Pamer, 2006). These specialised and fundamental roles of chemokines 
demonstrate the importance of accurately profiling chemokine receptor 
expression. With a detailed and reliable picture of receptor expression we can 
further the understanding of the function of particular immune cells. However, 
in the case of many murine receptors, including CCR2 and D6, there is limited 
knowledge of their expression profiles mainly due to poor sensitivity of available 
reagents. Therefore, to achieve the original aim of this project (determining 
how CCR2 contributes to the regulation of its ligands through chemokine 
scavenging), a comprehensive flow cytometric characterisation of CCR2 and D6 
expression by mouse leukocytes was required. The data generated from these 
experiments altered the direction of my project, and my subsequent aims were 
to explore the regulation, specificity and function of CCL2 receptors on these 
cell populations. 
6.2 Expression of CCR2 in steady-state animals 
Most studies that provide information about CCR2 expression do so by monitoring 
transcript levels or by detecting cell surface levels of CCR2 protein using 
antibodies. Determining the level of transcript provides some indication about 
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where CCR2 is expressed, however without quantification of expression it is 
difficult to determine relative level of expression between tissues or cell types. 
Data generated by the Immunological Genome Project can provide details of 
CCR2 transcript levels in cell populations relative to others. Alternatively, 
numerous studies published throughout the duration of this PhD have been 
conducted using CCR2 reporter mice, CCR2-GFP or CCR2-RFP, these have 
provided information about CCR2 expression on individual cells by both flow 
cytometry and analysis of tissue sections (Saederup et al., 2010; Mizutani et al., 
2011; Shi et al., 2011; Jarchum et al., 2012). 
6.2.1 Antibody mediated detection of CCR2 
In the initial experiments described in Chapter 3, the surface levels of CCR2 was 
defined using two commercially available antibodies and the most commonly 
used anti-mouse CCR2 antibody, MC-21. Both commercial antibodies were tested 
at a range of concentrations and incubation times, but they failed to detect 
CCR2 on BM cells (Figure 3-1). In contrast, MC-21 could detect CCR2 expression 
in the spleen, BM and blood. The majority of CCR2 specific staining was limited 
to Ly6C+ cell populations (Figure 3-3). The antibody had high levels of non-
specific background staining, as staining profiles of WT and CCR2 KO samples 
were very similar in most cell populations. This was despite the low level of 
staining with isotype control antibodies suggesting that many of these 
populations contained MC-21+ (i.e. CCR2+) subsets (Figure 3-4). Thus, a 
comparison of MC-21 staining of WT cells to isotype staining alone, without the 
use of MC-21-stained CCR2 KO controls, could lead to the generation of false 
positives. For example, BM and blood neutrophils, in the absence of CCR2 KO 
samples, would be considered to be CCR2+. This could perhaps explain some of 
discrepancies that have been reported in CCR2 expression by neutrophils, with 
some groups reporting neutrophils to be CCR2+ and others CCR2- (Maus et al., 
2003; Reichel et al., 2006; Souto et al., 2011). 
MC-21 has been used in many studies to assess CCR2 expression, including 
studies that included the necessary CCR2 KO controls. For example, Maus et al. 
showed that F4/80+ cells in the peripheral blood of mice had specific staining of 
CCR2, which was absent in CCR2 KOs (Maus et al., 2003). Therefore, even though 
MC-21 was tested at a number of different concentrations, there is a possibility 
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that the poor surface CCR2 detection revealed by the WT/CCR2 KO comparison 
might result from the suboptimal performance of the batch of MC-21 utilised in 
these experiments. To resolve this issue, further experiments with new MC-21 
batches would be required. The difficulties encountered using this non-
commercially available antibody, highlights the requirement of a new technique 
for the robust and reliable detection of CCR2. 
6.2.2 Profiling CCL2 receptor activity using the CCL2AF647 assay 
The failure of commercial antibodies to reliably detect CCR2, plus the apparent 
risk of generating false positives using MC-21, meant that previous profiling 
completed in the absence of CCR2 KO controls might have painted a false 
picture of CCR2 expression within the immune system. Furthermore, MC-21 has 
also been used to validate both the CCR2-GFP and CCR2-RFP reporter mice, 
illustrating that the majority, but not all, GFP+ or RFP+ cells were also positive 
for staining with MC-21 (Hohl et al., 2009; Saederup et al., 2010). This means 
that CCR2 transcript levels might not fully correlate with CCR2 surface levels. I 
developed a novel approach using fluorescently labelled human CCL2 that would 
facilitate the accurate identification of CCR2-, CCR2lo and CCR2hi cells. CCR2 is 
not the only CCL2 binding receptor, as the atypical chemokine receptor D6 can 
also bind CCL2. Thus appropriate controls are required to distinguish CCR2 
activity from D6. The use of mCCL22 to compete D6 activity was specific and not 
simply due to the addition of surplus chemokine, as competition with a non-D6 
ligand, mCCL19 had no affect on D6 dependent uptake of CCL2AF647 (Figure 3-6). 
mCCL7 competition on the other hand can be used to specifically identify CCR2 
mediated uptake, as it is a ligand for CCR2 but not D6. However, as I shall 
discuss later in section 6.4.1, CCR2 on different cell types can have different 
affinities for mCCL7. The assay also determined that in all tested tissues, 
including the spleen, BM, LN and blood, the majority of CCL2AF647 uptake was 
CCR2 dependent, with only low levels of D6 activity detected. 
Within the BM and blood samples of the CCR2 KO mice there was a population of 
cells, defined as Ly6C+CCL2lo (BM) or Ly6C+CCL2+ (blood) that exhibited some 
non-specific uptake of CCL2AF647, in that it could not be completely competed by 
mCCL22 (Figure 3-7) or numerous other CC ligands, including mCCL2 (Figure 3-
8). D6 ligands caused a small reduction in CCL2AF647 uptake that was not present 
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when uptake was competed with non-D6 ligands, such as mCCL7, mCCL8, 
mCCL19 or mCCL21. DARC has also been shown to strongly bind CCL2, however it 
is unlikely to be responsible for the CCR2/D6 independent uptake of CCL2AF647, as 
mCCL7, the only tested DARC ligand that does not also bind to D6, did not 
compete CCL2AF647 uptake (Hansell et al., 2011a). Therefore, the remaining 
uptake present in CCR2 KO samples following competition with a D6 ligand is 
probably non-specific uptake, perhaps involving pinocytosis. This indicates a 
caveat of the assay design, as some cells, particularly myeloid cells with 
phagocytic capabilities, might internalise CCL2AF647 non-specifically, i.e. 
independently of CCR2, D6 or other unknown CCL2 receptors that might exist. 
Although this might complicate the issue of detecting CCR2 and D6 activity on 
highly phagocytic cells, with the appropriate controls (e.g. CCR2 KO and mCCL22 
competition) it should still be feasible to detect both CCR2 and D6. We would 
expect the level of inhibition of CCL2AF647 uptake to vary between cell types, 
with cells with phagocytic potential possessing higher background levels of 
CCL2AF647 uptake. 
Using this methodology I have completed a comprehensive analysis of CCR2 and 
D6 expression in cells of the spleen, PLNs, BM and blood. This data is 
summarised in Tables 6-1 to 6-4 and discussed in more detail in the following 
sections. 
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Name Identification CCR2 D6 Systemic Inflammation  
   WT KO  
Monocytes Ly6ChiGr1loCD11b+ ++++ - -  
Neutrophils Ly6CloGr1hiCD11b+ - - - ↑ D6 in WT and KO 48 and 72 hrs after LPS. 
NK cells DX5+ +++ - - D6 activity in both WT and KO 48 hrs after LPS. 
pDCs B220
+CD11c+Ly6C+ 
CD11b- +++ + + 
↑ D6 in WT and KO 48 and 
72 hrs after LPS. No CCR2 
activity at 72 hrs. 
CD11b+ cDCs CD11c
hiMHCIIhiCD8α-
CD11b+ ++ - -  
CD8α+ cDCs CD11c
hiMHCIIhiCD8α+ 
CD11b- ++ + - 
D6 activity in both WT 
and KO 48 hrs after LPS.  
Macrophages* CD11b+F4/80+ + ND +  
CD4+ T cells* CD3+CD8- + ND -  
CD8+ T cells* CD3+CD8+ + ND -  
γδ T cells* γδ+ + ND -  
MZ-B cells CD19
+IgMhiIgDlo 
CD21+ - + + 
↑ D6 in WT and KO 48 and 
72 hrs after LPS. 
B cells* CD19+ - ND +  
Table 6-1: CCR2 and D6 activity of splenic leukocyte populations. 
Expression of CCR2 was examined by comparing CCL2AF647 uptake profiles in WT and CCR2 KO. 
Expression of D6 was examined in both WT and CCR2 KO cells by competition of CCL2AF647 
uptake with mCCL22. Expression of CCR2 and D6 is denoted by +, whereby + signifies low levels 
and ++++ signifies high levels; - denotes lack of activity; ND indicates that D6 activity was not 
determined on WT cells. Splenic populations were also examined for the effect of LPS on CCR2 
and D6 activity. * indicates populations that were not examined for the effect of LPS on CCL2 
receptor activity. All analysed CCR2+ populations, except pDCs had a decrease in CCR2 activity 
24 hrs after LPS, which was restored or upregulated 48 hrs after LPS treatment. In addition, in the 
absence of CCR2 all populations had a significant upregulation of D6, which was limited to 48 hrs 
after LPS treatment. Comments in the systemic inflammation column describe alterations to D6 
activity following LPS treatment. 
Name Identification CCR2 D6 
   WT KO 
γδ T cells CD3-CD19-γδ+ + ND - 
αβ T cells CD3+CD19- - ND - 
B cells CD19+MHCII+ - ND - 
Migratory cDCs CD11c+MHCIIhi - ND - 
Resident cDCs CD11c+MHCIIlo +++ ND - 
pDCs B220+CD11c+Ly6C+CD11b- +++ + + 
Table 6-2: CCR2 and D6 activity of PLN leukocyte populations. 
Expression of CCR2 was examined by comparing CCL2AF647 uptake profiles in WT and CCR2 KO. 
Expression of D6 was examined in both WT and CCR2 KO cells by competition of CCL2AF647 
uptake with mCCL22. Expression of CCR2 and D6 is denoted by +, whereby + signifies low levels 
and ++++ signifies high levels; - denotes lack of CCL2 receptor activity; ND indicates that D6 
activity was not determined on WT cells. 
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Name Identification CCR2 D6 
   WT KO 
Monocytes Ly6C+Gr1loCD11b+CD115+ ++++ + + 
Neutrophils Ly6C+Gr1hiCD11b+CD115- - ND - 
Population A Ly6CloGr1loCD11b+CD115+ ++++ ND + 
Population B Ly6C+Gr1loCD11b+CD115- - ND - 
Population C Ly6CloGr1loCD11b+CD115- - ND - 
B cells B220+CD11c- - ND - 
pDCs B220+CD11c+Ly6C+CD11b- +++ + + 
CD11c+ cells B220-CD11c+ ++ ND + 
Table 6-3: CCR2 and D6 activity of BM leukocyte populations. 
Expression of CCR2 was examined by comparing CCL2AF647 uptake profiles in WT and CCR2 KO. 
Expression of D6 was examined in both WT and CCR2 KO cells by competition of CCL2AF647 
uptake with mCCL22. Expression of CCR2 and D6 is denoted by +, whereby + signifies low levels 
and ++++ signifies high levels; - denotes lack of CCL2 receptor activity; ND indicates that D6 
activity was not determined on WT cells. 
Name Identification CCR2 D6 
   WT KO 
Monocytes Ly6C+Gr1loCD11b+CD115+ ++++ - - 
Neutrophils Ly6C+Gr1hiCD11b+CD115- - ND - 
Population A Ly6CloGr1loCD11b+CD115+ +++ ND - 
Population B Ly6C+Gr1loCD11b+CD115- ++++ ND - 
Population C Ly6CloGr1loCD11b+CD115- - ND - 
B cells B220+CD11c- - ND - 
pDCs B220+CD11c+Ly6C+CD11b- +++ + + 
CD11c+ cells B220-CD11c+ +++ ND - 
Table 6-4: CCR2 and D6 activity of blood leukocyte populations. 
Expression of CCR2 was examined by comparing CCL2AF647 uptake profiles in WT and CCR2 KO. 
Expression of D6 was examined in both WT and CCR2 KO cells by competition of CCL2AF647 
uptake with mCCL22. Expression of CCR2 and D6 is denoted by +, whereby + signifies low levels 
and ++++ signifies high levels; - denotes lack of CCL2 receptor activity; ND indicates that D6 
activity was not determined on WT cells. 
6.2.2.1 Myeloid cells 
The majority of CCR2 dependent uptake was associated with cells of the innate 
immune system CCR2 activity was highest on Ly6Chi monocytes in all tested 
tissues and, consistent with published observations using CCR2 reporter mice, 
these cells were uniformly positive for CCR2 (Serbina et al., 2009; Saederup et 
al., 2010; Lewis et al., 2011). In all other cell populations none, or only a 
fraction of cells, became CCL2+ after CCL2AF647 uptake. This is consistent with 
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published results and data presented in this thesis using the MC-21 antibody 
(Mack et al., 2001). The expression of a chemokine receptor by a proportion of a 
cell population has often segregated that cell population into functionally 
distinct subsets. For example, CCR2 expression by monocytes can delineate the 
inflammatory and “resident” monocyte populations (Geissmann et al., 2003; 
Serbina and Pamer, 2006) and CCR9 is used as a marker of tolerogenic pDCs 
(Hadeiba et al., 2008; Björck et al., 2011; Schlitzer et al., 2011). Therefore, the 
presence of CCR2 activity on a proportion of each population might delineate a 
functionally distinct subset of these cells. Furthermore, expression of CCR2 
might lead to differences in the migratory potential of the two subsets of cells, 
and perhaps the presence of CCR2 alters their localisation in the spleen and LN 
before or during inflammation. 
Both the Ly6Chi and Ly6Clo populations of monocytes have been reported to give 
rise to macrophages (Yona and Jung, 2010). Inflammatory Ly6Chi monocytes 
express CCR2 and are recruited to sites of inflammation, where they 
differentiate into macrophages that are important in the clearance of 
pathogens. The differentiation of human peripheral blood CCR2+CD14+ 
inflammatory monocytes into macrophages has been reported to cause a 
decrease in CCR2 expression, both at the level of mRNA and surface protein. The 
decrease in CCR2 was associated with a parallel decrease in functional responses 
to CCL2, such as chemotaxis (Fantuzzi et al., 1999). However, splenic 
macrophages and other tissue resident macrophages, such as microglia are 
reported to arise from the differentiation of Ly6CloCCR2- monocytes (Gordon and 
Taylor, 2005). In addition, a recent report indicates that many macrophages 
develop independently of haematopoietic stem cells, as they originate from the 
yolk sac (Schulz et al., 2012). Examination of CCR2 transcript levels showed that 
yolk sac macrophages are CCR2-, and only a proportion of haematopoietic stem 
cell derived macrophages are CCR2+ (Schulz et al., 2012). Consistent with these 
observations, my results indicate that only a small proportion of splenic 
macrophages (~12%) are CCL2+ (Figure 3-10), which is significantly lower than 
the percentage of CCL2+ monocytes (~85%). Furthermore, in contrast to 
monocytes, splenic macrophages also possessed low levels of D6 activity (Figure 
3-10). 
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Results presented in this thesis demonstrate that neutrophils in unchallenged 
animals in the tested tissues do not internalise CCL2AF647 indicating that they do 
not possess active CCR2 or D6 (Figures 3-10, 3-12 and 3-14). However, 
neutrophils were the only splenic cell population to show no CCL2 uptake 
activity at all, and even small numbers of lymphocytes including B and T cells 
internalised CCL2AF647 via CCR2.  However, it should be noted that the assay only 
provides information about functionally active receptors, as CCL2AF647 must be 
both bound and internalised by CCR2, therefore it cannot be excluded that 
neutrophils express inactive CCR2 that does not internalise CCL2AF647. 
6.2.2.2 B cells 
In accordance with observations published from the Nibbs lab during the course 
of my studies (Appendix 2), a large proportion, if not all of the observed splenic 
D6 dependent uptake was associated with MZ-B cells (Hansell et al., 2011b). PLN 
B cells did not possess detectable D6 activity, presumably due to the low 
abundance and absence of D6 expressing B1 B cells and MZ-B cells, respectively 
in the LN (Hansell et al., 2011b) (Figure 3-13). However, in contrast to published 
observations (Hansell et al., 2011b) D6 activity was not detected on BM (Figure 
3-12) and blood (Figure 3-14) B cells. The inconsistency between the published 
observations and my results might be due to a strain difference. Here I examined 
D6 activity in the total B cell population in CCR2 KO animals and found that B1 B 
cells in the blood and BM of CCR2 KO mice do not possess D6 activity, whereas 
Hansell et al. examined D6 activity in WT mice (Hansell et al., 2011b). However, 
further work to delineate the B cell populations in the BM and blood of CCR2 KO 
animals would need to be performed in order to confirm this. Although D6 
activity was not found on B cells in any tissue, other than the spleen, there were 
significant levels of D6 detected on other cell populations in each tissue e.g. 
pDCs in each tissue possessed both CCR2 and D6 (Figure 5-3). 
There was a very small population of CCR2+ B cells within the spleen (Figure 3-
6), BM (Figure 3-12) and blood (Figure 3-13), which was not present in the LNs 
(Figure 3-13). Upon examination of the physical properties of these cells they 
were much larger than typical lymphocytes. Doublet cells had been excluded 
from the analysis so it is unlikely that they were doublets consisting of a B cell 
and a CCR2+ cell. One possibility is that they could be plasmablasts, due to 
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previous evidence of CCR2 expression by plasma cells (Delogu et al., 2006). In 
fact, CCR2 has been reported to play a vital role in plasma cell differentiation. 
Pax5 is a transcription factor that represses lineage inappropriate genes, 
including CCR2, whilst activating B cell specific genes in B cells. Deletion of Pax5 
leads to a deficiency in B cells, as in its absence lineage inappropriate genes, 
such as myeloid and T cell genes are reactivated. Using chimeric mice that were 
reconstituted with a 1:1 mixture of BM from mice deficient in CCR2 and Pax5, 
Delogu et al. showed that mice formed normal germinal centres, but had 
impaired immune responses, demonstrated by a decrease in Ag specific IgG1 in 
serum, indicating a requirement of CCR2 for normal plasma cell function (Delogu 
et al., 2006). However, it should be noted that in this study there were only 2 
CCR2 KO biological replicates (Delogu et al., 2006). Plasmablasts have low 
expression of CD19 (Delogu et al., 2006), however I found that total B cells and 
the CCR2+ B cell population did not possess any significant differences in their 
CD19 expression, as quantified by comparison of CD19 ΔMFI (data not shown). 
This would suggest that these cells are not plasmablasts. 
6.2.2.3 Populations A, B and C 
Several populations of cells of uncertain origin, and designated Population A, B 
and C, were identified in the BM (Figure 3-12) and blood (Figure 3-13) of WT and 
CCR2 KO mice. Each population was characterised by differences in the 
expression of four markers: Ly6C, CD11b, Gr1 and CD115. Population A was 
identified as CD115+CD11b+Ly6CloGr1lo in both the BM and blood. In these tissues 
Population A had high levels of CCR2 dependent uptake of CCL2AF647, but CCR2 
activity was lower in the blood (~50% CCL2+) than the BM (~85% CCL2+), with an 
overall decrease in the level of CCL2AF647 uptake observed on a cell-by-cell basis. 
BM and blood Population A cells had similar physical properties to Ly6Chi 
monocytes. Their expression of CD115 firmly points to a monocytic origin, 
indicating that they could Ly6Clo monocytes or monocytes of intermediary 
phenotype (Ly6Cinter monocytes), which are produced during the conversion of 
Ly6Chi monocytes into Ly6Clo monocytes. This conversion results in the 
downregulation of both CCR2 and Ly6C, and the parallel acquisition of higher 
levels of CX3CR1 (Sunderkötter et al., 2004; Serbina and Pamer, 2006; Tacke and 
Randolph, 2006). There is controversy surrounding the tissue in which this 
conversion occurs. Some groups report that Ly6Chi monocytes, in the absence of 
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inflammation, traffic back to the BM were they are converted into Ly6Clo 
monocytes (Varol et al., 2007; Shi and Pamer, 2011). In contrast, others report 
that this conversion occurs in the blood, and that the BM monocyte population is 
almost exclusively composed of Ly6Chi monocytes (Sunderkötter et al., 2004; 
Gordon and Taylor, 2005). The data presented here supports the second 
observation, as limited numbers of cells from Population A were observed in the 
BM, while their numbers increased in the blood. Furthermore, CCR2 activity of 
the population, although reduced in comparison to BM Ly6Chi monocytes, was 
further reduced in the blood. 
Cells from Population B were Gr1loCD115-CD11b+Ly6C+. The expression of Gr1 
increases with maturation of neutrophils, thus immature neutrophils can be 
identified as Gr1loCD115- (Hestdal et al., 1991). In the BM, Population B cells 
may represent immature neutrophils, as this population had little CCR2 activity, 
which is consistent with the absence of CCR2 activity on mature neutrophils. 
However, the physical properties of these cells suggest they are more monocyte-
like than neutrophil-like. Furthermore, Population B in the blood had high levels 
of CCR2 activity, similar to the profiles produced by Ly6Chi monocytes. The only 
observed difference in the surface immunophenotype of Population B in the 
blood and Ly6Chi monocytes was their expression of CD115. I was unable to 
identify this population in the spleen, as, in my hands, anti-CD115 did not stain 
splenic monocytes. Anti-CD115 antibodies have been used by others to 
successfully identify resting (Swirski et al., 2009) or activated (Drutman et al., 
2012) splenic Ly6Chi monocytes, but my data would at least suggest that CD115 is 
reduced on splenic Ly6Chi monocytes. 
CD115 is typically considered to be a monocyte marker, as it is crucially involved 
in their development (Auffray et al., 2009). However, recently Rose et al. 
described the identification of a population of CD115- splenic 
monocytes/macrophages (Rose et al., 2011). Therefore, it is possible that 
Population B are CD115- monocytes, and that their emigration from the BM is 
accompanied by a large increase in CCR2 activity. Alternatively, these cells 
might not be monocytes, but a precursor that upon entry in the periphery 
mature and acquire CCR2 activity. The splenic pre-cDC population that was 
discussed in the Introduction (section 1.5.1) has a similar surface phenotype. 
Splenic pre-cDCs have been identified as CD11c+CD11bloF4/80loLy6C+Ly6G- and 
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the same population was shown to exist in the blood (Naik et al., 2006). The pre-
cDCs were not examined for CD115 expression, or Gr1. However, anti-Gr1 binds 
to both Ly6C and Ly6G, expressed by monocytes and neutrophils, respectively 
(Daley et al., 2008). Naik et al. illustrated that the pre-cDCs were Ly6C+ and 
Ly6G- (Naik et al., 2006), thus perhaps the low expression of Gr1 detected on 
Population B is explained by the presence of only Ly6C on these cells. Both of 
these theories suggest that BM Population B cells are developmental precursors 
of blood Population B cells and that their maturation is accompanied by an 
increase in CCR2 activity. Si et al. have examined surface expression of CCR2 
during the differentiation of BM haematopoietic stem cells and haematopoietic 
progenitors (Si et al., 2010). According to staining with MC-21, BM 
haematopoietic stem cells and haematopoietic progenitor cells express CCR2 and 
their differentiation along the myeloid lineage is accompanied by an increase in 
CCR2 expression (Si et al., 2010). These observations, and the lack of CD115 
expression by BM Population B, make it unlikely that they are of myeloid 
lineage. Therefore, BM and blood Population B cells might not be linked 
developmentally. Population B in the blood might derive from Ly6Chi monocytes 
that have lost their expression of CD115. Further investigations into the surface 
phenotype and function of these cells are required to prove the identity of cells 
within Population B. 
Population C was identified in the blood and BM as Ly6CloCD11b+Gr1loCD115-. 
These cells did not possess significant levels of CCR2 or D6 activity in either 
tissue or possess physical characteristic that were similar to monocytes, 
neutrophils or lymphocytes. They were very large granular cells. The physical 
properties and surface phenotype of these cells suggest that they might be 
eosinophils, as Rose et al. have identified eosinophils as 
SSChiCD11b+Ly6CinterGr1inter cells (Rose et al., 2011). Confirmation of the identity 
of these cells as eosinophils could be gained by examining their expression of the 
eosinophil specific marker SiglecF (Zhang et al., 2007). 
6.2.2.4 Population D and CD11c+MHCII- cells 
Two additional populations of cells whose identity was uncertain were found in 
the spleen of both WT and CCR2 KO animals. These were named Population D 
(Figure 5-1) and CD11c+MHCII- cells (Figure 3-11). Both populations had high 
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levels of CCR2 dependent CCL2AF647 uptake and Population D also possessed low 
levels of D6. In Chapter 5 I have already speculated over the identity of 
Population D, suggesting that it might contain a subset of NK cells. Blasius et al. 
have identified an NK cell subset that is B220+CD11c+NK1.1+CD11b+ (Blasius et 
al., 2007). Population D cells were identified as B220+CD11c+Ly6C+/-CD11b+/- 
cells (i.e. heterogeneous for CD11b and Ly6C) but importantly were negative for 
the pDC markers, PDCA1 and SiglecH. These observations have important 
implications in the identification of pDCs, because they indicate that 
B220+CD11c+ gating alone is not sufficient to identify pDCs. Such a population 
would be substantially contaminated by cells lacking SiglecH and PDCA1, which I 
would not consider to be pDCs. The results presented in Chapter 3 have 
illustrated that NK cells have high levels of CCR2 activity (Figure 3-9), a feature 
that fits with the description of Population D. However, NK cells identified as 
simply DX5+ did not possess any D6 activity. Therefore, D6 activity might be 
limited to the B220+CD11c+NK1.1+ subset of NK cells. DX5 was originally 
considered to be a pan-NK cell marker but has also been shown to be expressed 
by basophils (Arase et al., 2001; Obata et al., 2007). However, the observed 
uptake can be assigned to NK cells due to the physical properties of the cells, as 
they were similar in size to lymphocytes, rather than the larger basophils. 
Initial investigations into the surface phenotype of CD11c+MHCII- cells suggest 
the population contains a mix of several cell types. The cells were examined for 
the expression of a number of surface markers, such as F4/80, Gr1, CD11b, DX5 
and B220. By process of elimination I was able to surmise that the population 
does not contain B cells, T cells or NK cells, as all were excluded at the time of 
live cell gating. However, the presence of a proportion of DX5+ cells within this 
population suggests not all NK cells were excluded from the analysis and could 
account for some of the CCR2 activity. The cells were also B220- and CD11b+, 
indicating that they are not pDCs. The expression of CD11b+ and differential 
expression of Gr1 by the population suggests that it might contain Ly6Chi 
monocytes, but their uptake is not as pronounced as Ly6Chi monocytes. Further 
work is needed to confirm the identity of this population, but their physical 
properties indicate that the cells are of a lymphocytic origin, having FSC and SSC 
lower than neutrophils. CD11c is typically considered to be a marker of DCs, 
however these results clearly indicate additional markers are required to 
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accurately identify DC populations. Gating on the basis of CD11c alone would 
segregate a population of cells that includes DCs, but this population would be 
heavily contaminated with cells of various origins (e.g. B cells, NK cells and 
macrophages). Therefore, care must be taken when interpreting results 
produced using CD11c-DTR mice, which have DTR under the control of the CD11c 
promoter. CD11c-DTR mice have been used to examine cDC biology and 
determine the affects of depletion of cDCs in numerous models (Hochweller et 
al., 2009; Jung et al., 2002). However, treatment of CD11c-DTR mice with 
diphtheria toxin does not lead to a specific depletion of cDCs, as it also leads to 
partial depletion of B cells, T cells and NK cells (Hochweller et al., 2008). 
6.2.2.5 T cells 
Mack et al. reported that 5-15% CD4+ T cells and 2-10% CD8+ T cells expressed 
CCR2, as determined by using the MC-21 antibody (Mack et al., 2001). When the 
percentage of CCL2+ cells found in CCR2 KO T cell populations was subtracted 
from the percentage of CCL2+ in WT mice, it was observed that similar 
frequencies of CD4+ (13.27%) and CD8α+ (6.82%) T cells possessed CCR2 activity. 
In Figure 3-9, CD4+ T cells were not identified by their expression of CD4, but by 
their absence of CD8α, therefore it might be considered inaccurate to 
characterise these cells as CD4+ T cells. However, experiments conducted by 
Chris Hansell (personal communication) have illustrated the CD3+CD4+ cells have 
similar profiles to the ones shown in Figure 3-9. Furthermore, the proportions of 
CD8α+CCR2+ (2-10% Mack paper vs. 6.82%) and CD4+CCR2+ (5-15% Mack paper vs. 
13.27%) T cells that were measured using either technique were similar, with 
there being a greater proportion of CD4+CCR2+ than CD8α+CCR2+ (Mack et al., 
2001). In contrast to splenic T cells, TCR αβ+ T cells (gated as CD3+) in the LN 
had virtually no CCR2 dependent uptake of CCL2AF647. This might be explained by 
a difference in the phenotype of the T cell population between the spleen and 
LN (Weninger et al., 2001). The spleen is a rich source of effector and memory T 
cells, which have downregulated CCR7 expression and express inflammatory 
chemokine receptors, including CCR2 (Sallusto et al., 1999; Weninger et al., 
2001). The LN T cell population may possess more naïve T cells that are rich in 
expression of CCR7, but lack expression of inflammatory chemokine receptors 
(Sallusto et al., 1999; Weninger et al., 2001). Work by Ross Kinstrie and Eric 
Cruikshank in our group has shown that that CCR5 and CXCR3 are restricted to 
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CD44+ memory T cells (CD4+ and particularly CD8α+) (personal communication). 
It would be interesting to determine whether CCL2AF647 uptake by CD4+ and 
CD8α+ T cells correlated with expression of CD44, and other markers of T cell 
phenotypes, such as CD62L and CD25. 
Splenic and LN γδ T cells had a higher proportion of CCR2+ cells than the TCR αβ+ 
T cells. Similar to cells of the innate immune system, γδ T cells contribute to the 
early defence against pathogens, as in addition to their ability to recognise Ag 
via MHC, they can also recognise Ag in the absence of processing and 
presentation by MHC (Kozbor et al., 1989; Matis et al., 1989; Holoshitz et al., 
1992). Thus, akin to other cells of innate immune systems γδ T cells use CCR2 to 
mobilise to sites of inflammation and provide the first line of defence against 
invading pathogens (Penido et al., 2008). 
6.2.2.6 cDCs 
In a resting animal most cDCs within the secondary lymphoid organs are 
phenotypically immature, as characterised by their low expression of MHCII and 
the costimulatory molecule, CD86 (Wilson et al., 2003). Immature cDCs are 
reported to express inflammatory chemokine receptors, such as CCR2, which are 
downregulated upon cDC maturation and CCR7 is upregulated (Dieu et al., 1998; 
Sallusto et al., 1998; Sozzani et al., 1999; 2000; Alvarez et al., 2008). Therefore, 
although Wilson et al. did not study the expression of chemokine receptors by 
splenic cDCs their immature phenotype might indicate that they possess 
inflammatory chemokine receptors (Wilson et al., 2003). In accordance with this 
hypothesis, data presented in this thesis shows that both CD8α+ and CD11b+ 
splenic cDCs possess CCR2 activity, with a larger proportion of CD8α+ cDCs 
showing CCR2 activity (Figure 3-11). Consistent with my observations, work 
conducted by Lewis et al. illustrated that in the spleen of CCR2-RFP mice, CD8α+ 
cDCs had high levels of RFP/CCR2 (Lewis et al., 2011). Furthermore, they 
defined two subsets of CD11b+ cDCs based on the expression of the C-type lectin 
Clec12a. CD11b+Clec12a+ cDCs were RFP/CCR2+, whereas CD11b+Clec12a- cDCs 
expressed little RFP/CCR2+ (Lewis et al., 2011). Therefore, within the population 
of CD11b+ cDCs that I gated there exists two populations of cDCs, which possess 
differences in their CCR2 expression. In future experiments, it would be 
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interesting to determine if CCL2AF647 uptake correlates with expression of 
Clec12a by CD11b+ cDCs. 
In PLNs only resident cDCs were found to have CCR2 activity, as migratory cDC 
populations contained very few CCL2+ cells. Similar to the spleen, LN resident 
cDCs are typically immature cDCs (Wilson et al., 2003; Sixt et al., 2005), thus 
the expression of CCR2 by an immature cDC population is not surprising. 
However, resident cDCs, gated as CD11c+MHCIIlo, would also include pDCs, which 
have been shown to possess high levels of CCR2 in several tissues, including LNs 
(Figure 5-3). Therefore, since the CD11c+MHCIIlo population contains cDCs in 
addition to pDCs, we can conclude that CCL2AF647 uptake by CD11c+MHCIIlo cells is 
not exclusively due to pDCs. It would suggest in fact that non-pDC CD11c+MHCIIlo 
cells, most of which are likely to be cDCs, are capable of CCR2-dependent 
CCL2AF647 uptake. This would be consistent with data from the spleen where a 
substantial subset of cDCs have CCR2 activity. 
The lack of CCR2 activity amongst migratory cDCs was expected, because their 
arrival from peripheral tissues is associated with their maturation and the 
downregulation of inflammatory chemokine receptors, with a parallel 
upregulation of CCR7 (Dieu et al., 1998; Sallusto et al., 1998). Migratory cDCs 
had significantly higher background levels of CCL2AF647 uptake than resident 
cDCs, perhaps indicating that they possess a high phagocytic capacity. However, 
migratory cDCs are mature cDCs that should demonstrate a decreased 
phagocytic potential compared to immature cDCs, such as LN resident cDCs 
(Cella et al., 1997; Kamath et al., 2000; Sallusto and Lanzavecchia, 2002; Wilson 
et al., 2003).  
Sixt et al. have reported that immature LN resident cDCs are immobilised on the 
basement membrane of the fibroblastic reticular cell network. It is only 
following their maturation that they become highly motile (Sixt et al., 2005). 
However, CCR2 might allow a subset of LN resident cDCs to respond to CCR2 
ligands present in the LN during homeostasis and inflammation. During 
inflammation, inflammatory chemokines such as CCL2 are produced at 
peripheral inflammatory sites, which can be transported in lymph to the 
subcapsular sinus of the draining LN. The fibroblastic reticular cell network can 
channel CCL2 from the subcapsular sinus to HEVs (Gretz et al., 2000; Andrian 
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and Mempel, 2003). Therefore, immobilised CCR2+ resident cDCs might be 
provided with cues for migration by exposure to CCL2 present within the 
fibroblastic reticular cell network. Interestingly, according to data on the 
Immgen website (http://www.immgen.org), CCL2 and CCL7 transcripts, but not 
those encoding CCL12, are produced at high levels by fibroblast reticular cells 
isolated from resting skin-draining and mesenteric LNs. Thus, CCR2 expression by 
LN DCs might be significant even in the absence of inflammation.  
The three methods that are now used to detect CCR2 i.e. transcript levels, CCR2 
reporter mice and MC-21 antibody, have produced some conflicting results with 
regards to CCR2 expression by individual cell populations (Mack et al., 2001; 
Saederup et al., 2010; Yamaski et al., 2012). My data might help to clarify some 
of these inconsistencies. Saederup et al. reported that expression of detectable 
CCR2 protein was more restricted than CCR2 mRNA, so some cells that were 
found to be CCR2+ at the transcript level, did not possess surface CCR2. 
Likewise, a percentage of GFP+ cells within CCR2-GFP reporter mice did not 
possess detectable CCR2 surface protein (Hohl et al., 2009). Analysis of RFP 
expression by flow cytometry illustrated that 5-10% of T cells and 85-95% of NK 
cells were RFP+. However, Saederup et al. did not detect any surface expression 
of CCR2 on NK cells or T cells, according to staining with MC-21 (Saederup et al., 
2010). This is in contrast to Mack et al. that reported surface CCR2 protein was 
expressed by a small number of CD4+ and CD8+ T cells (Mack et al., 2001). 
Yamaski et al. summarised these inconsistencies, reporting that although several 
cell types, such as monocytes, basophils and immature cDCs have been found to 
express CCR2 both at transcript and protein level, other populations have only 
been found to express CCR2 mRNA and their surface levels of CCR2 has yet to be 
definitively confirmed (Yamaski et al., 2012). Immature B cells, T cells and NK 
cells have all been reported to express CCR2 at the transcript level: however 
their level of CCR2 surface protein has not been confirmed (Yamaski et al., 
2012). Data presented in this thesis has shown that low numbers of both CD4+ 
and CD8α+ T cells possess low levels of CCR2 activity and NK cells possess 
significant levels CCR2 activity. CCR2 activity was only found on a very small 
number of B cells (Figure 3-9). Furthermore, splenic macrophages possessed low 
levels of CCR2 activity, whereas use of CCR2-GFP mice illustrated that lung 
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macrophages were negative for CCR2- (Hohl et al., 2009). This difference might 
be due to tissue-specific differences in CCR2 expression. 
Each cell population had varying levels of CCR2 activity, ranging from CCR2-, 
CCR2lo to CCR2hi. Where the presence of high or low levels of CCR2 might have a 
functional significance. Volpe et al. have shown that upon binding of ligand, 
CCR2 on Ly6Chi monocytes was rapidly internalised. However, this internalisation 
of CCR2 did not affect the responsiveness of Ly6Chi monocytes to further CCR2 
ligands, as monocytes were still able to migrate in response to CCR2 ligands. 
Thus, CCR2 must either be rapidly recycled back to the surface where it can 
bind more ligand, or there are sufficient numbers of CCR2 receptors on the 
surface of Ly6Chi monocytes to maintain high levels of responsiveness following 
the internalisation of some receptors (Volpe et al., 2012). This feature might be 
limited to cell populations with high CCR2 activity, as internalisation of CCR2 in 
response to CCR2 ligands might render populations with low CCR2 activity 
unresponsive to further ligand, both in terms of migration and signalling. In vitro 
transwell migration assays or calcium ion flux assays could be used to determine 
the migratory and signalling potential of both CCR2hi and CCR2lo populations in 
response to varying concentrations of CCR2 ligands. 
6.3 Effect of systemic inflammation induced by LPS on 
CCR2 and D6 activity 
LPS mediated activation of TLR4 has previously been described to downregulate 
CCR2 expression in human (Xu et al., 2000; Parker et al., 2004) and murine 
(Zhou et al., 1999) monocytes, as measured by antibody mediated detection of 
surface CCR2 levels. Results presented in Chapter 4 firmly support this 
observation, as both splenic (Figure 4-1) and BM (Figure 4-11) Ly6Chi monocytes 
showed a substantial reduction in CCR2 dependent uptake of CCL2AF647 24 hrs 
after LPS treatment. Furthermore, CD11b+ and CD8α+ cDCs, both of which are 
reported to express TLR4 (Mazzoni and Segal, 2004), were shown to have a 
complete loss of CCR2 activity 24 hrs after LPS administration (Figure 4-7 and 
Figure 4-8). This might be explained by cDC maturation, which is associated with 
downregulation of inflammatory chemokine receptors and the upregulation of 
CCR7 (Dieu et al., 1998; Sallusto et al., 1998; Alvarez et al., 2008). Indeed, 
reduction of CCR2 dependent uptake of CCL2AF647 was coincident with acquisition 
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of the activation marker CD86 (Figure 4-9). The expression of TLR4 by NK cells 
and pDCs is controversial. NK cells have been shown to possess TLR4 at the 
transcript level and to carry intracellular TLR4 protein, but they have been 
reported to express little surface TLR4 protein (Souza-Fonseca-Guimaraes et al., 
2012). Several conflicting results have also been published with regards to TLR4 
expression by pDCs. Boonstra et al. found that BM-derived pDCs and splenic pDCs 
did not express TLR4 (Boonstra et al., 2002), whereas Edwards et al. reported 
that splenic pDCs did (Edwards et al., 2003). Both groups determined expression 
only at the transcript level (Boonstra et al., 2002; Edwards et al., 2003). 
Regardless of the controversies in expression of TLR4 by NK cells and pDCs, my 
results suggest that the CCR2 activity of both cell populations is affected by LPS 
treatment, as 24 hrs after LPS administration both NK cells (Figure 4-3) and pDCs 
(Figure 4-6) had a large reduction in CCR2 dependent uptake of CCL2AF647. 
Interestingly, at the 24 hr time-point, LPS did not appear to affect the D6 
activity of cell populations that were shown to exhibit D6 dependent uptake of 
CCL2AF647 in untreated animals. For example, splenic MZ-B cells (Figure 4-5), 
splenic pDCs (Figure 4-6) and BM monocytes (Figure 4-11) maintained D6 activity 
24 hrs after LPS treatment. 
Neutrophils did not possess CCR2 activity in resting animals, or at any time-point 
after LPS administration (Figure 4-4). In contrast to results presented here, 
another group has illustrated that BM neutrophils are dependent on CCR2 for 
their infiltration into organs during a model of sepsis induced by caecal puncture 
(Souto et al., 2011). Souto et al. confirmed CCR2 expression by flow cytometry 
using the anti-CCR2 antibody from Novus (Souto et al., 2011), which in my hands 
was unable to detect CCR2 (Figure 3-1). The group reported very low levels of 
expression of CCR2 on untreated neutrophils, but after treatment with LPS for 2 
hrs surface CCR2 was upregulated, but was still expressed at low levels. They 
also illustrated that LPS exposed neutrophils isolated from BM of WT animals 
could respond in chemotactic assays to CCR2 ligands. Migration towards CCL2 
and CCL7 by LPS activated neutrophils was mediated by CCR2, as no migration 
was observed by CCR2 deficient animals (Souto et al., 2011). Therefore, perhaps 
neutrophils rapidly upregulate CCR2 following exposure to LPS, but by 24 hrs 
CCR2 activity is lost. In addition, although neutrophils did not possess D6 
dependent uptake of CCL2AF647 in a resting animal, my results suggest that 
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activation of TLR4 on neutrophils by LPS exposure results in significant 
upregulation of D6 activity 48 and 72 hrs after LPS treatment (Figure 4-4). Work 
conducted in Gerry Graham’s lab suggests that D6 expression by neutrophils 
controls the positioning of neutrophils within inflamed tissues by regulating their 
migrational responses to inflammatory CC chemokines (personal communication 
from Gerry Graham and Rob Nibbs). In the absence of D6, neutrophils had 
enhanced migratory responses to the CCR1 ligand, CCL3 in chemotaxis assays. 
Furthermore, neutrophil accumulation in TPA induced skin inflammation is 
exaggerated in the absence of D6, which leads to exacerbated skin 
inflammation. However, neutrophil accumulation was blocked by the antagonism 
of CCR1 (Gerry Graham and Rob Nibbs personal communication). Thus, 
upregulation of D6, 48 and 72 hrs after LPS administration might function to 
regulate neutrophil migration to sites of inflammation by controlling their 
migratory responses to inflammatory chemokines. 
Following the downregulation of CCR2 dependent uptake by 24 hrs, CCR2 activity 
was restored or upregulated in the majority of cases. For example, BM and 
splenic monocytes, NK cells, and CD11b+ and CD8α+ cDCs all restored or 
upregulated CCR2 activity at the later time-points in the LPS time-course. 
Interestingly, pDCs, which possess CCR2 and low levels of D6 activity in a resting 
animal, did not restore CCR2 activity following its downregulation at 24 hrs, but 
instead had a significant upregulation of D6 dependent CCL2AF647 uptake 72 hrs 
after LPS administration (Figure 4-6). In contrast, 48 hrs after LPS treatment, 
WT pDCs did not possess significant levels of D6, but CCL2AF647 uptake was 
mediated by CCR2. CCR2 might therefore be important for pDC migration at this 
time-point, but there was no affect on the frequency of pDCs, so it is not 
required for the entry or exit of pDCs from the spleen. However, pDCs might 
exhibit intra-splenic migration that is CCR2 dependent. CCR2 might facilitate 
pDC localisation to an area in spleen where the later upregulated D6 can 
sequester inflammatory chemokines. To test this hypothesis, distribution of WT 
and CCR2 KO pDCs 48 hrs after LPS injection could be examined in splenic tissue 
sections stained with antibodies against PDCA1 or SiglecH. 
These later time-points in the LPS time-course may be part of the resolution 
phase of inflammation, and CCR2 and D6 may participate in this process. My 
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results and other published work for D6 (Hansell et al., 2011b) and CCR2 (Volpe 
et al., 2012) have shown that both receptors possess scavenging activity. 
Therefore, upregulation of CCR2 or D6 activity at the later time-points might aid 
in the resolution of inflammation by sequestering remaining proinflammatory 
chemokines produced during times of inflammation (Kopydlowski et al., 1999; Xu 
et al., 2000). Calculation of the percentage of CCL2+ cells within each cell 
population illustrated a striking phenotype. In the CCR2 KO samples, each cell 
population at the 48 hr time point was found to have a proportion of cells that 
had taken up CCL2AF647 in a D6 dependent manner. This appeared to be limited 
to the 48 hr time-point, as by 72 hrs all populations, except pDCs, neutrophils 
and MZ-B cells had lost D6 activity. In the majority of cell types this 
phenomenon was only detectable in CCR2 KOs. In addition, although not shown 
here, data produced by Chris Hansell and I suggest that splenic pDCs from D6 KO 
animals have increased CCR2 activity at later time-points in the LPS time-course. 
These results suggest that in the absence of one CCL2 binding receptor the other 
receptor plays a more important role in scavenging CCR2 ligands. Maus et al. 
have illustrated that intratracheal administration of LPS in CCR2 KO animals is 
associated with increased levels of CCL2 in bronchial alveolar lavage fluid 
compared to WT animals (Maus et al., 2005). They performed a dose response 
curve of LPS, and found that each concentration of LPS produced different 
profiles of CCL2 production in bronchial alveolar lavage fluid. At the two highest 
concentrations of LPS (10 or 20 µg), peak CCL2 production was 72 or 48 hrs after 
LPS administration, respectively (Maus et al., 2005). These concentrations are 
similar to the amount of LPS administered intravenously in my study, therefore 
perhaps the upregulation of D6 by CCR2 KO cells can be coordinated with peak 
production of CCL2. Upregulation of D6 might serve to scavenge excess CCL2, 
which could aid in the resolution of inflammation. This can be explored in future 
experiments by examining the level of CCL2 (and the other CCR2/D6 ligand 
CCL12) present in the serum at each time-point of the LPS time-course in CCR2 
KO, D6 KO and CCR2/D6 double KO mice. 
These results have helped to expand our current understanding of D6 expression. 
It has been observed that several populations of cells in WT spleens, such as 
pDCs and CD8α+ cDCs, along with BM Ly6Chi monocytes possess significant levels 
of CCR2 and D6 activity. The expression of D6 on B1 B cells has been shown to 
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regulate their sensitivity to the CXCR5 ligand, CXCL13 (Hansell et al., 2011b). 
The co-expression of D6 and CXCR5 by B1 B cells can lead to decreased CXCL13 
induced migration of B1 B cells, as in the absence of D6 migratory responses to 
CXCL13 were significantly enhanced (Hansell et al., 2011b). D6 deletion did not 
affect the surface expression of CXCR5, and the effects of D6 on CXCR5 activity 
were hypothesised to arise via chemokine-independent phosphorylation of D6 
which drives the redistribution of β-arrestins from the cytoplasm to the 
membrane (McCulloch et al., 2008; Hansell et al., 2011; Gerry Graham and Rob 
Nibbs personal communication). This is not required for D6 mediated chemokine 
scavenging, but could theoretically influence the activity of chemokine 
receptors co-expressed with D6 (McCulloch et al., 2008; Hansell et al., 2011b; 
Gerry Graham and Rob Nibbs personal communication). Therefore, perhaps D6 
can regulate the function of CCR2 by either altering the migration potential of 
cells by scavenging ligands to reduce chemotactic signals, or, akin to D6 and 
CXCR5, by regulating the sensitivity of CCR2 for its ligands. This hypothesis 
might explain the reported increase in Ly6Chi monocytes in the secondary 
lymphoid organs of animals deficient in D6 (Savino et al., 2012). Savino et al. 
have reported that during inflammation D6 might be important in the regulation 
of CCR2 dependent Ly6Chi monocyte egress from the BM (Savino et al., 2012). 
Data shown in Figure 4-11 suggests that BM Ly6Chi monocytes possess CCR2 and 
D6. Therefore, perhaps within the BM, D6 sequesters CCR2 ligands and in doing 
so, might regulate CCR2 dependent mobilisation of Ly6Chi monocytes from the 
BM during inflammation. In the absence of D6 there would be less scavenging of 
CCR2 ligands and as a consequence, egress of Ly6Chi monocytes would be 
increased. 
6.4 Advantages and disadvantages of the CCL2AF647 
assay 
6.4.1 CCL2AF647 assay versus antibodies 
Data presented in this thesis establish CCL2AF647 uptake assay as a reliable, 
sensitive and specific method to detect CCL2 receptors. Consistent with 
published observations high levels of D6 activity was observed on MZ-B cells 
(Figure 3-9) (Hansell et al., 2011b), and all populations possessing CCR2 activity 
in the CCL2AF647 uptake assay have previously been reported to express CCR2 at 
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either the transcript level or by antibody mediated detection of surface CCR2. 
However, the proportion of CCR2+ cells of each population differs depending on 
which detection method was utilised. Typically a greater number of CCR2+ cells 
were found when using the CCL2AF647 assay. Prime examples are the CD8α+ cDCs, 
pDCs and NK cells. Thus, the CCL2AF647 assay appears to be more sensitive than 
the anti-CCR2 antibody MC-21, as the assay was able to detect CCR2hi, CCR2lo 
and CCR2- populations.  
Another advantage of the assay over the use of antibodies is that in addition to 
the simple role of detecting surface CCL2 receptors, it also provides information 
about their activity. However, the assay fails to distinguish if the observed 
CCL2AF647 uptake is facilitated by small amounts of receptors highly active for 
uptake, or large numbers of receptors with low overall uptake capacity. 
Therefore, levels of CCR2/D6 activity detected using the CCL2AF647 assay might 
not reflect the surface expression level of CCR2 or D6. Nonetheless the 
comparison of my results to published profiles of CCR2 expression produced 
using the MC-21 antibody indicate that in mice it probably does, at least to some 
extent, correlate with CCR2 surface levels. The lack of a reliable anti-murine D6 
antibody means that a similar comparison cannot be conducted. As discussed 
earlier (section 3.2), a caveat associated with the CCL2AF647 assay is that it only 
provides information about functionally active receptors. Therefore CCR2 might 
be present on a cell, but if it does not bind and internalise CCL2AF647 it would be 
reported as being CCR2-. The functional significance of the presence of CCR2/D6 
on the cell surface when the receptor cannot internalise CCL2AF647 is unclear. 
There are many other variables that might affect the cell specific differences in 
CCR2/D6 activity. For example, CCL2 receptors might have different affinities 
for CCL2AF647 depending on the cell it is expressed on. Indeed, my data provides 
evidence of cell-type specific interactions of CCR2 with its ligands and these 
shall be discussed later in this section. The capacity of CCR2 to signal in 
response to its ligands might also be subject to cell-type specific differences. 
The ability of cell populations to internalise CCL2AF647 might be affected by cell 
specific differences in the rate of receptor recycling, which would influence the 
number of available receptors, and as a consequence alter the cells ability to 
internalise CCL2AF647. In addition, the rate of CCL2AF647 internalisation and 
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subsequent degradation may well differ between cell populations. Therefore, 
altering the length of the 1 hr incubation with CCL2AF647 could generate different 
results. Some cell populations might be able to rapidly internalise CCL2AF647 and 
would be CCL2+ even during short incubation periods, whereas other populations 
requiring longer periods of time to internalise CCL2AF647 would appear CCL2-. This 
might also apply to the rate of CCL2AF647 degradation, as cell populations that 
rapidly degrade CCL2AF647 following its internalisation might appear CCL2- at 
later time-points. In contrast, cell populations that possess a slower CCL2AF647 
degradation rate would still appear CCL2+. 
Similar to reliable antibodies against chemokine receptors that can be used to 
measure downregulation of receptor level in response to inflammatory stimuli, 
or stimulation with chemokine, the CCL2AF647 assay can measure downregulation 
of CCL2 receptor activity. Furthermore, the use of competitor ligands to 
compete CCL2AF647 uptake provided information about receptor specificity and 
potentially receptor occupancy. A range of CCR2 ligands were used to compete 
CCR2 dependent uptake of CCL2AF647, including mCCL2, mCCL7 and mCCL12 
(Figure 3-17). mCCL8 was not included, as although it was originally considered 
to be a CCR2 ligand, this is now known to be false, as CCL8 in mice is in fact a 
ligand of CCR8 (Islam et al., 2011). This fits with results produced by the Nibbs 
lab demonstrating that CCL8 had no action on either CCR2 or D6 mediated 
uptake of CCL2AF647 (Hansell et al., 2011b). Traditionally, CCL3 is not considered 
to be a CCR2 ligand, and was included in competition experiments as a negative 
control, as it should compete D6 but not CCR2 dependent uptake. However, 
recent data from our lab has shown that mCCL3, although less effective than 
other CCR2 ligands, can also inhibit CCR2 dependent uptake by peritoneal T cells 
and splenic Ly6Chi monocytes (Hansell et al., 2011b). I found that mCCL3 had 
minimal affects on CCR2 dependent CCL2AF647 uptake by Ly6C+ cells. This 
discrepancy in results might be explained by differences in the concentration of 
mCCL3 used. Hansell et al. used 100 nM of mCCL3 to partially block CCR2 
dependent CCL2AF647 uptake (Hansell et al., 2011b), whereas the highest 
concentration used in my co-incubation competition experiments was 25 nM 
(Figure 3-17). Perhaps mCCL3 has lower affinity for CCR2 than other CCR2 
ligands, thus higher concentrations of mCCL3 are required to inhibit CCL2AF647 
uptake. However, these lower doses of mCCL3 did cause a decrease in D6 
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dependent uptake by the Ly6C- fraction of cells, which contains D6+ MZ-B cells. 
Likewise, both mCCL2 and mCCL12 were also able to compete D6 dependent 
uptake by Ly6C- cells, but the non-D6 ligand CCL7 was not. All three ligands 
were, however, able to compete CCL2AF647 uptake by Ly6Chi monocytes and Ly6C-
CD11b+ cells in a dose-dependent manner. At the highest concentration tested 
(25 nM) mCCL2 was nearly able to completely block CCL2AF647 uptake, which 
might indicate that at this concentration most receptors are occupied. 
Interestingly, although there were no significant differences in the ability of 
mCCL2, mCCL7 and mCCL12 to compete CCL2AF647 uptake by Ly6Chi monocytes, 
mCCL7 and mCCL12 were much less effective at inhibiting CCL2AF647 uptake by 
Ly6C-CD11b+ cells than mCCL2. These results suggest that CCR2 on different cells 
has different interactions with its ligands. 
The assay can also be used to test the ability of ligands to desensitise CCR2, by 
monitoring CCR2 activity following exposure of WT splenocytes to an excess of 
unlabelled CCR2 ligands, such as mCCL2, mCCL7 or mCCL12, or the control 
ligand mCCL3 (Figure 3-18). Similar to co-incubation experiments each 
chemokine produced distinct profiles of uninhibited CCL2AF647 uptake. Prior 
exposure to mCCL3 did not appear to have any effect on CCR2 activity, whereas 
mCCL2, mCCL7 and mCCL12 were all able to desensitise CCR2 on Ly6Chi 
monocytes in a concentration dependent manner. CCL2 was superior at 
desensitising CCR2 on Ly6Chi monocytes, particularly at higher concentrations. 
This observation was more striking in Ly6C-CD11b+ cells, as mCCL7 and mCCL12 
were unable to inhibit CCL2AF647 uptake at all concentrations, other than at 
250nM when minimal inhibition was observed. These results were not entirely 
surprising as other chemokine ligands have been shown to have differential 
effects on the desensitisation of their receptor, for example CCR5 and its ligands 
(Oppermann et al., 1999). Desensitisation of chemokine receptors is controlled 
by the phosphorylation of the receptor by GRKs, which leads to the recruitment 
of β-arrestin proteins. Binding of the β-arrestin proteins to the receptor prevents 
the interaction of G proteins to the receptor, thereby inhibiting further 
signalling from the receptor and can also mediate internalisation of the receptor 
(Rot and Andrian, 2004; Neel et al., 2009). Each CCR5 ligand activates GRKs, but 
do so with different efficiency. This can lead to alterations in the 
phosphorylation of the receptor, thereby modulating the number of functional 
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receptors on the surface (Oppermann et al., 1999). Accordingly, CCR2 ligands 
may also have differential effects on the phosphorylation of CCR2, and 
consequently on the desensitisation of the receptor, as determined by receptor 
silencing or internalisation. Therefore, the ability of a CCR2+ cell to migrate in 
response to a particular CCR2 ligand might be affected by prior exposure to 
other CCR2 ligands. 
Desensitisation of CCR2 required considerably higher concentrations of ligand 
relative to the low amounts necessary for competition during co-incubation. As 
mentioned earlier, co-incubation experiments might give an indication of 
receptor occupancy, as it appeared that 25 nM of mCCL2 could nearly 
completely prevent uptake of CCL2AF647 by Ly6Chi monocytes and Ly6C-CD11b+ 
cells (Figure 3-17). Thus, only low concentrations of ligands were required to 
occupy most CCR2 receptors. In contrast, pre-incubation of splenocytes with 25 
nM of mCCL2 only caused partial desensitisation of CCR2, as further reductions 
in CCL2AF647 uptake were observed when splenocytes were pre-incubated with 
higher concentrations of mCCL2. The observations by Volpe et al. (described in 
section 6.2.2.6) provide some insight into CCR2 desensitisation and perhaps 
explain the requirement of high concentrations of ligands to do so. The group 
showed that Ly6Chi monocytes have a uniform expression of CCR2 on their 
surface, which helps to maintain responsiveness to ligands following 
internalisation of some receptors (Volpe et al., 2012). Therefore, in order to 
desensitise CCR2 on Ly6Chi monocytes an excess of ligand would be required to 
inundate all available CCR2. My earlier results illustrated that of the analysed 
cell populations, Ly6Chi monocytes possessed the greater level of CCR2 activity. 
Thus, perhaps monocytes behave differently to other cells because of their high 
CCR2 activity. My data provide support for this hypothesis because they suggest 
that the interaction of CCR2 with its ligands is cell-type specific, as although 
mCCL2, mCCL7 and mCCL12 were all able to desensitise CCR2 on Ly6Chi 
monocytes, only mCCL2 was able to desensitise CCR2 on Ly6C-CD11b+ cells. 
Further investigations are needed to confirm this observation, and it would be 
interesting to repeat the competition and pre-incubation experiments with some 
of the other CCR2hi populations, such as NK cells and pDCs to determine whether 
they also generate cell specific CCR2 ligand binding profiles. 
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An advantage of using antibodies over fluorescent chemokines relates to cost. 
CCL2AF647 is a relatively expensive reagent, so some groups might elect to use 
antibodies over the more sensitive CCL2AF647 uptake assay. However, there are 
limited numbers of reliable antibodies targeted against murine CCR2 and no 
reliable anti-murine D6 antibodies exist. Furthermore, with the exception of 
humans, even fewer antibodies are targeted against CCR2/D6 in other 
mammalian and non-mammalian species. Some antibodies targeted against 
murine or human CCR2 have been reported to possess cross-reactivity to rat 
CCR2, and Yrlid et al. described CCR2 expression on rat monocytes using an anti-
rat CCR2 antibody (Yrlid et al., 2006). However, to my knowledge no antibody 
has been generated that specifically identifies CCR2 on primary cells in species 
other than mouse, rat and humans. The final advantage of the CCL2AF647 assay is 
that due to the highly conserved nature of chemokines and their receptors (Allen 
et al., 2007), the assay is not subject to the same species restrictions as 
antibodies and is likely to work in multiple mammals. The results presented in 
Chapter 3, demonstrate that the assay works cross-species, and is able to detect 
human and rat CCR2 (Figure 3-16). Amanda Guth (Colorado State University, 
USA) has also demonstrated that the assay can detect CCR2 on canine cells 
(personal communication). However, it failed to detect D6 activity on pDCs from 
human peripheral blood or rat spleen, which are a population of cells shown to 
express D6 both in the spleen and blood of mice (Figures 3-11 and 3-13). 
Consistent with murine data (Figure 3-13), D6 activity was not detected on 
human blood B cells (Figure 3-16). No rat CCL22 was available commercially, 
thus CCL2AF647 uptake in the rat samples was competed with mCCL22. It is 
unknown whether mCCL22 is bioactive on rat D6, therefore the use of mCCL22 is 
an imperfect control to detect D6 as it might not actually be able to compete 
with CCL2AF647 for binding to D6. These results also suggested that expression of 
chemokine receptors by specific cell populations might differ between species. 
Murine splenic NK cells possessed high CCR2 activity, whereas human peripheral 
blood NK cells had minimal levels of CCR2 activity. These data also suggested 
that a proportion of CD43- monocytes in the rat, the equivalent of Ly6ChiCCR2hi 
monocytes in mice, did not uptake CCL2AF647, indicating that perhaps not all rat 
CD43- monocytes are like murine Ly6Chi monocytes. The CCL2- population are 
unlikely to be functional equivalents of murine Ly6Clo cells, as in mice these 
cells also possess appreciable levels of CCR2 activity. Furthermore, in rats only 
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one homogenous population of pDCs based on their CCR2 activity was identified, 
rather than the two populations found in mice and humans. This might indicate 
that the role of CCR2 on these cells is different in each species, or that the 
method used to identify rat pDCs does not include all pDC subsets. 
Our lab has optimised the use of several fluorescent chemokine assays to detect 
a range of receptors, such as D6, CXCR2, CXCR3, CCR7, CCX-CKR, CCR4, CCR1 
and CCR5 (Bordon et al., 2009; Hansell et al., 2011b; Rob Nibbs personal 
communication). Two such assays using CCL2AF647 or CCL22AF647 to detect D6 
activity have been published. One assesses the role of D6 in the development 
and resolution of DSS-induced colitis, illustrating D6 activity was present on 
colonic B cells (Bordon et al., 2009). This paper also showed expression of CCR4 
by colonic T cells (Bordon et al., 2009). The second and most recent paper, to 
which I made a contribution (Appendix 2), described D6 activity on innate-like B 
cells (Hansell et al., 2011b). Other assays that have been optimised by the lab 
are the CXCL8AF647 assay, which we have found can detect CXCR2 in mice, 
humans and rats. This assay demonstrated high CXCR2 activity on neutrophils in 
each species. CCR7 activity was examined using CCL19AF647 by a previous member 
of our lab, Catherine Hurson (Hurson, 2011), and has recently been adapted by 
Darren Asquith to confirm expression of CCX-CKR by LN lymphatic endothelial 
cells (confirmed by recent microarray data from Immgen, Malhotra et al., 2012). 
Lastly, the presence of CCR5 activity and other CCL5 receptors on a range of 
cells has been analysed using a CCL5AF647 assay. All of this work, and the data 
presented in this thesis help to establish the use of fluorescent chemokines as a 
reliable and sensitive means to detect chemokine receptors in mice and other 
mammalian species. Furthermore, they illustrate some of the additional 
applications of fluorescent chemokine assays, such as determining receptor 
specificity, regulation and occupancy. 
6.4.2 CCL2AF647 assay versus knock-in reporter mice 
Despite the numerous applications of fluorescent chemokine assays, they are 
subject to several functional limitations when compared to knock-in mice, such 
as CCR2-GFP and CCR2-RFP. Fluorescent chemokines cannot currently be used to 
establish CCR2 activity within tissue sections, thus they are incapable of 
determining localisation of CCR2+ cells within a tissue. In contrast, both CCR2-
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GFP and CCR2-RFP mice have been used in numerous studies to establish 
localisation of cells via immunohistochemistry. For example, Saederup et al. 
elegantly showed the distribution of CCR2 and/or CX3CR1 in sections of naïve 
and inflamed brains using CCR2-RFP mice crossed with CX3CR1-GFP mice 
(Saederup et al., 2010). In resting brains there were very few CCR2-RFP+ cells in 
the brain parenchyma of CCR2RFP/+CX3CR1GFP/+ mice. In contrast, following 
induction of EAE, CCR2-RFP+ cells were found in parenchymal and perivascular 
regions of the brain at peak disease severity. These cells were found to be Ly6Chi 
inflammatory monocytes, as they were absent in mice deficient in CCR2, but not 
CX3CR1 (CCR2RFP/RFPCX3CR1GFP/+), and were positively stained with 7/4, a marker 
of Ly6Chi monocytes (Saederup et al., 2010). CCR2RFP/+CX3CR1GFP/+ knock-in 
reporter mice have also been used to examine CCR2 and CX3CR1 expression in 
neuronal tissues of a developing embryo (Mizutani et al., 2011). CCR2-GFP mice 
have been used to examine localisation of Ly6Chi monocytes within sections of 
colonic lamina propria during Clostridium difficile induced colitis (Jarchum et 
al., 2012). This study revealed that although Ly6Chi monocytes are recruited to 
colonic lamina propria they do not enter gut lumen, and that neutrophils are 
crucial for the early defence against Clostridium difficile (Jarchum et al., 2012). 
CCR2-GFP mice have also been used to examine recruitment and localisation of 
Ly6Chi monocytes in the liver of mice infected with Listeria monocytogenes (Shi 
et al., 2010). Within the liver, Ly6Chi monocytes surrounded the foci of infection 
and formed lesions. It was within these foci that monocytes differentiated into 
TipDCs, and CCR2-GFP+ cells could be colocalised with immunofluorescent 
staining for iNOS (Shi et al., 2010). This study also highlighted another advantage 
of knock-in reporter mice compared to fluorescent chemokines, as knock-in 
reporter mice, such as CCR2-GFP can facilitate the analysis of cell trafficking by 
intravital microscopy. For example, Shi et al. monitored trafficking of Ly6Chi 
monocytes into livers of infected CCR2-GFP mice (Shi et al., 2010). Therefore, 
although fluorescent chemokines are a sensitive and reliable method to detect 
receptor activity, they are severely limited in their ability to detect receptors in 
situ. 
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6.5 Cellularity of lymphoid organs and blood in CCR2 KO 
6.5.1 Steady-state 
The cellularity of the lymphoid organs and the blood of steady-state CCR2 KO 
animals was similar to WT animals (Figure 3-15). However, consistent with 
published observations (Sunderkötter et al., 2004; Serbina and Pamer, 2006; 
Tacke and Randolph, 2006), CCR2 KOs had a significantly decreased frequency of 
Ly6Chi monocytes in spleen and blood, with a parallel increase in Ly6Chi 
monocytes detected in the BM. Furthermore, there was a significant reduction in 
the frequency of Population B cells detected in the blood of CCR2 KO animals 
(Figure 3-15C). Earlier in section 6.2.2.3 it was proposed that Population B might 
represent a population of CD115- monocytes or pre-cDCs. Therefore, perhaps 
akin to the highly CCR2 dependent mobilisation of Ly6Chi monocytes from the 
BM, the decrease in Population B cells in the blood of CCR2 KO animals might be 
explained by an increase in the BM. However, there was no corresponding 
increase in the BM of CCR2 KOs, which suggests that Population B are not 
dependent on CCR2 for their emigration from the BM, unless any excess cells in 
this population die in the BM. Interestingly, these cells do not appear to acquire 
CCR2 activity until they are in the blood. An alternative explanation is that CCR2 
might play a role in their retention in the spleen, and it will be of interest in 
future experiments to try to identify Population B cells within the spleen and 
determine their relative frequency in the spleens of WT and CCR2 KO animals. 
Another theory to explain the decrease in Population B in the blood of CCR2 KOs 
is that the absence of CCR2 effects their survival. CCR2 deletion has been 
associated with enhanced turnover and apoptosis of BM myeloid cell progenitors 
(Reid et al., 1999). Reid et al. did not elucidate the exact mechanism of CCR2 
induced survival, but their results suggest that CCR2 signals enhance the survival 
of BM myeloid cell progenitors (Reid et al., 1999). Thus, in the absence of CCR2, 
perhaps Population B cells do not receive a survival signal and are subject to 
apoptosis. A final explanation is that Population B cells in blood are derived from 
Ly6Chi monocytes. These CD115- cells might have a different function from 
CD115+ Ly6Chi monocytes in vivo, such as the regeneration of cDCs in response 
to inflammation-induced cDC death. If so, their paucity in CCR2 KO blood might 
underlie the deficit in CD11b+ and CD8α+ cDCs 24 hrs after LPS administration. 
Clearly, further experiments are required to assess these ideas. 
Chapter 6  272 
 
There was also a significant increase in the frequency of B cells and decrease in 
T cell frequency detected in the PLNs of CCR2 KO mice compared to WT (Figure 
3-15). T and B cells from PLNs were negative for CCR2 activity (Figure 3-14). 
Therefore, it is unlikely that a deficiency in CCR2 affected their ability to 
migrate to or from LNs, or caused any other cell autonomous defects in these 
cells. Instead, the effect of CCR2 deletion on T and B cell frequency might be 
secondary to structural changes in LNs or changes in the distribution of other 
cell types. 
6.5.2 Systemic inflammation 
The absence of CCR2 in steady-state animals only affected the frequency of one 
splenic cell population, namely Ly6Chi monocytes. In contrast, treatment of WT 
and CCR2 KO animals with 15 µg LPS led to marked alterations in the frequency 
of several populations in the spleen. 
6.5.2.1 Neutrophils 
Peak accumulation of neutrophils in inflammatory exudate occurs 6 to 24 hrs 
after LPS administration (Ulich et al., 1991). In the WT spleen, however, 
neutrophil abundance did not peak until 48 hrs after LPS injection. 
Unexpectedly, neutrophils peaked in the CCR2 KO at 24 hrs when they were 
more abundant than in WT. This is in contrast to observations by Souto et al. 
who reported that LPS induced infiltration of neutrophils into lungs, heart and 
kidney was dependent on CCR2 (Souto et al., 2011). Other receptors have been 
reported to coordinate neutrophil mobilisation into the spleen during LPS 
induced inflammation, such as CXCR4. CXCR4 is upregulated on splenic 
Gr1+CD11b+ granulocytes 12 hrs after induction of systemic inflammation by 
caecal ligation. The mobilisation of neutrophils into the spleen was inhibited by 
blockade of the CXCR4 ligand, CXCL12 (Delano et al., 2011). Therefore, perhaps 
CXCR4 can over-compensate for the loss of CCR2, and in the absence of CCR2 
plays a greater role in neutrophil migration to the spleen than observed in WT 
animals, explaining the increased neutrophil frequency in the spleen of CCR2 KO 
animals. Alternatively, LPS treatment might cause the release of more 
neutrophils from CCR2 KO BM, as in the absence of CCR2 the BM has been 
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described to have defects, such as retention of Ly6Chi monocytes (Serbina et al., 
2006) 
6.5.2.2 Monocytes 
Serbina et al. have illustrated that during the early stages of infection with 
Listeria monocytogenes pre-existing BM Ly6Chi monocytes are recruited to the 
spleen (Serbina et al., 2009). In contrast, at later stages of infection the 
frequency of BM Ly6Chi monocytes increased rather than decreased, as robust 
expansion of BM monocyte precursors supported continuous recruitment of 
Ly6Chi monocytes to the spleen (Serbina et al., 2009). Consistent with these 
observations, results presented in Chapter 4 illustrated that LPS treatment 
resulted in an increase in the frequency of Ly6Chi monocytes in spleen (Figure 4-
2) and BM (Figure 4-11) of WT mice. However, there appeared to be no 
preliminary decrease in Ly6Chi monocytes in the BM (Figure 4-11). The use of 
different mice models of inflammation might account for this discrepancy, as 
results by Shi et al. suggest that LPS induced monocyte mobilisation is very rapid 
occurring within hrs, rather than days (Shi et al., 2011). 
Using a combination of CCR2-GFP and CCL2-GFP reporter mice, Shi et al have 
examined Ly6Chi monocytes emigration from the BM in response to low doses of 
TLR ligands (Shi et al., 2011). The study illustrated that very low amounts of LPS 
(2 ng) delivered i.p. induced rapid monocyte mobilisation (Shi et al., 2011). 3 hrs 
after LPS treatment there was a significant reduction in the frequency of BM 
Ly6Chi monocytes, which coincided with an increase in the blood (Shi et al., 
2011). Rapid release of monocytes from the BM in response to low doses of LPS is 
CCR2 dependent. Moreover, conditional deletion of CCL2 from BM mesenchymal 
cells led to a significant decrease in circulating monocytes 4 hrs after treatment 
with 20 ng LPS, indicating that Ly6Chi monocyte emigration from the BM is 
mediated by CCL2 production by BM mesenchymal cells (Shi et al., 2011). It is 
possible that this rapid CCR2-dependent monocyte release also happened in 
response to the 15 µg dose of LPS that I used, and that it was missed because of 
analysing too late after LPS administration (i.e. 24 hrs). 
Interestingly, 24 hrs after treatment with 15 µg LPS the resting deficit in 
peripheral Ly6Chi monocytes in CCR2 KO animals was absent (Figure 4-2), and 
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was accompanied by a marked decrease in the frequency of CCR2 KO BM Ly6Chi 
monocytes that was not seen in WT mice (Figure 4-11). The deficit in peripheral 
monocytes was restored at the later time-points (Figure 4-2). Thus, LPS 
treatment led to CCR2-independent mobilisation of Ly6Chi monocytes from the 
BM into the periphery. Monocyte mobilisation in CCR2 KOs induced by treatment 
with 15 µg LPS may occur via another inflammatory chemokine receptor. There 
is a high degree of redundancy in chemokine receptors, and in the absence of 
one receptor, another can compensate for its loss and perform similar roles to 
that of the missing receptor (Krueger et al., 2010). I theorised that other 
inflammatory chemokine receptors expressed by Ly6Chi monocytes might be 
responsible for the observed LPS driven CCR2 independent mobilisation. Our lab 
and others have shown that BM Ly6Chi monocytes express CXCR2 (Traves et al., 
2004; Boisvert et al., 2006), however CXCR2 antagonism had no effect on LPS 
induced monocyte mobilisation in the CCR2 KO (Figure 4-12). Thus, the 
mechanisms responsible for LPS induced loss of CCR2 dependence for monocyte 
release from the BM remains to be defined. 
6.5.2.3 cDCs 
In accordance with published observations (Zanoni et al., 2009), treatment with 
15 µg of LPS resulted in a significant reduction in the abundance of cDCs in WT 
and CCR2 KO spleens (Figure 4-10). The frequency of cDCs did not recover within 
the time-scale of the experiment. 72 hrs after LPS administration CD11b+ and 
CD8α+ cDCs were significantly reduced in WT and CCR2 KO animals compared to 
PBS controls. cDCs were gated as CD11chiMHCIIhi cells, but Singh-Jasuja et al. 
have demonstrated that LPS activated cDCs downregulate their expression of 
CD11c (Singh-Jasuja et al., 2012). Therefore, the decreased cDC frequency 
might be explained by the downregulation of CD11c and the absence of cDCs 
from the CD11chiMHCIIhi gate. However, other groups have reported that LPS 
induced activation of cDCs causes an increase in their turnover rate (Kamath et 
al., 2000; 2002) and results in their death by apoptosis, and as a consequence 
decreases the number of splenic cDCs (Zanoni et al., 2009). Therefore, the 
observed decrease in cDC abundance may be a result of cDC death following 
their activation by LPS. LPS treatment also resulted in a significant decrease in 
the frequency of CD11b+ and CD8α+ cDCs detected in CCR2 KO spleens compared 
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with those of the WT. This suggests that CCR2 KO cDCs may have an increased 
rate of death compared to WT cDCs. 
A decrease in splenic cDC numbers triggers the differentiation of splenic cDC 
precursors. Depletion or reduction of the splenic cDC frequency is associated 
with an increase in Flt3L, which was reported to trigger differentiation of cDC 
precursors. Upon restoration of cDC numbers Flt3L availability is decreased and 
cDC precursor differentiation is reduced (Hochweller et al., 2009). Splenic cDC 
numbers in WT animals are reported to recover 5 days after LPS administration 
(Zanoni et al., 2009). It would be interesting to establish whether CCR2 KO cDCs 
recover within the same time-scale, and to define the affect of LPS on the 
frequency of Population B in the blood and spleen. If Population B is truly a 
population of pre-cDCs, one might expect that as the frequency of cDCs 
decreases, there would be a parallel increase in the differentiation of the cells 
within this population and perhaps their frequency within the spleen. However, 
CCR2 KOs have a deficit in blood Population B, so the number of cells present 
that could differentiate into cDCs might be substantially reduced in comparison 
to WT animals. CCR2 KOs might therefore exhibit delays in the restoration of 
their splenic cDC populations. This might also explain the CCR2 KO specific 
decrease in cDC frequency 24 hrs after LPS (Figure 4-10). The decrease in cDCs 
would trigger Flt3L production, which would drive differentiation of precursors 
to replace the diminishing cDC population. However, the reduction in Population 
B cells in CCR2 KOs would mean that there are fewer precursors available to 
differentiate and as a consequence, compared to a WT population there would 
be a decrease in the cDC population. 
An alternative hypothesis that might explain the CCR2 KO specific decrease in 
cDC frequency 24 hrs after LPS is an indirect effect of the absence of peripheral 
Ly6Chi monocytes in CCR2 KO animals. During inflammatory conditions, Ly6Chi 
monocytes can differentiate into inflammatory cDCs (Tam and Wick, 2004; Naik 
et al., 2006; Shortman and Naik, 2007). The resting defect in Ly6Chi monocytes 
in CCR2 KO mice might lead to a peripheral deficit in inflammatory cDCs 24 hrs 
after LPS (Tam and Wick, 2004; Naik et al., 2006; Serbina and Pamer, 2006; 
Shortman and Naik, 2007). To examine whether the deficit in Population B or 
Ly6Chi monocytes are responsible for the CCR2 KO specific decrease in cDCs 24 
hrs after LPS, we could transfer either WT Population B cells or WT Ly6Chi 
Chapter 6  276 
 
monocytes into CCR2 KO animals before the start of the LPS time-course and 
determine whether either cell type restores the reduction in cDC numbers at 24 
hrs. 
The observed LPS induced decrease in cDC frequency was subsequent to the 
acquisition of the activation marker CD86 in WT cells, or simultaneous in the 
case of CCR2 KOs, as CD86 was specifically upregulated 24 hrs after LPS 
treatment (Figure 4-9). CCR2 KO splenic cDCs have been reported to have lower 
expression levels of activation markers (Fiorina et al., 2008). However, my 
results using CD86 did not reveal any noticeable differences in expression. This is 
consistent with published results as Fiorina et al. showed that only CD80 and not 
CD86 was affected by loss of CCR2 (Fiorina et al., 2008). CD80 and CD86 have 
distinct functions in the activation of T cells. CD86 is thought to be the initial 
costimulatory ligand as it is expressed earlier than CD80 and is more abundant, 
whereas CD80 ligation supports the generation of T cells with regulatory 
functions (Hathcock et al., 1994; Sharpe and Freeman, 2002; Sansom et al., 
2003). The defective maturation of CCR2 KO cDCs, as characterised by 
expression of the activation marker CD80 might also correlate specifically with 
the decrease in CCR2 KO cDC numbers. 
Decreased cDC frequency in WT mice was associated with increased or recovery 
of CCR2 activity in the cDC subsets (Figures 4-7 and 4-8). Therefore, very low 
numbers of cDCs compared to the PBS control are responsible for the restoration 
of CCR2 dependent CCL2AF647 uptake. As LPS treatment potentially results in the 
apoptosis of the original cDC population, newly recruited or recently 
differentiated pre-cDCs are likely to be responsible for the high levels of CCR2 
activity detected at the later time-points in the LPS time-course. In accordance 
with this hypothesis, Population B and Ly6Chi monocytes in the blood have high 
levels of CCR2 activity (Figure 3-13) coincident with the re-emergence of CCR2 
activity of cDCs. 
Collectively, these results have shown that in resting mice there is little effect 
of CCR2 deletion on the frequency of the majority of CCL2+ cell populations, 
with the notable exception of Ly6Chi monocytes and closely related Population B 
cells. During systemic inflammation, CCR2 deficiency drastically affected the 
frequency of Ly6Chi monocytes and cDCs. There were no apparent effects of 
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CCR2 deletion on the splenic frequency of the other CCL2+ populations, both 
during homeostasis and inflammation. This might indicate that CCR2 is not 
required for their migration to or from the spleen, or there survival in this 
organ. However, CCR2 might be involved in their intra-splenic migration. By 
examining the localisation of cells within resting or inflamed spleens of WT and 
CCR2 KO animals via immunohistochemistry, we might find that inflammation 
induces CCR2 dependent migration of CCL2+ populations within the spleen. 
6.6 CCL2 receptors and pDCs 
Chapter 5 details the characterisation of two subsets of pDCs that were 
identified based on CCR2 activity. The difference in CCR2 expression was 
demonstrated both by CCL2AF647 uptake activity and variation in CCR2 
transcripts. Both CCR2hi/lo pDC subsets were shown to have no differences in the 
expression of the pDC markers, PDCA1 and SiglecH in resting animals (Figure 5-
2). 
Approximately 50% of pDCs in the majority of the tested lymphoid organs and 
blood had high levels of CCR2 activity (Figure 5-3). This is in sharp contrast to 
results produced using the MC-21 antibody: both others and myself found only 
very low levels of MC-21+ pDCs. Wendland et al. reported that only 25% of WT 
BM pDCs were MC-21+ when compared to isotype control stained WT cells 
(Wendland et al., 2007). Furthermore, within each tested tissue, competition 
with mCCL22 provided evidence of D6 activity in WT and CCR2 KO pDCs. In 
addition, the microarray of splenic pDCs demonstrated that there were no 
differences in D6 expression at the transcript level between the two subsets 
(Figure 5-23). However, the relative proportion of pDCs possessing CCR2 and D6 
activity was different within each tissue. The tissue specific differences in 
expression of both of these inflammatory chemokine receptors might be 
explained by differences in the maturation or activation state of the two 
subsets. The BM is a rich source of pDC progenitors and immature pDCs, so CCR2 
might be a marker of more terminally differentiated pDCs. However, comparison 
of the surface phenotype of splenic and BM WT pDCs did not indicate any major 
differences in the expression of a range of markers, including activation and 
maturation markers (Figure 5-31 and 5-32). 
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6.6.1 Surface phenotype of CCL2hi and CCL2lo pDCs 
As summarised in the Introduction, many groups have described subsets of pDCs 
based on their maturation status. In brief, O’Keeffe et al. have reported that 
CD4+ pDCs are terminal differentiated mature pDCs and approximately 66% of 
splenic pDCs identified as B220+CD11c+ cells are CD4+ (O'Keeffe et al., 2002). 
Furthermore, mature pDCs (gated as B220+CD11c+ cells following exclusion of 
lymphocytes and myeloid cells) are also reportedly CD9-, with CD9 
downregulated upon differentiation into mature pDCs (Björck et al., 2011). 
Consistent with these results and despite the inadequacy of using B220+CD11c+ to 
identify pDCs, it was found that a high proportion of both CCL2hi and CCL2lo 
expressed CD4 (Figure 5-12), and that approximately 64% of total WT splenic 
pDCs expressed CD4 (Figure 5-32). My results also illustrated that the majority of 
splenic pDCs were CD9-, with a minor proportion (~8%) being immature CD9+ 
pDCs (Figure 5-31), and there were no significant differences in CD9 expression 
between the two subsets (Figure 5-12). These results suggest that there are no 
major differences in the maturation state of the two subsets, and that most 
pDCs identified would be classified as mature. Ly49Q is also considered to be a 
marker of pDC maturation, as pDCs acquire expression of Ly49Q before exiting 
the BM, and approximately 87% of splenic pDCs are Ly49Q+ (Omatsu et al., 2005; 
Toma-Hirano et al., 2007). In my hands, both the CCL2 subsets (Figure 5-12) and 
total splenic pDCs (Figure 5-31) were Ly49Q-. However, this is likely a false 
negative due to the poor sensitivity of the anti-Ly49Q antibody, as it failed to 
detect Ly49Q on any splenic cells (Figure 5-12C).  
The gut homing chemokine receptor CCR9 has been described by three groups to 
be a marker of mature pDCs (Hadeiba et al., 2008; Björck et al., 2011; Schlitzer 
et al., 2011). These groups illustrated that the majority of splenic pDCs 
(identified as simply B220+CD11c+ cells (Hadeiba et al., 2008); B220+CD11c+ cells 
after the exclusion of myeloid and lymphocyte cells (Björck et al., 2011); or 
PDCA1+CD11c+ cells (Schlitzer et al., 2011)) were CCR9+. However, Schlitzer et 
al. (Schlitzer et al., 2011) and Björck et al. (Björck et al., 2011) reported that a 
small population of splenic pDCs ~11-12% were CCR9-. I also found that the 
majority (~87%) of splenic pDCs were CCR9+ (Figure 5-31). Significantly, more 
CCL2lo pDCs expressed CCR9. A small population, representing approximately 
25% of CCL2hi pDCs were CCR9-, and essentially all CCR9- pDCs were in the CCL2hi 
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subset (Figure 5-11). This might indicate that a small proportion of CCL2hi pDCs 
are immature pDCs. Recently, Schlitzer et al. proposed that CCR9- pDCs are in 
fact a SiglecH+PDCA1+ intermediary precursor of pDCs and that they are mainly 
found in the BM. In contrast, I found that nearly all BM WT pDCs were CCR9+ 
(~86%) compared to the reported ~66% (Schlitzer et al., 2011). 
In the BM, CCR9- precursors preferentially give rise to pDCs (Schlitzer et al., 
2012). However, in the periphery they have the potential to give rise to both 
pDCs and cDCs (Schlitzer et al., 2012). Furthermore, CCR9- precursors 
spontaneously gave rise to fully differentiated CCR9+ pDCs in vitro when cultured 
in media alone or media supplemented with Flt3L. However, when cultured with 
media supplemented with granulocyte macrophage-colony stimulating factor 
(GM-CSF) they differentiated into cDCs (Schlitzer et al., 2011; 2012). A similar 
experiment could be performed to examine whether purified CCR9-CCL2hi pDCs 
possess the ability to differentiate into fully differentiated CCR9+ pDCs or cDCs. 
Interestingly, CCR9- pDCs have also been reported to be proinflammatory, 
producing high levels of the IL-6, IL-12 and TNFα compared to CCR9+ pDCs 
(Hadeiba et al., 2008; Björck et al., 2011). Therefore, this small population of 
splenic pDCs might perform the proinflammatory roles of pDCs and CCR2 might 
coordinate their migration. 
CCR9+ pDCs are described to possess tolerogenic properties (Hadeiba et al., 
2008; Björck et al., 2011; Schlitzer et al., 2011), as are CD8α+ pDCs (Lombardi et 
al., 2012). Tolerogenic pDCs are thought to induce generation of Tregs that 
secrete the anti-inflammatory cytokine, IL-10 (Colonna et al., 2004; Ito et al., 
2007; Baba et al., 2009; Matta et al., 2010). The majority of CCL2hi/lo pDCs were 
found to express both CCR9 and CD8α, indicating that both subsets are likely to 
contain tolerogenic pDCs. 
The expression of several other chemokine receptors was also examined in these 
two CCL2 pDC subsets (Figure 5-11). The two subsets had relatively minor, but 
statistically significant differences in expression of CX3CR1. Furthermore, 
consistent to published observations which illustrated that pDCs possess CCR1 
and CCR5 transcripts (Yoneyama et al., 2004; Wendland et al., 2007), the total 
pDC population internalised CCL5AF647 in a receptor-mediated fashion by one or 
more of the CCL5 binding receptors, CCR1, CCR3 , CCR5 or D6. Competition with 
Chapter 6  280 
 
mCCL4 indicated that pDCs possessed significant levels of either D6 or CCR5, as 
it caused a significant decrease in CCL5AF647 uptake. mCCL5 provided more 
extensive inhibition of CCL5AF647 uptake suggesting that other CCL5 receptors, 
most likely CCR1, are also present (Figure 5-11D). I could not determine the 
relative proportions of each subset that possessed CCL5 receptor activity, as 
both chemokines, CCL5 and CCL2 were labelled with the same fluorophore, 
AF647. However, no differences in expression of CCL5 receptors were seen in the 
microarray data (Figure 5-24). I also examined the expression of two integrins, 
CD62L and α4β7 (Figure 5-12), both of which have been shown to be involved in 
pDC migration (Wendland et al., 2007; Seth et al., 2011). Both were expressed 
at very low levels by the CCL2 pDC subsets, however there was a significant 
decrease in CD62L expression by CCL2lo pDCs compared to CCL2hi pDCs. CD62L, 
like CCR7 is involved in the transmigration of pDCs into PLNs (Nakano et al., 
2001; Diacovo et al., 2005; Seth et al., 2011). This might indicate that CCL2lo 
pDCs are less efficient at entry into PLNs. However, there were no differences in 
the proportion of CCL2hi to CCL2lo pDCs in PLNs (Figure 5-3). 
Interestingly, following activation with CpG-C, a small proportion (~15%) of each 
subset upregulated SiglecH, but again there were no differences in expression 
between the two subsets (Figure 5-29). To my knowledge, the upregulation of 
SiglecH by activated pDCs has not been described. However, Björck et al. 
associated the maturation of CD9+ into the terminally differentiated CD9- pDCs 
with an increase in SiglecH expression (Björck et al., 2011). The majority of the 
CCL2hi and CCL2lo pDCs did not express CD9, indicating that they are mature fully 
differentiated pDCs. Furthermore, Björck et al. reported that upregulation of 
SiglecH occurred as a natural part of their maturation and did not require 
activation of the cells (Björck et al., 2011). Therefore, I do not believe that the 
observed upregulation of SiglecH expression following activation of pDCs with 
CpG-C was due to the maturation of the cells. The expression of the activation 
markers CD86 and ICOS-L was limited to the SiglecHhi population of each of the 
CCL2 subsets. This might indicate that activation of pDCs results in an increase 
in SiglecH expression. SiglecH can function as an endocytic receptor mediating 
Ag uptake, which can then be cross-presented by pDCs to CD8α+ T cells (Zhang 
et al., 2006). Furthermore, Takagi et al. have shown that SiglecH modulates pDC 
function, and in its absence pDCs have an altered capacity to prime CD4+ and 
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CD8α+ T cells (Takagi et al., 2011). Therefore, in future it would be interesting 
to compare the relative abilities of CpG-induced SiglecHhi and SiglecHlo pDCs to 
cross-present Ag to CD8α+ T cells. Data presented in Chapter 5 illustrates that 
unstimulated Ag loaded pDCs were able to induce naïve Ag-specific CD8α+ T cell 
proliferation (Figure 5-17) and furthermore, TLR7 mediated activation of pDCs 
enhanced their ability to prime and stimulate proliferation of naïve CD8α+ T cells 
(Figure 5-19). Based on these results it can be hypothesised that the enhanced 
proliferative stimulatory capacity of TLR7 activated pDC might be due to the 
presence of a SiglecHhi population of pDCs. By purifying SiglecHhi and SiglecHlo 
pDCs it would be possible to determine which population was responsible for the 
observed proliferation. The Ag presenting properties of the two subsets shall be 
discussed in more detail in section 6.7. 
6.6.2 CCR2- or D6-deficiency affects pDCs phenotype 
The impact of CCR2- or D6-deficiency on the pDC subsets was examined next 
(Figure 5-30 to 5-33). One of the most striking phenotypes, although not 
consistent between repeat experiments, was observed in the D6 KO animals. 
Often these animals only possessed CCL2hi pDCs and lacked CCL2lo pDCs (Figure 
5-30). As discussed earlier, there is a high degree of redundancy in chemokine 
receptors, and in the absence of one receptor, another receptor can compensate 
for its lost (Krueger et al., 2010). As such, CCR2 might compensate for loss of 
D6. Both D6 and CCR2 possess scavenging capabilities (Hansell et al., 2006; 
Volpe et al., 2012) and perhaps in the absence of D6, CCR2 is upregulated to 
increase a cells scavenging capacity, through binding and internalising more 
CCL2. In contrast, CCR2 KO pDCs only internalised low levels of CCL2AF647 in a D6 
dependent manner. There were no difference in the absolute number of pDCs in 
the spleen of each mouse strain (Figure 5-33) and there were relatively few 
alterations in the expression of all the tested surface markers (Figure 5-31 and 
5-32). A significantly higher proportion of CCR2 KO BM pDCs expressed CCR9, but 
there were no significant differences in the expression of another tolerogenic 
marker CD8α (Lombardi et al., 2012) (Figure 5-32). These data suggest that 
CCR9- pDCs might be absent from animals deficient in CCR2. The potential roles 
of CCR9- pDCs as immature proinflammatory pDCs have already been discussed. 
Therefore, CCR2 KO animals might be deficient in proinflammatory pDCs, and all 
pDCs within these animals appear to be tolerogenic CCR9+ pDCs. This might have 
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significant consequences on the ability of CCR2 KO animals to mount protective 
proinflammatory responses against viral pathogens. CCR9 is also a marker of 
mature pDCs (Hadeiba et al., 2008; Björck et al., 2011; Schlitzer et al., 2011), 
and notably, a significantly higher proportion of CCR2 KO BM pDCs expressed the 
maturation marker CD4 (O'Keeffe et al., 2002). Immature pDCs can also be 
characterised by the expression of CD9, as maturation is accompanied by a 
downregulation of this proteins expression (Björck et al., 2011). Significantly 
fewer CCR2 KO BM pDCs were found to express CD9 compared to WT pDCs. 
Collectively, these results indicate that a greater proportion of pDCs in the BM of 
CCR2 KOs are terminally differentiated in comparison to WT and D6 KO animals. 
CCR2 KO and D6 KO BM pDCs had significantly lower expression of the integrin 
α4β7 compared to WT pDCs. α4β7 is involved in pDC migration to the small 
intestine and MLNs (Hadeiba et al., 2008). This might indicate that CCR2 KO and 
D6 KO pDCs are less efficient at entry into small intestine and MLNs. However, 
CCR2 KO and D6 KO pDCs had significantly higher expression of the gut homing 
chemokine receptor CCR9. It would be interesting to determine whether 
deficiency in CCR2 or D6 affected pDC migration to MLNs or small intestine. The 
most striking observation was that D6 KO BM contained over 12-fold more CD9+ 
pDCs compared to WT, and a 100-fold more than CCR2 KO BM. This might 
indicate that surface expression of CD9 is suppressed in the presence of D6. 
Furthermore, CD9 is a marker of immature pDCs, thus D6 KO BM pDCs are likely 
to be immature. However, there were no significant differences in the 
expression of CD9 by splenic pDCs in the three mice strains, as relatively few 
splenic pDCs expressed CD9. This might indicate that the absence of D6 alters 
the maturation process of BM pDCs, perhaps D6 is required for optimal terminal 
differentiation of BM pDCs. This could be determined by examining 
downregulation of CD9 by purified BM pDCs from each mouse strain in the 
presence of media or media supplemented with Flt3L. In addition to being a 
marker for immature pDCs, CD9 is a tetraspanin protein that has reported to 
regulate integrin-dependent cell migration and can promote clustering of ICAM1 
and VCAM1 on leukocytes (Barriero et al., 2005; Powner et al., 2011). This might 
indicate that increased CD9 expression by D6 KO BM pDCs modulates their 
adhesion and migration properties. However, analysis of all the phenotypes 
identified in D6 KO pDCs must be interpreted with some caution. I have 
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illustrated that pDCs from animals deficient in D6 can present with two CCL2AF647 
uptake profiles: one similar to WT animals, while in the second all pDCs are 
CCL2hi. The reason for this is not known, but it suggests that there is marked 
variability in pDCs from D6 KO animals, which cannot be explained by 
differences in the age, gender or housing conditions of the animals. 
6.6.3 Microarray analysis 
Microarray analysis facilitated a comprehensive comparison of transcript levels 
between the two CCL2 pDC subsets (Figure 5-24), and revealed that the pDC 
subsets were very similar in terms of their expression of a broad range of genes. 
The subsets did not differ in their expression of pDC specific genes (Figure 5-27) 
and flow cytometry also confirmed that there were no differences in their 
expression of pDC specific cell surface molecules SiglecH and PDCA1 (Figure 5-
2). Consistent with T cell stimulatory data, the two subsets did not differ in their 
expression of Ag presentation genes, such as CD86 and MHCII. However, and 
most importantly, microarray analysis showed that CCR2 was differentially 
expressed between the two subsets, although there was no difference in D6 
expression (Figure 5-24). Other genes that were differentially expressed 
between the two subsets could not be clustered based on functional 
categorisation i.e. inflammatory vs. tolerance. However, several tumour 
suppressor genes were upregulated in CCL2lo pDCs. Furthermore, two ifitm 
genes, ifitm-1 and 3, involved in viral defence were expressed at higher levels in 
CCL2hi pDCs. This might be consistent with the presence of the CCR9- 
proinflammatory immature pDCs within this subset. Several surface receptors, 
such as IL-13Ra1 and CD200R, were differentially expressed between the two 
subsets. These receptors were of interest as engagement of either receptor on 
pDCs has been shown to modulate pDC function. Activation of CD200R1 on pDCs 
by cells expressing its ligand CD200 has been shown to induce IFNα release 
(Manlapat et al., 2007). Tel et al. have shown that TLR9 mediated activation of 
pDCs can be modulated by the addition of IL-13, which causes a decrease in the 
expression of costimulatory molecules, CD83 and CD86 (Tel et al., 2010). 
Validation of the microarray results was initially performed via QPCR. However, 
the QPCR malfunctioned and no accurate readings could be determined for gene 
expression. The QPCR was not repeated as it used all remaining pDC RNA that 
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was generated for the microarray and time restrictions of this PhD meant that it 
could not be repeated due to the required cell sorting experiments to obtain 
more RNA. As an alternative method to perform qualitative analysis of the 
microarray data, flow cytometry was utilised in an effort to confirm expression 
of some of the surface receptor markers shown to be differentially expressed at 
the transcript level on the microarray between the two subsets (Figure 5-28). 
Antibody staining of the CCL2hi/lo pDC subsets revealed no significant differences 
in the expression of CD200R1. Furthermore, CD200R1 KO animals had similar 
expression to WT animals, indicating that there was a high degree of non-
specific staining with the anti-CD200R1 antibody. The lack of a reliable antibody 
to examine CD200R1 hindered this analysis. However, in the future, it would be 
interesting to determine if CD200R1 engagement led to differences in IFNα 
production by the two pDC subsets. 
The microarray and the later antibody staining of IL-13Ra1 illustrated that the 
IL-13 receptor is differentially expressed by the two pDC subsets, with CCL2hi 
pDCs having greater expression (Figures 5-27 and 5-28). However, my results 
showed that there was no affect on the CpG-C induced activation of pDCs, 
quantified by the expression of costimulatory molecules CD86 and ICOS-L, 
following the addition of IL-13 (Figure 5-29). Tel et al. did not describe any 
effect of IL-13 on ICOS-L: it was decided to use ICOS-L because it has been 
shown to be expressed at significantly higher levels on CpG activated pDCs than 
CD86 (Ito et al., 2007). 
The microarray analysis also illustrated that incubation of pDCs at 37°C in 
CCL2AF647 caused a substantial change in gene expression in pDCs (Figure 5-26). 
The majority of genes that were affected by culture were those reported to be 
highly expressed by Langerhans cells and cDCs. As the FACS-purified pDC 
populations had >95% purity at the start of the incubation, these results might 
indicate that culture in vitro initiated some form of differentiation of pDCs 
towards LC/cDC-like cells. Schlitzer et al. have illustrated that purified CCR9- 
pre-pDCs could differentiate into cDCs when cultured with GM-CSF for 48 hrs 
(Schlitzer et al., 2011; 2012). CCR9- pDCs cultured in media alone differentiated 
into CCR9+ pDCs. CCR9+ pDCs, as previously discussed are terminally 
differentiated pDCs, which do not possess the ability to differentiate into cDCs 
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in response to GM-CSF (Schlitzer et al., 2011; 2012). Interestingly, my results 
suggest that splenic pDCs, the majority of which are CCR9+, did undergo some 
differentiation in response to culture at 37°C. 
Recently, a core cDC signature that distinguishes cDCs from pDCs and 
macrophages at the transcript level has been identified. This signature is 
composed of 24 genes that were expressed 2-fold higher in cDCs than 
macrophages (Miller et al., 2012). This signature could not be identified in the 
list of genes upregulated as a consequence of culture (Appendix 1). 
Furthermore, lymphoid and non-lymphoid tissue cDCs were found to express 125 
genes that are absent from pDCs (Miller et al., 2012). Of these 125 genes, only 6 
(atf3, cd83, ifitm2, lfng, nr4a3 and rasgef1b) were present in the list of genes 
affected by culture (Appendix 1). These results indicate that incubation for 1 hr 
at 37°C in CCL2AF647 did cause upregulation of several cDC specific genes. 
However, and not unexpectedly, this short incubation period did not cause full 
differentiation of pDCs into cDCs. Therefore, a longer incubation period of cells 
with CCL2AF647 at 37°C might trigger full differentiation of pDCs into cDCs. 
Despite the alteration in genetic profiles, antibody staining of the pDC specific 
markers, PDCA1 and SiglecH indicated that the two subsets were still positive for 
pDC markers following the incubation, thus although many genes are altered, it 
appears that the pDC specific genes are not. Furthermore, regardless of the 
upregulation of cDC and Langerhans cell specific genes, CCL2hi and CCL2lo pDCs 
maintain many hallmark features of pDCs (i.e. ability to response to TLR7/9 
agonists and IFNα production), but they may contain a small proportion of cells 
that are starting to become cDC-like. 
pDCs represent only a small proportion of the splenic cell populations. Thus in 
many of my experiments, including sorting of pDCs for the microarray, Flt3L was 
used to expand the number of pDCs in the periphery. Reizis et al. have 
discouraged the use of Flt3L to expand the pDC pool or to drive the in vitro 
generation of BM-pDCs, stating that the tumour and the above physiological 
Flt3L levels might lead to alterations in the profiles and functions of pDCs (Reizis 
et al., 2011b). However, as shown in Figure 5-8, B16FL treated animals had no 
apparent alterations in their CCR2 activity, with CCL2hi pDCs comprising ~50% of 
the pDC population in both the spleen and PLNs. This is in contrast to Wendland 
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et al. who reported that pDCs from the spleen of a Flt3L treated animal 
possessed significantly more MC-21 immunoreactivity than BM pDCs from an 
untreated animal (Wendland et al., 2007). Flt3L exposure did, however, lead to 
differences in IL-13Ra1 expression (Figure 5-28). Nonetheless, the method of 
pDC expansion, a necessary step to generate enough pDCs to do the work, must 
be borne in mind when interpreting the data. 
6.7 What role does CCR2 play on pDCs? 
My results showed that pDCs can migrate in vitro in response to CCL2 (Figure 5-
10), which is in sharp contrast to Penna et al. that showed that human steady-
state pDCs do not migrate in response to inflammatory chemokines (Penna et 
al., 2001), which is surprising given that all human peripheral blood pDCs are 
highly active for CCL2AF647 uptake (Figure 3-16). The migration of the subsets to 
CCL2 could not be examined, as the segregation of the two subsets requires 
exposure to CCL2AF647, which will desensitise CCR2 to further exposure of CCR2 
ligands (Figures 3-17 and 3-18). CCR2 is unlikely to be required for pDC migration 
from the BM or into the spleen, as there were no significant differences in the 
absolute number of pDCs detected in WT and CCR2 KO animals (Figure 5-33). 
Furthermore, LPS induced inflammation did not significantly affect the 
frequency of splenic pDCs in WT and CCR2 KO animals, indicating that CCR2 was 
not required during inflammation (Figure 4-6). However, there is controversy 
about whether pDCs express TLR4, thus it is not known whether LPS would act 
directly or indirectly on pDCs (Krug et al., 2001; Edwards et al., 2003). 
Therefore, CCR2 might only play a role in pDC migration following direct 
activation of pDCs via TLR7 or TLR9. 
The application of a TLR7 agonist, imiquimod to the skin has been reported to 
cause CCL2 dependent recruitment of pDCs to the inflamed skin (Drobits et al., 
2012). Shortly after imiquimod treatment (24 hrs) of the skin, CCL2 production 
was induced in a TLR7 and IFNα/β receptor 1 dependent fashion. In the absence 
of TLR7, CCL2 production was significantly reduced and pDC recruitment to the 
skin was diminished. Likewise, animals deficient in CCL2 did not recruit pDCs to 
the skin (Drobits et al., 2012). Drobits et al. proposed that TLR7+ mast cells in 
the dermis were responsible for the imiquimod induced CCL2 release, as they 
illustrated that BM-derived mast cells produced significant levels of CCL2 
Chapter 6  287 
 
following incubation with imiquimod (Drobits et al., 2012). Here I showed CCR2 
KO animals had significantly more, rather than fewer, pDCs recruited to 
imiquimod treated skin compared to WT mice (Figure 5-34). Furthermore, there 
were no significant differences in the number of pDCs in the draining inguinal 
LN, spleen, BM or blood of CCR2 KO mice treated with imiquimod compared to 
similarly treated WT controls (Figure 5-35 to 5-38). Thus, CCR2 was not required 
for pDC migration to the skin. The low number of cells retrieved from skin 
preparations meant that pDCs could not be examined for their CCR2 activity, 
thus the relative contributions of the CCL2hi/lo subsets to the skin pDC population 
could not be determined. Furthermore, in contrast to Langerhans cells, which 
are highly dependent on CCR2 for their migration from the skin to the draining 
LNs (Sato et al., 2000), pDCs did not appear to require CCR2 for escape to the 
draining inguinal LNs (Figure 5-35). Therefore, regardless of their ability to 
migrate in vitro in response to CCL2 (Figure 5-10), in an in vivo model in which 
pDCs are reported to exhibit CCL2 dependent migration into the skin (Drobits et 
al., 2012), my results suggest that they did not require CCR2 to migrate. 
The CCL2 dependent migration of pDCs might be due to an indirect effect. 
Perhaps pDCs do not migrate to inflamed skin in a CCR2 or CCL2 dependent 
manner, but CCL2 recruits an intermediary cell population that once activated in 
the skin produces pDC-recruiting chemokines. For example, Jimenez et al. have 
reported that CCR2 KO mice have reduced levels of the CCR7 ligand, CCL19, and 
hypothesised that a link exists between CCR2 and activation of the CCR7-CCL19 
axis (Jimenez et al., 2010). However, if this hypothesis were true, a decrease in 
pDCs would still be expected, as a consequence of the loss of the intermediary 
cell population. These results might indicate that CCL2 is functioning 
independently of CCR2. In section 1.6.1.4 some of the divergent phenotypes of 
CCR2 KO and CCL2 KO animals were described. CCR2 KO mice have diminished 
Th1 responses (Boring et al., 1997; Peters et al., 2000; Chiu et al., 2004), 
whereas CCL2 KO mice have diminished Th2 responses (Boring et al., 1997; 
deSchoolmeester et al., 2003). Therefore, an alternative conclusion is that the 
CCR2 independent CCL2 dependent migration of pDCs might be another 
divergent phenotype of animals deficient in the receptor or its ligand. 
A consistent phenotype observed in each tissue was that following imiquimod 
treatment, pDCs lost CCR2 activity, and there was a significant reduction in the 
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proportion of CCL2hi pDCs in the inguinal LNs, spleen and BM (Figure 5-35 to 5-
37). However, similar to results produced with LPS, D6 activity was not affected, 
as pDCs within each tissue maintained D6 activity. The loss of CCR2 activity 
might indicate that, similar to cDCs, following activation, pDCs downregulate 
inflammatory chemokine receptors and upregulate CCR7 (Dieu et al., 1998; 
Sallusto et al., 1998). Thus, perhaps CCR2 is not involved in the migration of 
pDCs to a specific organ, but may coordinate their migration within the organ 
itself. It would be of interest to establish the location of each subset within 
splenic tissue sections. However, CCL2AF647 cannot be used to distinguish the two 
subsets in tissue sections and no other marker has fully coordinated with CCR2 
expression, therefore to confirm the location of the two subsets within the 
section the CCL2 subsets would need to be purified and each subset individually 
labelled. Following adoptive transfer of the labelled cells it should be possible to 
assess their distribution within the tissues. 
I have shown that there are no substantial functional differences between CCL2hi 
and CCL2lo pDCs. They do not possess gross morphological differences, except 
that some CCL2lo pDCs have vacuoles present in their nuclei (Figure 5-14). The 
presence of vacuoles within the nuclei of CCL2lo pDCs could be due to apoptosis 
induced by the stress of sorting. However, they were not present in CCL2hi pDCs 
and no differences in the viability of either subset (Figure 5-29) or in the 
expression of apoptosis associated genes in the microarray data were observed 
(Figure 5-24). Furthermore, the vacuoles in the nuclei of CCL2lo pDCs were not 
detrimental to pDC function, as both subsets were able to produce IFNα/β in 
response to CpG or R848 stimulation (Figure 5-21). pDCs possess the ability to 
produce high levels of IFNα/β in response to TLR7 (R848) or TLR9 (CpG) 
stimulation (Naik et al., 2005; Reizis et al., 2011a). However, similar to results 
by Ito et al. CCL2hi/lo pDCs stimulated with CpG-A made significantly more IFNα 
than R848 stimulated pDCs (Ito et al., 2006). Most groups have demonstrated 
both mature and immature pDCs can produce IFNα/β (O'Keeffe et al., 2002; 
Omatsu et al., 2005; Toma-Hirano et al., 2007). However, Björck et al. showed 
that BM CD9+ immature pDCs had a greater capacity to produce IFNα than 
mature peripheral CD9- pDCs (Björck et al., 2011). In contradiction to these 
observations, splenic CCL2hi/lo subsets were CD9- and capable of producing IFNα 
in response to TLR7 and TLR9 stimulation. However, a positive control of 
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immature pDCs to compare the capacity of immature (CD9+) and the two 
CCL2hi/lo CD9- subsets to produce IFNα was not included. Thus, the two CCL2hi/lo 
CD9- subsets might have a lower capacity to produce IFNα than the CD9+ 
immature pDCs. 
There were no differences in the T cell stimulatory capacity of the two CCL2 
pDC subsets (Figures 5-15 to 5-20) and consistent with published observations 
(Asselin-Paturel et al., 2001; Blasius and Colonna, 2006; Villadangos and Young, 
2008), the pDCs were far less efficient at processing and presenting Ag to T cells 
than cDCs. However, both CCL2 subsets were able to stimulate T cell 
proliferation in similar capacities. Many groups have investigated the T cell 
stimulatory capacity of pDCs. Some reported that pDCs can stimulate memory 
CD8+ and effector Th1 cells (Colonna, 2003; Fonteneau et al., 2003), whereas 
other groups have reported that pDCs possess the ability to prime naïve T cells 
(Asselin-Paturel et al., 2001; Mouriès et al., 2008). Similar to results generated 
by Asselin-Paturel et al. (Asselin-Paturel et al., 2001), total pDCs and the two 
CCL2 pDC subsets were only able to prime and stimulate minimal proliferation of 
naïve CD4+ T cells (Figure 5-15 and 5-16). In contrast, both subsets were 
significantly more efficient at processing and cross-presenting OVA to CD8α+ T 
cells (Figure 5-18). This is also consistent with published observations, as pDCs 
are reported to be efficient at priming and stimulating proliferation of naïve 
CD8+ T cells by cross-presentation of exogenous Ag on MHCI (Mouriès et al., 
2008). I initially wanted to confirm the tolerogenic properties of the subsets, 
both have been shown to express CCR9 and CD8α, markers of tolerogenic pDCs. 
My aim was to examine the expression of FoxP3, the key transcription factor 
expressed by Tregs (Boehmer and Nolting, 2008). However, the inferior CD4+ 
stimulatory capacity of the pDCs and the resulting low T cell numbers made this 
extremely difficult. 
Resting non-stimulated pDCs express low levels of MHCII and costimulatory 
molecules, and imaging studies have shown that their interaction with T cells is 
not stable and are only transient contacts (Mittelbrunn et al., 2009). In contrast, 
following their activation pDCs can maintain sustained contacts with T cells and 
have a higher immunogenic capacity than resting pDCs (Mittelbrunn et al., 
2009). Accordingly, many groups have reported that the T cell stimulatory 
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capacity of pDCs is enhanced by their activation (Asselin-Paturel et al., 2001; 
Boonstra et al., 2002; Colonna et al., 2004; Salio et al., 2004; Mouriès et al., 
2008). For example, Mouriès et al. reported that CpG or R848 activated pDCs 
have significantly enhanced ability to cross-present and prime naïve CD8+ T cells 
(Mouriès et al., 2008). Consistent with these observations, following activation 
with R848, CCL2hi and CCL2lo pDCs had increased CD8α+ T cell stimulatory 
capacity, as there was a significant increase in the proportion of T cells that 
have divided. Furthermore, there was a significant increase in the number of T 
cells in the later division generations following activation of pDCs with R848 
(Figure 5-19). I also found that following activation with CpG-C, both subsets 
upregulated costimulatory molecules CD86 and ICOS-L, which may in part 
explain their enhanced T cell stimulatory capacity (Figure 5-29). 
These results also suggest that activation of CCR2 signalling does not affect the 
T cell stimulatory capacity of the two subsets, as addition of exogenous CCL2 to 
co-cultures had no affect on their T cell stimulatory capacity (Figure 5-20). 
Exposure of pDCs to CCL2AF647 was required to facilitate purification of the two 
pDC subsets. This prior exposure to CCL2 might have desensitised CCR2. 
However, the co-culture experiments were performed over a three day period, 
therefore it was expected that CCR2 activity would be restored within this time. 
An alternative method to examine whether CCR2 affects the T cell stimulatory 
capacity of the two subsets would be to determine the ability of total pDCs to 
prime T cell proliferation in the presence and absence of CCL2. T cell 
stimulatory capacity could also be compared between total pDCs from WT and 
CCR2 KO animals. 
6.8 Conclusions and future directions 
These studies have helped to establish the use of the CCL2AF647 assay as a 
reliable, sensitive and versatile method for CCR2 detection. They have also 
furthered our understanding about CCR2 and D6 expression and regulation. 
Furthermore, the assay facilitated the identification of two distinct pDC subsets 
based on CCR2 expression. The microarray analysis of the two subsets confirmed 
the difference in CCR2 expression, in addition to the identification of several 
other genes that were differentially expressed by the subsets. For example, IL-
13Ra1 was expressed at higher levels in CCL2hi pDCs, as confirmed by microarray 
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results and antibody staining. However, addition of IL-13 did not appear to have 
any effect on CpG induced pDC maturation. Subsequent to a further attempt at 
validating the microarray results by QPCR it would be of interest to determine 
the role that differentially expressed genes may have in the pDC subsets. 
My preliminary investigations have not revealed any indispensible role for CCR2 
in pDC function or an association of CCR2 activity with a particular pDC 
phenotype. The two subsets had similar T cell stimulatory and IFNα production 
capacity. Furthermore, although my in vitro data shows that mouse pDCs can 
migrate in response to CCL2, CCR2 was not required for the CCL2 dependent 
migration of pDCs to imiquimod inflamed skin. The time-restrictions of this PhD 
have meant that I have only been able to examine the role of CCR2 in pDC 
migration in one model of inflammation and although CCR2 was not found to 
function in pDC migration within this model, a role for CCR2 in the migration of 
pDCs should not be discounted. CCR2 expression by Ly6Chi monocytes has been 
shown to be crucial in the defence against Listeria monocytogenes (Serbina and 
Pamer, 2006), and perhaps similarly CCL2hi pDCs might play a central role in 
defence against other specific pathogens. 
By establishing a role of CCR2 on pDCs, it may help us to determine why CCR2 is 
expressed at a higher level on a proportion of pDCs, as the mechanism by which 
this occurs is as yet unknown. My early results provide evidence that differences 
in chemokine receptor expression are not a consequence of differences in the 
activation or maturation states of the subsets. I have shown that CCL2hi pDCs can 
downregulate their CCR2 activity in response to inflammation, either directly 
mediated by TLR7 stimulation or indirectly by TLR4 stimulation. However, it has 
yet to be confirmed whether the two subsets can interconvert i.e. can CCL2lo 
pDCs become CCL2hi, or vice versa. This could be done either in vitro, by 
purifying the two subsets and incubating them with Flt3L or alternatively, 
purified CCL2hi/lo subsets could be labelled and injected i.v. into steady-state 
and/or inflamed mice. After a short incubation period of 24-48 hrs the relative 
proportions of labelled CCL2hi/lo pDCs in peripheral lymphoid organs could be 
determined. If the two subsets can indeed interconvert it may not occur within 
this short time-period. Long-term transfers might be achieved by purifying 
CCL2hi/lo pDCs from mice expressing one of the two identifiable alleles of CD45, 
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CD45.1 or CD45.2. The purified cells can then be injected i.v. into mice 
expressing the other allele, which would allow for the later identification of the 
transferred cells by flow cytometry. 
Collectively these results have helped enhance our understanding of CCR2 and 
D6 expression within the immune system. Further to this, I have identified a 
previously uncharacterised subset of pDCs that express CCR2 and have provided 
initial observations of their function in steady-state and inflammatory settings. 
Finally, understanding the consequences of CCR2 and D6 expression on pDCs is of 
paramount importance, as it will provide further insight into pDC biology and 
their roles in inflammatory disease.
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Appendices 
Gene Symbol 
FC CCL2hi pDCs 
vs. total pDCs 
FC CCL2lo pDCs 
vs. total pDCs 
FC CCL2hi pDCs 
vs. CCL2lo pDCs 
Hspb1 29.3394 22.7519 1.28954 
Cdkn1a 9.3763 6.45646 1.45224 
Il1r2 9.29091 4.80465 1.93373 
Hsph1 8.81644 8.38109 1.05194 
Vdr 8.72108 5.01912 1.73757 
Atf3 7.41372 5.57453 1.32993 
Bag3 6.93039 4.8588 1.42636 
Tnip3 6.80021 2.85079 2.38538 
Cables1 6.66265 7.60426 -1.14133 
Plk2 6.5466 2.7754 2.3588 
Tnfsf9 6.35579 3.11829 2.03823 
Nr4a2 6.28692 2.86412 2.19506 
Pde3b 6.2139 5.46505 1.13703 
Nr4a3 6.14912 4.59796 1.33736 
Bcl2l11 6.10685 5.7635 1.05957 
Rasgef1b 6.05559 4.06192 1.49082 
Ramp3 5.8075 4.05765 1.43125 
Id3 5.66284 6.86889 -1.21298 
Gcnt2 5.61535 3.62012 1.55115 
Gla 5.50683 6.59929 -1.19838 
Emp1 5.46121 2.6863 2.03299 
Dennd4a 5.43378 4.46489 1.217 
Hspa1a 5.427 5.22977 1.03771 
Trp53inp2 5.38456 5.00378 1.0761 
Hspa1a 5.22672 5.16817 1.01133 
Galnt6 5.13271 2.22194 2.31001 
Fam129b 5.0343 2.74365 1.83489 
Lmna 4.98433 4.76647 1.04571 
Celsr1 4.82361 3.55044 1.3586 
Plk3 4.76339 3.94427 1.20767 
Cd83 4.6511 3.24859 1.43173 
Dnajb1 4.58822 4.31528 1.06325 
Ppp1r16b 4.43456 4.0806 1.08674 
Hspa1a 4.41382 4.01133 1.10034 
Chst11 4.39513 4.85164 -1.10387 
Cenpa 4.19494 3.86498 1.08537 
Ifrd1 4.16067 3.45817 1.20314 
Gprc5a 4.10197 2.70364 1.5172 
B3gnt5 4.06822 2.95382 1.37727 
Lfng 4.02826 2.32985 1.72898 
Gp49a 3.9923 2.1546 1.85292 
Crip2 3.96321 2.51599 1.57521 
Hspd1 3.9097 3.45377 1.13201 
Ccl3 3.9048 4.19582 -1.07453 
Ifitm2 3.88561 1.48872 2.61003 
Dusp8 3.8822 3.82797 1.01417 
Dnaja1 3.8725 3.63439 1.06552 
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Phlpp1 3.87027 3.30063 1.17259 
Nfil3 3.80038 2.55519 1.48731 
Stat4 3.77151 2.871 1.31366 
Grhl3 3.76737 4.94526 -1.31265 
Grasp 3.74881 3.57292 1.04923 
Hspa1l 3.73597 2.44837 1.5259 
Spsb1 3.69163 5.48259 -1.48514 
Hspd1 3.68323 3.26767 1.12717 
Vps37b 3.61875 3.16576 1.14309 
Klrb1b 3.57996 1.3344 2.68282 
Erf 3.56601 3.60638 -1.01132 
Jup 3.5653 1.69426 2.10434 
Uck2 3.51091 2.27667 1.54213 
5430435G22Rik 3.50327 2.47347 1.41634 
Fam46c 3.49869 4.16328 -1.18995 
Odc1 3.4286 3.41412 1.00424 
Ppp1r15a 3.3956 3.44792 -1.01541 
Kcnn4 3.39427 2.97902 1.13939 
Dennd4a 3.3351 2.86955 1.16224 
Itga5 3.28626 1.74703 1.88105 
Slc5a3 3.26697 2.42071 1.34959 
Lzts1 3.24352 3.24243 1.00034 
Vegfa 3.23476 2.56818 1.25955 
Mir22 3.22557 2.65768 1.21368 
Smad3 3.14949 3.28379 -1.04264 
Dusp16 3.14569 2.74328 1.14669 
Kdm6b 3.13961 3.29647 -1.04996 
Zfand2a 3.13943 2.62853 1.19437 
Dennd4a 3.13292 2.82385 1.10945 
Gfod1 3.08547 2.889 1.06801 
Klf10 3.0764 2.57153 1.19633 
Ier3 3.06985 2.68807 1.14203 
Dennd4a 3.06708 2.56484 1.19582 
Lrrc8d 3.04231 3.00515 1.01237 
Pvr 3.03921 2.19614 1.38389 
Hsp90aa1 3.03691 3.08098 -1.01451 
Mir155 3.03072 2.2659 1.33753 
Ets2 3.01579 2.45296 1.22945 
Rhobtb2 -3.00233 -1.7683 -1.69786 
Gm10790 -3.01111 -2.53447 -1.18806 
Cyp2r1 -3.02515 -1.82511 -1.65751 
Gm12250 -3.21138 -2.52557 -1.27155 
Ppm1e -3.39078 -2.26043 -1.50006 
Mlh3 -3.41029 -2.08797 -1.6333 
Appendix 1: List of genes examined for alterations in expression as an effect of incubation 
in Figure 5-26. 
The FC differences between CCL2hi pDC vs. total pDCs, CCL2lo pDCs vs. total pDCs and CCL2hi 
vs. CCL2lo pDCs for all genes with a FC of <-3.0 or >3.0  and p value of p<0.005 between the 
CCL2hi pDCs and total pDCs. Each gene was examined for its relative expression in cell types 
using Immgen. Genes with high expression in Langerhan cells (LCs) are shown in blue, high 
expression in cDCs (red) and high expression in cells other than LCs, pDCs and cDCs (black). 
Furthermore, genes that were expressed at a higher level in pDCs than LCs are shown in pink and 
genes with similar expression in pDCs and LCs are shown in green. 
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